

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

INDEX

VOLUME 25
2005

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment
ISSN: 0250-7005

VOLUME 25
2005

This volume is dedicated to the memory of
G. F. SAUNDERS

Editorial Board

F. A. Anderer	Friedrich-Miescher-Laboratorium der Max-Planck-Gesellschaft, Tübingen, Germany
J. P. Armand	Institut Gustav-Roussy, Villejuif, France
D. Assimakopoulos	Department of Otorhinolaryngology, Medical School, University of Ioannina, Greece
V. I. Avramis	Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA
R. C. Bast	Department of Translational Research, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
G. Bauer	Abteilung Virologie, Inst. f. Med. Microbiol. u. Hygiene, Freiburg, Germany
E. E. Baulieu	Département de Chimie Biologique, Université de Paris Sud, Bicetre, France
Y. Becker	Department of Molecular Virology, Hebrew University of Jerusalem, Israel
J. Bergh	Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden
J. L. Biedler	Memorial Sloan-Kettering Cancer Center, New York, NY, USA
D. D. Bigner	Department of Pathology, Duke University Medical Center, Durham, NC, USA
A. Böcking	Institute for Cytopathology, University of Düsseldorf, Germany
G. Bonadonna	Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
F. T. Bosman	Institute of Pathology, University of Lausanne, Switzerland
G. Bounous	Montreal General Hospital, Montreal, Québec, Canada
G. Broich	ASL Lodi, Lodi, Italy
J. M. Brown	Department of Radiation Oncology, Stanford Medical Center, Stanford, CA, USA
Ø. S. Bruland	Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway
M. M. Burger	Novartis, Basel, Switzerland
M. Carbone	Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL, USA
J. Carlsson	Department of Biomedical Radiation Sciences, Uppsala University, Sweden
A. F. Chambers	Department of Oncology, London Regional Cancer Center, London, Ontario, Canada
P. Chandra	Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany
C. A. Cudennec	Laboratoires Jacques Logeais, Issy-Les-Moulineaux, France
E. De Clercq	Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
W. De Loecker	Department of Biochemistry, Katholieke Universiteit Leuven, Belgium
P.H.M. De Mulder	Department of Medical Oncology, University Medical Center, Nijmegen, The Netherlands
W. Den Otter	Division of Cell Biology and Histology, Department of Biochemistry, Utrecht University, The Netherlands
E.P. Diamandis	Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
G. Th. Diamandopoulos	Department of Pathology, Harvard Medical School, Boston, MA, USA
W. Ebert	Thoraxclinic HD-Rohrbach, Heidelberg, Germany
U. Eppenberger	Laboratory of Biochemistry/Endocrinology, University Clinic, Basel, Switzerland
J. A. Fernandez-Pol	Metalloproteomics, LLC, Chesterfield, MO, USA
I. J. Fidler	M. D. Anderson Hospital and Tumor Institute, Texas Medical Center, Houston, TX, USA
W. Fiers	Institute of Biotechnology, Flanders Interuniversity, University of Ghent, Belgium
N. E. Fusenig	Institut für Biochemie, Deutsches Krebsforschungszentrum, Heidelberg, Germany
G. Gabbiani	Department of Pathology, University of Geneva, Switzerland
A. F. Gazdar	Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA
A. Giordano	Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA
G. Gitsch	Department of Gynecology and Obstetrics, University of Freiburg, Germany
R. H. Goldfarb	Sopherion Therapeutics, Inc., New Haven, CT, USA
J. W. Gorrod	Toxicology Unit, University of Essex, UK
S. Hammarström	Department of Immunology, University of Umea, Sweden
I. Hellström	Harborview Medical Center, Seattle, WA, USA
L. Helson	Department of Experimental Therapeutics, New York Medical College, Valhalla, NY, USA
R. B. Herberman	Pittsburgh Cancer Institute, Pittsburgh, PA, USA

- R. M. Hoffman** Department of Surgery, University of California, San Diego, CA, USA
C. G. Ioannides Department of Gynecology, M. D. Anderson Cancer Center, Houston, TX, USA
M. Ishizuka Institute of Cancer Research, Shizuoka, Japan
S. C. Jhanwar Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J. V. Johannessen Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
B. Kaina Institute of Toxicology, University of Mainz, Germany
H. E. Kaiser Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA
B. K. Keppler School of Medicine, University of Vienna, Austria
D. G. Kieback Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, USA
J. Kieler The Fibiger Institute, Copenhagen, Denmark
R. Klapdor Medical Clinic, University of Hamburg, Germany
U. R. Kleeberg Hämatologisch - Onkologisch - Praxis Altona, Hamburg, Germany
P. Kleihues International Agency for Research on Cancer, Lyon, France
E. Klein Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden
S. von Kleist Institut für Immunologie der Universität der Freiburg, Germany
S. Kobayashi Aichi Sannomaru Hospital, Nagoya, Japan
A. Koestner Department of Veterinary Pathobiology, College of Veterinary Medicine, Ohio State University, Columbus, OH, USA
S. D. Kottaridis Department of Virology, Hellenic Anticancer Institute, Athens, Greece
G. R. F. Krueger Center of Anatomy II, University of Cologne Medical School, Cologne, Germany
D. W. Kufe Division of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA
Pat Kumar Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK
Shant Kumar Department Pathology, University of Manchester Medical School, Manchester, UK
O. D. Laerum Department of Pathology, The Gade Institute, University of Bergen, Norway
F. J. Lejeune Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland
C. J. Link Human Gene Therapy Research Institute, Des Moines, IA, USA
L. A. Liotta Department of Pathology and Laboratory Medicine, Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, MD, USA
G. Litwack Jefferson Cancer Institute, Philadelphia, PA, USA
L. F. Liu Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA
D. M. Lopez Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA
E. Lundgren Unit of Applied Cell and Molecular Biology, University of Umea, Sweden
H. T. Lynch Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE, USA
J. Marescaux IRCAD, University of Strasbourg, France
J. Mark Department of Pathology, Kärnsjukhuset, Skövde, Sweden
D. Medina Department of Cell Biology, Baylor College of Medicine, Houston, TX, USA
S. Mitra Sealy Center for Molecular Science, University of Texas Medical Branch, Galveston, TX, USA
F. M. Muggia New York University Cancer Institute, School of Medicine, NY, USA
M. J. Murphy Jr Hipple Cancer Research Center, Dayton, OH, USA
R. Narayanan Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA
K. Nilsson Department of Pathology, The Wallenberg Laboratory, University of Uppsala, Sweden
J. F. Novak Department of Biology, Bucknell University, Lewisburg, PA, USA
S. Pathak Department of Cell Biology, University of Texas, Houston, TX, USA
S. Pestka Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA
A. Pihl Department of Biochemistry, Norsk Hydro's Institute for Cancer Research, Oslo, Norway
G. J. Pilkington Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK

- C.D. Platsoucas** Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA, USA
- F. Podo** Laboratory of Cell Biology, Istituto Superiore di Sanità, Rome, Italy
- A. Polliack** Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel
- N. Prajda** National Institute of Oncology, Budapest, Hungary
- M. F. Rajewsky** Institut für Zellbiologie, Universität St Essen, Germany
- G. Rebel** IRCAD, Hopitaux Universitaires, Strasbourg, France
- M. Rigaud** Laboratory Biochimie et Génétique Molecules, Fac. Médecine de Limoges, France
- U. Ringborg** Department of General Oncology, Karolinska Hospital, Stockholm, Sweden
- M. Roselli** Department of Medical Oncology, University of Rome "Tor Vergata", Italy
- F. P. Rossini** Department of Oncology, San Giovanni Hospital, Torino, Italy
- G. F. Saunders** Department of Biochemistry and Molecular Biology, University of Texas, Houston, TX, USA
- A. Schauer** Zentrum Pathologie, Georg-August Universität, Göttingen, Germany
- M. Schneider** Department of Organic Chemistry, Bergische University, Wuppertal, Germany
- A. Seth** Laboratory of Molecular Pathology, Sunnybrook and Women's College, Health Science Center, Toronto, Ontario, Canada
- G. V. Sherbet** Cancer Research Unit, University of Newcastle -upon- Tyne, UK
- G. -I. Soma** Institute for Health Sciences, Tokushima Bunri University, Tokushima, Japan
- G. S. Stein** Department of Cell Biology, University of Massachusetts Medical Center, Worcester, MA, USA
- K. Takagi** Kennan Takagi Clinic, Kumamoto, Japan
- H. Tanaka** Department of Biophysics, Institute for Virus Research, Kyoto, Japan
- D. Tarin** University of California at San Diego, Cancer Center, La Jolla, CA, USA
- G. B. de Thé** Institut Pasteur, Paris, France
- T. M. Theophanides** Department of Chemistry, Technical University of Athens, Greece
- B. Toth** The Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE, USA
- E. Trelle** Department of General Practice and Primary Care, Faculty of Health Sciences, University of Linköping, Sweden
- G.P. Tryfiates** Department of Biochemistry, West Virginia University, Morgantown, WV, USA
- P. M. Ueland** Clinical Pharmacology Unit, Department of Pharmacology, University of Bergen, Norway
- P.T. Vihko** Department of Clinical Chemistry, University of Oulu, Finland
- M. Volm** German Cancer Research Center, Heidelberg, Germany
- G. Weber** Laboratory of Experimental Oncology, Indiana University, Indianapolis, IN, USA
- I. B. Weinstein** Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York, NY, USA
- B. Westermark** Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden
- S. Zimmer** Department of Microbiology and Immunology, University of Kentucky Medical Center, Lexington, KY, USA
- B. Zumoff** Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA

Acknowledgements

The following Organisations supported many of the works published in Anticancer Research, Volume 25, 2005.

- Aakre Foundation, Tromsø, Norway
 ABNOBA-Heilmittel GmbH, Pforzheim, Germany
 Academia Sinica (M.T.L.), Taiwan, R.O.C.
 Academy of Finland
 Academy of Sciences of the Czech Republic
 Adele R. Decof Cancer Center, U.S.A.
 Agence Nationale de Valorisation de la Recherche,
 (ANVAR), France
 A.I.R.C.
 Akibene Foundation, U.S.A.
 A. Krupp von Bohlen and Halbach Foundation, Essen,
 Germany
 American Cancer Society, U.S.A.
 American Diagnostica Inc., Greenwich, U.S.A.
 American Foundation for Biological Research
 American Heart Association, U.S.A.
 American Lebanese Syrian Associated Charities
 American Society of Transplantation Women's and
 Minority Faculty Grant (AV), U.S.A.
 Anandamahidol Foundation, Thailand
 Antisoma Research Ltd., U.K.
 A. P. Moller and Chastine Mc-Kinney Moller Foundation,
 Region of Copenhagen, the Faeroe Islands and
 Greenland
 Association de Bretagne Occidentale pour le
 Developpement des Etudes Cytogenetiques, France
 Association de Recherche Contre le Cancer, France
 Association Nationale de la Recherche Contre le Cancer,
 France
 Association pour la Recherche sur le Cancer, France
 Associazione Italiana per la Ricerca sul Cancro (AIRC)
 Atlantic Chapter of the Canadian Breast Cancer
 Foundation
 Autonomous University of Nuevo Leon, Mexico
 Aventis GmbH, Bad Soden, Germany
 Aventis Pharmaceuticals
 Avon Foundation

 Barncancerfonden, Sweden
 Basic Research Program of the Korea Science and
 Engineering Foundation
 Bauer Foundation of the University of Hamburg,
 Germany
 Bavarian Research Foundation
 Bayer Vital Diagnostika, Fernwald, Germany

 Bioland Inc., Greece
 Biotechnology and Biological Science Research Council, U.K.
 Bone Care International, U.S.A.
 Bristol-Myers Squibb, Belgium
 Bristol-Myers Squibb, Munich, Germany
 Bulgarian Foundation for Biomedical Research
 Byk-Sangtec Diagnostica, Dietzenbach, Germany

 California Breast Cancer Research Program, U.S.A.
 California Cancer Research Program, U.S.A.
 Canadian Institute of Health Research
 Cancer Research Campaign of Great Britain
 Cancer Research Foundation in Northern Sweden
 Cancer Research Fund, Sweden
 Cancer Research, U.K.
 Cancer Society, Stockholm, Sweden
 Cancerfonden, Sweden
 Catholic University of Louvain, Belgium
 Center for Cancer Research, U.S.A.
 Centre for Clinical Research, Falun, Sweden
 Centre National de la Recherche Scientifique (CNRS),
 France
 Chang Gung Medical Research Fund, Taiwan, R.O.C.
 Children's Cancer Foundation of Sweden
 CIMO
 College of Veterinary Medicine, The Ohio State
 University, U.S.A.
 Comite de la Loire de la Ligue Nationale Contre le
 Cancer, France
 Consejo Nacional de Ciencia y Tecnologia, Mexico
 Conselho Nacional de Desenvolvimento Cientifico e
 Tecnológico (CNPq), Brazil
 Conselleria d'Innovacio i Energia del Govern de les Illes
 Balears, Spain
 Cooperative Link of Unique Science and Technology for
 Economy Revitalization (CLUSTER) Project of Japan
 Crown Princess Lovisa's Association for Child Medical
 Care, Sweden
 CTT Company Ltd., Finland

 Daiwa Pharmaceutical Co. Ltd., Tokyo, Japan
 Danish Cancer Society
 Danish Hospital Foundation for Medical Research,
 Region of Copenhagen, the Faeroe Islands and
 Greenland

- Danish Medical Research Council
 Department of Defence, Taipei, Taiwan, R.O.C.
 Department of Defense Breast Cancer Research Program, U.S.A.
 Department of Internal Medicine, National Shikoku Cancer Center Hospital, Japan
 Department of Internal Medicine, Okayama Institute of Health and Prevention Hospital, Japan
 Department of Internal Medicine, Okayama University, Japan
 Department of Medicine I, Tokyo Women's Medical University, Japan
 Department of Obstetrics and Gynecology, Hiroshima City Hospital, Japan
 Department of Obstetrics and Gynecology, Hyogo College of Medicine, Japan
 Department of Obstetrics and Gynecology, Hyogo Prefectural Nishinomiya Hospital, Japan
 Department of Obstetrics and Gynecology, Nara Prefectural Mimuro Hospital, Japan
 Department of Obstetrics and Gynecology, National Mito Hospital, Japan
 Department of Obstetrics and Gynecology, Osaka University, Japan
 Department of Obstetrics and Gynecology, Saiseikai Tondabayashi Hospital, Japan
 Department of Oral Biology and Maxillofacial Pathology, Medical College of Georgia, U.S.A.
 Department of Otorhinolaryngology, Nihon University Itabashi Hospital, Japan
 Department of Pulmonary Medicine, Saitama Cancer Center, Japan
 Department of Radiology, Tokyo University, Japan
 Department of Surgery II, Chiba University, Japan
 Department of Thoracic Surgery, Asahikawa Medical University Hospital, Japan
 Department of Urology of the University of Erlangen-Nuremberg and of the University of Tuebingen, Germany
 Department of Urology, Institute of Human Genetics of the University of Erlangen-Nuremberg, Germany
 Department of Urology, Takaraduka City Hospital, Japan
 Deutsche Forschungsgemeinschaft, Bonn, Germany
 Deutsche Kinderkrebsstiftung, Germany
 Deutsche Krebshilfe, Germany
 Dirección General de Enseñanza Superior e Investigación Científica, Spain
 DOD Breast Cancer Research Programs, U.S.A.
 Dutch Cancer Society, Holland
 EC Marie Curie Training Site Fellowship
 Emmanuel Foundation, U.S.A.
 European Commission, INCO-DEV Programme
 Faculty of Medicine, Uppsala University, Sweden
 Faculty of Medicine, University of Goeteborg, Sweden
 Federal Ministry of Education and Research, Germany
 Financiadora de Estudos e Projetos, Brazil
 Finnish Cancer Foundation
 Finnish Cancer Society, Finland
 Flight Attendant Medical Research Institute, U.S.A.
 Fondazione del Monte, di Bologna e Ravenna, Italy
 Fondo de Investigaciones Sanitarias, Madrid, Spain
 Fondo per gli Investimenti della Ricerca di Base, Italy
 Foundation for Polish Science, Poland
 Foundation for Strategic Environmental Research, Sweden
 Frontier Functional Human Genome Project from the Ministry of Science and Technology of Korea
 Fundação de Amparo á Pesquisa do Estado de São Paulo, Brazil
 German Research Foundation
 GR Goodwill Research
 Grader Foundation, U.S.A.
 Grant Agency of the Ministry of Health of the Czech Republic
 Greek Secretariat of Research and Technology, Greece
 Gunnar, Arvid and Elisabeth Nilsson Foundation, Sweden
 Hamburger Stiftung zur Foerderung der Krebsbekaempfung, Hamburg, Germany
 Health Canada, Vancouver Centre of Excellence for Prostate Cancer Research
 Health Ministry, Hungary
 Helsinki University Central Hospital, Finland
 Hungarian Ministry of Education, Hungary
 Hungarian National Research Fund, Hungary
 Hungarian Scientific Research, Hungary
 IASIS
 IGA, Ministry of Health, Czech Republic
 Immunology Programs, Ohio State University
 Comprehensive Cancer Center, U.S.A.

- Institut Fédératif de Recherche, France
 Institut National de la Santé et de la Recherche Médicale (INSERM, France)
 Institute for Clinical Research, Department of National Hospitals, Ministry of Health, Labour and Welfare of Japan
 Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland
 Instituto de Salud Carlos III
 Italian C.N.R. Project "Methods and Systems to Support Decisions" (MSSD)
 Italian Ministry of Education
- Japan Society for the Promotion of Science, Japan
 Japanese Society of Strategies for Cancer Research and Therapy
 Jean Sindab African American Breast Cancer Project, U.S.A.
 Jesus de Gangoiti Barrera Foundation
 Johannes and Frieda Marohn Foundation, Erlangen, Germany
 John Sealy Memorial Endowment Fund, U.S.A.
 Jubilaeumsfonds der Oesterreichischen National Bank, Austria
 Junta de Andalucia, Spain
- K.A. Johansson Foundation, Finland
 Karl and Veronica Carstens Foundation, Essen, Germany
 Karolinska Institute, Sweden
 Karolinska University Hospital, Sweden
 Keck Foundation, U.S.A.
 Korea Science and Engineering Foundation
 Kuopio University Hospital, Finland
 Kuwait University, Kuwait
 Kyung Hee University Research Fund, Korea
- La Faculté de Médecine de Rennes, France
 La Ligue Contre le Cancer, Comity of Loire-Atlantique, France
 La Ligue Nationale Contre le Cancer, France
 La Ligue Nationale Française de Lutte Contre le Cancer, France
 Laryngeal Foundation, Sweden
 Larynx Foundation, Stockholm, Sweden
 L'Association "Biologie du Cancer et Dynamiques Complexes", France
 L'Association de la Recherche Contre le Cancer, Villejuif, France
- L'Association pour la Recherche Contre le Cancer
 Le Comité 22 and Grand Ouest de la Ligue Contre le Cancer, France
 Lega Italiana per la Lotta Contro i Tumori Sezione Cosenza, Italy
 Lega Italiana per la Lotta Contro i Tumori, Naples, Italy
 Leukemia and Lymphoma Society, U.S.A.
 Ligue Contre le Cancer, France
 Ligue Nationale Contre le Cancer, Comité Du Nord, France
 Ligue Nationale Contre le Cancer, Comité de Paris, France
 L'Institut Français de la Recherche et l'Exploitation de la Mer (IFREMER), France
 Lombardi Cancer Center, U.S.A.
 Lund Health District Organization, Sweden
 Lund University Medical Faculty, Sweden
 Lynne Cohen Foundation, U.S.A.
- Massachusetts Institute of Technology, U.S.A.
 Mauritzen-La Fontaine Family Foundation, Region of Copenhagen, the Faeroe Islands and Greenland
 Mayo Cancer Center, U.S.A.
 M.D. Anderson Core Grant, U.S.A.
 Medical Faculty Lund University, Lund, Sweden
 Medical Faculty, Umeå University, Umeå, Sweden
 Medical University of Bydgoszcz, Poland
 Meltzer Høyskolefond, Felleslegatet til Fordel
 Merck KG aA, Darmstadt, Germany
 Miami Children's Hospital Foundation, Florida, U.S.A.
 Ministère de la Recherche, France
 Ministère de l'Éducation Nationale de la Recherche et de la Technologie, France
 Ministère de l'Éducation Nationale, France
 Ministerio de Ciencia y Tecnología, Spain
 Ministero della Salute, Italy
 Ministero dell'Instruzione, dell'Università e della Ricerca, Italy
 Ministry for Education, University and Research (MIUR) "Progetti di Ricerca di Interesse Nazionale", Italy
 Ministry of Education, Culture, Sports, Science and Technology of Japan
 Ministry of Education, Science and Sports of the Republic of Slovenia
 Ministry of Health, Hungary
 Ministry of Health, Italy
 Ministry of Health, Labor and Welfare, Japan
 Ministry of Health, Social and Family Affairs, Hungary

- Ministry of Informatics and Science, Warsaw, Poland
 Ministry of Science and Technology, Korea
 Ministry of Science, Technology and Environment,
 Malaysia
 MIUR, Rome, Italy
 Molecular Carcinogenesis and Chemoprevention, Ohio
 State University Comprehensive Cancer Center,
 U.S.A.
 Mrs. Berta Kamprad Foundation, Sweden
- National Agency of Scientific and Technological
 Promotion, Argentina
 National Cancer Institute, U.S.A.
 National Consortium of Oncology, Hungary
 National Council for Science and Technology,
 Mexico
 National Development Program for Key Basic
 Research of China
 National Institutes of Health, U.S.A.
 National Research Foundation of South Africa
 National Research Program for Genomic Medicine,
 Taiwan, R.O.C.
 National Science Council of Taiwan, R.O.C.
 National Science Foundation Graduate Research
 Fellowship, U.S.A.
 New Jersey Agricultural Experimentation Station Project,
 U.S.A.
 New Jersey Commission on Cancer Research, U.S.A.
 Norrlands University Hospital, Sweden
 Norwegian Cancer Society, Norway
 Norwegian Ministry of Health, Norway
 Norwegian Research Council, Norway
 Numico Research Netherlands
- Ohio Agricultural Research and Development Center,
 The Ohio State University, U.S.A.
 Oncogene Science/Bayer Health Care
 Oncologia Ca' Granda ONLUS, Milan, Italy
 Origenix Technologies, Inc., Quebec, Canada
 Oxigene, Inc., Waltham, MA, U.S.A.
- Paavo Koistinen Foundation, Finland
 Päijät-Häme Central Hospital, Finland
 Pfizer, Belgium
 Philip Morris U.S.A. Inc. and Philip Morris International
 Phytohealth
 Piedmont Regional Government (Regione Piemonte)
 Polish Foundation for the Development of Pharmaceutical
 Sciences (FRNF)
- Public Health Service, U.S.A.
 Public Trust Surgery Research Fund, Japan
- Red Tematica del Cancer, Instituto de Salud Carlos III,
 Spain
 Region Wallone de Belgique, Belgium
 Research Council of Norway
 Research Section of China Medical University, Taichung
 city, Taiwan, R.O.C.
 Riviera Country Club, IL, U.S.A.
 Robert E. and May R. Wright Foundation, U.S.A.
 Rochester Research Committee, Mayo Foundation,
 U.S.A.
 Roger Williams Medical Center, U.S.A.
 Rudolf-Bartling-Stiftung, Hannover, Deutsche Krebshilfe,
 Bonn, Germany
 Russian Foundation for Basic Research
- Sahlgrenska University Hospital, Sweden
 Sankyo Foundation of Life Science, Japan
 Servicios Tecnicos de Investigacion, Spain
 Sibyl Pharmaceutical Inc., OH, U.S.A.
 Slovak Governmental Research and Development Sub-
 programme
 Slovak Grant Agency VEGA
 Smoking Research Foundation, Japan
 Société Française d' Hématologie, France
 Special Research Fund, Ghent University, Belgium
 State Committee for Scientific Research, Poland
 Stavros Niarchos Foundation for Charity, Greece
 Stockholm Cancer Society, King Gustav V's Jubili-
 um
 Foundation, Sweden
 Stockholm Cancer Society, Sweden
 Stockholm City Council, Sweden
 Stockholm County Council, Sweden
 S.U.S.A.n G. Komen Breast Cancer Foundation, U.S.A.
 Swedish Cancer and Allergy Society
 Swedish Cancer Foundation
 Swedish Cancer Society
 Swedish Council for Environment, Agricultural Sciences
 and Spatial Planning
 Swedish Environmental Protection Agency
 Swedish Medical Research Council
 Swedish Medical Society
 Swedish Research Council
 Szeged Foundation of Cancer Research, Hungary
- Taichung Veterans General Hospital Research Program,
 Taiwan, R.O.C.

Texas Advanced Technology Program, U.S.A.
The Concern Foundation, Los Angeles, U.S.A.
The Science and Technology Foundation, Portugal
The Susan G. Komen Breast Cancer Foundation,
U.S.A.
The Welch Foundation, Waltham, MA, U.S.A.
Tobacco-Related Disease Research Program,
University of California, U.S.A.
Tokyo Ri-Igaku Kenjkyujo, Japan
Tor Vergata University of Rome, Italy
Tri-Service General Hospital, Taiwan, R.O.C.
Turku University Central Hospital, Finland
Turku University Hospital Clinical Research Foundation,
Finland

Uehara Memorial Foundation, Japan
UICC International Cancer Technology Transfer
Fellowship

United States Department of Defense
Universidad de Jaen, Spain
University Grant Commission, New Delhi and Rameswar
Das Birla Smarak Kosh, Mumbai, India
University Hospital of Heraklion, Crete, Greece
University of Graz, Austria
University of Louisville Brown Cancer Center, U.S.A.
University of Occupational and Environmental Health,
Kitakyushu, Japan
University of the Basque Country

Veterans Administration Merit Review, U.S.A.
Veterans General Hospital, Taiwan, R.O.C.
Virginia Commonwealth University, U.S.A.

Werner und Klara Kreitz-Stiftung, Germany
Wilhelm Sander-Stiftung, Germany

Contents, Volume 25, 2005

Number 1A

Experimental Studies

Androgen and Androgen Receptor Antagonist Responsive Primary African-American Benign Prostate Epithelial Cell Line. Y. GU, K.-H. KIM, D. KO, S. SRIVASTAVA, J.W. MOUL, D.G. MCLEOD, J.S. RHIM (<i>Bethesda, MD; Washington, DC, USA</i>)	1
Preparation and Preclinical Assessment of Folate-conjugated, Radiolabelled Antibodies. G. HENRIKSEN, Ø.S. BRULAND, R.H. LARSEN (<i>Oslo, Norway</i>)	9
Tyrosine Kinase Inhibitor SU6668 Inhibits Peritoneal Dissemination of Gastric Cancer <i>Via</i> Suppression of Tumor Angiogenesis. J. TOKUYAMA, T. KUBOTA, Y. SAIKAWA, M. YOSHIDA, T. FURUKAWA, Y. OTANI, K. KUMAI, M. KITAJIMA (<i>Tokyo, Japan</i>)	17
Surface Expression and CEA Binding of hnRNP M4 Protein in HT29 Colon Cancer Cells. L. LAGUINGE, O. BAJENOVA, E. BOWDEN, J. SAYYAH, P. THOMAS, H. JUHL (<i>Washington, DC; Boston, MA, USA; Hamburg, Germany</i>)	23
Radionuclide Imaging of Tumor Xenografts in Mice Using a Gelatinase-targeting Peptide. O.P. MEDINA, K. KAIREMO, H. VALTANEN, A. KANGASNIEMI, S. KAUKINEN, I. AHONEN, P. PERMI, A. ANNILA, M. SNECK, J.M. HOLOPAINEN, S.-L. KARONEN, P.K.J. KINNUNEN, E. KOIVUNEN (<i>Helsinki, Finland</i>).....	33
Preclinical Studies Comparing Different Bispecific Antibodies for Redirecting T Cell Cytotoxicity to Extracellular Antigens on Prostate Carcinomas. H. E. LUM, M. MILLER, P.A. DAVOL, R.C. GRABERT, J.B. DAVIS, L.G. LUM (<i>Madison, WI; Oneonta, NY; Providence, RI; Boston, MA, USA</i>)	43
A Comparison of Response to Cisplatin, Radiation and Combined Treatment for Cells Deficient in Recombination Repair Pathways. G.P. RAAPHORST, J. MAUDE LEBLANC, L.F. LI (<i>Ottawa, Ont., Canada</i>)	53
A Rapid HPLC Method for the Measurement of Ultra-low Plasma Methionine Concentrations Applicable to Methionine Depletion Therapy. X. SUN, Y. TAN, Z. YANG, S. LI, R.M. HOFFMAN (<i>San Diego, CA, USA</i>) ...	59
Role of p21 ^{WAF1} in Green Tea Polyphenol-induced Growth Arrest and Apoptosis of Oral Carcinoma Cells. S. HSU, K. FARREY, J. WATAHA, J. LEWIS, J. BORKE, B. SINGH, H. QIN, C. LAPP, D. LAPP, T. NGUYEN, G. SCHUSTER (<i>Augusta; Albany, GA, USA</i>)	63
Gene Transfer of Inhibitor KappaB in Human Lung Cancer Cell Line NCI-H460 Inhibits Tumorigenesis and Angiogenesis <i>In Vivo</i> . J. NI, K. TAKAYAMA, N. INOSHIMA, J. UCHINO, A. HARADA, T. MINAMI, T. HARADA, C. ZHOU, Y. NAKANISHI (<i>Fukuoka, Japan; Shanghai, China</i>).....	69
The Relationship Between Bone Metastasis from Human Breast Cancer and Integrin $\alpha_v\beta_3$ Expression. S. TAKAYAMA, S. ISHII, T. IKEDA, S. MASAMURA, M. DOI, M. KITAJIMA (<i>Tokyo; Kanagawa-ken, Japan</i>).....	79
Tumor-draining Lymph Nodes of Primary Lung Cancer Patients: A Potent Source of Tumor-specific Killer Cells and Dendritic Cells. H. KIMURA, K. DOBRENKOV, T. IIDA, M. SUZUKI, S. ANDO, N. YAMAMOTO (<i>Chiba, Japan</i>)	85
ET-18-OCH3 Inhibits the Phosphorylation and Activation of p70 S6 Kinase in MCF-7 Cells. G. ARTHUR, P. SAMADDER, R. BITTMAN (<i>Winnipeg, Manitoba, Canada; Flushing, NY, USA</i>).....	95

Blockage of Cyclin cdk's, PKC and Phosphoinositol 3-kinase Pathways Leads to Augmentation of Apoptosis in Drug-resistant Leukemia Cells: Evidence for Interactive Effects of Flavopiridol, LY 294002, Roscovitine, Wortmannin and UCN-01. A.H. CORY, L. SOMERVILLE, J.G. CORY (Greenville, NC, USA)	101
The Effect of Cyclooxygenase-2 (COX-2) Inhibition on Human Prostate Cancer-induced Osteoblastic and Osteolytic Lesions in Bone. S.C. GAMRADT, B.T. FEELEY, N.Q. LIU, J. ROOSTAEIAN, Y.Q. LIN, L.X. ZHU, S. SHARMA, S.M. DUBINETT, J.R. LIEBERMAN (Los Angeles, CA, USA)	107
<i>In Vitro</i> Antimutagenicity of Capsaicin Toward Heterocyclic Amines in <i>Salmonella typhimurium</i> Strain TA98. H.T. HUYNH, R.W. TEEL (La Jolla; Loma Linda, CA, USA)	117
Pituitary Tumor-transforming Gene (PTTG): A Novel Target for Anti-tumor Therapy. C. SOLBACH, M. ROLLER, S. PETERS, M. NICOLETTI, M. KAUFMANN, R. KNECHT (Frankfurt am Main, Germany)	121
Wogonin Inhibits N-acetyltransferase Activity and Gene Expression in Human Leukemia HL-60 Cells. C.-S. YU, F.-S. YU, Y.-C. CHUANG, H.-F. LU, S.-Y. LIN, T.-H. CHIU, J.-G. CHUNG (Taichung; Taipei; Taiwan)	127
Roxithromycin Inhibits Angiogenesis of Human Hepatoma Cells <i>In Vivo</i> by Suppressing VEGF Production. D. AOKI, S. UENO, F. KUBO, T. OYAMA, T. SAKUTA, K. MATSUSHITA, I. MARUYAMA, T. AIKOU (Kagoshima, Japan)	133
Apoptosis of Human Prostate Androgen-dependent and -independent Carcinoma Cells Induced by an Isopropanolic Extract of Black Cohosh Involves Degradation of Cytokeratin (CK) 18. K. HOSTANSKA, T. NISSLEIN, J.FREUDENSTEIN, J. REICHLING, R. SALLER (Zürich, Switzerland; Salzgitter; Heidelberg, Germany)	139
Optimal Drug and Gene Delivery in Cancer Cells by Ultrasound-induced Cavitation. I.V. LARINA, B. MARK EVERS, R.O. ESENALIEV (Galveston, TX, USA)	149
Paradoxical Effect of Cytosine Arabinoside on Mouse Leukemia Cell Line L ₁₂₁₀ Cells. T. NAKAYAMA, S. SAKAMOTO, S. SASSA, S. SUZUKI, H. KUDO, H. NAGASAWA (Tokyo, Japan)	157
Hydroquinone-induced Apoptosis in HL-60 Cells. H. TERASAKA, S. REZA M.D. MORSHED, K. HASHIMOTO, H. SAKAGAMI, S. FUJISAWA (Saitama, Japan)	161
Involvement of Angiopoietins in Cancer Progression in Association with Cancer Cell – Fibroblast Interaction. E. MARUYAMA, T. SAKAMOTO, H. AZUMA, Y. ITO, Y. KATSUOKA, Y. OTSUKI (Osaka, Japan)	171
HBME-1 Expression in Follicular Tumor of the Thyroid: an Investigation of Whether it Can be Used as a Marker to Diagnose Follicular Carcinoma. Y. ITO, H. YOSHIDA, C. TOMODA, A. MIYA, K. KOBAYASHI, F. MATSUZUKA, K. KAKUDO, K. KUMA, A. MIYAUCHI (Wakayama, Japan)	179
Identification of Metastasis-associated Genes in Prostate Cancer by Genetic Profiling of Human Prostate Cancer Cell Lines. L. TROJAN, A. SCHAAF, A. STEIDLER, M. HAAK, G. THALMANN, T. KNOLL, N. GRETZ, P. ALKEN, M.S. MICHEL (Mannheim, Germany; Bern, Switzerland)	183
Serum Enkephalin-degrading Aminopeptidase Activity in N-Methyl Nitrosourea-induced Rat Breast Cancer. M.P. CARRERA, M.J. RAMÍREZ-EXPÓSITO, M.T. VALENZUELA, B. DUEÑAS, M.J. GARCÍA, M.D. MAYAS, J.M. MARTÍNEZ-MARTOS (Jaén; Granada; Spain)	193
Antiangiogenesis and Anticancer Efficacy of TA138, a Novel $\alpha\beta 3$ Antagonist. S.A. MOUSA, S. MOHAMED, E.J. WEXLER, J.S. KERR (Albany, NY; West Point, PA, USA)	197
Digoxin Inhibits Neuroblastoma Tumor Growth in Mice. E. SVENSSON, F. AZARBAYJANI, U. BÄCKMAN, T. MATSUMOTO, R. CHRISTOFFERSON (Uppsala, Sweden)	207

Comparative Assessment of the Functional p53 Status in Glioma Cells. E.L. KIM, K. YOSHIZATO, L. KLUWE, H. MEISSNER, G. WARNECKE, S. ZAPF, M. WESTPHAL, W. DEPPERT, A. GIESE (Lübeck; Hamburg, Germany)	213
Growth Inhibitory Effect of Celecoxib and Rofecoxib on Human Colorectal Carcinoma Cell Lines. B. BUECHER, D. BOUANCHEAU, A. BROQUET, S. BEZIEAU, M.G. DENIS, C. BONNET, M.-F. HEYMANN, A. JARRY, J.-P. GALMICHE, H.M. BLOTTIÈRE (Nantes, France)	225
1,24(S)-Dihydroxyvitamin D ₂ , an Endogenous Vitamin D ₂ Metabolite, Inhibits Growth of Breast Cancer Cells and Tumors. G.M. ZINSER, E. TRIBBLE, M. VALRANCE, C.M. URBEN, J.C. KNUTSON, R.B. MAZESS, S.A. STRUGNELL, J. WELSH (Notre Dame, IN; Middleton, WI, USA)	235
Progesterone Induces BRCA1 mRNA Decrease, Cell Cycle Alterations and Apoptosis in the MCF7 Breast Cancer Cell Line. Y. ANSQUER, A. LEGRAND, A.-F. BRINGUIER, N. VADROT, B. LARDEUX, L. MANDELBROT, G. FELDMANN (Paris; Colombes Cedex, France)	243
Action of Fenretinide (4-HPR) on Ovarian Cancer and Endothelial Cells. V. GOLUBKOV, A. GARCIA, F.S. MARKLAND (Los Angeles, CA, USA)	249
Consequences of Chemoresistance for the Herpes Simplex Virus Thymidine Kinase/Ganciclovir-induced Bystander Effect in a Human Small Cell Lung Cancer Cell Line Model. I.J. VAN DILLEN, N.H. MULDER, W.J. SLUITER, C. MEIJER, S. DE JONG, J. LONCAREK, M. MESNIL, E.F.J. DE VRIES, W. VAALBURG, G.A.P. HOSPERS (Groningen, The Netherlands; Zagreb, Croatia; Poitiers Cedex, France)	255
Protein Expression and Gene Copy Number Analysis of Topoisomerase 2 α , HER2 and P53 in Minimally Invasive Urothelial Carcinoma of the Urinary Bladder – a Multitissue Array Study with Prognostic Implications. S KRÜGER, I. LANGE, I. KAUSCH, A.C. FELLER (Lübeck, Germany)	263
Cyclin D1 Overexpression is Associated with Estrogen Receptor Expression in Caucasian but not African-American Breast Cancer. A.K. JOE, L. MEMEO, J. McKOY, M. MANSUKHANI, H. LIU, A. AVILA-BRONT, J. ROMERO, H. LI, A. TROXEL, H. HIBSHOOSH (New York, NY, USA)	273
Protection by Antioxidants of Copper-induced Decline of Proliferation and SOD Activity. N. KINOSHITA, K. HASHIMOTO, T. YAMAMURA, H. TERANUMA, T. KOIZUMI, K. SATOH, T. KATAYAMA, H. SAKAGAMI (Saitama; Tokyo, Japan)	283
Photochemical Enhancement of Gene Delivery to Glioblastoma Cells is Dependent on the Vector Applied. A. BONSTED, A. HØGSET, F. HOOVER, K. BERG (Oslo; Bergen, Norway)	291
Vaccination of Apoptotic Fas Ligand-expressing Tumors Decreased Antitumor Responses by Enhanced Production of Immunosuppressive Cytokines. A. WADA, Y. TADA, O. SHIMOZATO, Y. TAKIGUCHI, K. TATSUMI, T. KURIYAMA, M. TAGAWA (Chiba, Japan)	299
Cytotoxic Activity of Azulenequinones Against Human Oral Tumor Cell Lines. H. WAKABAYASHI, M. NISHISHIRO, S. ARIKAWA, K. HASHIMOTO, H. KIKUCHI, H. NISHIKAWA, T. KURIHARA, S. TERAUBO, Y. SHOJI, H. NAKASHIMA, N. MOTOHASHI, H. SAKAGAMI (Saitama; Kanagawa; Tokyo, Japan)	305
A Sesquiterpenelactone from <i>Inula britannica</i> Induces Anti-tumor Effects Dependent on Bcl-2 Phosphorylation. M.M. RAFI, N.-S. BAI, C.-T. HO, R.T.ROSEN, E. WHITE, D. PEREZ, R.S. DIPAOLA (New Brunswick; Piscataway NJ, USA)	313
A Novel Chromatographic Method for Ep-CAM mRNA Detection in Peripheral Blood and Bone Marrow of Patients with Metastatic Colorectal Cancer. C. KARANIKIOTIS, I. SKIADAS, M. KARINA, S. GEORGAKOPOULOU, E. GEORGAKOPOULOS, G. FOUNTZILAS (Athens; Thessaloniki, Greece)	319

Growth Inhibitory Effect of the Somatostatin Structural Derivative (TT-232) on Leukemia Models. M. TEJEDA, D. GAAL, O. CSUKA, GY. KÉRI (<i>Budapest, Hungary</i>)	325
Preclinical Safety, Pharmacokinetics and Antitumor Efficacy Profile of Liposome-entrapped SN-38 Formulation. A. PAL, S. KHAN, Y.-F. WANG, N. KAMATH, A.K. SARKAR, A. AHMAD, S. SHEIKH, S. ALI, D. CARBONARO, A. ZHANG, I. AHMAD (<i>Waukegan, IL, USA</i>)	331
<i>In Vivo</i> Antitumor Activity of Folate Receptor-targeted Liposomal Daunorubicin in a Murine Leukemia Model. X.Q. PAN, R.J. LEE (<i>Columbus, OH, USA</i>)	343
* B-cell Differentiation, Apoptosis and Proliferation in Diffuse Large B-cell Lymphomas. M. BAI, A. SKYRLAS, N.J. AGNANTIS, S. KAMINA, A. PAPOUDOU-BAI, P. KITSOULIS, P. KANAVAROS (<i>Ioannina, Greece</i>)	347
Induction of Apoptosis in Human Promyelocytic Leukemia Cells by a Natural Trachylobane Diterpene. S. BLOCK, P. GERKENS, O. PEULEN, O. JOLOIS, M.-P. MINGEOT-LECLERCQ, M.-CL. DE PAUW-GILLET, J. QUETIN-LECLERCQ (<i>Bruxelles; Liège, Belgium</i>)	363
Caveolin-1 Down-regulation Activates Estrogen Receptor Alpha Expression and Leads to 17 β -Estradiol-stimulated Mammary Tumorigenesis. X. ZHANG, P. SHEN, M. COLEMAN, W. ZOU, B.W. LOGGIE, L.M. SMITH, Z. WANG (<i>Omaha, NE; Bothell, WA, USA; Hangzhou; Dalian, China</i>)	369
Cadherin-6 Gene Expression in Conventional Renal Cell Carcinoma: A Useful Marker to Detect Circulating Tumor Cells. G. LI, K. PASSEBOSC-FAURE, A. GENTIL-PERRET, C. LAMBERT, C. GENIN, J. TOSTAIN (<i>Saint-Etienne, France</i>)	377
Human Sarcoma Cell Lines MES-SA and MES-SA/Dx5 as a Model for Multidrug Resistance Modulators Screening. O. WESOŁOWSKA, M. PAPROCKA, J. KOZLAK, N. MOTOHASHI, D. DUS, K. MICHALAK (<i>Wroclaw, Poland; Tokyo, Japan</i>)	383
Induction of Apoptosis by Sodium Fluorosilicate Treatment in Human Osteogenic Sarcoma (HOS) Cells. J.S. SONG, Y.D. PARK, J.W. HYUN, J.H. KIM (<i>Seoul; Jeju, Korea</i>)	391
Novel D-ring Analog of Epigallocatechin-3-gallate Inhibits Tumor Growth and VEGF Expression in Breast Carcinoma Cells. N. S. WALEH, W.-R. CHAO, A. BENSARI, N.T. ZAVERI (<i>Menlo Park, CA, USA</i>)	397
* Review (page 347)	

Number 1B

Clinical Studies

Plasma von Willebrand Factor Antigen Levels in Non-small Cell Lung Cancer Patients. F. MARTINI, P. FERRONI, F. GUADAGNI, S. BASILI, A. SPILA, R. D'ALESSANDRO, D. MINEO, A. LAUDISI, I. PORTARENA, S. MARIOTTI, V. AMBROGI, T.C. MINEO, M. ROSELLI (<i>Rome, Italy</i>)	403
Paclitaxel Plus Gemcitabine in Advanced Non-small Cell Lung Cancer Patients with Low Performance Status. F. RECCHIA, G. SAGGIO, A. CESTA, G. CANDELORO, S. REA (<i>Avezzano; Rome; L'Aquila, Italy</i>)	409
Sudden Onset of Interstitial Lung Disease Induced by Gefitinib in a Lung Cancer Patient with Multiple Drug Allergy. K. AOE, A. HIRAKI, T. MURAKAMI, T. MAEDA, Y. UMEMORI, H. KATAYAMA, R. EDA, H. TAKEYAMA (<i>Ube, Yamaguchi, Japan</i>)	415

The Influence of Surgical Volume on Hospital Mortality and 5-Year Survival for Carcinoma of the Oesophagus and Gastric Cardia. J. WENNER, T. ZILLING, A. BLADSTRÖM, T.A. ALVEGARD (<i>Lund, Sweden</i>)	419
High Exposure to Polycyclic Aromatic Hydrocarbons May Contribute to High Risk of Esophageal Cancer in Northeastern Iran. F. KAMANGAR, P.T. STRICKLAND, A. POURSHAMS, R. MALEKZADEH, P. BOFFETTA, M.J. ROTH, C.C. ABNET, M. SAADATIAN-ELAHI, N. RAKHSHANI, P. BRENNAN, A. ETEMADI, S.M. DAWSEY (<i>Bethesda; Baltimore, MD, USA; Tehran, Iran; Lyon Cedex, France</i>)	425
Development of Malignant Mesothelioma During Treatment for Prolymphocytic Leukemia: Is Asbestos or Simian Virus 40 a Link? T. TANVETYANON, A.G. ELMISHAD, M. CARBONE (<i>Maywood, IL, USA</i>).....	429
Analysis of the Response and Toxicity to Gefitinib of Non-small Cell Lung Cancer. J. KONISHI, K. YAMAZAKI, I. KINOSHITA, H. ISOBE, S. OGURA, S. SEKINE, T. ISHIDA, R. TAKASHIMA, M. NAKADATE, S. NISHIKAWA, T. HATTORI, H. ASAHINA, M. IMURA, E. KIKUCHI, J. KIKUCHI, N. SHINAGAWA, H. YOKOUCHI, M. MUNAKATA, H. DOSAKA-AKITA, M. NISHIMURA (<i>Sapporo; Fukushima, Japan</i>)	435
Effects of PSK on T and Dendritic Cells Differentiation in Gastric or Colorectal Cancer Patients. M. KANAZAWA, K. YOSHIHARA, H. ABE, M. IWADATE, K. WATANABE, S. SUZUKI, Y. ENDOH, K.-I. TAKITA, K. SEKIKAWA, S. TAKENOSHITA, T. OGATA, H. OHTO (<i>Fukushima, Japan</i>).....	443
Circulating Hormone Levels in Breast Cancer Patients. Correlation with Serum Tumor Markers and the Clinical and Biological Features of the Tumors. L. HERNÁNDEZ, M.-J. NUÑEZ-VILLAR, F. MARTÍNEZ-ARRIBAS, M. POLLÁN, J. SCHNEIDER (<i>Madrid; Toledo, Spain</i>).....	451
Adenoid Cystic Carcinoma of the Breast: Truly Uncommon or Easily Overlooked? S.-M. SHEEN-CHEN, H.-L. ENG, W.-J. CHEN, Y.-F. CHENG, S.-F. KO (<i>Kaohsiung Hsien, Taiwan, ROC</i>)	455
Occult Cancer Detected by Positron Emission Tomography/Computed Tomography Image Fusion. S.-I. WATANABE, D. TANAKA, Y. NAKAMURA, K. KARIATSUMARI, K. FUKUMORI, J. OHKUBO, R. SAKATA, K. TAKAGI (<i>Kagoshima; Tokyo, Japan</i>).....	459
Role of Tumor-associated Macrophages (TAM) in Advanced Gastric Carcinoma: The Impact on FasL-mediated Counterattack. S. OHNO, H. INAGAWA, D.K. DHAR, T. FUJII, S. UEDA, M. TACHIBANA, Y. OHNO, N. SUZUKI, M. INOUE, G.-I. SOMA, N. NAGASUE (<i>Ishikawa; Shimane; Tokushima; Chiba, Japan</i>).....	463
Efficacy of Gemcitabine – Cisplatin Treatment in Stage IIIA ("bulky"N2), IIIB and IV Non-small Cell Lung Cancer. G. OSTOROS, K. SZONDY, E. GERGELY-FARNOS, P. MAGYAR, J. STRAUSZ, E. FERENCZI, G. KOVÁCS (<i>Budapest, Hungary</i>)	471
Continuous Hepatic Arterial Infusion Chemotherapy for Liver Metastasis from Biliary Tract and Pancreatic Cancers. Y. KATO, A. TSUYUKI, K. KIKUCHI, J. TOKUYAMA, N. KURIHARA, Y. KUMAMOTO, Y. FUJISHIRO, H. EBINUMA (<i>Tokyo, Japan</i>)	477
A Computer-aided Diagnosis (CAD) System in Lung Cancer Screening with Computed Tomography. Y. ABE, K. HANAI, M. NAKANO, Y. OHKUBO, T. HASIZUME, T. KAKIZAKI, M. NAKAMURA, N. NIKI, K. EGUCHI, T. FUJINO, N. MORIYAMA (<i>Kanagawa; Tokushima; Tokyo, Japan</i>)	483
Serum Tenascin-C as a Potential Predictive Marker of Angiogenesis in Non-small Cell Lung Cancer. T. ISHIWATA, K. TAKAHASHI, Y. SHIMANUKI, R. OHASHI, R. CUI, F. TAKAHASHI, K. SHIMIZU, K. MIURA, Y. FUKUCHI (<i>Tokyo, Japan</i>)	489
A Risk Model for Non-small Cell Lung Cancer Using Clinicopathological Variables, Angiogenesis and Oncoprotein Expression. L. RUBIO, F.J. VERA-SEMPERE, J.A. LOPEZ-GUERRERO, J. PADILLA, M.J. MORENO-BAYLACH (<i>Valencia, Spain</i>)	497

Malignant Fibrous Histiocytoma of the Breast. Report of Two Cases and Review of the Literature. A. DE CESARE, E. FIORI, A. BURZA, A. CIARDI, M. BONONI, L. IZZO, P. VOLPINO, A. CAVALLARO, V. CANGEMI (<i>Rome, Italy</i>)	505
Telomerase Activity in Thyroid Neoplasms Evaluated by the Expression of Human Telomerase Reverse Transcriptase (hTERT). Y. ITO, H. YOSHIDA, C. TOMODA, T. URUNO, Y. TAKAMURA, A. MIYA, K. KOBAYASHI, F. MATSUZUKA, K. KUMA, A. MIYAUCHI (<i>Kobe, Japan</i>)	509
Epithelial Splenic Cysts. I. PALMIERI, E. NATALE, F. CRAFA, A. CAVALLARO, P.L. MINGAZZINI (<i>Rome, Italy</i>)	515
Acute Myopathy in a Patient with Lung Adenocarcinoma Treated with Gemcitabine and Docetaxel. A.S. ARDAVANIS, G.N. IOANNIDIS, G.A. RIGATOS (<i>Athens, Greece</i>)	523
Metastatic Rhabdomyosarcoma to the Breast. S.-M. SHEEN-CHEN, H.-L. ENG, S.-F. KO (<i>Kaohsiung Hsien, Taiwan, ROC</i>)	527
Stressful and Adverse Life Experiences in Patients with Breast Symptoms; a Prospective Case-control Study in Kuopio, Finland. P. OLLONEN, J. LEHTONEN, M. ESKELINEN (<i>Kuopio, Finland</i>)	531
Polymorphisms in the DNA Base Excision Repair Genes <i>APEX1</i> and <i>XRCC1</i> and Lung Cancer Risk in Xuan Wei, China. M. SHEN, S.I. BERNDT, N. ROTHMAN, J.L. MUMFORD, X. HE, M. YEAGER, R. WELCH, S. CHANOCK, P. KEOHAVONG, M. DONAHUE, T. ZHENG, N. CAPORASO, Q. LAN (<i>Bethesda, MD; Research Triangle Park, NC; Pittsburgh, PA; New Haven, CT, USA; Beijing, China</i>)	537
Poor Oral Health as a Risk Factor for Esophageal Squamous Dysplasia in Northeastern Iran. A. SEPEHR, F. KAMANGAR, S. FAHIMI, F. SAIDI, C.C. ABNET, S.M. DAWSEY (<i>Bethesda, MD; Boston, MA, USA; Lyon Cedex, France; Tehran, Iran</i>)	543
Gefitinib ('Iressa', ZD1839) May Restore Chemosensitivity in NSCLC Patients? K. FUJIWARA, K. KIURA, K. GEMBA, Y. OGATA, K. HOTTA, D. KISHINO, M. TABATA, H. UEOKA, M. TANIMOTO (<i>Okayama, Japan</i>)	547
* Prostate Cancer Therapy: Standard Management, New Options and Experimental Approaches. L. TROJAN, K. KIKNAVELIDZE, T. KNOLL, P. ALKEN, M.S. MICHEL (<i>Mannheim, Germany</i>)	551
* FOLFOX Versus FOLFIRI: A Comparison of Regimens in the Treatment of Colorectal Cancer Metastases. L.M. PASETTO, A. JIRILLO, G. IADICICCO, E. ROSSI, M.K. PARIS, S. MONFARDINI (<i>Padova, Italy</i>)	563
Gn-RH Antagonist Possible Response, After Gn-RH Agonist Failure in a Man with Metastatic Prostate Cancer. B. ROCCO, M. FERRARI, E. SCARDINO, D.V. MATEI, F. VERWEIJ, R. VARELA, O. DE COBELLI (<i>Milan, Italy</i>)	577
Synchronous Collecting Duct Carcinoma and Papillary Renal Cell Carcinoma: A Case Report and Review of the Literature. D.-V. MATEI, B. ROCCO, R. VARELA, F. VERWEIJ, E. SCARDINO, G. RENNE, O. DE COBELLI (<i>Milan, Italy</i>)	579
Immunohistochemical Staining of Cathepsins B, L and Stefin A in Human Hypophysis and Pituitary Adenomas. T.J. STROJNIK, T.T. LAH, B. ŽIDANIK (<i>Maribor; Ljubljana, Slovenia</i>)	587
Color-Doppler Using Contrast Medium in Evaluating the Response to Neoadjuvant Treatment in Patients with Locally Advanced Breast Carcinoma. P. VALLONE, R. D'ANGELO, S. FILICE, T. PETROSINO, M. RINALDO, A. DE CHIARA, A. GALLIPOLI (<i>Naples, Italy</i>)	595

Influence of Complementary <i>Viscum album</i> (Iscador®) Administration on Microcirculation and Immune System of Ear, Nose and Throat Carcinoma Patients Treated with Radiation and Chemotherapy. R. KLOPP, W. SCHMIDT, E. WERNER, M. WERNER, W. NIEMER, J. BEUTH (<i>Greifswald; Koeln, Germany; Arlesheim, Switzerland</i>)	601
Correlation Between Serum Estradiol/Progesterone Ratio and Survival Length in Invasive Squamous Cell Cervical Cancer. D. HELLBERG, A.K. LINDSTRÖM, U. STENDAHL (<i>Falun; Bjursås; Umeå, Sweden</i>)	611
CD44v6 as a Prognostic Factor in Cervical Carcinoma FIGO Stage IB. J. BOUDA, L. BOUDOVA, O. HES, M. HAVIR, C. TEMPFER, P. KOHLBERGER, T. SVOBODA, Z. ROKYTA, P. SPEISER (<i>Plzeň, Czech Republic; Freiburg, Germany; Vienna, Austria</i>)	617
Tissue Inhibitor of Metalloproteinases-4 is Expressed in Cervical Cancer Patients. F. LIZARRAGA, M. ESPINOSA, V. MALDONADO, J. MELENDEZ-ZAJGLA (<i>Mexico, D.F. Mexico</i>)	623
Addition of Oxaliplatin to Neo-adjuvant Radiochemotherapy for Irresectable Rectal Cancer, a Phase I Study. O. REERINK, N.H. MULDER, R.C.J. VERSCHUEREN, T. WIGGERS, B.G. SZABO, G.A.P. HOSPERS (<i>Groningen, The Netherlands</i>)	629
Four Tumour Markers for Urinary Bladder Cancer – Tissue Polypeptide Antigen (TPA), HER-2/neu (ERBB2), Urokinase-type Plasminogen Activator Receptor (uPAR) and TP53 Mutation. T.H. ECKE, H.H. SCHLECHTE, G. SCHULZE, S.V. LENK, S.A. LOENING (<i>Bad Saarow; Berlin, Germany</i>)	635
The Spleen Plays an Immunosuppressive Role in Patients with Gastric Cancer: Involvement of CD62L+ Cells and TGF-beta. K. NOMA, Y. YAMAGUCHI, R. OKITA, K. MATSUURA, T. TOGE (<i>Hiroshima, Japan</i>)	643
Pneumocystis <i>Carinii</i> pneumonia in Patients with Solid Tumors and Lymphomas: Predisposing Factors and Outcome. V. BARBOUNIS, G. APERIS, E. GAMBLETSAS, G. KOUMAKIS, M. DEMIRIS, M. VASSILOMANOLAKIS, A. EFREMIDIS (<i>Athens, Greece</i>)	651
Persistence of K-ras Mutations in Plasma after Colorectal Tumor Resection. U. LINDFORSS, H. ZETTERQUIST, N. PAPADOGIANNAKIS, H. OLIVECRONA (<i>Huddinge; Stockholm, Sweden</i>)	657
High-dose Alkylating Agents with Autologous Hematopoietic Stem Cell Support and Trastuzumab in ERBB2 Overexpressing Metastatic Breast Cancer: A Feasibility Study. A. GONÇALVES, A.C. BRAUD, F. VIRET, C. TARPIN, E. CHARAFFE-JAUFFRET, J. JACQUEMIER, D. MARANINCHI, P. VIENS (<i>Marseille, France</i>)	663
A New Dose-intense Epoetin Alfa Regimen Effective in Anemic Cancer Patients Receiving Chemotherapy: An Open-label, Non Randomized, Pilot Study. D. SANTINI, B. VINCENZI, A. LA CESA, V. VIRZI, F. NAVAJAS, V. MALAFARINA, G. DICUONZO, R. CASSANDRO, V. ESPOSITO, V. MONTESARCHIO, A.M. GROEGER, G. TONINI (<i>Rome; Naples, Italy; Silver Spring, MD, USA; Vienna, Austria</i>)	669
Differential Cyclooxygenase-2 Enzyme Expression in Radiosensitive versus Radioresistant Glioblastoma Multiforme Cell Lines. A. KARIM, K. MCCARTHY, A. JAWAHAR, D. SMITH, B. WILLIS, A. NANDA (<i>Shreveport, LA, USA</i>)	675
Errata	681

* Reviews (pages 551, 563)

Number 2A

Experimental Studies

Immunophenotypic and Molecular Cytogenetic Features of the Cell Line UP-LN1 Established from a Lymph Node Metastasis of a Poorly-differentiated Carcinoma. C.T.-R. CHANG, W.-H. WENG, A. S.-B. CHOU, C.-K. CHUANG, A. PORWIT-MCDONALD, S.-T. PANG, C. LARSSON, S.-K. LIAO (*Taoyuan, Taiwan, ROC; Stockholm, Sweden*)..... 683

The Role of Macrophages in Angiogenesis. Comparison Between HIV+ and HIV- Populations with Anal Dysplasia and Anal Cancer. J. MULLERAT, C.W. PERRETT, F. DEROIDE, M.C. WINSLET, M. BOFILL, L.W. POULTER (*London, UK; Badalona, Spain*)..... 693

A Potential Role for Vascular Endothelial Growth Factor-D as an Autocrine Growth Factor for Human Breast Carcinoma Cells. M. AKAHANE, T. AKAHANE, A. SHAH, E. OKAJIMA, U.P. THORGEIRSSON (*Bethesda, MD, USA; Tokyo, Japan*)..... 701

Involvement of Proinflammatory Cytokines IL-1 β and IL-6 in Progression of Human Gastric Carcinoma. H. KAI, Y. KITADAI, M. KODAMA, S. CHO, T. KURODA, M. ITO, S. TANAKA, Y. OHMOTO, K. CHAYAMA (*Hiroshima; Tokushima, Japan*)..... 709

Stimulation of Human T Cells by an Influenza A Vector Expressing a CTL Epitope from the HER-2/neu Protooncogene Results in Higher Numbers of Antigen-specific TCR^{hi} Cells than Stimulation with Peptide. Divergent Roles of IL-2 and IL-15. C.L. EFFERSON, K. KAWANO, N. TSUDA, P. PALESE, A. GARCÍA-SASTRE, C.G. IOANNIDES (*Houston, TX; New York, NY, USA*) 715

Carboxyamido-triazole (CAI) Reverses the Balance between Proliferation and Apoptosis in a Rat Bladder Cancer Model. F.G.E. PERABO, A.W. DEMANT, A. WIRGER, D.H. SCHMIDT, M. SITIA, E. WARDELMANN, S.C. MÜLLER, E.C. KOHN (*Bonn; Lübeck, Germany; Bethesda, MD, USA*) 725

WNT5A Expression in Human Breast Cancer. A.C.A. LERIS, T.R. ROBERTS, W.G. JIANG, R.F. NEWBOLD, K. MOKBEL (*London; Uxbridge; Middlesex; Cardiff, UK*)..... 731

Paclitaxel Inhibits Natural Killer Cell Binding to Target Cells by Down-regulating Adhesion Molecule Expression. O. LOUBANI, D.W. HOSKIN (*Halifax, Nova Scotia, Canada*)..... 735

Effect of Low-dose Tumor Necrosis Factor- α in Combination with STEALTH[®] Liposomal Cisplatin (SPI-077) on Soft-tissue- and Osteosarcoma-bearing Rats. S. HOVING, S.T. VAN TIEL, A.M.M. EGGERMONT, T.L.M. TEN HAGEN (*Rotterdam, The Netherlands*)..... 743

The Expression of Integrin α v β 6 Promotes the Epithelial Cell Morphology and Suppresses Invasive Behavior in Transformed Oral Keratinocytes. S. MOGI, D. DANG, C. VAN WAES, D. ELLIS, A. ATAKILIT, D.M. RAMOS (*San Francisco, CA; Bethesda, MD, USA*)..... 751

Thrombospondin-1 (TSP-1) and TSP-1-derived Heparin-binding Peptides Induce Promyelocytic Leukemia Cell Differentiation and Apoptosis. A. BRUEL, M. TOUHAMI-CARRIER, A. THOMAIDIS, C. LEGRAND (*Paris, France*)..... 757

Activity and Therapeutic Potential of ORI-1001 Antisense Oligonucleotide on Human Papillomavirus Replication Utilizing a Model of Dysplastic Human Epithelium. S. ALAM, J. BROMBERG-WHITE, M. MCLAUGHLIN-DRUBIN, E. SEN, J.M. BODILY, C. MEYERS (*Hershey, PA, USA*)..... 765

Apoptotic Anticancer Effect of Alvaradoin E Isolated from *Alvaradoa haitiensis*. Q. MI, D. LANTVIT, E. REYES-LIM, H. CHAI, S.S. PHIFER, M.C. WANI, M.E. WALL, G.T. TAN, G.A. CORDELL, N.R. FARNSWORTH, A.D.KINGHORN, J.M. PEZZUTO (*Chicago, IL; Research Triangle Park, NC, USA*)..... 779

Inhibition of mTOR Suppresses Experimental Liver Tumours. M. RIZELL, P. LINDNER (<i>Göteborg, Sweden</i>)	789
Pre-clinical Evaluation of the Activity of Irinotecan as a Basis for Regional Chemotherapy. C. HOFMANN, K. BUTTENSCHOEN, J. STRAETER, D. HENNE-BRUNS, M. KORNMANN (<i>Ulm, Germany</i>).....	795
Antiproliferative and Antimigratory Effects of Doxorubicin in Human Osteosarcoma Cells Exposed to Extracellular Matrix. R. HARISI, J. DUDÁS, F. TÍMÁR, G. POGÁNY, S. PAKU, J. TÍMÁR, I. KOVALSZKY, M. SZENDROI, A. JENEY (<i>Budapest, Hungary</i>).....	805
Urinary Trypsin Inhibitor Suppresses Surgical Stress-facilitated Lung Metastasis of Murine Colon 26-L5 Carcinoma Cells. I. YOSHIOKA, Y. TSUCHIYA, Y. AOZUKA, Y. ONISHI, H. SAKURAI, K. KOIZUMI, K. TSUKADA, I. SAIKI (<i>Toyama, Japan</i>).....	815
Experimental Study on Fluorescent Microspheres as a Tracer for Sentinel Node Detection. H. UENO, J. HIHARA, K. SHIMIZU, A. OSAKI, Y. YAMASHITA, K. YOSHIDA, T. TOGE (<i>Hiroshima, Japan</i>).....	821
HER2-specific Cytotoxic Activity of Lymphokine-activated Killer Cells in the Presence of Trastuzumab. Y. YAMAGUCHI, K. HIRONAKA, M. OKAWAKI, R. OKITA, K. MATSUURA, A. OHSHITA, T. TOGE (<i>Hiroshima, Japan</i>).....	827
Expression of P8 Protein in Breast Carcinoma; an Inverse Relationship with Apoptosis. Y. ITO, H. YOSHIDA, Y. MOTOO, J.L. IOVANNA, Y. NAKAMURA, K. KAKUDO, T. URUNO, Y. TAKAMURA, A. MIYA, S. NOGUCHI, K. KUMA, A. MIYAUCHI (<i>Kanazawa; Wakayama; Osaka, Japan; Marseille, France</i>).....	833
Effective Treatment of Perianal Tumors in Dogs with Electrochemotherapy. N. TOZON, V. KODRE, G. SERSA, M. CEMAZAR (<i>Ljubljana, Slovenia</i>).....	839
Platelet Factor 4 Gene Transfection into Tumor Cells Inhibits Angiogenesis, Tumor Growth and Metastasis. K. YAMAGUCHI, K. OGAWA, T. KATSUBE, K. SHIMAO, S. KONNO, T. SHIMAKAWA, K. YOSHIMATSU, Y. NARITAKA, H. YAGAWA, K. HIROSE (<i>Tokyo, Japan</i>).....	847
Neuroendocrine Differentiation in Primary Merkel Cell Carcinoma – Possible Prognostic Significance. V. KOLJONEN, C. HAGLUND, E. TUKIAINEN, T. BÖHLING (<i>Helsinki, Finland</i>).....	853
Modified Arabinoxylan Rice Bran (MGN-3/Biobran) Enhances Yeast-induced Apoptosis in Human Breast Cancer Cells <i>In Vitro</i> . M. GHONEUM, S. GOLLAPUDI (<i>Los Angeles; Irvine, CA, USA</i>).....	859
Decreased MCF-7 Breast Cancer Cell Proliferation by Serum from a Selected Line of Beef Cattle. M.S. UPDIKE, M.E. DAVIS, L.-S. WANG, Y.-W. HUANG, M. WICK, Y.C. LIN (<i>Columbus, OH, USA</i>)	871
Biological Effect of Irradiation on Adhesion Molecules in Human Colon Cancer Cells <i>In Vitro</i> . T. HASEGAWA, M. SATO, M. KURIMOTO, H. TAKAHASHI, T. KAWASHIMA, Y. MATSUO, M. YAMAMOTO, H. SAWAI, H. FUNAHASHI, Y. OKADA, H. TAKEYAMA, T. MANABE (<i>Nagoya, Japan</i>).....	875
A Potential for Tissue Restrictive Gene Therapy in Renal Cell Carcinoma Using MN/CA IX Promoter. Y.-C. OU, T.A. GARDNER, C. KAO, H.E. ZHAU, L.W. CHUNG (<i>Taichung; Nantou Hsien, Taiwan, ROC; Indianapolis, IN; Atlanta, GA, USA</i>)	881
Induction of Tumor-specific Cytotoxicity and Apoptosis by Doxorubicin. F. SUZUKI, K. HASHIMOTO, H. KIKUCHI, H. NISHIKAWA, H. MATSUMOTO, J. SHIMADA, M. KAWASE, K. SUNAGA, T. TSUDA, K. SATOH, H. SAKAGAMI (<i>Saitama; Tokyo, Japan</i>)	887

Dextran Sulfate Suppresses Cell Adhesion and Cell Cycle Progression of Melanoma Cells. T. TAKAGI, C. SAKAKURA, S. KIN, Y. NAKASE, K. FUKUDA, K. SHIMOMURA, T. ITO, J. FUJIYAMA, J. YAMASAKI, H. TSUJIMOTO, Y. OKAZAKI, Y. HAYASHIZAKI, H. YAMAGISHI, A. HAGIWARA (Kyoto; Yokohama, Japan).....	895
Gastric Hamartomatous Tumours in a Transgenic Mouse Model Expressing an Activated Dioxin/Ah Receptor. P. ANDERSSON, C. RUBIO, L. POELLINGER, A. HANBERG (Stockholm, Sweden).....	903
Allelic Imbalance on Distal 7q (7q36.1-q36.3) in Gastric Cardia and Oesophageal (Barrett's) Adenocarcinoma. K.J. VISSERS, W.N.M. DINJENS, P.H.J. RIEGMAN, H.W. TILANUS, H. VAN DEKKEN (Rotterdam, The Netherlands).....	913
5-FU Uptake in Peritoneal Metastases after Pretreatment with Radioimmunotherapy or Vasoconstriction: an Autoradiographic Study in the Rat. H. MAHTEME, A. SUNDIN, B. LARSSON, H. KHAMIS, K. AROW, W. GRAF (Uppsala, Sweden).....	917
Thymidylate Synthase and Dihydropyrimidine Dehydrogenase in Non-small Cell Lung Cancer: Relationship between mRNA Expression and Activity. T. MIYOSHI, K. KONDO, H. FUJINO, Y. TAKAHASHI, N. SAWADA, S. SAKIYAMA, M. TSUYUGUCHI, S. KIMURA, M. SUMITOMO, Y. MONDEN (Tokushima, Japan).....	923
Evaluation of Chemosensitivity Testing with Highly Purified Tumor Cells in 435 Patients with Gastric Carcinoma Using an MTT Assay. K. NOGUCHI, M. IWAHASHI, M. TANI, M. NAKAMURA, M. NAKAMORI, Y. NAKATANI, K. UEDA, K. ISHIDA, T. NAKA, T. OJIMA, T. HOTTA, S. MIZOBATA, H. YAMAUE (Wakayama, Japan).....	931
Evaluation of <i>HER2</i> Gene Status in Breast Cancer by Chromogenic <i>In Situ</i> Hybridization: Comparison with Immunohistochemistry. S. KOUNELIS, N. KAPRANOS, N. MALAMOS, E. KOURI-BAIRAKTARI (Athens, Greece).....	939
Osteogenic Progenitor Cell Potency After High-dose Chemotherapy (COSS-96). M. JÄGER, A. SCHULTHEIS, B. WESTHOFF, R. KRAUSPE (Duesseldorf, Germany).....	947
Differential Expression of VEGF Isoforms and VEGF Receptors in Cartilaginous Tumors. K. YUKATA, Y. MATSUI, T. GOTO, T. KUBO, N. YASUI (Tokushima, Japan).....	955
Baicalein Induced Cell Cycle Arrest and Apoptosis in Human Lung Squamous Carcinoma CH27 Cells. H.Z. LEE, H.W.C. LEUNG, M.Y. LAI, C.H. WU (Taichung; Tainan, Taiwan, ROC).....	959
Kinetic Evaluation of Polyamines as Radical Scavengers. S. FUJISAWA, Y. KADOMA (Saitama; Tokyo, Japan).....	965
Ellagic Acid Induced p53/p21 Expression, G1 Arrest and Apoptosis in Human Bladder Cancer T24 Cells. T.-M. LI, G.-W. CHEN, C.-C. SU, J.-G. LIN, C.-C. YEH, K.-C. CHENG, J.-G. CHUNG (Taichung, Taiwan, ROC).....	971
Human Squamous Cell Carcinoma of the Tongue and Colon Undergoes Apoptosis upon Phagocytosis of <i>Saccharomyces cerevisiae</i> , the Baker's Yeast, <i>In Vitro</i> . M. GHONEUM, J. HAMILTON, J. BROWN, S. GOLLAPUDI (Los Angeles; Irvine, CA, USA).....	981
Arsenic Trioxide Circumvents Multidrug Resistance Based on Different Mechanisms in Human Leukemia Cell Lines. T. SEO, Y. URASAKI, H. TAKEMURA, T. UEDA (Fukui, Japan).....	991
Involvement of Bax, Bcl-2 and Caspase 3 in Hydroxyurea- or Etoposide-induced Apoptosis of Mouse Interleukin-3-dependent Lymphoma Cells. G. OLMOS, A. PRIETO, A. HERRÁEZ, M.C. TEJEDOR, M. ALVAREZ-MON, J.C. DIEZ (Madrid, Spain).....	999

Transmission Electron Microscopy Study of the Effects Produced by Wide-band Low-power Millimeter Waves on MCF-7 Human Breast Cancer Cells in Culture. A. BENEDUCI, G. CHIDICHIMO, S. TRIPEPI, E. PERROTTA (<i>Arcavacata di Rende (CS), Italy</i>)	1009
Interleukin-12 has no Effect on Vascular Density, Perfusion, Hypoxia and Proliferation of an Implanted Human Squamous Cell Carcinoma Xenograft Tumour Despite Up-regulation of ICAM-1. C.M.L. VAN HERPEN, J. BUSSINK, A.J. VAN DER KOGEL, W.J.M. PEETERS, R. VAN DER VOORT, A. VAN SCHIJNDEL, P.C.M. DE WILDE, G.J. ADEMA, P.H.M. DE MULDER (<i>Nijmegen, The Netherlands</i>)	1015
Frequency and Irradiation Time-dependent Antiproliferative Effect of Low-power Millimeter Waves on RPMI 7932 Human Melanoma Cell Line. A. BENEDUCI, G. CHIDICHIMO, R. DE ROSE, L. FILIPPELLI, S.V. STRAFACE, S. VENUTA (<i>Arcavacata di Rende (CS); Catanzaro, Italy</i>)	1023
Diagnostic Evaluation of Carbon Tetrachloride-induced Rat Hepatic Cirrhosis Model. G.-P. LEE, W.-I. JEONG, D.-H. JEONG, S.-H. DO, T.-H. KIM, K.-S. JEONG (<i>Daegu, Korea</i>)	1029
Comparison of Different Protocols for Telomere Length Estimation by Combination of Quantitative Fluorescence <i>In Situ</i> Hybridization (Q-FISH) and Flow Cytometry in Human Cancer Cell Lines. H. DERRADJI, S. BEKAERT, P. VAN OOSTVELDT, S. BAATOUT (<i>Mol; Ghent, Belgium</i>)	1039
Origin of Cells Cultured <i>In Vitro</i> from Human Breast Carcinomas Traced by Cyclin D1 and HER2/neu FISH Signal Numbers. E. MATOUSKOVA, I. KUDLACKOVA, A. CHALOUPKOVA, M. BROZOVA, I. NETIKOVA, P. VESELY (<i>Prague, Czech Republic</i>)	1051
Irradiation Dose-response Effects on Angiogenesis and Involvement of Nitric Oxide. C. HADJIMICHAEL, D. KARDAMAKIS, S. PAPAIOANNOU (<i>Patras, Greece; Nicosia, Cyprus</i>)	1059
New Model for the Induction of Osteoblastic Bone Metastases in Rat. K. LIEPE, H. GEIDEL, M. HAASE, O. W. HAKENBERG, R. RUNGE, J. KOTZERKE (<i>Dresden, Germany</i>)	1067
The JNK Interacting Protein JIP-1 and Insulin Like Growth Factor II Genes are Co-expressed in Human Embryonic Tumours. W. ENGSTRÖM, A. RISING, S. GRIP (<i>Uppsala, Sweden</i>)	1075
Presence and Incidence of DNA Sequences of Human Polyomaviruses BKV and JCV in Colorectal Tumor Tissues. B. CASINI, L. BORGESSE, F. DEL NONNO, G. GALATI, L. IZZO, M. CAPUTO, R. PERRONE DONNORSO, M. CASTELLI, G. RISULEO, P. VISCA (<i>Rome; Italy</i>)	1079
Tumour Therapy with Genes Encoding Apoptin and E4orf4. I. MITRUS, E. MISSOL-KOLKA, A. PLUCIENNICZAK, S. SZALA (<i>Gliwice; Warsaw, Poland</i>)	1087
Efficacy of Two Commercial Preparations of Interferon- α on Human Papillomavirus Replication. E. SEN, M. MCLAUGHLIN-DRUBIN, C. MEYERS (<i>Hershey, PA, USA</i>)	1091
Anatomical Distribution of Small Cell Lung Cancer: Effects of Lobe and Gender on Brain Metastasis and Survival. A.E. SAHMOUN, L.D. CASE, T.J. SANTORO, G.G. SCHWARTZ (<i>Fargo, ND; Winston-Salem, NC, USA</i>)	1101
Inhibition of Angiogenic Activity of Renal Carcinoma by an Antisense Oligonucleotide Targeting Fibroblast Growth Factor-2. E. CENNI, F. PERUT, M. ZUNTINI, D. GRANCHI, I. AMATO, S. AVNET, M.L. BRANDI, A. GIUNTI, N. BALDINI (<i>Bologna; Florence, Italy</i>)	1109
Adhesion Molecule CD44 as a Prognostic Factor in Laryngeal Cancer. F. ESTEBAN, J.J. BRAVO, M.A. GONZÁLEZ-MOLES, M. BRAVO, I. RUIZ-ÁVILA, J.A. GIL-MONTOYA (<i>Sevilla; Granada; Jaen, Spain</i>)	1115

The Expression of p21/WAF-1 and Cyclin B1 Mediate Mitotic Delay in X-irradiated Fibroblasts. M.J. CARIVEAU, C.J. KOVACS, R.R. ALLISON, ROBERTA M. JOHNKE, GERHARD W. KALMUS, MARK EVANS (<i>Greenville, NC, USA</i>)	1123
MCI-186 Inhibits Tumor Growth Through Suppression of EGFR Phosphorylation and Cell Cycle Arrest. R. SUZUKI, R.K. GOPALRAO, H. MAEDA, P. RAO, M. YAMAMOTO, Y. XING, S. MIZOBUCHI, S. SASAGURI (<i>Kochi, Japan</i>)	1131
Structure-Activity Relationships of a New Class of Aromatic Bisphosphonates that Inhibit Tumor Cell Proliferation <i>In Vitro</i> . E. GUENIN, D. LEDOUX, O. OUDAR, M. LECOUCVEY, M. KRAEMER (<i>Bobigny, France</i>).....	1139
Resistance Mechanisms Following Cisplatin and Oxaliplatin Treatment of the Human Teratocarcinoma Cell Line 2102EP. A. RENNICKE, W. VOIGT, T. MUELLER, A. FRUEHAUF, H.-J. SCHMOLL, C. BEYER, W. DEMPKE (<i>Halle/Saale, Germany</i>)	1147
Proenzyme Therapy of Cancer. J.F. NOVAK, F. TRNKA (<i>Lewisburg, PA, USA; Ceske Budejovice, Czech Republic</i>)	1157
Mono- or Di-fluorinated Analogues of Flavone-8-acetic Acid: Synthesis and <i>In Vitro</i> Biological Activity. M. CARRARA, A. ZAMPIRON, M. BARBERA, A. CAPUTO, A. BISI, S. GOBBI, F. BELLUTI, L. PIAZZI, A. RAMPA, P. VALENTI (<i>Padova; Bologna, Italy</i>)	1179
Quantitative and Functional Assay of MDR1/P170-mediated MDR in Ascites Cells of Patients with Ovarian Cancer. Z.T. KRASZNAI, E. FRIEDLÄNDER, A. NAGY, G. SZABÓ, G. VEREB, K. GODA, Z. HERNÁDI (<i>Debrecen, Hungary</i>)	1187

Number 2B

Clinical Studies

* Molecular Genetic Tumor Markers in Non-small Cell Lung Cancer. T. OYAMA, T. OSAKI, T. BABA, Y. NAGATA, M. MIZUKAMI, T. SO, S. NAKATA, Y. ICHIKI, H. URAMOTO, M. SUGAYA, T. YOSHIMATSU, M. MORITA, T. HANAGIRI, K. SUGIO, T. KAWAMOTO, K. YASUMOTO (<i>Kitakyushu, Japan</i>)	1193
Identification of Serum Proteins Related to Adverse Effects Induced by Docetaxel Infusion from Protein Expression Profiles of Serum Using SELDI ProteinChip System. Y. HEIKE, M. HOSOKAWA, S. OSUMI, D. FUJII, K. AOGI, N. TAKIGAWA, M. IDA, H. TAJIRI, K. EGUCHI, M. SHIWA, R. WAKATABE, H. ARIKUNI, Y. TAKAUE, S. TAKASHIMA (<i>Ehime; Tokyo; Kanagawa, Japan</i>)	1197
Immunohistochemical Analysis of EGFR and HER-2 in Patients with Metastatic Squamous Cell Carcinoma of the Skin. E. MAUBEC, P. DUVILLARD, V. VELASCO, B. CRICKX, M.-F. AVRIL (<i>Paris; Villejuif, France</i>).....	1205
Sequential Administration of Epirubicin and Paclitaxel for Advanced Breast Cancer. A Phase I Randomised Trial. C. FOCAN, M.P. GRAAS, M. BEAUDUIN, J.L. CANON, J.P. SALMON, G. JERUSALEM, D. FOCAN-HENRARD, J.P. LOBELLE, D. SCHALLIER (<i>Haine Saint-Paul; Charleroi; Verviers; Liège; Jette, Belgium</i>)	1211
Cancer in First Degree Relatives of Latin American Women with Cervical Cancer. A Pilot Study. W. WEBER, M.S. DE SABATA, R.M.M. PAREDES, G. RODRIGUEZ, C. SANTOS, J.U. SABILLON, M. ZWAHLEN (<i>Basel; Geneva; Bern, Switzerland; Santo Domingo, Dominican Republic; Montevideo, Uruguay; Lima, Peru; Sula, Honduras</i>)	1219

Clinical Trial of Photodynamic Therapy Using Acridine Orange with/without Low Dose Radiation as New Limb Salvage Modality in Musculoskeletal Sarcomas. K. KUSUZAKI, H. MURATA, T. MATSUBARA, S. MIYAZAKI, A. OKAMURA, M. SETO, A. MATSUMINE, H. HOSOI, T. SUGIMOTO, A. UCHIDA (<i>Mie; Kyoto, Japan</i>)	1225
Expression of Dihydropyrimidine Dehydrogenase, Thymidylate Synthase, p53 and p21 in Metastatic Liver Tumor from Colorectal Cancer after 5-Fluorouracil-based Chemotherapy. S. YAMAGISHI, H. SHIMADA, T. ISHIKAWA, S. FUJII, K. TANAKA, H. MASUI, S. YAMAGUCHI, Y. ICHIKAWA, S. TOGO, H. IKE (<i>Yokohama, Japan</i>)	1237
Macrocytic Anemia during Low-dose Cisplatin and 5-Fluorouracil through Implanted Infusion Port for Unresectable Hepatobiliary Malignancies. N. YAMAMOTO, K. MURATA, H. FUKE, T. INOUE, Y. YAMANAKA, Y. SAITOU, K. ITO, K. SUGIMOTO, M. KOYAMA, K. SHIRAKI, T. NAKANO (<i>Mie, Japan</i>)	1243
<i>SI00A2</i> Overexpression is Frequently Observed in Esophageal Squamous Cell Carcinoma. M. IMAZAWA, K. HIBI, S.-I. FUJITAKE, Y. KODERA, K. ITO, S. AKIYAMA, A. NAKAO (<i>Nagoya, Japan</i>)	1247
A New Staging System for Colorectal Carcinoma with Liver Metastasis. H. KATO, K. YOSHIMATSU, K. ISHIBASHI, K. WATANABE, S. SHIOZAWA, A. TSUCHIYA, R. YAMADA, T. SAKAMOTO, S. HAGA (<i>Tokyo, Japan</i>)	1251
Phase I/II Study of Bi-weekly Irinotecan plus Cisplatin in the Treatment of Advanced Gastric Cancer. W. KOIZUMI, M. KURIHARA, A. SATOH, H. TAKIUCHI, S. TANABE, K. SHIMADA, R. IWASAKI, K. SAIGENJI (<i>Kanagawa; Tokyo; Osaka; Shizuoka, Japan</i>)	1257
Comparison of Ante- and Post-Mortem PSA Levels for Epidemiological Studies. R.F. JONES, R. SUNHEIMER, H. FRIEDMAN, D. MILLER, R. GINSBURG, M. JUMBELIC, G. THREATTE, G.P. HAAS (<i>Syracuse; Albany, NY, USA</i>)	1263
The Role of Tumour Budding at the Front of Invasion and Recurrence of Rectal Carcinoma. K. GUZINSKA-USTYMOWICZ (<i>Bialystok, Poland</i>)	1269
Determination of Optimal Dosage for Nedaplatin Based on Pharmacokinetic and Toxicodynamic Analysis. T. ISHIBASHI, Y. YANO, T. OGUMA (<i>Osaka, Japan</i>)	1273
Optimal Sampling and Limited Sampling Strategies for Estimation of Unbound Platinum AUC After Nedaplatin Infusion. T. ISHIBASHI, K. FUKUMURA, Y. YANO, T. OGUMA (<i>Osaka, Japan</i>)	1283
A Combination Phase I Study of Weekly Paclitaxel and Doxifluridine in Advanced Gastric Cancer Patients. I. TAKEYOSHI, F. MAKITA, Y. TANAHASHI, T. YOKOMORI, S. IWAZAKI, Y. KAWASHIMA, K. IWANAMI, T. YAMADA, S. KAWATE, K. HAMADA, Y. SUNOSE, M. YOSHIDA, J. HORIGUCHI, H. IESATO, M. KOBAYASHI, Y. MORISHITA (<i>Maebashi; Shibukawa; Ojiya, Japan</i>)	1291
A Phase II Multicentric Trial of S-1 Combined with 24 h-infusion of Cisplatin in Patients with Advanced Gastric Cancer. H. IWASE, M. SHIMADA, T. TSUZUKI, Y. HORIUCHI, S. KUMADA, J. HARUTA, T. YAMAGUCHI, M. SUGIHARA, K. INA, K. KUSUGAMI, S. GOTO (<i>Nagoya; Gifu, Japan</i>)	1297
Role of a <i>CYP17</i> Promoter Polymorphism for Familial Prostate Cancer Risk in Germany. Z. VESOVIC, K. HERKOMMER, W. VOGEL, T. PAISS, C. MAIER (<i>Ulm, Germany</i>)	1303
Sequential Docetaxel Followed by Epirubicin-Vinorelbine as First-line Chemotherapy in Advanced Breast Cancer. P. VICI, P. FOGGI, G. COLUCCI, E. CAPOMOLLA, M. BRANDI, F. GIOTTA, N. GEBBIA, L. DI LAURO, M.R. VALERIO, G. PAOLETTI, F. BELLI, C. PIZZA, D. GIANNARELLI, M. LOPEZ (<i>Rome; Bari; Palermo; Naples, Italy</i>)	1309

Ribavirin in the Treatment of Hepatitis C. M.E. ABONYI, P.L. LAKATOS (<i>Budapest, Hungary</i>).....	1315
Neutron Therapy, Prognostic Factors and Dedifferentiation of Adenoid Cystic Carcinomas (ACC) of Salivary Glands. S. BRACKROCK, A. KRÜLL, K. RÖSER, R. SCHWARZ, L. RIETHDORF, W. ALBERTI (<i>Neumünster; Hamburg, Germany</i>)	1321
Clinical Significance of Serum CEA Protein and CEA mRNA After Resection of Colorectal Liver Metastases. M. KIJIMA, S. TOGO, Y. ICHIKAWA, M. MIURA, S. YAMAGISHI, K. MATSUO, K. TANAKA, H. MASUI, T. ISHIKAWA, H. IKE, H. SHIMADA (<i>Yokohama, Japan</i>)	1327
Phase II Trial of Carboplatin, Paclitaxel Plus Vinorelbine in Non-small Cell Lung Cancer Patients. A. SCHMITTEL, J.M. SIEHL, M. SCHULZE, K. SCHULZE, E. THIEL, U. KEILHOLZ (<i>Berlin; Zittau, Germany</i>)	1333
Histological Vascular Invasion by Tumors is a Risk Factor for Distant Metastasis in Malignant Fibrous Histiocytoma. T. YONEMOTO, S.-I. TATEZAKI, T. ISHII, S. IWATA, Y. TAKEUCHI, A. ARAKI (<i>Chiba, Japan</i>)	1337
Primary Chemotherapy with Epirubicin and Vinorelbine in Women with Locally Advanced Breast Cancer. C. NISTICÒ, A. DE MATTEIS, E. ROSSI, F. CARNINO, R. VALENZA, B. AGOSTARA, E. BRIA, A. FARRIS, M. CREMONESI, A.M. D'OTTAVIO, A. VACCARO, C. GARUFI, S. GIUNTA, C. BOTTI, F. PERRONE, E. TERZOLI (<i>Rome; Napoli; Torino; Palermo; Sassari; Treviglio, Italy</i>)	1343
Feasibility of Sentinel Node Concept in Gastric Carcinoma: Clinicopathological Analysis of Gastric Cancer with Solitary Lymph Node Metastases. S.P. MOENIG, T. LUEBKE, S.E. BALDUS, W. SCHROEDER, E. BOLLSCHWEILER, P.M. SCHNEIDER, A. H. HOELSCHER (<i>Cologne, Germany</i>).....	1349
Serrated and Microtubular Colorectal Adenomas in Italian Patients. A 5-year Survey. C.A. RUBIO, G. NESI, L. MESSERINI, G. ZAMPI (<i>Florence, Italy</i>)	1353
Expression of Retinoblastoma and p53 Pathway-related Proteins in Resectable Invasive Ductal Carcinoma of the Pancreas: Potential Cooperative Effects on Clinical Outcome. K. HASHIMOTO, Y. NIO, M. KOIKE, M. ITAKURA, S. YANO, T. HIGAMI, R. MARUYAMA (<i>Izumo, Japan</i>)	1361
Clinical Impact of Metastatic Lymph Node Ratio in Advanced Gastric Cancer. C. KUNISAKI, H. SHIMADA, M. NOMURA, G. MATSUDA, Y. OTSUKA, H. ONO, H. AKIYAMA (<i>Yokohama, Japan</i>)	1369
Preoperative CEA and PPD Values as Prognostic Factors for Immunochemotherapy Using PSK and 5-FU. Y. TAKAHASHI, M. MAI, H. NAKAZATO (<i>Kanazawa; Nagoya, Japan</i>)	1377
Carcinogenesis: A Cellular Model for Age-dependence. A. NEJAKO, B. ARANTON, D. DIX (<i>West Hartford, CT, USA</i>)	1385
Phase II Trial of Irinotecan and Raltitrexed in Chemotherapy-naive Advanced Colorectal Cancer. S. CHIARA, M.T. NOBILE, L. TOMASELLO, M. ACQUATI, P. TAVEGGIA, C. MUROLO, P. PERCIVALE, R. ROSSO (<i>Genova, Italy</i>)	1391
Significance of RNA Reference in Tumour-related Gene Expression Analyses by cDNA Array. N. LAYTRAGOON-LEWIN, M. LAGERLUND, J. LUNDGREN, B. NORDLANDER, G. ELMBERGER, T. SÖDERGREN, C. LAGERROS, L.E. RUTQVIST, F. LEWIN (<i>Stockholm, Sweden</i>)	1397
Intravascular Papillary Endothelial Hyperplasia (Masson's Hemangioma) Presenting as a Soft-tissue Sarcoma. D.P. KORKOLIS, M. PAPAЕVANGELOU, G. KOULAXOUZIDIS, N. ZIRGANOS, H. PSICHOGIOU, P.P. VASSILOPOULOS (<i>Athens, Greece</i>).....	1409

The Apoptotic Response of Liver and Colorectal Liver Metastases to Focal Hyperthermic Injury. M. NIKFARJAM, V. MURALIDHARAN, C. MALCONTENTI-WILSON, C. CHRISTOPHI (<i>Melbourne, Victoria, Australia</i>)	1413
Prevalence and Risk of Cancer of Focal Thyroid Incidentaloma Identified by ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography for Cancer Screening in Healthy Subjects. Y.-K. CHEN, H.-J. DING, K.-T. CHEN, Y.-L. CHEN, A.C. LIAO, Y.-Y. SHEN, C.-T. SU, C.-H. KAO (<i>Taipei; Kaohsiung; Taichung, Taiwan, ROC</i>)	1421
Triplet Chemotherapy with Docetaxel, Gemcitabine and Liposomal Doxorubicin, Supported with Subcutaneous Amifostine and Hemopoietic Growth Factors, in Advanced Non-small Cell Lung Cancer. G. PATLAKAS, D. BOUROS, S. TSANTEKIDOU-POZOVA, M.I. KOUKOURAKIS (<i>Alexandroupolis, Greece</i>)	1427
Tissue Expression and Serum Levels of the Oncoprotein HER-2/ <i>neu</i> in 157 Primary Breast Tumours. C. PALLUD, J.M. GUINEBRETIERE, S. GUEPRATTE, K. HACENE, R. NEUMANN, W. CARNEY, M.F. PICHON (<i>Saint-Cloud, France; Leverkusen, Germany; Cambridge, MA, USA</i>)	1433
Temozolomide and Cisplatin in Advanced Malignant Melanoma. A. DAPONTE, P.A. ASCIERTO, A. GRAVINA, M. MELUCCI, S. SCALA, A. OTTAIANO, E. SIMEONE, G. PALMIERI, G. COMELLA (<i>Naples; Alghero, Italy</i>)	1441
Search for Meaningful Support and the Meaning of Illness in German Cancer Patients. A. BÜSSING, T. OSTERMANN, P.F. MATTHIESSEN (<i>Herdecke, Germany</i>)	1449
Clinical Value of Bone Remodelling Markers in Patients with Bone Metastases Treated with Zoledronic Acid. D. PECTASIDES, M. NIKOLAOU, D. FARMAKIS, I. KANAKIS, A. GAGLIA, P. KOUNTOURAKIS, N.K. KARAMANOS, T. ECONOMOPOULOS, S.A. RAPTIS (<i>Athens; Piraeus; Patras, Greece</i>)	1457
No Association Between Genetic Polymorphisms in <i>NAD(P)H Oxidase p22phox</i> and <i>Paraoxonase 1</i> and Colorectal Cancer Risk. E.M.J. VAN DER LOGT, C.H.J.M. JANSSEN, Z. VAN HOOIJDONK, H.M.J. ROELOFS, T. WOBBS, F.M. NAGENGAST, W.H.M. PETERS (<i>Nijmegen, The Netherlands</i>)	1465
Solitary Parenchymal Splenic Recurrence of Ovarian Adenocarcinoma: A Case Report and Review of the Literature. A. TSERKEZOGLU, S. KONTOU, G. HATJIELEFTHERIOU, M.-E. NIKOLAIDOU, G. PLATANIOTIS, N. APOSTOLIKAS, G. MAGIAKOS (<i>Athens, Greece</i>)	1471

* Review (page 1193)

Number 3A

**Proceedings of the 12th International Hamburg Symposium on Tumor Markers,
November 30 - December 2, 2003, Hamburg, Germany
Special Issue Edited by R. Klapdor**

Identification of Genes Associated with Tumor Progression Using Microarrays. G. GEBAUER, A. KRONES-HERZIG, A.B. GLINSKII, G.V. GLINSKY (<i>San Diego, CA, USA; Heidelberg, Germany</i>)	1477
* Antibody Therapy for Breast Cancer. A. WILLEMS, K. GAUGER, C. HENRICH, N. HARBECK (<i>Munich, Germany</i>)	1483

PINP as Serum Marker of Metastatic Spread to the Bone in Breast Cancer Patients. D. LÜFTNER, D. JOZEREAU, S. SCHILDHAUER, R. GEPPERT, C. MÜLLER, G. FIOKA, K.-D. WERNECKE, K. POSSINGER (<i>Berlin, Germany</i>).....	1491
* Current Approaches in Chemotherapy of Advanced and Metastatic Non-small Cell Lung Cancer (NSCLC). M. RECK (<i>Grosshansdorf, Germany</i>).....	1501
Improved Sensitivity in the Diagnosis of Gastro-intestinal Tumors by Fuzzy Logic-based Tumor Marker Profiles Including the Tumor M2-PK. J. SCHNEIDER, N. BITTERLICH, G. SCHULZE (<i>Giessen; Chemnitz; Berlin, Germany</i>).....	1507
TPS, Thymidine Kinase, VEGF and Endostatin in Cytosol of Thyroid Tissue Samples. R. PIKNER, M. LUDVÍKOVÁ, A. RYŠKA, I. KHOLOVÁ, L. HOLUBEC JR., O. TOPOLČAN, L. PECEN, J. FÍNEK (<i>Prague; Plzeň; Hradec Králové, Czech Republic</i>).....	1517
Results and Follow-up of Locally Advanced Cancer of the Exocrine Pancreas Treated with Radiochemotherapy. O. MICKE, S. HESSELMANN, F. BRUNS, E. HORST, A. DEVRIES, P. SCHÜLLER, N. WILLICH, U. SCHÄFER (<i>Münster, Germany; Innsbruck, Austria</i>).....	1523
Brain Metastases in Breast Cancer – an <i>In Vitro</i> Study to Evaluate New Systemic Chemotherapeutic Options. A. HONIG, L. RIEGER, A. SUTTERLIN, M. KAPP, J. DIETL, M.W. SUTTERLIN, U. KÄMMERER (<i>Wuerzburg, Germany</i>).....	1531
Tumor Markers and Lymphatic Metastasis in Head and Neck Cancer Patients. J. BÜNTZEL, A. HORNIG, M. GLATZEL, O. MICKE, F. BRUNS, U. SCHÄFER, D. FRÖHLICH (<i>Nordhausen; Borna; Suhl; Münster; Hannover, Germany</i>).....	1539
No Predictive Value of β -hCG in Patients with Stage I Seminoma – Results of a Long-term Follow-up Study after Adjuvant Radiotherapy. F. BRUNS, M. RAUB, U. SCHAEFER, O. MICKE (<i>Hannover; Muenster, Germany</i>).....	1543
Serum Chromogranin-A Assay in Differential Diagnosis of Incidentally Discovered Adrenal Mass. L. GIOVANELLA (<i>Bellinzona, Switzerland</i>).....	1547
Evaluation of CA125, Physical and Radiological Findings in Follow-up of Ovarian Cancer Patients. T. FEHM, F. HELLER, S. KRÄMER, W. JÄGER, G. GEBAUER (<i>Tuebingen; Schwäbisch Hall; Nuremberg; Duesseldorf; Heidelberg, Germany</i>).....	1551
PSA Course after Definitive High-dose Radiotherapy of Localized Prostate Cancer. P. SCHÜLLER, U. SCHÄFER, O. MICKE, J.E. PANKE, N. WILLICH (<i>Münster; Hamburg, Germany</i>).....	1555
Smooth Muscle Tumours of the Uterine Corpus: a Clinicopathologic Study with Immunohistochemical Aspects. J. WALDMANN, A. STACHS, H. TERPE, G. STROPAHL, J. MAKOVITZKY (<i>Rostock, Germany</i>).....	1559
Primary Melanoma of the Female Genital System: A Report of 10 Cases and Review of the Literature. A. JAHNKE, J. MAKOVITZKY, V. BRIESE (<i>Rostock, Germany</i>).....	1567
Induction of Apoptosis in Human Breast Cancer and Trophoblast Tumor Cells by Galectin-1. I. WIEST, C. SELIGER, H. WALZEL, K. FRIESE, U. JESCHKE (<i>Munich; Rostock, Germany</i>).....	1575
Development of Monoclonal and Polyclonal Antibodies and an ELISA for the Determination of Glycodelin in Human Serum, Amniotic Fluid and Cystic Fluid of Benign and Malignant Ovarian Tumors. U. JESCHKE, A. BISCHOF, R. SPEER, V. BRIESE, D.-U. RICHTER, C. BERGEMANN, I. MYLONAS, N. SHABANI, K. FRIESE, U. KARSTEN (<i>Munich; Rostock; Berlin, Germany; Bethesda, MD, USA</i>).....	1581

The Use of Complexed PSA for the Early Detection of Prostate Cancer. K. FISCHER, H. LOERTZER, P. FORNARA (<i>Halle, Germany</i>)	1591
Markers of Cellular Adhesion in Diagnosis and Therapy Control of Colorectal Carcinoma. L. HOLUBEC Jr., O. TOPOLCAN, J. FINEK, S. HOLDENRIEDER, P. STIEBER, M. PESTA, R. PIKNER, L. HOLUBEC SEN., A. SUTNAR, V. LISKA, S. SVOBODOVA, V. VISOKAI, S. KORMUNDA (<i>Pilsen; Prague, Czech Republic; Munich, Germany</i>).....	1597
Malignant Melanoma and Fibrothecoma – an Ovarian Mixed Tumor. J. NICKEL, V. BRIESE, J. BRIESE, E. REHDA (<i>Rostock; Luebeck, Germany</i>).....	1603
Polymorphisms in the Human Progesterone Receptor (PGR) Gene of Two Human Prostate Adenocarcinoma Cell Lines. D.G. ENGEHAUSEN, S. ENDELE, S.F. KRAUSE, T. RITH, K.M. SCHROTT, Z. AKÇETIN (<i>Erlangen, Germany</i>)	1607
Polymorphisms of Human Androgen Receptor (hAR) Gene in Prostate Cancer Cell Lines PC-EW and PC-OR. D.G. ENGEHAUSEN, F.S. KRAUSE, J. FLEISCHMANN, Z. AKÇETIN, K.M. SCHROTT, S. ENDELE (<i>Erlangen, Germany</i>)	1611
Expression of Sialyl Lewis X, Sialyl Lewis a, E-Cadherin and Cathepsin-D in Human Breast Cancer: Immunohistochemical Analysis in Mammary Carcinoma <i>In Situ</i> , Invasive Carcinomas and their Lymph Node Metastasis. U. JESCHKE, I. MYLONAS, N. SHABANI, C. KUNERT-KEIL, C. SCHINDLBECK, B. GERBER, K. FRIESE (<i>Munich; Karlsburg, Germany</i>)	1615
Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer. Z. AKÇETIN, J. TODOROV, E. TÜZEL, D.G. ENGEHAUSEN, F.S. KRAUSE, R. SAUER, K.M. SCHROTT, C. RÖDEL (<i>Erlangen, Germany</i>)	1623
Does the Distance to Normal Renal Parenchyma (DTNRP) in Nephron-sparing Surgery for Renal Cell Carcinoma have an Effect on Survival? Z. AKÇETIN, V. ZUGOR, D. ELSÄSSER, F.S. KRAUSE, B. LAUSEN, K.M. SCHROTT, D.G. ENGEHAUSEN (<i>Nuremberg, Germany</i>)	1629
Parathyroid Hormone-related Peptide (PTH-rp) in Normal, Hyperplastic and Malignant Endometrial Tissue: an Immunohistochemical Analysis. I. MYLONAS, J. MAKOVITZKY, N. SHABANI, D.-U. RICHTER, U. JESCHKE, V. BRIESE, K. FRIESE (<i>Munich; Rostock, Germany</i>)	1633
Measurement of Glycodelin A in Fluids of Benign Ovarian Cysts, Borderline Tumours and Malignant Ovarian Cancer. A. BISCHOF, V. BRIESE, D.-U. RICHTER, C. BERGEMANN, K. FRIESE, U. JESCHKE (<i>Rostock; München, Germany</i>).....	1639
Vaginal Metastasis of Lung Cancer: A Case Report. A. JAHNKE, R. DOMKE, J. MAKOVITZKY, H. NIZZE, V. BRIESE (<i>Rostock, Germany</i>).....	1645
Heat Shock Protein 27 is Associated with Decreased Survival in Node-negative Breast Cancer Patients. F. THANNER, M.W. SÜTTERLIN, M. KAPP, L. RIEGER, A.K. MORR, P. KRISTEN, J. DIETL, A.M. GASSEL, Th. MÜLLER (<i>Würzburg, Germany</i>).....	1649
Clinical Relevance of Tumor Markers for the Control of Chemotherapy. J. FINEK, L. HOLUBEC JR., O. TOPOLCAN, J. SALVET, R. PIKNER, S. HOLDENRIEDER, P. STIEBER, R. LAMERZ, L. HOLUBEC SEN, S. SVOBODOVA, V. VISOKAI, E. HELMICOVA (<i>Pilsen; Prague, Czech Republic; Munich, Germany</i>).....	1655
PSA Quick Test in Capillary Blood. H. LOERTZER, K. FISCHER, P. FORNARA (<i>Halle, Germany</i>)	1659

The Impact of Squamous Cell Carcinoma (SCC) Antigen in Patients with Advanced Cancer of Uterine Cervix Treated with (Chemo-)Radiotherapy. O. MICKE, F. BRUNS, U. SCHÄFER, F.-J. PROTT, N. WILLICH (<i>Münster, Germany</i>).....	1663
Tumor Markers (Pregnancy Protein 1, Placental-specific Tissue Protein 10, Placental-specific Tissue Protein 12, α 1-Fetoprotein) in Patients with Bronchial Carcinoma. V. BRIESE, D. G. SZABO, G. N. THAN, P. O. WILLROTH, J. BRIESE (<i>Rostock; Luebeck, Germany; Pécs, Hungary</i>).....	1667
Alpha-Fetoprotein-positive Carcinoma of the Pancreas: A Case Report. S.B. MUELLER, O. MICKE, H. HERBST, U. SCHAEFER, N. WILLICH (<i>Münster, Germany</i>).....	1671
Expression of the Thomsen-Friedenreich (TF) Tumor Antigen in Human Abort Placentas. D.-U. RICHTER, U. JESCHKE, C. BERGEMANN, J. MAKOVITZKY, F. LÜTHEN, U. KARSTEN, V. BRIESE (<i>Rostock; Munich; Berlin-Buch, Germany</i>).....	1675
Normal and Malignant Human Endometrium Express Immunohistochemically Estrogen Receptor Alpha (ER- α), Estrogen Receptor Beta (ER- β) and Progesterone Receptor (PR). I. MYLONAS, U. JESCHKE, N. SHABANI, C. KUHN, A. BALLE, S. KRIEGEL, M. S. KUPKA, K. FRIESE (<i>Munich, Germany</i>).....	1679
Further Evidence for Prolongation of Survival of Pancreatic Cancer Patients by Efficacy Orientated Sequential Polychemotherapy (EOSPC) Based on Serial Tumor Marker Determinations (CA 19-9/CEA). R. KLAPDOR, M. BAHLO, A. BABINSKY (<i>Hamburg, Germany</i>).....	1687
Diagnosis, Treatment and Follow-up Control in 124 Patients with Basal Cell Carcinoma of the Maxillofacial Region Treated from 1992 to 1997. R.E. FRIEDRICH, M. GIESE, L. LI, Y. SCHENK, R. SCHMELZLE (<i>Hamburg, Germany</i>).....	1693
Malignant Peripheral Nerve Sheath Tumors (MPNST) in Neurofibromatosis Type 1 (NF1): Diagnostic Findings on Magnetic Resonance Images and Mutation Analysis of the <i>NF1</i> Gene. R.E. FRIEDRICH, L. KLUWE, C. FÜNSTERER, V.F. MAUTNER (<i>Hamburg, Germany</i>).....	1699
Pleomorphic Adenoma of the Salivary Glands: Analysis of 94 Patients. R.E. FRIEDRICH, L. LI, J. KNOP, M. GIESE, R. SCHMELZLE (<i>Hamburg, Germany</i>).....	1703
Hyperfractionated Externally Irradiated Primary Oral Squamous Cell Carcinomas: Vital Tumor Cells in Resection Specimens. R.E. FRIEDRICH (<i>Hamburg, Germany</i>).....	1707
Serum Selenium in Head and Neck Cancer Patients – A New Marker of Tumor Activity? J. BÜNTZEL, O. MICKE, M. GLATZEL, D. FRÖHLICH, F. BRUNS, R. MÜCKE, K.G. SCHÖNEKAES (<i>Nordhausen; Münster; Suhl; Hannover; Wiesbaden; Minden, Germany</i>).....	1711
Stimulation of Endometrial Glandular Cells with Genistein and Daidzein and their Effects on ER α - and ER β -mRNA and Protein Expression. S. STAAR, D.-U. RICHTER, J. MAKOVITZKY, V. BRIESE, C. BERGEMANN (<i>Rostock, Germany</i>).....	1713
Expression of Her2/neu, Steroid Receptors (ER and PR), Ki67 and p53 in Invasive Mammary Ductal Carcinoma Associated with Ductal Carcinoma <i>In Situ</i> (DCIS) Versus Invasive Breast Cancer Alone. I. MYLONAS, J. MAKOVITZKY, U. JESCHKE, V. BRIESE, K. FRIESE, B. GERBER (<i>Munich; Rostock, Germany</i>).....	1719
Expression of Inhibin/Activin Subunits, Sialyl-Lewis A (CA 19-9, sLea) and Sialyl-Lewis X (sLex) Carbohydrate Antigens in a Hydatidiform Mole with Persistent Polymorphic Trophoblastic Hyperplasia. I. MYLONAS, J. MAKOVITZKY, M. VOGEL, N. SHABANI, U. JESCHKE, K. FRIESE (<i>Munich; Rostock; Berlin, Germany</i>).....	1725

TGF- α , c-erbB-2 Expression and Neoangiogenesis in Vulvar Squamous Cell Carcinoma. P. HANTSCHMANN, U. JESCHKE, K. FRIESE (<i>Altötting; München, Germany</i>)	1731
p53 Expression in Vulvar Carcinoma, Vulvar Intraepithelial Neoplasia, Squamous Cell Hyperplasia and Lichen Sclerosus. P. HANTSCHMANN, S. STERZER, U. JESCHKE, K. FRIESE (<i>Altötting; München, Germany</i>)	1739
S100 as an Immunohistochemically-detected Marker with Prognostic Significance in Endometrial Carcinoma. A. HONIG, N. SCHALLER, J. DIETL, J. BACKE, U. KAMMERER (<i>Wuerzburg, Germany</i>)	1747
Immunohistochemical Studies of Mucinous Mammary Carcinomas and their Metastases. L. GUNKEL, I. MYLONAS, D.U. RICHTER, J. MAKOVITZKY (<i>Rostock; Munich, Germany</i>)	1755
Expression of Glycodelin in Human Breast Cancer: Immunohistochemical Analysis in Mammary Carcinoma <i>In Situ</i> , Invasive Carcinomas and their Lymph Node Metastases. N. SHABANI, I. MYLONAS, C. KUNERT-KEIL, V. BRIESE, W. JANNI, B. GERBER, K. FRIESE, U. JESCHKE (<i>Munich; Karlsburg; Rostock, Germany</i>)	1761
CYFRA 21.1 in Patients with Cervical Cancer: Comparison with SCC and CEA. R. MOLINA, X. FILELLA, J.M. AUGÉ, E. BOSCH, A. TORNE, J. PAHISA, J.A. LEJARCEGUI, A. ROVIROSA, B. MELLADO, J. ORDI, A. BIETE (<i>Barcelona, Spain</i>)	1765
Pro-gastrin-releasing Peptide (ProGRP) in Patients with Benign and Malignant Diseases: Comparison with CEA, SCC, CYFRA 21-1 and NSE in Patients with Lung Cancer. R. MOLINA, J.M. AUGÉ, X. FILELLA, N. VIÑOLAS, J. ALICARTE, J.M. DOMINGO, A.M. BALLESTA (<i>Barcelona, Spain</i>)	1773
S-100 β and MIA in Advanced Melanoma in Relation to Prognostic Factors. J.M. AUGÉ, R. MOLINA, X. FILELLA, E. BOSCH, M. GONZALEZ CAO, S. PUIG, J. MALVEHY, T. CASTEL, A.M. BALLESTA (<i>Barcelona, Spain</i>)	1779
Heterogeneity in Prostate Cancer: Prostate Specific Antigen (PSA) and DNA Cytophotometry. F. STEFFEN KRAUSE, GERHARD FEIL, KARL-HORST BICHLER, KARL M. SCHROTT, ZIYA Y. AKCETIN, DIRK G. ENGEHAUSEN (<i>Erlangen; Tuebingen, Germany</i>)	1783
Adjuvant Radiochemotherapy of Stage II and III Rectal Adenocarcinoma: Role of CEA and CA 19-9. C. WEISSENBERGER, G. VON PLEHN, F. OTTO, A. BARKE, F. MOMM, M. GEISLER (<i>Freiburg, Germany</i>)	1787
Circulating Nucleosomes and Cytokeratin 19-Fragments in Patients with Colorectal Cancer During Chemotherapy. S. HOLDENRIEDER, L. HOLUBEC Jr., O. TOPOLCAN, J. FINEK, P. STIEBER (<i>Munich, Germany; Pilsen, Czech Republic</i>)	1795
Combination of Immunomagnetic Enrichment with Multiplex RT-PCR Analysis for the Detection of Disseminated Tumor Cells. V. ZIEGLSCHMID, C. HOLLMANN, B. GUTIERREZ, W. ALBERT, D. STROTHOFF, E. GROSS, O. BÖCHER (<i>Langenhagen; Hamburg, Germany</i>)	1803
Human Chorionic Gonadotropin (hCG) as Inhibitor of E-selectin-mediated Cell Adhesion. R. STAHN, S. GOLETZ, R. STAHN, R. WILMANOWSKI, X. WANG, V. BRIESE, K. FRIESE, U. JESCHKE (<i>Berlin; Rostock; Munich, Germany</i>)	1811
Flax-seed Extracts with Phytoestrogenic Effects on a Hormone Receptor-positive Tumour Cell Line. J. WALDSCHLÄGER, C. BERGEMANN, W. RUTH, U. EFFMERT, U. JESCHKE, D.-U. RICHTER, U. KRAGL, B. PIECHULLA, V. BRIESE (<i>Rostock; Munich, Germany</i>)	1817
Small Cell Carcinoma of the Endometrium: Light Microscopic and Immunohistochemical Study of a Case. A. STACHS, J. MAKOVITZKY, V. BRIESE (<i>Rostock, Germany</i>)	1823

Potential Impact of Molecular Imaging in Oncology. S. KLUTMANN, M. CLAUSEN (<i>Hamburg, Germany</i>)	1827
The Lectin <i>Helix pomatia</i> Agglutinin as a Marker of Metastases – Clinical and Experimental Studies. U. SCHUMACHER, S.A. BROOKS, J. MESTER (<i>Hamburg, Germany; Oxford, UK</i>)	1829
Changes of Thymidine Kinase (TK) During Adjuvant and Palliative Chemotherapy. O. TOPOLCAN, L. HOLUBEC Jr., J. FINEK, P. STIEBER, S. HOLDENRIEDER, R. LAMERZ, L. HOLUBEC Sen., S. SVOBODOVA, V. VISOKAI, L. LIPSKA (<i>Pilsen; Prague, Czech Republic; Munich, Germany</i>)	1831
Proliferative Markers in Diagnosis of Thyroid Tumors: A Comparative Study of MIB-1 and Topoisomerase II- α Immunostaining. M. LUDVÍKOVÁ, L. HOLUBEC Jr., A. RYSKA, O. TOPOLCAN (<i>Plzen; Hradec Králové, Czech Republic</i>).....	1835
* Reviews (pages 1483, 1501)	

Number 3B

Experimental Studies

WP-1034, A Novel JAK-STAT Inhibitor, with Proapoptotic and Antileukemic Activity in Acute Myeloid Leukemia (AML). S. FADERL, A. FERRAJOLI, D. HARRIS, Q. VAN, W. PRIEBE, Z. ESTROV (<i>Houston, TX, USA</i>)	1841
Functional Role of CD105 in TGF- β 1 Signalling in Murine and Human Endothelial Cells. K. WARRINGTON, M. CHANTAL HILLARBY, C. LI, M. LETARTE, S. KUMAR (<i>Manchester, UK; Toronto, Ont., Canada</i>)	1851
NLCQ-1 (NSC 709257) in Combination with Radiation Against Human Glioma U251 Xenografts. M.V. PAPAPOPOULOU, W.D. BLOOMER, M.G. HOLLINGSHEAD (<i>Evanston, IL; Frederick, MD, USA</i>).....	1865
Iressa (ZD 1839) Inhibits Phosphorylation of Three Different Downstream Signal Transducers in Head and Neck Cancer (SCCHN). M. HAMBEK, M. BAGHI, H. BAUMANN, K. STREBHARD, O. ADUNKA, W. GSTÖTTNER, R. KNECHT (<i>Frankfurt, Germany</i>).....	1871
The Cytotoxic Effect of Two Chemotypes of Essential Oils from the Fruits of <i>Angelica archangelica</i> L. S. SIGURDSSON, H.M. ÖGMUNSDOTTIR, S. GUDBJARNASON (<i>Reykjavik, Iceland</i>)	1877
Down-regulation of Skp2 is Correlated with p27-associated Cell Cycle Arrest Induced by Phenylacetate in Human Prostate Cancer Cells. T. SHIBAHARA, T. ONISHI, O.E. FRANCO, K. ARIMA, Y. SUGIMURA (<i>Tsu, Mie, Japan</i>)	1881
Development of a Modified Hollow Fibre Assay for Studying Agents Targeting the Tumour Neovasculature. S.D. SHNYDER, J. HASAN, P.A. COOPER, E. PILARINOU, E. JUBB, G.C. JAYSON, M.C. BIBBY (<i>Bradford; Manchester, UK; Tallahassee, FL, USA</i>)	1889
Her-2/neu Expression in Breast Cancer – A Comparison of Different Diagnostic Methods. P. BENÖHR, V. HENKEL, R. SPEER, U. VOGEL, K. SOTLAR, B. AYDENİZ, A. REISER, H. NEUBAUER, K. TABITI, D. WALLWIENER, S.E. CLARE, R. KUREK (<i>Göttingen; Tübingen, Germany; Indianapolis, IN, USA</i>)	1895
Membranous Expression and Prognostic Implications of Epidermal Growth Factor Receptor Protein in Human Renal Cell Cancer. A.S. MERSEBURGER, J. HENNENLOTTER, P. SIMON, S. KRUCK, E. KOCH, M. HORSTMANN, U. KUEHS, R. KÜFER, A. STENZL, M.A. KUCZYK (<i>Tübingen; Ulm, Germany</i>)	1901

Pamidronate and 1,24(S)-Dihydroxyvitamin D ₂ Synergistically Inhibit the Growth of Myeloma, Breast and Prostate Cancer Cells. D.P. WIGINGTON, S.A. STRUGNELL, J.C. KNUTSON (<i>Middleton, WI, USA</i>)	1909
Centrosome Impairments and Consequent Cytokinesis Defects are Possible Mechanisms of Taxane Drugs. J. ZHU, E.C. BEATTIE, Y. YANG, H.-J. WANG, J.-Y. SEO, L.-X. YANG (<i>San Francisco, CA, USA</i>)	1919
Telomerase Activity as a Marker of Invasive Ductal Breast Carcinomas on FNABs and Relationship to Other Prognostic Variables. A. KALOGERAKI, M. KAFOUSI, P. IEROMONACHOU, E. GIANNIKAKI, T. VREKOUSIS, O. ZORAS, D. TSIFTISIS, E. STATHOPOULOS (<i>Heraklion, Greece</i>)	1927
* The MLL Gene and Translocations Involving Chromosomal Band 11q23 in Acute Leukemia. M. DE BRAEKELEER, F. MOREL, M.-J. LE BRIS, A. HERRY, N. DOUET-GUILBERT (<i>Brest, France</i>)	1931
Intracellular Glutathione Levels Determine Cell Sensitivity to Apoptosis Induced by the Antineoplastic Agent N-(4-hydroxyphenyl)retinamide. M.-C. MORALES, G. PÉREZ-YARZA, N. NIETO-REMENTERIA, M.-D. BOYANO, M. JANGI, R. ATENCIA, A. ASUMENDI (<i>Bizkaia, Spain</i>)	1945
<i>In Vitro</i> and <i>In Vivo</i> Characterizations of Tetrandrine on the Reversal of P-Glycoprotein-mediated Drug Resistance to Paclitaxel. X. ZHU, M. SUI, W. FAN (<i>Charleston, SC, USA</i>)	1953
Depletion of CD8+ or CD4+ Lymphocytes Enhances Susceptibility to Transplantable Ultraviolet Radiation-induced Skin Tumours. A. VANBUSKIRK, T.M. OBERYSZYN, D.F. KUSEWITT (<i>Columbus, OH, USA</i>)	1963
Anticancer Activity of a Lectin-rich Mistletoe Extract Injected Intratumorally into Human Pancreatic Cancer Xenografts. M. ROSTOCK, R. HUBER, T. GREINER, P. FRITZ, R. SCHEER, J. SCHUELER, H.H. FIEBIG (<i>Freiburg; Stuttgart; Pforzheim, Germany</i>)	1969
High Hydrostatic Pressure-induced Cell Death in Human Chondrocytes and Chondrosarcoma Cells. F.-D. NAAL, K. MENGELE, J. SCHAUWECKER, H. GOLLWITZER, L. GERDESMEYER, U. REUNING, W. MITTELMEIER, R. GRADINGER, M. SCHMITT, P. DIEHL (<i>Muenchen; Rostock, Germany</i>)	1977
Cell Cycle Arrest and Apoptosis Induced by <i>SART-1</i> Gene Transduction. M. HOSOKAWA, R. KADOTA, S. SHICHIJO, K. ITOH, I. DMITRIEV, V. KRASNYKH, D.T. CUIEL, Y. TAKUE, H. WAKASUGI, S. TAKASHIMA, Y. HEIKE (<i>Tokyo; Ehime; Fukuoka, Japan; Birmingham, AL, USA</i>)	1983
Bioactivities of Anastasia Black (Russian Sweet Pepper). Y. SHIRATAKI, M. KAWASE, H. SAKAGAMI, H. NAKASHIMA, S. TANI, T. TANAKA, Y. SOHARA, Z. SCHELZ, J. MOLNAR, N. MOTOHASHI (<i>Saitama; Kanagawa, Tokyo, Japan; Szeged, Hungary</i>)	1991
P53 Expression in Small Cell Carcinoma of the Urinary Bladder: Biological and Prognostic Implications. XI. WANG, T.D. JONES, G.T. MACLENNAN, X.J. YANG, A. LOPEZ-BELTRAN, J.N. EBLE, M.O. KOCH, H. LIN, L.A. BALDRIDGE, M. TRETIAKOVA, L. CHENG (<i>Indianapolis, IN; Cleveland, OH; Chicago, IL; New Haven, CT, USA; Cordoba, Spain</i>)	2001
Does c-erbB-2 Play a Role in the First Steps of Lung Carcinogenesis? A.-P. MEERT, B. MARTIN, J.-M. VERDEBOUT, V. NINANE, J.-P. SCULIER (<i>Brussels, Belgium</i>)	2005
Quantitative Analysis of <i>BRCA1</i> , <i>BRCA2</i> and <i>Hmsh2</i> mRNA Expression in Colorectal Lieberkóhnien Adenocarcinomas and Matched Normal Mucosa: Relationship with Cellular Proliferation. L. LE CORRE, C. VISSAC-SABATIER, N. CHALABI, Y.-J. BIGNON, A. DAVER, A. CHASSEVENT, D.J. BERNARD-GALLON (<i>Clermont-Ferrand; Angers, France</i>)	2009
Targeting of Focal Adhesion Kinase by Flavonoids and Small-interfering RNAs Reduces Tumor Cell Migration Ability. Y.-T. HUANG, L.-T. LEE, P.-P.H LEE, Y.-S. LIN, M.-T. LEE (<i>Kaohsiung; Chia-I; Taipei, Taiwan, ROC</i>)	2017

Prognostic Significance of T Helper 1 and 2 and T Cytotoxic 1 and 2 Cells in Patients with Non-small Cell Lung Cancer. N. ITO, Y. SUZUKI, Y. TANIGUCHI, K. ISHIGURO, H. NAKAMURA, S. OHGI (<i>Tottori, Japan</i>)	2027
Tumor-specific Cytotoxicity of 3,5-Dibenzoyl-1,4-dihydropyridines. S. REZA M.D. MORSHED, K. HASHIMOTO, Y. MUROTANI, M. KAWASE, A. SHAH, K. SATOH, H. KIKUCHI, H. NISHIKAWA, J. MAKI, H. SAKAGAMI (<i>Saitama; Tokyo; Kanagawa, Japan; Rajkot, India</i>)	2033
* Nuclear Phospholipase C Signaling Through Type 1 IGF Receptor and its Involvement in Cell Growth and Differentiation. I. FAENZA, A.M. BILLI, M. YUNG FOLLO, R. FIUME, A.M. MARTELLI, L. COCCO, L. MANZOLI (<i>Bologna, Italy</i>)	2039
Influence of the Structure of New Anthracycline Antibiotics on their Biological Properties. M. WASOWSKA, I. OSZCZAPOWICZ, J. WIETRZYK, A. OPOLSKI, J. MADEJ, S. DZIMIRA, J. OSZCZAPOWICZ (<i>Warsaw; Wroclaw, Poland</i>)	2043
Oncolytic Herpesvirus with Secretable Angiostatic Proteins in the Treatment of Human Lung Cancer Cells. C.-T. YANG, Y.-C. LIN, C.-L. LIN, J. LU, X. BU, Y.-H. TSAI, W.W.-G JIA (<i>Chiayi; Taoyuan, Taiwan, ROC; Vancouver, BC, Canada</i>)	2049
Tumor-specificity and Apoptosis-inducing Activity of Stilbenes and Flavonoids. S. ALI CHOWDHURY, K. KISHINO, R. SATOH, K. HASHIMOTO, H. KIKUCHI, H. NISHIKAWA, Y. SHIRATAKI, H. SAKAGAMI (<i>Saitama, Japan</i>)	2055
Cyclooxygenase-2 Expression is Associated with Increased Size in Human Sporadic Colorectal Adenomas. C. PISANO, A. OTTAIANO, F. TATANGELO, M. DI BONITO, M. FALANGA, V.R. IAFFAIOLI, G. BOTTI, S. PIGNATA, A.M. ACQUAVIVA (<i>Naples, Italy</i>)	2065
(-)-Menthol Inhibits DNA Topoisomerases I, II α and β and Promotes NF- κ B expression in Human Gastric Cancer SNU-5 Cells. J.-P. LIN, H.-F. LU, J.-H. LEE, J.-G. LIN, T.-C. HSIA, L.-T. WU, J.-G. CHUNG (<i>Taichung; Taipei, Taiwan, ROC</i>)	2069
Paracrine Calcitonin in Prostate Cancer is Linked to CD44 Variant Expression and Invasion. K.A. ICZKOWSKI, A.L.OMARA-OPYENE, T.R. KULKARNI, M. PANSARA, G.V. SHAH (<i>Gainesville, FL; Monroe, LA, USA</i>).....	2075
Changes in Fluoride Sensitivity During <i>In Vitro</i> Senescence of Normal Human Oral Cells. R. SATOH, K. KISHINO, S. REZA, MD. MORSHED, F. TAKAYAMA, S. OTSUKI, F. SUZUKI, K. HASHIMOTO, H. KIKUCHI, H. NISHIKAWA, T. YASUI, H. SAKAGAMI (<i>Saitama, Japan</i>).....	2085
Efficient Testing of the <i>RET</i> Gene by DHPLC Analysis for MEN 2 Syndrome in a Cohort of Patients. K. PAZAITOU-PANAYIOTOU, A. KAPRARA, L. SARIKA, T. ZOVOILIS, I. BELOGIANNI, I. VAINAS, G. NASIOULAS (<i>Thessaloniki; Athens, Greece</i>).....	2091
The <i>In Vitro</i> Effect of Paclitaxel on a LacZ-transfected Malignant Transitional Cell Line. V. VATNE, J. LITLEKALSOEY, T. WENTZEL-LARSEN, J. HOSTMARK (<i>Bergen, Norway</i>).....	2097
Expression of Family A Melanoma Antigen in Human Gastric Carcinoma. E.J. JUNG, M.A KIM, H.S. LEE, H.K. YANG, Y.M. LEE, B.L. LEE, W.H. KIM (<i>Seoul, Korea</i>).....	2105
Effect of Chemotherapy on the Mutation Frequency of Ovarian Cancer Cells at the HPRT Locus. C. GERCEL-TAYLOR, J.J. SCOBEE, D.D. TAYLOR (<i>Louisville, KY, USA</i>)	2113
Sabarubicin- (MEN 10755) and Paclitaxel Show Different Kinetics in Nuclear Factor-KappaB (NF-kB) Activation: Effect of Parthenolide on their Cytotoxicity. D. BELLAROSA, M. BINASCHI, C.A. MAGGI, C. GOSO (<i>Pomezia, Italy</i>)	2119

Inhibitory Effect of Fucoidan on the Adhesion of Adenocarcinoma Cells to Fibronectin. J.M. LIU, J. BIGNON, F. HAROUN-BOUHEDJA, P. BITTOUN, J. VASSY, S. FERMANDJIAN, J. WDZIECZAK-BAKALA, C. BOISSON-VIDAL (<i>Paris; Gif sur Yvette; Villejuif, France</i>)	2129
Cytokine Expression in Colon Carcinoma. P.K. BAIER, G. WOLFF-VORBECK, S. EGGSTEIN, U. BAUMGARTNER, U.T. HOPT (<i>Freiburg, Germany</i>)	2135
Fractal Dimension as a Prognostic Factor for Laryngeal Carcinoma. A. DELIDES, I. PANAYIOTIDES, A. ALEGAKIS, A. KYROUDI, C. BANIS, A. PAVLAKI, E. HELIDONIS, C. KITTAS (<i>Piraeus; Athens; Heraklion, Greece</i>)	2141
Iodinated Nitroimidazoles as Radiosensitizers. W. KRAUSE, A. JORDAN, R. SCHOLZ, J.-L. MARTIN JIMENEZ (<i>Berlin, Germany; Madrid, Spain</i>)	2145
Frequent Methylation of p16 ^{INK4A} /p14 ^{ARF} Promoters in Tumorigenesis of Epstein-Barr Virus Transformed Lymphoblastoid Cell Lines. E. NAGY, G. VERESS, K. SZARKA, E. CSOMA, Z. BECK (<i>Debrecen, Hungary</i>)	2153
Mechanisms Involved in the Potentiation of Paclitaxel or 5-FU by the Hypoxic Cytotoxin NLCQ-1 (NSC 709257) <i>In Vitro</i> . M.V. PAPADOPOULOU, X. JI, W.D. BLOOMER (<i>Evanston, IL, USA</i>)	2161
Her2 Expression on Disseminated Tumor Cells from Bone Marrow of Breast Cancer Patients. S. BECKER, G. BECKER-PERGOLA, T. FEHM, D. WALLWIENER, E.-F. SOLOMAYER (<i>Tübingen, Germany</i>)	2171
<i>Ex Vivo</i> Expansion of Antitumor Cytotoxic Lymphocytes with Tumor-associated Antigen-loaded Dendritic Cells. A. GERVAIS, F. BOUET-TOUSSAINT, O. TOUTIRAI, C.T. DE LA PINTIERE, N. GENETET, V. CATROS-QUEMENER (<i>Rennes, France</i>)	2177
pRb2/p130, p107 and p53 Expression in Precancerous Lesions and Squamous Cell Carcinoma of the Uterine Cervix. M. CENCI, T. PISANI, D. FRENCH, M. ALDERISIO, A. VECCHIONE (<i>Rome, Italy</i>)	2187
Relationship between Topoisomerase II-DNA Cleavable Complexes, Apoptosis and Cytotoxic Activity of Anthracyclines in Human Cervix Carcinoma Cells. B.M. GRUBER, E.L. ANUSZEWSKA, I. BUBKO, A. GOZDZIK, W. PRIEBE, I. FOKT (<i>Warsaw, Poland; Houston, TX, USA</i>)	2193
Effects of Alpha-hederin and Thymoquinone, Constituents of <i>Nigella sativa</i> , on Human Cancer Cell Lines. S. ROONEY, M.F. RYAN (<i>Dublin, Ireland</i>)	2199
Induction of Apoptosis by <i>Eurycoma longifolia</i> Jack Extracts. T.T. THIAM, A.H. LOPE PIHIE (<i>Banggi, Selangor, Malaysia</i>)	2205
c-kit Expression in Dedifferentiated and Well-differentiated Liposarcomas; Immunohistochemistry and Genetic Analysis. S. TAYAL, E. CLASSEN, L. BEMIS, W.A. ROBINSON (<i>Denver, CO, USA</i>)	2215
Xanthorrhizol Induces Apoptosis <i>Via</i> the Up-regulation of Bax and p53 in HeLa Cells. N. ISMAIL, A.H. LOPE PIHIE, M. NALLAPAN (<i>Banggi, Selangor, Malaysia</i>)	2221
Antileukemic Activity of Glycated Fibrinogen-Methotrexate Conjugates. U. KANSKA, M. SALAH OMAR, R. BUDZYNSKA, D. NEVOZHAY, M. JAGIELLO, A. OPOLSKI, J. BORATYNSKI (<i>Wroclaw; Czestochowa, Poland</i>)	2229
Correlation between VDR Expression and Antiproliferative Activity of Vitamin D ₃ Compounds in Combination with Cytostatics. M. PELCZYNSKA, J. WIETRZYK, I. JAROSZEWICZ, D. NEVOZHAY, M. SWITALSKA, A. KUTNER, M. ZABEL, A. OPOLSKI (<i>Wroclaw; Warsaw; Czestochowa, Poland</i>)	2235
Cytotoxicity and Apoptosis-inducing Activity of Bisphenol A and Hydroquinone in HL-60 Cells. H. TERASAKA, Y. KADOMA, H. SAKAGAMI, S. FUJISAWA (<i>Saitama; Tokyo, Japan</i>)	2241

Polymorphisms of 5,10-Methylenetetrahydrofolate Reductase and Risk of Stomach Cancer in a Korean Population. J.K. KIM, S. KIM, J.H. HAN, H.J. KIM, S.Y. CHONG, S. P. HONG, S.G. HWANG, J.Y. AHN, K.Y. CHA, D. OH, N.K. KIM (<i>Seongnam, South Korea</i>).....	2249
Cytotoxicity of Cortivazol in Childhood Acute Lymphoblastic Leukemia. J. STYCZYNSKI, A. KURYLAK, M. WYSOCKI (<i>Torun, Poland</i>).....	2253
The Role of p27 in Controlling the Oxygen-dependent Checkpoint of Mammalian Cells in Late G ₁ . P. GRAFF, Ø. AMELLEM, J. SEIM, T. STOKKE, E.O. PETTERSEN (<i>Oslo, Norway</i>)	2259
Enterolactone Induces Apoptosis and Inhibits Growth of Colo 201 Human Colon Cancer Cells both <i>In Vitro</i> and <i>In Vivo</i> . N. DANBARA, T. YURI, M. TSUJITA-KYUTOKU, R. TSUKAMOTO, N. UEHARA, A. TSUBURA (<i>Osaka, Japan</i>).....	2269
ABSTRACTS OF THE SECOND INTERNATIONAL SYMPOSIUM ON VITAMIN D ANALOGS IN CANCER PREVENTION AND THERAPY, 7-8 May 2005, Lübeck, Germany.....	2277
ABSTRACTS OF THE INTERNATIONAL CONFERENCE ON OXIDATIVE STRESS IN SKIN BIOLOGY AND MEDICINE, 18-21 September 2003, Andros, Greece.....	2299
* Reviews (pages 1931, 2039)	

Number 3C

Clinical Studies

* Pharmacokinetics of Therapeutic Monoclonal Antibodies Used in Oncology. D. LEVÊQUE, S. WISNIEWSKI, F. JEHL (<i>Strasbourg, France</i>)	2327
* Contemporary Definitions of Tumor Specific Antigens, Immunogens and Markers as Related to the Adaptive Responses of the Cancer-bearing Host. J.H. COGGIN JR., A.L. BARSOUM, J.W. ROHRER, M. THURNHER, M. ZEIS (<i>Mobile, AL, USA; Innsbruck, Austria; Hamburg, Germany</i>)	2345
* Phytoestrogens in Cancer Prevention and Therapy – Mechanisms of their Biological Activity. J. WIETRZYK, G. GRYNKIEWICZ, A. OPOLSKI (<i>Wroclaw; Warsaw; Czestochowa, Poland</i>).....	2357
Differential Effect of Anti-apoptotic Genes <i>Bcl-xL</i> and <i>c-FLIP</i> on Sensitivity of MCF-7 Breast Cancer Cells to Paclitaxel and Docetaxel. Z. WANG, R. GOULET III, K.J. STANTON, M. SADARIA, H. NAKSHATRI (<i>Indianapolis, IN, USA</i>).....	2367
Intravesical Gemcitabine in Recurrent Superficial Bladder Carcinoma: Preliminary Results on Ablative Efficacy and Tolerability. F. CAMPODONICO, G. CANEPA, G. CAPPONI, L. BOZZO, M. MAFFEZZINI (<i>Genoa, Italy</i>).....	2381
Prognostic Role of p53 in Stage III Non-small Cell Lung Cancer. T. BERGHMANS, C. MASCAUX, B. MARTIN, V. NINANE, J.-P. SCULIER (<i>Brussels, Belgium</i>)	2385
Inhibition of Mammary Tumor Growth by a Novel Nontoxic Retinoid: Chemotherapeutic Evaluation of a C-Linked Analog of 4-HPR-Glucuronide. G.A. ALSHAFIE, J.R. WALKER, R.W. CURLEY JR., M. CLAGETT-DAME, M.A. HIGHLAND, N.J. NIEVES, L.A. STONEROCK, H. ABOU-ISSA (<i>Columbus, OH; Madison, WI, USA</i>)	2391

Caffeine-potentiated Chemotherapy for Metastatic Carcinoma and Lymphoma of Bone and Soft Tissue. M. HAYASHI, H. TSUCHIYA, N. YAMAMOTO, M. KARITA, T. SHIRAI, H. NISHIDA, A. TAKEUCHI, K. TOMITA (<i>Kanazawa, Japan</i>).....	2399
Feasibility Study of Adoptive Immunotherapy for Metastatic Lung Tumors Using Peptide-pulsed Dendritic Cell-activated Killer (PDAK) Cells. Y. YAMAGUCHI, K. OHTA, Y. KAWABUCHI, A. OHSHITA, R. OKITA, M. OKAWAKI, K. HIRONAKA, K. MATSUURA, T. TOGE (<i>Hiroshima, Japan</i>)	2407
Treatment of Giant Intramuscular Hemangioma: A Multistep Approach in Three Patients. S. BROZZETTI, A. POLISTENA, M. DE ANGELIS, M. BONONI, M. MICCINI, G. MAZZONI, A. TOCCHI (<i>Rome, Italy</i>)	2417
Is Total Laparoscopic Surgery for Endometrial Carcinoma at Risk of Local Recurrence? A Long-term Survival. R. SERACCHIOLI, S. VENTUROLI, M. CECCARINI, M. CANTARELLI, M. CECCARONI, E. PIGNOTTI, D. DE ALOYSIO, P. DE IACO (<i>Bologna; Rome; Verona, Italy</i>).....	2423
Phase I Study of Irinotecan and Amrubicin in Patients with Advanced Non-small Cell Lung Cancer. K. HOTTA, N. TAKIGAWA, K. KIURA, M. TABATA, S. UMEMURA, A. OGINO, A. UCHIDA, A. BESSHO, Y. SEGAWA, T. SHINKAI, N. NOGAMI, S. HARITA, N. OKIMOTO, H. UEOKA, M. TANIMOTO (<i>Okayama; Matsuyama; Fukuyama, Japan</i>).....	2429
Successful Treatment of Hypertrophic Osteoarthropathy by Gefitinib in a Case with Lung Adenocarcinoma. M. HAYASHI, A. SEKIKAWA, A. SAIJO, W. TAKADA, I. YAMAWAKI, S.-I. OHKAWA (<i>Tokyo, Japan</i>)	2435
Free / Total Prostate Specific Antigen Ratio for Prostate Cancer Detection: A Prospective Blind Study. C.-R. YANG, C.-K. SU, K.-Y. CHIU, H.-C. HO, Y.-C. OU, C.-LI.CHENG, H. LEE (<i>Taichung; Taipei; Hsien, Taiwan, ROC</i>)	2439
Therapeutic Administration of Pegfilgrastim Instead of Prophylactic Use. G.P. STATHOPOULOS, E. DIMOU, J. STATHOPOULOS, J. XYNOTROULAS (<i>Athens, Greece</i>).....	2445
Carotid Body Paraganglioma and SDHD Mutation in a Greek Family. C.D. LIAPIS, J.K. BELLOS, A. HALAPAS, P. LEMBESSIS, M. KOUTSILIERIS, A. KOSTAKIS (<i>Athens, Greece</i>).....	2449
Expression and Regulation of Retinoid-inducible Gene 1 (RIG1) in Breast Cancer. R.-Y. SHYU, S.-C. CHANG, J.-C. YU, S.-J. HSU, J.-M. CHOU, M.-S. LEE, S.-Y. JIANG (<i>Taipei, Taiwan, ROC</i>)	2453
Malignant Solitary Fibrous Tumor of the Thigh Accompanied by Hypoglycemic Coma. A Case Report. S. NAKAMURA, M. FUKUI, H. TAKESHITA, Y. TSUJI, H. MURATA, T. KUBO (<i>Kyoto, Japan</i>)	2461
Accuracy Rates of US-guided Vacuum-assisted Breast Biopsy. A. BONIFACINO, V. PETROCELLI, T. PISANI, S. GIANNERINI, A. GIOVAGNOLI, A. VECCHIONE, P.L. MINGAZZINI, M.R. GIOVAGNOLI (<i>Rome; Bologna, Italy</i>)	2465
High Expression of S-phase Kinase-associated Protein 2 (Skp2) is a Strong Prognostic Marker in Oral Squamous Cell Carcinoma Patients Treated by UFT in Combination with Radiation. K. HARADA, SUPRIATNO, S.-I. KAWAGUCHI, Y. KAWASHIMA, Y. ITASHIKI, H. YOSHIDA, M. SATO (<i>Tokushima, Japan</i>).....	2471
Ultrasound Contrast Media in the Study of Salivary Gland Tumors. A. GALLIPOLI, G. MANGANELLA, E. DE LUTIO DI CASTELGUIDONE, A. MASTRO, F.IONNA, L. PEZZULLO, P. VALLONE (<i>Naples, Italy</i>).....	2477
Phenotypic and Functional Characterization of Lymphocytes in Autoimmune Thyroiditis and in Papillary Carcinoma. S. MARDENTE, L. LENTI, E. LOCOCO, F. CONSORTI, C. DELLA ROCCA, S. ROMEO, R. MISASI, A. ANTONACI (<i>Rome, Italy</i>).....	2483

Vinorelbine and Cisplatin in Advanced Squamous Cell Carcinoma of the Cervix: The South African Experience. L. GOEDHALS, G. FALKSON, B. LYNN SMITH, C.I. FALKSON, J. GASMI, A. LATEGAN, J.-P. BURILLON, P. HIS (<i>Pretoria; Sandton, South Africa</i>).....	2489
Intravesical Gemcitabine in Superficial Bladder Cancer: a Phase II Safety, Efficacy and Pharmacokinetic Study. F. MATTIOLI, A. CUROTTO, V. MANFREDI, M. GOSMAR, C. GARBERO, C. AMBRUOSI, G. CARMIGNANI, A. MARTELLI (<i>Genoa, Italy</i>).....	2493
* A Practical Overview of Aromatase Inhibitors. J. YOUNUS, T.A. VANDENBERG (<i>London, Ont., Canada</i>)	2497
Possible Mechanism Connected with the Progression of Submucosal Invasion in Colorectal Neoplasias. C.A. RUBIO (<i>Stockholm, Sweden</i>)	2503
Neutropenic Enterocolitis in an Advanced Epithelial Ovarian Cancer Patient Treated with Paclitaxel/Platinum-based Chemotherapy: A Case Report and Review of the Literature. A. GADDUCCI, A. GARGINI, E. PALLA, A. FANUCCHI, A.R. GENAZZANI (<i>Pisa, Italy</i>)	2509
Sulfotransferase1A1 and Risk of Postmenopausal Breast Cancer. P.-L. JEREVALL, A. AHMADI, M. BERGMAN, O. STÅL, S. WINGREN (<i>Linköping, Sweden</i>)	2515
Neoadjuvant Chemotherapy in Breast Cancer: Which Diagnostic Procedures Can be Used? C.R. LOEHLBERG, M.P. LUX, S. ACKERMANN, U.G. POEHLS, M.R. BANI, R. SCHULZ-WENDTLAND, T. PAPADOPOULOS, M. SCHMUCKER, M.W. BECKMANN, P.A. FASCHING (<i>Erlangen, Germany</i>)	2519
Anxiety, Depression, and the History of Psychiatric Symptoms in Patients with Breast Disease: A Prospective Case-control Study in Kuopio, Finland. P. OLLONEN, J. LEHTONEN, M. ESKELINEN (<i>Kuopio, Finland</i>)	2527
Immunohistochemical Staining of Estrogen and Progesterone Receptors: Aspects for Evaluating Positivity and Defining the Cutpoints. P. JALAVA, T. KUOPIO, R. HUOVINEN, J. LAINE, Y. COLLAN (<i>Turku; Jyväskylä, Finland</i>).....	2535
Recorded Quadrant Incidence of Female Breast Cancer in Great Britain Suggests a Disproportionate Increase in the Upper Outer Quadrant of the Breast. P.D. DARBRE (<i>Reading, UK</i>).....	2543
Development of a Safety Index of Transarterial Chemoembolization for Hepatocellular Carcinoma to Prevent Acute Liver Damage. J.-I. HWANG, W.-K. CHOW, S.-W. HUNG, T.-C. LI, Y.-P. CHENG, Y.-J. HO, C.-C. LIN (<i>Taichung, Taiwan, ROC</i>)	2551
Carboplatin and Weekly Paclitaxel in Non-small Cell Lung Cancer Patients Unfit for or Pretreated with Chemotherapy. G. NUMICO, I. COLANTONIO, M. GASCO, G. BERTELLI, O. GARRONE, M. OCCELLI, E. FEA, G. DI COSTANZO, C. GRANETTO, A. HEOUAINE, E. RUSSI, M. MERLANO (<i>Cuneo, Italy; Swansea, UK</i>)	2555
Are Factor V and Prothrombin Mutations Associated with Increased Risk of Oral Cancer? E. VAIRAKTARIS, C. YAPIJAKIS, J. WILTFANG, J. RIES, A. VYLLIOTIS, S. DERKA, S. VASILIOU, F.W. NEUKAM (<i>Athens, Greece; Erlangen, Germany</i>)	2561
Gastric Mucosa Alterations in First-degree Relatives of Gastric Cancer Patients. A. ROMITI, A. ZULLO, S. TOMAO, C. HASSAN, I. SARCINA, V. DE FRANCESCO, E. IERARDI, F. TOMAO, A. VECCHIONE, S. MORINI (<i>Rome; Foggia, Italy</i>).....	2567
Up-regulation of Eukaryotic Elongation Factor-1 Subunits in Breast Carcinoma. M. AL-MAGHREBI, J.T. ANIM, A.A. OLALU (<i>Safat, Kuwait</i>)	2573

Successful Treatment of a Patient with Synchronous Advanced Non-small Cell Lung Cancer and Acute Myeloid Leukemia by a Combination of Gefitinib, Low-dose Cytarabine and Aclarubicin. N.TAKIGAWA, M. TAKEUCHI, T. SHIBAYAMA, I. YOSHIDA, N. KAWATA, A. TADA, H. UEOKA, K. TAKAHASHI (<i>Okayama, Japan</i>).....	2579
High-dose Methotrexate Prior to Simultaneous Radiochemotherapy in Children with Malignant High-grade Gliomas. S. WAGNER, C. REINERT, H.-J. SCHMID, A.-K. LIEBESKIND, N. JORCH, A. LÄNGLER, N. GRAF, M. WARMUTH-METZ, T. PIETSCH, O. PETERS, J.E.A. WOLFF (<i>Regensburg; Hannover; Berlin; Bielefeld; Herdecke; Homburg; Würzburg; Bonn, Germany; Calgary, AB, Canada</i>)	2583
The Role of DNA Ploidy and Ki-67 in the Grading of Mucoepidermoid Carcinomas. W.F.P. VAN HEERDEN, E.J. RAUBENHEIMER, L. DREYER (<i>Pretoria, South Africa</i>)	2589
Intracellular and Extracellular myo-Inositol Hexakisphosphate (InsP ₆), from Rats to Humans. F. GRASES, A. COSTA-BAUZA, R.M. PRIETO (<i>Palma of Mallorca, Spain</i>).....	2593
Errata	2599
* Reviews (pages 2327, 2345, 2357, 2497)	

Number 4

Experimental Studies

* Murine Polyomavirus Virus-like Particles (VLPs) as Vectors for Gene and Immune Therapy and Vaccines against Viral Infections and Cancer. K. TEGERSTEDT, A. VLASTOS FRANZÉN, K. ANDREASSON, J. JONEBERG, S. HEIDARI, T. RAMQVIST, T. DALIANIS (<i>Stockholm, Sweden</i>).....	2601
Pharmacological Modulation of Lung Cancer Cells for Potassium Ion Depletion. B. ANDERSSON, P. BEHNAM-MOTLAGH, R. HENRIKSSON, K. GRANKVIST (<i>Umea, Sweden</i>)	2609
* The Elastin Connection and Melanoma Progression. W. HORNEBECK, A. ROBINET, L. DUCA, F. ANTONICELLI, J. WALLACH, G. BELLON (<i>Reims; Lyon, France</i>).....	2617
<i>RUNX3</i> Promoter Region is Specifically Methylated in Poorly-differentiated Colorectal Cancer. Y. IMAMURA, K. HIBI, M. KOIKE, M. FUJIWARA, Y. KODERA, K. ITO, A. NAKAO (<i>Nagoya, Japan</i>)	2627
Pretreatment with Interferon- α Radiosensitizes Daudi Cells Modulating Gene Expression and Biomarkers. J. Horiguchi-Yamada, S. IWASE, T. KAWANO, H. YAMADA (<i>Tokyo, Japan</i>).....	2631
Growth Inhibitory Effect of D-allose on Human Ovarian Carcinoma Cells <i>In Vitro</i> . L. SUI, Y. DONG, Y. WATANABE, F. YAMAGUCHI, N. HATANO, K. IZUMORI, M. TOKUDA (<i>Kagawa, Japan</i>)	2639
<i>DHX32</i> Expression Suggests a Role in Lymphocyte Differentiation. M. ABDELHALEEM, T.-H. SUN, M. HO (<i>Toronto, Ont., Canada</i>)	2645
The Evaluation of Thermal Cisplatin Sensitization in Normal and XP Human Cells Using Mild Hyperthermia at 40 and 41°C. G.P. RAAPHORST, D.P. YANG (<i>Ottawa, Ont., Canada</i>)	2649
Alendronate Inhibits Proliferation and Invasion of Human Epidermoid Carcinoma Cells <i>In Vitro</i> . S. MULLER, E. MIGIANU, M. LECOUEVEY, M. KRAEMER, O. OUDAR (<i>Bobigny, France</i>)	2655
Gene Expression Profiling in Chemoresistant Variants of Three Cell Lines of Different Origin. A. JOHNSON, J. VALLON-CHRISTENSSON, C. STRAND, T. LITMAN, J. ERIKSEN (<i>Lund, Sweden; Copenhagen, Denmark</i>)	2661

Cyclooxygenase-2 Expression in Human Soft-tissue Sarcomas is Related to Epithelial Differentiation. P. LASSUS, A. RISTIMÄKI, R. HUUHTANEN, E. TUKIAINEN, S. ASKO-SELJAVAARA, L.C. ANDERSSON, M. MIETTINEN, C. BLOMQVIST, C. HAGLUND, T. BÖHLING (<i>Helsinki, Finland; Washington DC, USA</i>)	2669
Cytokeratins 6 and 16 are Frequently Expressed in Head and Neck Squamous Cell Carcinoma Cell Lines and Fresh Biopsies. A.M. SESTERHENN, R. MANDIC, A.A. DÜNNE, J.A. WERNER (<i>Marburg, Germany</i>)	2675
Acetyl-L-Carnitine Prevents and Reverts Experimental Chronic Neurotoxicity Induced by Oxaliplatin, without Altering its Antitumor Properties. O. GHIRARDI, P. LO GIUDICE, C. PISANO, M. VERTECHY, A. BELLUCCI, L. VESCI, S. CUNDARI, M. MILOSO, L.M. RIGAMONTI, G. NICOLINI, C. ZANNA, P. CARMINATI (<i>Rome; Monza, Italy</i>)	2681
Effects of Calcitriol, Seocalcitol and Medium-chain Triglyceride on a Canine Transitional Cell Carcinoma Cell Line. T. KAEWSAKHORN, W.C. KISSEBERTH, C.C. CAPEN, K.A. HAYES, M.J. CALVERLEY, N. INPANBUTR (<i>Columbus, OH, USA; Lyngby, Denmark</i>)	2689
Mcl-1 Blocks Radiation-induced Apoptosis and Inhibits Clonogenic Cell Death. H. SKVARA, C. THALLINGER, V. WACHECK, B.P. MONIA, H. PEHAMBERGER, B. JANSEN, E. SELZER (<i>Vienna, Austria; Carlsbad, CA, USA; Vancouver, BC, Canada</i>)	2697
Myofibroblasts Correlate with Lymphatic Microvessel Density and Lymph Node Metastasis in Early-stage Invasive Colorectal Carcinoma. P. LIANG, J.-W. HONG, H. UBUKATA, G. LIU, M. KATANO, G. MOTOHASHI, T. KASUGA, Y. WATANABE, I. NAKADA, T. TABUCHI (<i>Ibaraki, Japan</i>)	2705
Modulation of Anti-apoptosis by Endogenous IAP Expression in MKN45 Human Gastric Cancer Cells. K. ENDO, S. KOHNOE, E. TSUJITA, A. WATANABE, H. NAKASHIMA, H. BABA, Y. MAEHARA (<i>Fukuoka, Japan</i>)	2713
Radioimmunotherapy and Apoptotic Induction on Ck19-overexpressing Human Cervical Carcinoma Cells with Re-188-mAbCx-99. C.-H. CHANG, L.-C. TSAI, S.-T. CHEN, C.-C. YUAN, M.-W. HUNG, B.-T. HSIEH, P.-L. CHAO, T.-H. TSAI, T.-W. LEE (<i>Taoyuan; Taipei; Taichung, Taiwan, ROC</i>)	2719
Involvement of ABC Transporters in Chemosensitivity of Human Renal Cell Carcinoma, and Regulation of MRP2 Expression by Conjugated Bilirubin. M. NOMURA, T. MATSUNAMI, K. KOBAYASHI, T. UCHIBAYASHI, K. KOSHIDA, M. TANAKA, M. NAMIKI, Y. MIZUHARA, T. AKIBA, K. YOKOGAWA, S. MORITANI, K.-I. MIYAMOTO (<i>Kanazawa; Tonami; Fukui, Japan</i>)	2729
Exogenous Expression of hRFI Induces Multidrug Resistance through Escape from Apoptosis in Colorectal Cancer Cells. T. KONISHI, S. SASAKI, T. WATANABE, J. KITAYAMA, H. NAGAWA (<i>Tokyo, Japan</i>)	2737
Endothelial p21 ^{WAF1/Cip1} Cell Cycle Inhibitor is Down-regulated in Breast Cancer. T. VREKOUSSIS, E.N. STATHOPOULOS, M. KAFOUSI, Z. SARIDAKI, E.SANIDAS, O. ZORAS (<i>Heraklion, Greece</i>)	2743
Predictors of Response to Chemo-radiotherapy and Radiotherapy for Esophageal Squamous Cell Carcinoma. T. MIYAZAKI, H. KATO, A. FARIED, M. SOHDA, M. NAKAJIMA, Y. FUKAI, N. MASUDA, R. MANDA, M. FUKUCHI, H. OJIMA, K. TSUKADA, H. KUWANO (<i>Gunma, Japan</i>)	2749
Recombinant Interleukin-2 Enhanced the Antitumor Effect of ADV/RSV-HSV-tk/ACV Therapy in a Murine Bladder Cancer Model. S. TERAOKA, T. SHIRAKAWA, K. GODA, S. KAMIDONO, M. FUJISAWA, A. GOTOH (<i>Kobe, Japan</i>)	2757
Serum Levels of Interleukin-6 in Patients with Primary Head and Neck Squamous Cell Carcinoma. F. RIEDEL, I. ZAISS, D. HERZOG, K. GÖTTE, R. NAIM, K. HÖRMANN (<i>Mannheim, Germany</i>)	2761

p53 Intronic G13964C Variant in Colon Cancer and its Association with HPV. N. BUYRU, A. TEZOL, N. DALAY (<i>Istanbul, Turkey</i>).....	2767
Microsatellite Analyses of Recurrence or Second Primary Tumor in Head and Neck Cancer. D. RONCHETTI, E. ARISI, A. NERI, G. PRUNERI, B. DIGIUNI, G. SAMBATARO, O. GALLO, L. PIGNATARO (<i>Milan; Florence, Italy</i>).....	2771
An Experimental Study on the Therapeutic Effect of Consecutive Low-dose Cisplatin with Caffeine in Sarcoma-bearing Mice. A. TAKEDA, H. TSUCHIYA, T. TAJINO, S.-I. KIKUCHI (<i>Fukushima, Kanazawa, Japan</i>).....	2777
Microsatellite Status and Immunohistochemical Features of Ovarian Clear-cell Carcinoma. H. UEDA, Y. WATANABE, H. NAKAI, H. HEMMI, M. KOI, H. HOSHIAI (<i>Osaka; Tokyo, Japan; Middlesex, UK</i>).....	2785
Cytokeratin Expression Correlates with Aneuploidy in Cytological Specimens of Melanoma Metastases. M. KORABIOWSKA, I. RUSCHENBURG, H. SCHULZ, A. STEINACKER, P. BORTKIEWICZ, M. SEVENICH, U. BRINCK, C. CORDON-CARDO, G. FISCHER (<i>Wilhelmshaven; Einbeck; Leer, Germany; Poznan, Poland; New York, NY, USA</i>).....	2789
Suppression of Tumour-promoting Factors in Fat-induced Colon Carcinogenesis by the Antioxidants Caroverine and Ubiquinone. H. NOHL, N. ROHR-UDILOVA, L. GILLE, W. BIEBERSCHULTE, D. JUREK, B. MARIAN, R. SCHULTE-HERMAN (<i>Vienna, Austria; Schaanwald, Liechtenstein</i>).....	2793
A Hematopoietic Stromal Lesion Associated with Fractionated Radiotherapy (FxRT): Time- and Dose-effects. C. J. KOVACS, M. J. EVANS, B.M. DALY (<i>Greenville, NC, USA</i>).....	2801
Active Succinate Dehydrogenase (SDH) and Lack of <i>SDHD</i> Mutations in Sporadic Paragangliomas. S. BRAUN, K. RIEMANN, S. KUPKA, P. LEISTENSCHNEIDER, K. SOTLAR, H. SCHMID, N. BLIN (<i>Tübingen, Germany</i>).....	2809
Simultaneous Precise Chemoradiation under Inhalation Anesthesia in an Experimental Mouse Tumor Model. M. ADAM, J. HENKE, C. NIEDER, W. ERHARDT, M. MOLLS (<i>Weilheim; München, Germany</i>).....	2815
Soluble CD44v6 is Not a Sensitive Tumor Marker in Patients with Head and Neck Squamous Cell Cancer. M. ANDRATSCHKE, S. CHAUBAL, C. PAULI, B. MACK, H. HAGEDORN, B. WOLLENBERG (<i>Munich; Lübeck, Germany</i>).....	2821
Control of Sulfatase Activity by Nomegestrol Acetate in Normal and Cancerous Human Breast Tissues. G.S. CHETRITTE, J.-L. THOMAS, J. SHIELDS-BOTELLA, J. CORTES-PRIETO, J.-C. PHILIPPE, J.R. PASQUALINI (<i>Paris, France; Monaco, Monaco; Madrid, Spain</i>).....	2827
2,3,7,8-Tetrachlorodibenzo-p-dioxin Activates ERK and p38 Mitogen-activated Protein Kinases in RAW 264.7 Cells. S.-J. PARK, W.-K. YOON, H.-J. KIM, H.-Y. SON, S.-W. CHO, K.-S. JEONG, T.-H. KIM, S.-H. KIM, S.-R. KIM, S.-Y. RYU (<i>Daegu; Daejeon; Kwangju, South Korea</i>).....	2831
<i>In Vitro</i> Anticancer Activity of Cyanidin-3-O- β -Glucopyranoside: Effects on Transformed and Non-transformed T Lymphocytes. C. FIMOIGNARI, F. BERTI, M. NÜSSE, G. CANTELLI-FORTI, P. HRELIA (<i>Bologna, Italy; Neuherberg, Germany</i>).....	2837
Hypoxia Alters Cathepsin B / Inhibitor Profiles in Oral Carcinoma Cell Lines. N.S. WICKRAMASINGHE, K. BANERJEE, N.S. NAGAR, N. VIGNESWARAN, W. ZACHARIAS (<i>Louisville, KY; Houston, TX, USA</i>).....	2841

Effects of Glycosaminoglycans on Cell Proliferation of Normal Osteoblasts and Human Osteosarcoma Cells Depend on their Type and Fine Chemical Compositions. D. NIKITOVIC, A. ZAFIROPOULOS, G.N. TZANAKAKIS, N.K. KARAMANOS, A.M. TSATSAKIS (<i>Heraklion; Patras, Greece</i>)	2851
Biological Evaluation of ω -(Dialkylamino)alkyl Derivatives of 6H-indolo[2,3-b]quinoline – Novel Cytotoxic DNA Topoisomerase II Inhibitors. J. GODLEWSKA, W. LUNIEWSKI, B. ZAGRODZKI, L. KACZMAREK, A. BIELAWSKA-POHL, D. DUS, J. WIETRZYK, A. OPOLSKI, M. SIWKO, A. JAROMIN, A. JAKUBIAK, A. KOZUBEK, W. PECZYŃSKA-CZOCH (<i>Warszawa; Wroclaw; Czestochowa, Poland</i>)	2857
Effect of Fraxiparine and Heparin on Experimental Tumor Metastasis in Mice. B. SZENDE, S. PAKU, G. RÁCZ, L. KOPPER (<i>Budapest, Hungary</i>)	2869
Radiation Sensitizing Effect of Estramustine is not Dependent on Apoptosis. K. STÅHLBERG, K. KAIREMO, K. ERKKILÄ, V. PENTIKÄINEN, P. SORVARI, K. TAARI, L. DUNKEL, S. RANNIKKO (<i>Helsinki, Finland</i>)	2873
E-cadherin and Fibronectin Expressions Have No Prognostic Role in Stage II Ductal Breast Cancer. G. SWIATONIEWSKI, R. MATKOWSKI, E. SUDER, S. BRUZEWICZ, M. SETTA, J. KORNAFEL, A. POLOZOWSKI, P. SUROWIAK (<i>Wroclaw, Poland</i>)	2879
Molecular Prognostic Markers in Recurrent and in Non-recurrent Epithelial Ovarian Cancer. A. DEMETER, I. SZILLER, Z. CSAPO, J. OLAH, G. KESZLER, A. JENEY, Z. PAPP, M. STAUB (<i>Budapest, Hungary</i>)	2885
* Prostate Cancer and Inositol Hexaphosphate: Efficacy and Mechanisms. R.P. SINGH, R. AGARWAL (<i>Denver, CO, USA</i>)	2891
Immunotherapy with T11TS / S-LFA-3 Specifically Induces Apoptosis of Brain Tumor Cells by Augmenting Intracranial Immune Status. J. MUKHERJEE, A. GHOSH, P. SARKAR, M. MAZUMDAR, C. BANERJEE, S. CHAUDHURI (<i>Kolkata, West Bengal, India</i>)	2905
Clinical Studies	
HER-2/neu Overexpression and Hormone Dependency in Endometrial Cancer: Analysis of Cohort and Review of Literature. A. MARIANI, T.J. SEBO, J.A. KATZMANN, D.L. RIEHLE, S.C. DOWDY, G.L. KEENEY, T.G. LESNICK, K.C. PODRATZ (<i>Rochester, MN, USA</i>)	2921
Severity and Duration of Chronic Dysphagia Following Treatment for Head and Neck Cancer. N.P. NGUYEN, C.C. MOLTZ, C. FRANK, U. KARLSSON, H.J. SMITH, P.D. NGUYEN, P. VOS, L.M. NGUYEN, S. ROSE, S. DUTTA, S. SALLAH (<i>Dallas, TX; Greenville, NC; Ann Arbor, MI; Los Angeles, CA, USA; Copenhagen, Denmark</i>)	2929
New Diagnostic Imaging of Gastrointestinal Tumors: A Preliminary Study of Three-dimensional Tumor Structure and Volumetry. S. KIKUCHI, M. KIDA, K. KOBAYASHI, T. YANO, S. SAKURAMOTO, M. WATANABE, K. KUBOTA, Y. ISOBE (<i>Kanagawa, Japan</i>)	2935
Predictive Value of EphA2 and EphrinA-1 Expression in Oesophageal Squamous Cell Carcinoma. F. XU, W. ZHONG, J. LI, Z. SHANSHEN, J. CUI, J.M. NESLAND, Z. SUO (<i>Oslo, Norway; Henan, China</i>)	2943
Postradiation Malignant Fibrous Histiocytoma and Osteosarcoma of a Patient with High Telomerase Activities. T. MATSUO, T. SUGITA, S. SHIMOSE, T. KUBO, Y. YASUNAGA, E. HIYAMA, M. OCHI (<i>Hiroshima, Japan</i>)	2951
Local Control by Breast-conserving Surgery with Nipple Resection. J. HORIGUCHI, Y. KOIBUCHI, K. IJIMA, T. YOSHIDA, D. TAKATA, N. ROKUTANDA, R. NAGAOKA, T. OYAMA, Y. IINO, H. SAKURAI, Y. MORISHITA (<i>Gunma, Japan</i>)	2957

Topical Budesonide for Treating Giant Rectal Pseudopolyposis. C. PILICHOS, A. PREZA, M. DEMONAKOU, D. KAPATSORIS, C. BOURAS (<i>Athens, Greece</i>)	2961
AFP-producing Hepatoid Adenocarcinoma in Association with Barrett's Esophagus with Multiple Liver Metastasis Responding to Paclitaxel/CDDP: A Case Report. N. CHIBA, T. YOSHIOKA, M. SAKAYORI, Y. MIKAMI, S. MIYAZAKI, S. AKIYAMA, K. OTSUKA, G. YAMAURA, H. SHIBATA, S. KATO, S. KATO, C. ISHIOKA (<i>Sendai, Japan</i>)	2965
Cyclooxygenase-2 Expression in Brain Metastases. A. KARIM, M. FOWLER, L. JONES, R. PATWARDHAN, P. VANNEMREDDY, K. MCCARTHY, A. NANDA (<i>Shreveport, LA, USA</i>)	2969
Phase II Study of Docetaxel Plus Cisplatin as a Second-line Combined Therapy in Patients with Advanced Gastric Carcinoma. C. KUNISAKI, T. IMADA, R. YAMADA, S. HATORI, H. ONO, Y. OTSUKA, G. MATSUDA, M. NOMURA, H. AKIYAMA, A. KUBO, H. SHIMADA (<i>Yohohama; Yokosuka, Japan</i>)	2973
* Impact of Cytogenetic and Molecular Cytogenetic Studies on Hematologic Malignancies. A. KOLIALEXI, G.TH. TSANGARIS, S. KITSIOU, E. KANAVAKIS, A. MAVROU (<i>Athens, Greece</i>)	2979
Pharmacokinetics and Metabolism of Irinotecan Combined with Capecitabine in Patients with Advanced Colorectal Cancer. M. CZEJKA, J. SCHUELLER, K. HAUER, E. OSTERMANN (<i>Vienna, Austria</i>)	2985
Phase II Study of Cisplatin-combined Schedules as Second-line Chemotherapy in Patients with Non-small Cell Lung Cancer. M. VESLEMES, D. ANTONIOU, N. GEORGATOU, P. GIAMBOUDAKIS, J. DIMITROULIS, K. KATIS, G.P. STATHOPOULOS (<i>Athens, Greece</i>)	2991
Clinical Application of Immunoreactivity of Dihydropyrimidine Dehydrogenase (DPD) in Gastric Scirrhus Carcinoma Treated with S-1, a New DPD Inhibitory Fluoropyrimidine. T. SHIMIZU, Y. YAMADA, H. YASUI, K. SHIRAO, M. FUKUOKA (<i>Tokyo; Osaka, Japan</i>)	2997
Expression of Hypoxia-inducible Factor (HIF-1 α), VEGF-C and VEGF-D in Non-invasive and Invasive Breast Ductal Carcinomas. K. OKADA, M. OSAKI, K. ARAKI, K. ISHIGURO, H. ITO, S. OHGI (<i>Tottori, Japan</i>)	3003
* Telomere Attrition as Ageing Biomarker. S. BEKAERT, T. DE MEYER, P. VAN OOSTVELDT (<i>Ghent, Belgium</i>)	3011
Impact of Spleen Preservation in Patients with Gastric Cancer. M. FATOUROS, D.H. ROUKOS, M. LORENZ, I. ARAMPATZIS, C. HOTTENTROTT, A. ENCKE, A.M. KAPPAS (<i>Ioannina, Greece; Frankfurt/Main, Germany</i>)	3023
Systemic Lipoplatin Infusion Results in Preferential Tumor Uptake in Human Studies. T. BOULIKAS, G.P. STATHOPOULOS, N. VOLAKAKIS, M. VOUGIOUKA (<i>Mountain View, CA, USA; Athens, Greece</i>)	3031
* The Biological Role of Smoking, Oral Contraceptive Use and Endogenous Sexual Steroid Hormones in Invasive Squamous Epithelial Cervical Cancer. D. HELLBERG, U. STENDAHL (<i>Falun; Uppsala; Umea, Sweden</i>)	3041
Combined Treatment of Metastatic Breast Cancer (MBC) by High-dose Chemotherapy (HDCT) and Bispecific Antibodies: A Pilot Study. H.J. STEMMLER, C. SALAT, H. LINDHOFER, H. MENZEL, M. UNTCH, S. KAHLERT, G. KONECNY, H. SAUER, G. LEDDEROSE, V. HEINEMANN, H.J. KOLB (<i>Munich, Germany</i>)	3047
Chemoradiation is a Tolerable Therapy for Older Adults with Esophageal Cancer. S. NALLAPAREDDY, G.E. WILDING, G. YANG, R. IYER, M. JAVLE (<i>Buffalo, NY, USA</i>)	3055
Investigation of HER2 Overexpression in Non-small Cell Lung Cancer. K. UGOCSAI, L. MÁNDOKY, L. TISZLAVICZ, J. MOLNÁR (<i>Budapest, Hungary</i>)	3061

Hepatocellular Carcinoma in Hepatectomized Patients: Biologic and Therapeutic Implications. T. MAKATSORIS, T. PETSAS, A.C. TSAMANDAS, N. PAGONI, Z. PAPATHANASSIOU, D. KARAVIAS, C. KARATZA, D. KARDAMAKIS, H. KALOFONOS (<i>Patras, Greece</i>).....	3067
Microvascular Density of Breast Cancer in Bone Metastasis: Influence of Therapy. T. LÖRINCZ, J. TÓTH, M. SZENDRÖI, J. TÍMÁR (<i>Budapest, Hungary</i>)	3075
Nuclear Area is a Prognostic Determinant in Advanced Colorectal Cancer. A. BUHMEIDA, R. RISTAMÁKI, H. LAMLUM, R. BENDARDAF, S. HEIKKILÄ, Y. COLLAN, K. SYRJÄNEN, S. PYRHÖNEN (<i>Turku, Finland</i>).....	3083
Carcinoma of the Vulva: Clinical Results of Exclusive and Adjuvant Radiotherapy. V. TOMBOLINI, N. RAFFETTO, M. SANTARELLI, M. VALERIANI, S. NECOZIONE, F. MASEDU, R. MAURIZI ENRICI (<i>Rome; L'Aquila, Italy</i>).....	3089
Norwegian Surgical and Medical Oncologists' Use of the Internet. A New Source for Professional Updating. J. NORUM, E.N. BERGLI (<i>Oslo, Norway</i>)	3095
Intraductal Serrated Adenoma of the Pancreas. A Case Report. C.A. RUBIO, L. GRIMELIUS, K. VON SIVERS, A. HÖÖG (<i>Stockholm, Sweden</i>)	3099
Gemcitabine Plus Pegylated Liposomal Doxorubicin in Patients with Advanced Epithelial Ovarian Cancer Resistant/Refractory to Platinum and/or Taxanes. A HECOG Phase II Study. D.V. SKARLOS, H.P. KALOFONOS, G. FOUNTZILAS, M.A. DIMOPOULOS, N. PAVLIDIS, E. RAZIS, T. ECONOMOPOULOS, D. PECTASIDES, H. GOGAS, P. KOSMIDIS, D. BAFALOUKOS, G. KLOUVAS, G. KYRATZIS, G. ARAVANTINOS (<i>Athens; Patras; Thessaloniki; Ioannina, Greece</i>).....	3103
Nuclear hTERT Immunohistochemical Expression is Associated with Survival of Patients with Urothelial Bladder Cancer. J. MAVROMMATIS, E. MYLONA, H. GAKIOPOULOU, C. STRAVODIMOS, A. ZERVAS, A. GIANNOPOULOS, L. NAKOPOULOU (<i>Athens, Greece</i>)	3109
Galectin-3 Expression is a Potent Prognostic Marker in Colorectal Cancer. K. ENDO, S. KOHNOE, E. TSUJITA, A. WATANABE, H. NAKASHIMA, H. BABA, Y. MAEHARA (<i>Fukuoka, Japan</i>)	3117
Immunohistochemical Expression of Bcl2 is an Independent Predictor of Time-to-biochemical Failure in Patients with Clinically Localized Prostate Cancer Following Radical Prostatectomy. K. REVELOS, C. PETRAKI, A. GREGORAKIS, A. SCORILAS, P. PAPANASTASIOU, M. KOUTSILIERIS (<i>Athens, Greece</i>).....	3123
Molecular Staging Using Qualitative RT-PCR Analysis Detecting Thyroglobulin mRNA in the Peripheral Blood of Patients with Differentiated Thyroid Cancer After Therapy. N. KARAVITAKI, P. LEMBESSIS, M. TZANELA, V. VLASSOPOULOU, N. THALASSINOS, M. KOUTSILIERIS (<i>Athens, Greece</i>)	3135
Prophylaxis of Central Venous Catheter-related Thrombosis with Minidose Warfarin: Analysis of Its Use in 427 Cancer Patients. M. MAGAGNOLI, G. MASCI, L. CASTAGNA, P.A. ZUCALI, E. MORENGHI, V. PEDICINI, A. SANTORO (<i>Milan, Italy</i>)	3143
Phase II Randomized Study of Interleukin-2 with or without 13- <i>cis</i> Retinoic Acid as Maintenance Therapy in Patients with Advanced Cancer Responsive to Chemotherapy. F. RECCHIA, G. SAGGIO, A. CESTA, E. ALESSE, R. GALLO, S. NECOZIONE, S. REA (<i>Monterotondo; L'Aquila, Italy</i>)	3149
Response of T Lymphocyte Populations in Prostate Cancer Patients Undergoing Radiotherapy: Influence of Neoajuvant Total Androgen Suppression. R.M. JOHNKE, J.M. EDWARDS, C.J. KOVACS, M.J. EVANS, B.M. DALY, U.L. KARLSSON, T.-K. LEE, R.R. ALLISON, H.H. ARASTU, M.J. CARIVEAU, K.F. O'BRIEN (<i>Greenville, NC, USA</i>)	3159

* Reviews (pages 2601, 2617, 2891, 2979, 3011, 3041)

Number 5

Experimental Studies

- Chitinase Induces Lysis of MCF-7 Cells in Culture and of Human Breast Cancer Xenograft B11-2 in SCID Mice. X.Q. PAN, C.C. SHIH, J. HARDAY (*Columbus, OH; Duarte, CA, USA*)..... 3167
- Inhibition of MRP1-mediated Efflux in Human Erythrocytes by Mono-anionic Bile Salts. L. MRÓWCZYNSKA, M. BOBROWSKA-HÄGERSTRAND, A. WRÓBEL, T. SÖDERSTRÖM, H. HÄGERSTRAND (*Poznan; Wroclaw, Poland; Turku, Finland*)..... 3173
- Characterization of *IGH* Rearrangements in Non-Hodgkin's B-cell Lymphomas by Fluorescence *In Situ* Hybridization. I. BERNICOT, N. DOUET-GUILBERT, M.-J. LE BRIS, P. MORICE, J.F. ABGRALL, C. BERTHOU, F. MOREL, M. DE BRAEKELEER (*Brest; St Brieuc, France*) 3179
- Soft and Hard Keratin Expression in Epstein-Barr- Virus-associated Gastric Carcinoma. H. UOZAKI, J.-M. CHONG, E. FUJIMOTO, M. ITOH, M. SAITO, K. SAKUMA, M. SUDO, T. USHIKU, T. NIKI, H. NAGAI, K. TAKADA, M. FUKAYAMA (*Tokyo; Tochigi; Yamanashi; Sapporo, Japan*)..... 3183
- Mice Transgenic for *NPM-ALK* Develop Non-Hodgkin Lymphomas. R. JÄGER, J. HAHNE, A. JACOB, A. EGERT, J. SCHENKEL, N. WERNERT, H. SCHORLE, A. WELLMANN (*Bonn; Aachen; Heidelberg, Germany*) 3191
- The Influence of High Doses of Vitamin C and Zinc on Oxidative DNA Damage. U. HARRÉUS, P. BAUMEISTER, S. ZIEGER, C. MATTHIAS (*München, Germany*) 3197
- Characterization of the 20S Proteasome in Human Glioblastomas. M. PICCININI, M.T. RINAUDO, A. ANSELMINO, C. RAMONDETTI, B. BUCCINÀ, V. FIANO, C. GHIMENTI, D. SCHIFFER (*Turin; Vercelli, Italy*) 3203
- Antibodies to Cerebellar Nerve Fibres in Two Patients with Paraneoplastic Cerebellar Ataxia. S. BALEGNO, M. CERONI, M. CORATO, D. FRANCIOTTA, B. GIOMETTO, K. MARINU-AKTIPU, R. NANO (*Pavia; Milan; Padua, Italy*) 3211
- Biomarkers of Anticancer Activity of R115777 (Tipifarnib, Zarnestra™) in Human Breast Cancer Models *In Vitro*. E. IZBICKA, D. CAMPOS, G. CARRIZALES, A. PATNAIK (*San Antonio, TX, USA*) 3215
- Increased Expression of Interleukin-1 α and Cyclooxygenase-2 in Human Gastric Cancer: A Possible Role in Tumor Progression. K. UEFUJI, T. ICHIKURA, H. MOCHIZUKI (*Fukuoka; Tokorozawa, Japan*) 3225
- Serum p53 Antibodies in Drainage Blood from the Azygos Vein in Patients with Esophageal Carcinoma. H. KATO, M. NAKAJIMA, M. FUKUCHI, T. MIYAZAKI, R. MANDA, H. KIMURA, A. FARIED, M. SOHDA, Y. FUKAI, N. MASUDA, K. TSUKADA, H. KUWANO (*Maebashi, Japan*) 3231
- α - and β -tubulin Expression in Rectal Cancer Development. E. GIARNIERI, G.P. DE FRANCESCO, E. CARICO, G. MIDIRI, C. AMANTI, L. GIACOMELLI, G. TUCCI, S. GIDARO, I. STROPPA, G. GIDARO, M.R. GIOVAGNOLI (*Rome, Italy*) 3237
- Differential Diagnosis and Evaluation of the Clinical Course of Transurethrally Resected T1G3 Urothelial Carcinoma of the Bladder by DNA Image Cytometry. S. BIESTERFELD, H. BORCHERS, H. JELLOUSCHEK, A.V. BONO, J.E. ALTWEIN, F. ALGABA, G. JAKSE (*Aachen; Munich, Germany; Verona, Italy; Barcelona, Spain*) 3243
- A New Method for Optimizing Multiplex DNA Microsatellite Analysis in Low Quality Archival Specimens. I. DROBINSKAYA, H. GABBERT, G. MOESLEIN, W. MUELLER (*Duesseldorf, Germany*) 3251

Inhibition of P-glycoprotein Transport Activity in a Resistant Mouse Lymphoma Cell Line by Diterpenic Lactones. M.-J. U. FERREIRA, N. GYÉMÁNT, A.M. MADUREIRA, J. MOLNÁR (<i>Lisboa, Portugal; Szeged, Hungary</i>).....	3259
Induction of Cytotoxicity and Apoptosis and Inhibition of Cyclooxygenase-2 Gene Expression by Eugenol-related Compounds. N. OKADA, A. HIRATA, Y. MURAKAMI, M. SHOJI, H. SAKAGAMI, S. FUJISAWA (<i>Saitama, Japan</i>).....	3263
5-Fluorouracil Up-regulates Interferon Pathway Gene Expression in Esophageal Cancer Cells. Y. MATSUMURA, M. YASHIRO, M. OHIRA, H. TABUCHI, K. HIRAKAWA (<i>Osaka; Kanagawa, Japan</i>).....	3271
Reversal of Hepatoma Cells Resistance to Anticancer Drugs is Correlated to Cell Proliferation Kinetics, Telomere Length and Telomerase Activity. N.P. CHAU, J. DESCHATRETTE, C. WOLFROM (<i>Paris; Orsay, France</i>).....	3279
Circulating Vascular Endothelial Growth Factor and Interferon- γ -inducible Protein-10 Levels in Pancreatic Cancer During Chemotherapy. G. BELLONE, A. NOVARINO, I. CHIAPPINO, C. GRAMIGNI, A. CARBONE, A. ADDEO, E. TONEL, O. BERTETTO, G. EMANUELLI (<i>Turin, Italy</i>).....	3287
Expression Profiles of Apoptotic Genes Induced by Curcumin in Human Breast Cancer and Mammary Epithelial Cell Lines. C. RAMACHANDRAN, S. RODRIGUEZ, R. RAMACHANDRAN, P.K. RAVEENDRAN NAIR, H. FONSECA, Z. KHATIB, E. ESCALON, S.J. MELNICK (<i>Miami, FL, USA</i>).....	3293
Binding of Recombinant Mistletoe Lectin (Aviscumine) to Resected Human Adenocarcinoma of the Lung. K. BLONSKI, U. SCHUMACHER, I. BURKHOLDER, L. EDLER, H. NIKBAKHT, I. BOETERS, A. PETERS, C. KUGLER, H.-P. HORNY, M. LANGER, K. WILHELM-OGUNBIYI, K. WITTHOHN, E. LAACK (<i>Hamburg-Eppendorf; Heidelberg; Harburg; Lóbeck; Bergisch-Gladbach, Germany</i>).....	3303
Blockade of B7-H1 with sPD-1 Improves Immunity against Murine Hepatocarcinoma. L. HE, G. ZHANG, Y. HE, H. ZHU, H. ZHANG, Z. FENG (<i>Wuhan, China</i>).....	3309
Sensitisation of Ehrlich Ascitic Tumour Cells to Methotrexate by Inhibiting Glutaminase. F.J. ALONSO, J.A. SEGURA, J. LORA, C. LOBO, B. FERNÁNDEZ-MOLINA, J. MÁRQUEZ, J.M. MATÉS (<i>Malaga, Spain</i>).....	3315
Proteasome Inhibitors Abolish Cell Death Downstream of Caspase Activation During Anti-microtubule Drug-induced Apoptosis in Leukemia Cells. K. NAGY, I. PETAK, G. IMRE, G. BARNA, M. GEZANEC-SORBA, A. SEBESTYEN, J.A. HOUGHTON, R. MIHALIK, L. KOPPER (<i>Budapest, Hungary; Memphis, TN, USA</i>).....	3321
* Progress in Molecular Mechanisms of Tumor Metastasis and Angiogenesis. A. HARLOZINSKA (<i>Wroclaw, Poland</i>).....	3327
Suppression of Renin-Angiotensin System Attenuates Hepatocarcinogenesis <i>Via</i> Angiogenesis Inhibition in Rats. H. YOSHIJI, R. NOGUCHI, S. KURIYAMA, J. YOSHII, Y. IKENAKA, K. YANASE, T. NAMISAKI, M. KITADE, M. YAMAZAKI, M. UEMURA, H. FUKUI (<i>Nara; Kagawa, Japan</i>).....	3335
The Diimide Drug PIPER has a Cytotoxic Dose-dependent Effect <i>In Vitro</i> and Inhibits Telomere Elongation in HELA Cells. R.T. PILLICH, G. SCARSELLA, G. GALATI, L. IZZO, A. IACOANGELI, M. CASTELLI, G. RISULEO (<i>Rome, Italy</i>).....	3341
Activation of p38 Mitogen-activated Protein Kinase is Necessary for Gemcitabine-induced Cytotoxicity in Human Pancreatic Cancer Cells. K. KOIZUMI, S. TANNO, Y. NAKANO, A. HABIRO, T. IZAWA, Y. MIZUKAMI, T. OKUMURA, Y. KOHGO (<i>Hokkaido, Japan</i>).....	3347

12-O-Retinoylphorbol-13-acetate (RPA) behaves like a Retinoid-derivative in Binding to Retinol-binding protein: a Correlation with its Specific Action as an Incomplete Tumor Promoter? K. SCHLATTERER, R. GMINSKI, J. SCHLATTERER, E. HECKER, P. CHANDRA, B. SCHLATTERER, G. KRAUTER, A. CHANDRA (<i>Berlin; Heidelberg; Frankfurt, Germany; Tallahassee, FL, USA</i>)	3355
Kinetics of Radical-scavenging Activity of Hesperetin and Hesperidin and their Inhibitory Activity on COX-2 Expression. A. HIRATA, Y. MURAKAMI, M. SHOJI, Y. KADOMA, S. FUJISAWA (<i>Saitama; Tokyo, Japan</i>)	3367
Isothiocyanates Induce Cell Cycle Arrest, Apoptosis and Mitochondrial Potential Depolarization in HL-60 and Multidrug-resistant Cell Lines. J. JAKUBIKOVA, Y. BAO, J. SEDLAK (<i>Norwich, UK; Bratislava, Slovak Republic</i>)	3375
Quantitative Estimation of Matrix Metalloproteinases 2 and 7 (MMP-2, MMP-7) and Tissue Inhibitors of Matrix Metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in Colorectal Carcinoma Tissue Samples. M. PESTA, L. HOLUBEC Jr., O. TOPOLCAN, M. CERNA, K. RUPERT, L. HOLUBEC Sen., V. TRESKA, S. KORMUNDA, L. ELGROVA, J. FINEK, R. CERNY (<i>Pilsen, Czech Republic</i>)	3387
Biochemical Changes of Mevalonate Pathway in Human Colorectal Cancer. M.G. CARUSO, M. NOTARNICOLA (<i>Castellana Grotte, Bari, Italy</i>)	3393
Evaluation of Anti-vascular Therapy with Texture Analysis. G. CHEN, S. JESPERSEN, M. PEDERSEN, Q. PANG, M.R. HORSMAN, H. STØDKILDE JØRGENSEN (<i>Aarhus C, Denmark; Jinan, China</i>).....	3399
Effects of Heavy Water (D ₂ O) on Human Pancreatic Tumor Cells. J. HARTMANN, Y. BADER, Z. HORVATH, P. SAIKO, M. GRUSCH, C. ILLMER, S. MADLENER, M. FRITZER-SZEKERES, N. HELLER, R.-G. ALKEN, T. SZEKERES (<i>Vienna, Austria; Neuenhagen, Germany</i>)	3407
Hyperoxia-induced Improvement of the <i>In Vitro</i> Response to Gemcitabine in Transitional Cell Carcinoma. G. FECHNER, F. DEDERICHS, D. SCHMIDT, S. MÜLLER, P. VAUPEL, P. ALBERS (<i>Bonn; Mainz; Kassel, Germany</i>)	3413
Expression of p8 Protein in Medullary Thyroid Carcinoma. Y. ITO, H. YOSHIDA, Y. MOTOO, J.L. IOVANNA, C. TOMODA, T. URUNO, Y. TAKAMURA, A. MIYA, K. KOBAYASHI, F. MATSUZUKA, K. KUMA, A. MIYAUCHI (<i>Kanazawa, Japan; Marseille, France</i>)	3419
The Combined Treatment of 1,25-dihydroxyvitamin D3 and a Non-steroid Anti-inflammatory Drug is Highly Effective in Suppressing Prostate Cancer Cell Line (LNCaP) Growth. V. GAVRILOV, M. STEINER, S. SHANY (<i>Beer-Sheva, Israel</i>)	3425
Glucose Transporter GLUT1 in Colorectal Adenocarcinoma Cell Lines is Inversely Correlated with Tumour Cell Proliferation. S. HAUPTMANN, V. GRÜNEWALD, D. MOLLS, W.D. SCHMITT, M. KÖBEL, K. KRIESE, A. SCHÜRMANN (<i>Halle; Aachen, Germany</i>)	3431
Clinical Studies	
Y-Box-binding Protein-1 Expression is not Correlated with p53 Expression but with Proliferating Cell Nuclear Antigen Expression in Non-small Cell Lung Cancer. T. YOSHIMATSU, H. URAMOTO, T. OYAMA, Y. YASHIMA, C. GU, M. MORITA, K. SUGIO, K. KOHNO, K. YASUMOTO (<i>Kitakyushu, Japan; Dalian, China</i>)	3437
Evaluation of a Dysfunctional and Short-lived Subset of Monocyte-derived Dendritic Cells from Cancer Patients. H. ONISHI, T. MORISAKI, H. KUROKI, K. MATSUMOTO, E. BABA, H. KUGA, MA. TANAKA, M. KATANO (<i>Fukuoka, Japan</i>)	3445

Individualized Adjuvant Chemotherapy Guided by Chemosensitivity Test Sequential to Extended Surgery for Advanced Gastric Cancer. M. IWAHASHI, M. NAKAMORI, M. NAKAMURA, K. NOGUCHI, K. UEDA, Y. NAKATANI, T. OJIMA, K. ISHIDA, TE. NAKA, H. YAMAUE (<i>Wakayama, Japan</i>)	3453
Classification of Recurrent Esophageal Cancer after Radical Esophagectomy with Two- or Three-field Lymphadenectomy. H. KATO, M. FUKUCHI, T. MIYAZAKI, M. NAKAJIMA, H. KIMURA, A. FARIED, M. SOHDA, Y. FUKAI, N. MASUDA, R. MANDA, H. OJIMA, K. TSUKADA, H. KUWANO (<i>Maebashi, Japan</i>)	3461
Comparing PAP Smear Cytology, Aided Visual Inspection, Screening Colposcopy, Cervicography and HPV Testing as Optional Screening Tools in Latin America. Study Design and Baseline Data of the LAMS Study. K. SYRJÄNEN, P. NAUD, S. DERCHAIN, C. ROTELI-MARTINS, A. LONGATTO-FILHO, S.TATTI, M. BRANCA, M. ERZEN, L.S. HAMMES, J. MATOS, R. GONTIJO, L. SARIAN, J. BRAGANCA, F.C. ARLINDO, M.Y.S. MAEDA, A. LÖRINCZ, G.B. DORES, S. COSTA, S. SYRJÄNEN (<i>Turku, Finland; Sao Paulo, Brazil; Braga, Portugal; Buenos Aires, Argentina; Rome; Bologna, Italy; Ljubljana, Slovenia; Gaithersburg, MD, USA</i>)	3469
Successful Pregnancy and Normal Delivery after Whole Craniospinal Irradiation in Two Patients. N. SHIGEMATSU, H. SHINMOTO, N. ITO, E. KUNIEDA, A. TAKEDA, T. OHASHI, O. KAWAGUCHI, T. KAWATA, H. ITO, S. KURIBAYASHI, A. KUBO (<i>Tokyo; Chiba, Japan</i>)	3481
Bi-weekly Administration of Docetaxel and Gemcitabine as First-line Therapy for Non-small Cell Lung Cancer: A Phase II Study. K.N. SYRIGOS, I. DANNOS, G. DIONELLIS, I. BOFOS, C. ALAMARA, E. DIMAKOU, G. STRATAKOS, S. PAPIRIS (<i>Athens, Greece</i>)	3489
Evaluation of Epoetin Supplemented with Oral Iron in Patients with Solid Malignancies and Chronic Anemia not Receiving Anticancer Treatment. K. MYSTAKIDOU, O. KALAIPOULOU, E. KATSOUDA, E. PARPA, E. KOUSKOUNI, C. CHONDROS, M.L. TSIATAS, A. VLAHOS (<i>Athens, Greece</i>).....	3495
Activity of Chemotherapy in Mucinous Epithelial Ovarian Cancer: A Retrospective Study. C. PISANO, S. GREGGI, R. TAMBARO, S. LOSITO, F. IODICE, M. DI MAIO, E. FERRARI, M. FALANGA, R. FORMATO, V.R. IAFFAIOLI, S. PIGNATA (<i>Naples, Italy</i>)	3501
Radical External Beam Radiotherapy for Clinically Localized Prostate Cancer in Japan: Changing Trends in the Patterns of Care Process Survey Between 1996-1998 and 1999-2001. K. OGAWA, K. NAKAMURA, H. ONISHI, T. SASAKI, M. KOIZUMI, Y. SHIOYAMA, T. KOMIYAMA, Y. MIYABE, T. TESHIMA, JAPANESE PATTERNS OF CARE STUDY WORKING SUBGROUP OF PROSTATE CANCER (<i>Okinawa; Fukuoka; Yamanashi; Kyoto; Osaka, Japan</i>).....	3507
The Efficacy of Endoscopic Mucosal Resection in the Diagnosis and Treatment of Group III Gastric Lesions. T. KATSUBE, S. KONNNO, K. HAMAGUCHI, T. SHIMAKAWA, Y. NARITAKA, K. OGAWA, M. AIBA (<i>Tokyo, Japan</i>)	3513
Survival in Untreated Early Stage Non-small Cell Lung Cancer. A.S. CHADHA, A.K. GANTI, J.S. SOHI, A.E. SAHMOUN, S.A. MEHDI (<i>Fargo, ND; Omaha, NE, USA</i>)	3517
Proptosis and Decreased Vision Secondary to Prostate Cancer Orbital Wall Metastasis. A.R. PATEL, K.B. OLSON, K.J. PIANTA (<i>Detroit; Ann Arbor, MI, USA</i>)	3521
Immunohistochemical Expression of Receptor-Tyrosine Kinase c-kit Protein and TGF-β1 in Invasive Ductal Carcinoma of the Pancreas. Y. NIO, H. OMORI, K. HASHIMOTO, M. ITAKURA, M. KOIKE, S. YANO, T. TOGA, T. HIGAMI, R. MARUYAMA (<i>Shimane, Japan</i>)	3523
Nail Disorders in a Woman Treated with Ixabepilone for Metastatic Breast Cancer. A. ALIMONTI, C. NARDONI, P. PAPALDO, G. FERRETTI, M.P. CALENO, P. CARLINI, A. FABI, D. RASIO, A. VECCHIONE, F. COGNETTI (<i>Rome, Italy</i>)	3531

Expression of <i>DeltaNp63</i> in Squamous Cell Carcinoma of the Esophagus. M. MORITA, H. URAMOTO, S. NAKATA, K. ONO, M. SUGAYA, T. YOSHIMATSU, T. OYAMA, T. HANAGIRI, K. SUGIO, K. YASUMOTO (<i>Kitakyushu, Japan</i>)	3533
Relationship between Interleukin-12-expressing Cells and Antigen-presenting Cells in Patients with Colorectal Cancer. Y. INOUE, Y. NAKAYAMA, N. MINAGAWA, T. KATSUKI, N. NAGASHIMA, K. MATSUMOTO, K. SHIBAO, Y. TSURUDOME, K. HIRATA, N. NAGATA, H. ITOH (<i>Kitakyushu, Japan</i>)	3541
Successful Analysis of Anticancer Drug Sensitivity by CD-DST Using Pleural Fluid and Ascites from Patients with Advanced Ovarian Cancer: Case Reports. M. KAWAGUCHI, K. BANNO, N. SUSUMU, M. YANOKURA, Y. KUWABARA, N. HIRAO, K. TSUKAZAKI, S. NOZAWA (<i>Tokyo, Japan</i>)	3547
Brain Metastases from Epithelial Ovarian Cancer. The Hellenic Cooperative Oncology Group (HeCOG) Experience and Review of the Literature. D. PECTASIDES, G. ARAVANTINOS, G. FOUNTZILAS, C. KALOFONOS, E. EFSTATHIOU, M. KARINA, N. PAVLIDIS, D. FARMAKIS, T. ECONOMOPOULOS, M.A. DIMOPOULOS (<i>Athens; Thessaloniki; Patras; Ioannina, Greece</i>)	3553
Docetaxel in Combination with Irinotecan (CPT-11) in Platinum-resistant Paclitaxel-pretreated Ovarian Cancer. A. POLYZOS, C. KOSMAS, H. TOUFEXI, N. MALAMOS, A. LAGADAS, C. KOSMIDIS, P. GINOPOULOS, N. ZIRAS, K. KANDILIS, V. GEORGOULIAS (<i>Athens; Piraeus; Patras; Heraklion, Greece</i>)	3559
Superantigen-activated Mononuclear Cells Induce Apoptosis in Transitional Cell Carcinoma. F.G.E. PERABO, P.L. WILLERT, A. WIRGER, D.H. SCHMIDT, A. VON RUECKER, S.C. MUELLER (<i>Bonn; Luebeck, Germany</i>).....	3565
MUC1 Peptide Vaccination in Patients with Advanced Pancreas or Biliary Tract Cancer. K. YAMAMOTO, T. UENO, T. KAWAOKA, S. HAZAMA, M. FUKUI, Y. SUEHIRO, Y. HAMANAKA, Y. IKEMATSU, K. IMAI, M. OKA, Y. HINODA (<i>Ube; Hamamatsu; Sapporo, Japan</i>)	3575
Chemokines in Human Colorectal Carcinoma. P.K. BAIER, S. EGGSTEIN, G. WOLFF VORBECK, U. BAUMGARTNER, U.T. HOPT (<i>Freiburg, Germany</i>)	3581
Treatment Arms Summarizing Analysis of 220 High-grade Glioma Studies. H. HAUCH, M. SAJEDI, J.E.A. WOLFF (<i>Regensburg, Germany; Calgary, AB, Canada; Houston, TX, USA</i>).....	3585
Expression of Vascular Endothelial Growth Factor and its Receptor, KDR/Flk-1, in Soft Tissue Sarcomas. E.E. PAKOS, A.C. GOUSSIA, P.G. TSEKERIS, D.J. PAPACHRISTOU, D. STEFANOY, N.J. AGNANTIS (<i>Ioannina, Greece</i>)	3591
A Phase II Study of Tamoxifen in Hormone-resistant Metastatic Prostate Cancer: Possible Relation with Prolactin Secretion. P. LISSONI, P. VIGANO, M. VAGHI, L. FRONTINI, C. GIUBERTI, V. MANGANINI, M. CASU, F. BRIVIO, R. NIESPOLO, G. STRADA (<i>Milan, Italy</i>)	3597
Serum Carcinoembryonic Antigen Level in pN1 Non-small Cell Lung Cancer Patients. M. TOMITA, Y. MATSUZAKI, T. SHIMIZU, M. HARA, T. AYABE, T. ONITSUKA (<i>Miyazaki, Japan</i>)	3601
Bisphosphonate Treatment does not Affect Serum Levels of Osteoprotegerin and RANKL in Hypercalcemic Cancer Patients. N. ZOJER, K. BRENNER, D. BEKE, S. KUDLACEK, G. HAWA, W. WOLOSZCZUK, L.C. HOFBAUER, M. PECHERSTORFER (<i>Vienna, Austria; Marburg, Germany</i>)	3607
Radiotherapy and Razoxane in Advanced Bile Duct Carcinomas. W. RHOMBERG, H. STEPHAN, F. BÖHLER, K. ERHART, H. EITER (<i>Feldkirch; Bregenz, Austria</i>)	3613

* Clinical Experience with Bevacizumab in Colorectal Cancer. N. SALESI, G. BOSSONE, E. VELTRI, B. DI COCCO, P. MAROLLA, U. PACETTI, G. LAROSA, R. MUNI, A. VECCHIONE (<i>Terracina; Rome, Italy</i>).....	3619
Adjusted Carbohydrate Antigen 19-9. Correlation with Histological Grade in Pancreatic Adenocarcinoma. J. ORTIZ-GONZÁLEZ, N.P. ALVAREZ-AGUILA, J.M. MEDINA-CASTRO (<i>México D.F, México</i>)	3625
Molecular Markers in Gastric Cancer: Can p53 and Bcl-2 Protein Expressions be Used as Prognostic Factors? K. ZAFIRELLIS, A. KARAMERIS, N. MILINGOS, G. ANDROULAKIS (<i>Athens, Greece</i>)	3629
Bevacizumab as Treatment for Chemotherapy-resistant Pancreatic Cancer. H.W. BRUCKNER, V.R. HREHOROVICH, H.S. SAWHNEY (<i>Brooklyn, NY, USA</i>)	3637
The Value of the ImmunoCyt/uCyt+ Test in the Detection and Follow-up of Carcinoma <i>In Situ</i> of the Urinary Bladder. C. MIAN, M. LODDE, E. COMPLOJ, S. PALERMO, M. MIAN, K. MAIER, A. PYCHA (<i>Bolzano, Italy</i>)	3641
Urinary Levels of Vascular Endothelial Growth Factor in Patients with Prostate Cancer as a Predictor of Disease Progression. H. MIYAKE, M. MURAMAKI, T. KURAHASHI, K. YAMANAKA, I. HARA (<i>Akashi; Kobe, Japan</i>)	3645
Use of Natriuretic Peptides for Detecting Cardiac Dysfunction in Long-term Disease-free Breast Cancer Survivors. P.J. PERIK, E.G.E. DE VRIES, F. BOOMSMA, W.T.A. VAN DER GRAAF, D.T. SLEIJFER, D.J. VAN VELDHUISEN, J.A. GIETEMA (<i>Groningen; Rotterdam, The Netherlands</i>).....	3651
Effects of Imatinib Mesylate on Adenoid Cystic Carcinomas. H.-J. OCHEL, G. GADEMANN, C. RÖCKEN, H. WÖRDEHOFF (<i>Magdeburg, Germany</i>).....	3659
The Efficacy of MRI with Ultrasmall Superparamagnetic Iron Oxide Particles (USPIO) in Head and Neck Cancers. M. BAGHI, M.G. MACK, M. HAMBEK, J. RIEGER, T. VOGL, W. GSTOETTNER, R. KNECHT (<i>Frankfurt/Main, Germany</i>)	3665
Mesothelioma: Treatment and Survival of a Patient Population and Review of the Literature. J. STATHOPOULOS, D. ANTONIOU, G.P. STATHOPOULOS, S.K. RIGATOS, J. DIMITROULIS, J. KOUTANDOS, P. MICHALOPOULOU, A. ATHANASIADES, M. VESLEMES (<i>Athens, Greece</i>).....	3671
* Reviews (pages 3327, 3619)	

Number 6A

**Proceedings of the Joint Meeting of the 8th Annual Meeting of the Society of Biotherapeutic Approaches and the 3rd Meeting of the Japan Research Association of Immunotherapeutics
4 December, 2004, Fukuoka, Japan
Special Issue Edited by M. Yamamoto, S. Goto,
G.-I. Soma, M. Kuroki, T. Fukushima**

* Multiple Roles of Cyclooxygenase-2 in Endometrial Cancer. S. OHNO, Y. OHNO, N. SUZUKI, H. INAGAWA, C. KOHCHI, G.-I. SOMA, M. INOUE (<i>Osaka; Ishikawa; Yamaguchi; Tokushima; Chiba, Japan</i>)	3679
* Gc Protein (Vitamin D-binding Protein): Gc Genotyping and GcMAF Precursor Activity. H. NAGASAWA, Y. UTO, H. SASAKI, N. OKAMURA, A. MURAKAMI, S. KUBO, K.L. KIRK, H. HORI (<i>Tokushima, Japan; Bethesda, MD, USA</i>).....	3689

Immunohistochemical Staining of Hedgehog Pathway-related Proteins in Human Thymomas. A. TASAKI, T. AKIYOSHI, K. KOGA, H. NAKASHIMA, N. YAMANAKA, M. KUBO, K. MATSUMOTO, M. KOJIMA, M. TANAKA, M. NAKAMURA, M. KATANO (<i>Fukuoka, Japan</i>).....	3697
Purification, Characterization and Biological Significance of Tumor-derived Exosomes. K. KOGA, K. MATSUMOTO, T. AKIYOSHI, M. KUBO, N. YAMANAKA, A. TASAKI, H. NAKASHIMA, M. NAKAMURA, S. KUROKI, M. TANAKA, M. KATANO (<i>Fukuoka, Japan</i>).....	3703
Efficacy of Immuno-cell Therapy in Patients with Advanced Pancreatic Cancer. T. KANEKO, S. GOTO, A. KATO, A. AKEYAMA, M. TOMONAGA, K. FUJIMOTO, Y. MIYAMOTO, M. ERIGUCHI, K. EGAWA (<i>Kanagawa; Tokyo; Osaka-fu; Fukuoka, Japan</i>).....	3709
Efficacy and Feasibility of Procarbazine, Ranimustine and Vincristine Chemotherapy, and the Role of Surgical Resection in Anaplastic Oligodendroglioma. M. YAMAMOTO, M. IWAASA, M. NONAKA, H. TSUGU, K. NABESHIMA, T. FUKUSHIMA (<i>Fukuoka, Japan</i>).....	3715
* Re-targeting of Cytotoxic T Lymphocytes and/or Natural Killer Cells to CEA-expressing Tumor Cells with Anti-CEA Antibody Activity. M. KUROKI, K. HACHIMINE, J. HUANG, H. SHIBAGUCHI, T. KINUGASA, S.-I. MAEKAWA, M. KUROKI (<i>Fukuoka, Japan</i>).....	3725
Preparation of Human IgG and IgM Monoclonal Antibodies for MK-1/Ep-CAM by Using Human Immunoglobulin Gene-transferred Mouse and Gene Cloning of their Variable Regions. M. KUROKI, H. YAMADA, H. SHIBAGUCHI, K. HACHIMINE, Y. HIROSE, T. KINUGASA, I. ISHIDA, M. KUROKI (<i>Fukuoka; Yokohama, Japan</i>).....	3733
Combined Immunocell Therapy Using Activated Lymphocytes and Monocyte-derived Dendritic Cells for Malignant Melanoma. S. GOTO, T. KANEKO, Y. MIYAMOTO, M. ERIGUCHI, A. KATO, T. AKEYAMA, K. FUJIMOTO, M. TOMONAGA, K. EGAWA (<i>Tokyo; Kanagawa; Osaka; Fukuoka, Japan</i>)	3741
Innate-immune Therapy for Lung Carcinoma Based on Tissue-macrophage Activation with Lipopolysaccharide. M. HINO, C. KOHCHI, T. NISHIZAWA, A. YOSHIDA, K. NAKATA, H. INAGAWA, H. HORI, K. MAKINO, H. TERADA, G.-I. SOMA (<i>Tokushima-shi; Noda-shi; Shimonoseki-shi, Japan</i>)	3747
Expression Levels of Thymidine Phosphorylase (TP) and Dihydropyrimidine Dehydrogenase (DPD) in Patients with Gastrointestinal Cancer. Y. NAKAYAMA, Y. INOUE, N. NAGASHIMA, T. KATSUKI, K. MATSUMOTO, K. KADOWAKI, K. SHIBAO, Y. TSURUDOME, K. HIRATA, T. SAKO, N. NAGATA, H. ITOH (<i>Kita-Kyushu, Japan</i>)	3755
Anti-allergic <i>Psidium guajava</i> Extracts Exert an Antitumor Effect by Inhibition of T Regulatory Cells and Resultant Augmentation of Th1 Cells. N. SEO, T. ITO, N. WANG, X. YAO, Y. TOKURA, F. FURUKAWA, M. TAKIGAWA, S. KITANAKA (<i>Shizuoka; Shenyang; Kitakyushu; Wakayama; Chiba, Japan</i>)	3763
Combination Therapy with Tumor Cell-pulsed Dendritic Cells and Activated Lymphocytes for Patients with Disseminated Carcinomas. M. KATANO, T. MORISAKI, K. KOGA, M. NAKAMURA, H. ONISHI, K. MATSUMOTO, A. TASAKI, H. NAKASHIMA, T. AKIYOSHI, M. NAKAMURA (<i>Fukuoka, Japan</i>)	3771
* Reviews (pages 3679, 3689, 3725)	

Number 6B

Experimental Studies

Increased Levels of PPAR β/δ and Cyclin D1 in Flat Dysplastic ACF and Adenomas in <i>Apc</i> ^{Min/+} Mice. H. K. KNUTSEN, H.B. ØLSTØRN, J.E. PAULSEN, T. HUSØY, I.L. GOVERUD, E.M. LØBERG, K. KRISTIANSEN, J. ALEXANDER (<i>Oslo, Norway; Odense M, Denmark</i>).....	3781
---	------

A Novel Human Monoclonal Antibody Derived from Tumor-infiltrating Lymphocytes in Lung Cancer Inhibits Cancer Cell Growth with Morphological Changes. M. AOKI, Y. SAIKAWA, S. HOSOKAWA, K. FUKUDA, K. KUMAI, T. KUBOTA, M. YOSHIDA, Y. OTANI, M. KITAJIMA (<i>Tokyo; Yokohama, Japan</i>)	3791
* Tumor Endothelial Cells are Targets for Selective Therapies: <i>In Vitro</i> and <i>In Vivo</i> Models to Evaluate Antiangiogenic Strategies. A. DUTOUR, M. RIGAUD (<i>Houston, TX, USA; Limoges, France</i>).....	3799
Osteoprotegerin is Expressed in Colon Carcinoma Cells. I. PETTERSEN, W. BAKKELUND, B. SMEDSRØD, B. SVEINBJØRNSSON (<i>Tromsø, Norway</i>).....	3809
Humanized Monoclonal Antibody Against Parathyroid Hormone-related Protein Suppresses Osteolytic Bone Metastasis of Human Breast Cancer Cells Derived from MDA-MB-231. H. SAITO, T. TSUNENARI, E. ONUMA, K. SATO, E. OGATA, H. YAMADA-OKABE (<i>Kanagawa; Ariake, Japan</i>)	3817
Local Delivery of Doxorubicin for the Treatment of Malignant Brain Tumors in Rats. M.S. LESNIAK, U. UPADHYAY, R. GOODWIN, B. TYLER, H. BREM (<i>Chicago, IL; Baltimore, MD, USA</i>)	3825
Hyperbaric Oxygen Inhibits Benign and Malignant Human Mammary Epithelial Cell Proliferation. E.V. GRANOWITZ, N. TONOMURA, R.M. BENSON, D.M. KATZ, V. BAND, G.P. MAKARI-JUDSON, B.A. OSBORNE (<i>Springfield; Amherst; Boston, MA, USA</i>)	3833
Expression of p27(KIP1) and Cell Proliferation in Human Retina and Retinoblastoma. S. KASE, K. YOSHIDA, K. OHGAMI, K. SHIRATORI, T. HARADA, S. OHNO (<i>Sapporo; Tokyo, Japan</i>).....	3843
Possible Inhibition of Cancer Cell Adhesion to the Extracellular Matrix in NK4-induced Suppression of Peritoneal Implantation. M. YOSHIMURA, H. FUJIWARA, T. KUBOTA, H. AMAIKE, K. TAKASHIMA, S. INADA, K. ATSUJI, Y. ARAKI, K. MATSUMOTO, T. NAKAMURA, H. YAMAGISHI (<i>Kyoto; Osaka, Japan</i>).....	3847
Morphological, Immunocytochemical and Flow Cytometric <i>In Vitro</i> Characterisation of a Surface-adherent Medulloblastoma. K. PARKER, G.J. PILKINGTON (<i>Portsmouth, UK</i>).....	3855
Combretastatin A-4 Resistance in H460 Human Lung Carcinoma Demonstrates Distinctive Alterations in β -Tubulin Isotype Expression. H. WEHBE, C.M. KEARNEY, K.G. PINNEY (<i>Waco, TX, USA</i>)	3865
The Photoreceptor Protector Zeaxanthin Induces Cell Death in Neuroblastoma Cells. M. MACCARRONE, M. BARI, V. GASPERI, B. DEMMIG-ADAMS (<i>Teramo; Rome, Italy; Boulder, CO, USA</i>).....	3871
FGF Receptor Phosphotyrosine 766 is a Target for Grb14 to Inhibit MDA-MB-231 Human Breast Cancer Cell Signaling. K. CAILLIAU, D. PERDEREAU, A. LESCUYER, H. CHEN, C. GARBAY, J.P. VILAIN, A.-F. BURNOL, E. BROWAEYS-POLY (<i>Villeneuve d'Ascq Cedex; Paris, France</i>)	3877
Scanning Electron Microscopy of Colonic Lesions in 1,2-Dimethylhydrazine-treated Rats. J.E. PAULSEN, E. NAMORK, J. ALEXANDER (<i>Oslo, Norway</i>).....	3883
CIITA Transformation Rescues the Apoptotic Function of MHC Class II in Melanoma Cells. E. LE, H. ZHANG, G. BLANCK (<i>Tampa, FL, USA</i>).....	3889
Antitumor Effect of Double Immunization of Mice with Mucin 1 and its Coding DNA. N. MUSHENKOVA, E. MOISEEVA, A. CHAADAEVA, W. DEN OTTER, E. SVIRSHCHEVSKAYA (<i>Moscow, Russia; Utrecht, The Netherlands</i>).....	3893
Preclinical Studies of the Novel Vascular Disrupting Agent MN-029. W. SHI, D.W. SIEMANN (<i>Gainesville, FL, USA</i>).....	3899

Distant Metastasis from Subcutaneously Grown E0771 Medullary Breast Adenocarcinoma. A. EWENS, E. MIHICH, M.J. EHRKE (<i>Buffalo, NY, USA</i>)	3905
Liposomal Transfection of Squamous Carcinoma Cells of the Head and Neck with IL-2 and B7 Plasmids Inducing an Autologous Immune Response <i>In Vitro</i> . A. MAYER, M. ANDRATSCHKE, C. PAULI, E. REITBERGER, K. KOLBOW, B. WOLLENBERG (<i>Neuherberg; Munich; Luebeck, Germany</i>)	3917
Differential Phosphorylation Patterns of P-glycoprotein Reconstituted into a Proteoliposome System: Insight into Additional Unconventional Phosphorylation Sites. I.H. LELONG-REBEL, C.O. CARDARELLI (<i>Strasbourg, France; Bethesda, MD, USA</i>).....	3925
Reverse Transcriptase-PCR Analysis of Apoptosis-regulating Gene Expression in Human Benign Prostatic Hyperplasia. C. ANGELUCCI, F. IACOPINO, G. LAMA, G. ZELANO, G. GIANESINI, G. SICA, A.V. BONO (<i>Rome; Varese, Italy</i>).....	3937
Conjugated Linoleic Acid Isomers and their Conjugated Derivatives Inhibit Growth of Human Cancer Cell Lines. A. DE LA TORRE, E. DEBITON, D. DURAND, J.-M. CHARDIGNY, O. BERDEAUX, O. LOREAU, C. BARTHOMEUF, D. BAUCHART, D. GRUFFAT (<i>Saint Genès-Champagnelle; Clermont-Ferrand; Dijon; Gif/Yvette Cedex, France</i>)	3943
Quantitative Structure-Cytotoxicity Relationship Analysis of Betulinic Acid and its Derivatives by Semi-empirical Molecular-orbital Method. M. ISHIHARA, H. SAKAGAMI, W.-K. LIU (<i>Saitama, Japan; Hong Kong, People's Republic of China</i>).....	3951
Clinical Significance of Double Staining of MIB-1 and AgNORs in Primary Breast Carcinoma. H. KIDOGAWA, A. NANASHIMA, H. YANO, M. MATSUMOTO, T. YASUTAKE, T. NAGAYASU (<i>Nagasaki, Japan</i>)	3957
Alteration in Platelet Function in Patients with Early Breast Cancer. G. McDOWELL, I. TEMPLE, C. LI, C.C. KIRWAN, N.J. BUNDRED, C.N. McCOLLUM, I.E. BURTON, S. KUMAR, G.J. BYRNE (<i>Manchester, UK</i>).....	3963
Introduction of a Survivin Gene-specific Small Inhibitory RNA Inhibits Growth of Pancreatic Cancer Cells. N. TSUJI, K. ASANUMA, D. KOBAYASHI, A. YAGIHASHI, N. WATANABE (<i>Sapporo, Japan</i>).....	3967
Antitumor Effects of Synthetic VEGF-receptor Binding Antagonist, VGA1155. Y. UEDA, T. YAMAGISHI, K. SAMATA, N. HIRAYAMA, Y. AOZUKA, M. TANAKA, S. NAKAIKE, I. SAIKI (<i>Saitama; Toyama, Japan</i>)	3973
Unfiltered Xenon Light is Useful for Photodynamic Therapy with Acridine Orange. H. UEDA, H. MURATA, H. TAKESHITA, G. MINAMI, S. HASHIGUCHI, T. KUBO (<i>Kyoto, Japan</i>)	3979
Reduction of Cisplatin Dosage by ZD 1839. M. HAMBEK, M. BAGHI, K. STREBHARD, H. BAUMANN, W. GSTØTTNER, R. KNECHT (<i>Frankfurt, Germany</i>).....	3985
Kinetic Studies of the Radical-scavenging Activity of Ebselen, a Seleno-organic Compound. S. FUJISAWA, Y. KADOMA (<i>Saitama; Tokyo, Japan</i>)	3989
Cytogenetic Investigations in Four Canine Lymphomas. S. WINKLER, H.M. ESCOBAR, N. REIMANN-BERG, J. BULLERDIEK, I. NOLTE (<i>Bremen; Hannover, Germany</i>).....	3995
* Nuclear Matrix Protein Expression in Prostate Cancer: Possible Prognostic and Diagnostic Applications. P. BARBORO, A. RUBAGOTTI, F. BOCCARDO, B. CARNEMOLLA, C. D'ARRIGO, E. PATRONE, C. BALBI (<i>Genoa, Italy</i>)	3999

Evaluation of Tumor Malignancy in Esophageal Squamous Cell Carcinoma Using Different Characteristic Factors. T. MIYAZAKI, H. KATO, H. KIMURA, T. INOSE, A. FARIED, M. SOHDA, M. NAKAJIMA, Y. FUKAI, N. MASUDA, R. MANDA, M. FUKUCHI, K. TSUKADA, H. KUWANO (<i>Gunma, Japan</i>)	4005
Silencing and CpG Island Methylation of GSTP1 is Rare in Ordinary Gastric Carcinomas but Common in Epstein-Barr Virus-associated Gastric Carcinomas. J. KIM, H.S. LEE, S.I. BAE, Y.M. LEE, W.H. KIM (<i>Seoul, South Korea</i>)	4013
The Effect of O6-methylguanine-DNA Methyltransferase (MGMT) and Mismatch Repair Gene (hMLH1) Status on the Sensitivity to Alkylating Agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-Nitrosourea (ACNU) in Gallbladder Carcinoma Cells. K. SATO, Y. KITAJIMA, Y. KOGA, K. MIYAZAKI (<i>Saga, Japan</i>).....	4021
Induction of Cytotoxicity and Apoptosis and Inhibition of Cyclooxygenase-2 Gene Expression, by Curcumin and its Analog, α -Diisoeugenol. T. ATSUMI, Y. MURAKAMI, K. SHIBUYA, K. TONOSAKI, S. FUJISAWA (<i>Saitama, Japan</i>).....	4029
Effect of Anticancer Agents on Codeinone-induced Apoptosis in Human Cancer Cell Lines. R. TAKEUCHI, H. HOSHIIJIMA, N. ONUKI, H. NAGASAKA, S.A. CHOWDHURY, M. KAWASE, H. SAKAGAMI (<i>Saitama, Japan</i>)	4037
Glycyrrhetic Acid and Related Compounds Induce G1 Arrest and Apoptosis in Human Hepatocellular Carcinoma HepG2. Y. SATOMI, H. NISHINO, S. SHIBATA (<i>Kyoto; Tokyo, Japan</i>)	4043
Under-representation of Bladder Transitional Cell Tumour 9q, 11p and 14q LOH in Urine and Impact on Molecular Diagnosis. D. FORNARI, K. STEVEN, A.B. HANSEN, H. VIBITS, J.V. JEPSEN, A.L. POULSEN, M. SCHWARTZ, T. HORN (<i>Herlev; Copenhagen, Denmark</i>).....	4049
Tumor-specific Cytotoxicity and Apoptosis-inducing Activity of Berberines. K. INOUE, U. KULSUM, S. ALI CHOWDHURY, S.-I. FUJISAWA, M. ISHIHARA, I. YOKOE, H. SAKAGAMI (<i>Saitama, Japan</i>)	4053
Effects of Human Breast Stromal Cells on Conjugated Linoleic Acid (CLA) Modulated Vascular Endothelial Growth Factor-A (VEGF-A) Expression in MCF-7 Cells. L.-S. WANG, Y.-W. HUANG, Y. SUGIMOTO, S. LIU, H.-L. CHANG, W. YE, S. SHU, Y.C. LIN (<i>Columbus, OH; Ann Arbor, MI, USA</i>)	4061
Aneuploidy of Chromosome 8 and C-MYC Amplification in Individuals from Northern Brazil with Gastric Adenocarcinoma. D. QUEIROZ CALCAGNO, M. FERREIRA LEAL, S. SATOMI TAKENO, P. PIMENTEL ASSUMPCÃO, S. DEMACHKI, M. DE ARRUDA C. SMITH, R. RODRIGUEZ BURBANO (<i>Belém, PA; São Paulo, SP, Brazil</i>)	4069
Generation of an Autologous Cell System for Immunotherapy of Squamous Cell Carcinoma of the Head and Neck. A. MAYER, M. ANDRATSCHKE, C. PAULI, H. GRAEFE, K. KRISTINA, B. WOLLENBERG (<i>Neuherberg; Munich; Lübeck, Germany</i>).....	4075
Effects of Age on Growth and ER β mRNA Expression of Canine Prostatic Cells. J. JIANG, H.-L. CHANG, Y. SUGIMOTO, Y.C. LIN (<i>Indianapolis, IN; Columbus, OH, USA</i>)	4081
γ -Irradiation Induced Apoptosis in Peritoneal Macrophages by Oxidative Stress. Implications of Antioxidants in Caspase Mitochondrial Pathway. G. HERNÁNDEZ-FLORES, P.C. GÓMEZ-CONTRERAS, J.R. DOMÍNGUEZ-RODRÍGUEZ, J.M. LERMA-DÍAZ, P.C. ORTÍZ-LAZARENO, R. CERVANTES-MUNGUÍA, J.E. SAHAGÚN-FLORES, S. ORBACH-ARBOUYS, D. SCOTT-ALGARA, A. BRAVO-CUELLAR (<i>Guadalajara; Tepatitlán, México; Villejuif; Paris, France</i>).....	4091
Prognostic Value of Matrix Metalloproteinase-2 (MMP-2) Expression in Endometrial Endometrioid Adenocarcinoma. A.TALVENSAARI-MATTILA, M. SANTALA, Y. SOINI, T. TURPEENNIEMI-HUJANEN (<i>Oulu, Finland</i>).....	4101

Development of Sex Cord Stromal Tumors after Heterotopic Transplantation of Cryopreserved Ovarian Tissue in Rats. A. MUELLER, T. MALTARIS, A. DIMMLER, I. HOFFMANN, M.W. BECKMANN, R. DITTRICH (<i>Erlangen, Germany</i>).....	4107
Different Roles for K ⁺ Channels in Cisplatin-resistant Cell Lines Argue Against a Critical Role for these Channels in Cisplatin Resistance. X.-J. LIANG, B. TAYLOR, C. CARDARELLI, J.-J. YIN, J.-P. ANNEREAU, S. GARFIELD, S. WINCOVITCH, G. SZAKÁCS, M.M. GOTTESMAN, A. ASZALOS (<i>Bethesda; College Park, MD, USA</i>).....	4113
Morphological and Histochemical Evidence of the Protective Effect of Procainamide Hydrochloride on Tissue Damage Induced by Repeated Administration of Low Doses of Cisplatin. C. FENOGLIO, E. BONCOMPAGNI, B. CHIAVARINA, S. CAFAGGI, M. CILLI, M. VIALE (<i>Pavia; Genova, Italy</i>).....	4123
Influence of Matrix Metalloproteinase 9 (MMP-9) on the Metastatic Behavior of Oropharyngeal Cancer. A.A. DÜNNE, A. GRÖBE, A.M. SESTERHENN, P. BARTH, C. DALCHOW, J.A. WERNER (<i>Marburg, Germany</i>).....	4129
Characterization of the Focal Adhesion Complex in Human Non-small cell Lung Cancer Cell Lines. V. FOREST, L. CAMPOS, J.-M. VERGNON, J. CORNILLON, D. GUYOTAT (<i>Saint-Etienne, France</i>).....	4135
The Relevance of Adhesion Molecules in the Classification of Squamous Cell Carcinoma of the Head and Neck. A.M. LIEDER, T.G.T. PRIOR, K.J. WOOD, J.A. WERNER (<i>Marburg, Germany; London; Oxford, UK</i>).....	4141
Berberine Decreased N-acetylation of 2-Aminofluorene through Inhibition of N-acetyltransferase Gene Expression in Human Leukemia HL-60 Cells. C.-C. LIN, S.-T. KAO, G.-W. CHEN, J.-G. CHUNG (<i>Taichung; Fong Yuan, Taiwan, ROC</i>).....	4149
Inhibition of LPS-stimulated NO Production in Mouse Macrophage-like Cells by Azulenequinones. M. NISHISHIRO, S. ARIKAWA, H. WAKABAYASHI, K. HASHIMOTO, K. SATOH, K. YOKOYAMA, S. UNTEN, H. KAKUTA, T. KURIHARA, N. MOTOHASHI, H. SAKAGAMI (<i>Saitama; Tokyo, Japan</i>).....	4157
Paclitaxel Decreases the Accumulation of Gemcitabine and its Metabolites in Human Leukemia Cells and Primary Cell Cultures. S.S. SHORD, J.R. CAMP, L.A.F. YOUNG (<i>Chicago, IL, USA</i>).....	4165
The Effects of Jatrophone Derivatives on the Reversion of MDR1- and MRP-mediated Multidrug Resistance in the MDA-MB-231 (HTB-26) Cell Line. M.-J.U. FERREIRA, N. GYÉMÁNT, A.M. MADUREIRA, M. TANAKA, K. KOÓS, R. DIDZIAPETRIS, J. MOLNÁR (<i>Lisbon, Portugal; Szeged, Hungary; Vilnius, Lithuania</i>).....	4173
Different Ways to Induce Apoptosis by Fenretinide and All-trans-retinoic Acid in Human B Lymphoma Cells. G. BARNA, A. SEBESTYÉN, S. WEISCHEDE, I. PETÁK, R. MIHALIK, F. FORMELLI, L. KOPPER (<i>Budapest, Hungary; Milan, Italy</i>).....	4179
Synergistic Role of Arabinoxylan Rice Bran (MGN-3/Biobran) in <i>S. cerevisiae</i> -induced Apoptosis of Monolayer Breast Cancer MCF-7 Cells. M. GHONEUM, S. GOLLAPUDI (<i>Los Angeles; Irvine, CA, USA</i>).....	4187
Caspase-3 Activation and Induction of PARP Cleavage by Cyclic Dipeptide Cyclo(Phe-Pro) in HT-29 Cells. S.C. BRAUNS, G. DEALTRY, P. MILNE, R. NAUDI, M. VAN DE VENTER (<i>Port Elizabeth, South Africa</i>).....	4197
Induction of Apoptosis and Cell Cycle Arrest in Glioma Cells by GL331 (a Topoisomerase II Inhibitor). Y. CHEN, Y.-H. SU, C.-H. WANG, J.-M. WU, J.-C. CHEN, S.-H. TSENG (<i>Taipei; Chia-Yi, Taiwan, ROC</i>).....	4203
The Auricular VX2 Carcinoma: Feasibility of Complete Tumor Resection. N. SAPUNDZHIEV, A.A. DÜNNE, A. RAMASWAMY, J.A. WERNER (<i>Sofia, Bulgaria; Marburg, Germany</i>).....	4209

Cell Death Induced by Taxanes in Breast Cancer Cells: Cytochrome c is Released in Resistant but not in Sensitive Cells. M. EHRLICHOVÁ, M. KOC, J. TRUKSA, Z. NALĎOVÁ, R. VÁCLAVÍKOVÁ, J. KOVÁŘ (<i>Prague, Czech Republic</i>).....	4215
Medullary Thyroid Carcinoma: Autologous Tumor Cell Lines for Dendritic Cell Vaccination. R. PFRAGNER, G. SKOFITSCH, H. HÖGER, M. JECH, B. RINNER, V. SIEGL, B. NIEDERLE, M. GNANT, J. FRIEDL, A. STIFT (<i>Graz; Himberg; Vienna, Austria</i>)	4225
Understanding the Response of Dendritic Cells to Activation by Streptococcal Preparation OK-432. N. KANZAKI, M. TERASHIMA, S. KASHIMURA, M. HOSHINO, S. OHTANI, S. MATSUYAMA, Y. HOSHINO, M. KOGURE, I. OSHIBE, H. ENDO, T. SAITO, H. YAGINUMA, M.GOTOH, H. OHTO (<i>Fukushima, Japan</i>).....	4231
Prednisolone Reduces TNF- α Release by PBMCs Activated with a Trifunctional Bispecific Antibody but not their Anti-tumor Activity. A. WALZ, M. ANDRATSCHKE, B. WOLLENBERG, H. LINDHOFER, R. ZEIDLER (<i>Luebeck; Munich, Germany</i>)	4239
Protective Effect of Melatonin on Human Peripheral Blood Hematopoietic Stem Cells against Doxorubicin Cytotoxicity. K. GREISH, I. SANADA, A. EL-DEIN SAAD, E. HASANIN, M. KAWASUJI, F. KAWANO, H. MAEDA (<i>Kumamoto, Japan; Ismailia, Egypt</i>)	4245
E-Cadherin and β -Catenin Expression in Normal, Inflamed and Cancerous Gallbladder Tissue. H. PUHALLA, B. HERBERGER, A. SOLEIMAN, M. FILIPITS, F. LAENGLE, T. GRUENBERGER, F. WRBA (<i>Vienna, Austria</i>).....	4249
Modes of Action of Alpha-hederin and Thymoquinone, Active Constituents of <i>Nigella sativa</i> , against HEp-2 Cancer Cells. S. ROONEY, M.F. RYAN (<i>Dublin, Ireland</i>)	4255
Cancer of the Uterine Cervix is Susceptible to Anti-EGF-R Antibody EMD 55,900 Therapy. C. SOLBACH, M. ROLLER, M. NICOLETTI, K. BUDISCHEWSKI, R. KNECHT, M. KAUFMANN (<i>Frankfurt am Main, Germany</i>).....	4261
Cox-2 Levels in Canine Mammary Tumors, Including Inflammatory Mammary Carcinoma: Clinicopathological Features and Prognostic Significance. F.L. QUEIROGA, M.D. PEREZ ALENZA, G. SILVAN, L. PEPA, C. LOPES, J.C. ILLERA (<i>Vila Real; Porto, Portugal; Madrid, Spain</i>).....	4269
4-OH Tamoxifen does not Interfere with Bicalutamide Inhibitory Effects on Human Prostatic Cancer Cells <i>In Vitro</i> . F. BOCCARDO, D. MEDICINA, F. GALMOZZI, L. EMIONITE, M. LO CASTO (<i>Genoa, Italy</i>).....	4277
Growth Inhibitory Effect of Doxazosin on Prostate and Bladder Cancer Cells. Is the Serotonin Receptor Pathway Involved? E.J. SIDDIQUI, M. SHABBIR, C.S. THOMPSON, F.H. MUMTAZ, D.P. MIKHAILIDIS (<i>London, UK</i>).....	4281
Expression Analysis of a Subset of Coregulators and Three Nuclear Receptors in Human Colorectal Carcinoma. R. GIANNINI, A. CAVALLINI (<i>Castellana Grotte, Italy</i>)	4287
Proposal of a New Grading System for Malignant Fibrous Histiocytomas. U. BRINCK, C. CORDON-CARDO, J. STACHURA, P. BORTKIEWICZ, G. FISCHER, M. KORABIOWSKA (<i>Wilhelmshaven, Germany; New York, NY, USA; Krakow; Poznan, Poland</i>)	4293
Molecular Changes in PDEGF and bFGF in Malignant Melanomas in Relation to the Stromal Microenvironment. M. FIURASKOVA, S. BRYCHTOVA, E. SEDLAKOVA, P. BENES, B. ZALESAK, A. HLOBILKOVA, M. TICHY, Z. KOLAR (<i>Olomouc, Czech Republic</i>).....	4299

Insulin-like Growth Factor-I Receptor Expression and Localization in Benign and Malignant Rat Mammary Tumors. C. COCCA, A. RANDI, A. GUTIÉRREZ, M. NÚÑEZ, M. CROCI, G. MARTÍN, G. CRICCO, V. MEDINA, N. MOHAMAD, E. RIVERA, D. KLEIMAN, R. BERGOC (<i>Buenos Aires, Argentina</i>)	4305
Endothelial Cell Survivin is Involved in the Growth of Ovarian Endometriotic Cysts. G. GOTERI, G. LUCARINI, T. PIERAMICI, A. FILOSA, A. PUGNALONI, N. MONTIK, G. BIAGINI, A.L. TRANQUILLI, G. FABRIS, A. CIAVATTINI, L. LO MUZIO (<i>Ancona; Foggia, Italy</i>).....	4313
Influence of hMLH1 Methylation, Mismatch Repair Deficiency and Microsatellite Instability on Chemoresistance of Testicular Germ-cell Tumors. J. OLASZ, L. MÁNDOKY, L. GÉCZI, I. BODROGI, O. CSUKA, M. BAK (<i>Budapest, Hungary</i>)	4319
Synergistic Cytotoxicity of Artemisinin and Sodium Butyrate on Human Cancer Cells. N.P. SINGH, H.C. LAI (<i>Seattle, WA, USA</i>).....	4325
Growth Inhibition of Cancer Cells by An Active Metabolite of a Novel Vitamin D Prodrug. Y-R. WANG, D. P. WIGINGTON, S.A. STRUGNELL, J.C. KNUTSON (<i>Middleton, WI, USA</i>).....	4333
Flavopiridol, an Inhibitor of Cyclin-dependent Kinases, Induces Growth Inhibition and Apoptosis in Bladder Cancer Cells <i>In Vitro</i> and <i>In Vivo</i> . A. WIRGER, F.G.E. PERABO, S. BURGEMEISTER, L. HAASE, D.H. SCHMIDT, C. DOEHN, S.C. MUELLER, D. JOCHAM (<i>Luebeck; Bonn, Germany</i>)	4341
Adenovirus-mediated Transfer of FRNK Augments Drug-induced Cytotoxicity in Cultured SCCHN Cells. L.J. KORNBERG (<i>Gainesville, FL, USA</i>).....	4349
Combined Radiation Sensitizing and Anti-angiogenic Effects of Ionizing Radiation and the Protease Inhibitor Ritonavir in a Head and Neck Carcinoma Model. L. MAGGIORELLA, B. WEN, V. FRASCOGNA, P. OPOLON, J. BOURHIS, E. DEUTSCH (<i>Villejuif Cedex, France</i>)	4357
Head and Neck Carcinoma Cell Lines are Sensitive to Vinflunine <i>In Vitro</i> . K. ERJALA, M. RAITANEN, J. KULMALA, R. GRÉNMAN (<i>Turku, Finland</i>)	4363
Absence of Interaction between Doppel and GFAP, Grb2, PrPC Proteins in Human Tumor Astrocytic Cells. A. AZZALIN, I. DEL VECCHIO, L.R. CHIARELLI, G. VALENTINI, S. COMINCINI, L. FERRETTI (<i>Pavia, Italy</i>).....	4369
* Reviews (pages 3799, 3999)	

Number 6C

Clinical Studies

P16 ^{INK4a} Correlates to Human Papillomavirus Presence, Response to Radiotherapy and Clinical Outcome in Tonsillar Carcinoma. H. MELLIN DAHLSTRAND, D. LINDQUIST, L. BJÖRNESTÅL, A. OHLSSON, T. DALIANIS, E. MUNCK-WIKLAND, G. ELMBERGER (<i>Stockholm, Sweden</i>)	4375
Congenital Anomalies of the Spleen Mimicking Hematological Disorders and Solid Tumors: a Single-center Experience of 2650 Consecutive Diagnostic Laparoscopies. R. ORLANDO, F. LUMACHI, F. LIRUSSI (<i>Padua, Italy</i>)	4385
Partial Resection of the Sternum for Osseous Metastasis of Differentiated Thyroid Cancer: Case Report. A. MEYER, M. BEHREND (<i>Deggendorf, Germany</i>).....	4389
	4907

Colorectal Cancer in Colonic Crohn's Disease – High Frequency of DNA-Aneuploidy. U. SJÖQVIST, R. BEFRITS, S. SÖDERLUND, Å. ÖST, P. KARLÉN, B. TRIBUKAIT, C. RUBIO, P. RUTGEERTS, K. GEBOES, R. LÖFBERG (<i>Stockholm, Sweden; Leuven, Belgium</i>)	4393
Antiprostasome Antibody Titres in Benign and Malignant Prostate Disease. A. MINELLI, G. RONQUIST, L. CARLSSON, E. MEARINI, O. NILSSON, A. LARSSON (<i>Perugia, Italy; Uppsala, Sweden</i>)	4399
Successful Treatment of Concurrent Chemoradiotherapy for Stage I Nasal NK/T Cell Lymphoma: A Report of Two Cases. Y. NIIBE, K. HAYAKAWA, M. KITANO, H. ISHIYAMA, M. NAKAYAMA, K. YAO, M. OKAMOTO (<i>Kanagawa, Japan</i>)	4403
Celiac Axis Infusion and Microembolization for Advanced Stage III/IV Pancreatic Cancer – A Phase II Study on 265 Cases. K.R. AIGNER, S. GAILHOFER (<i>Ransbach-Baumbach, Germany</i>)	4407
Sentinel Lymph Node Biopsy Reveals a Positive Popliteal Node in Clear Cell Sarcoma. Y. NISHIDA, Y. YAMADA, S. TSUKUSHI, S. SHIBATA, N. ISHIGURO (<i>Nagoya, Japan</i>)	4413
Multiple Gastric Carcinoids Associated with Hypergastrinemia. A Review of Five Cases with Clinicopathological Analysis and Surgical Strategies. K.-I. OKADA, H. KIJIMA, O. CHINO, M. MATSUYAMA, Y. OKAMOTO, S. YAMAMOTO, M. TANAKA, S. INOKUCHI, H. MAKUUCHI (<i>Kanagawa; Aomori, Japan</i>).....	4417
Paclitaxel Pharmacokinetics and Response to Chemotherapy in Patients with Advanced Cancer Treated with a Weekly Regimen. S. MIELKE, A. SPARREBOOM, D. BEHRINGER, K. MROSS (<i>Freiburg, Germany; Rotterdam, The Netherlands; Bethesda, MD, USA</i>).....	4423
Second Surgery and the Prognosis of Choroid Plexus Carcinoma – Results of a Meta-analysis of Individual Cases. B. WREDE, P. LIU, J. ATER, J.E.A.WOLFF (<i>Regensburg, Germany; Houston, TX, USA</i>).....	4429
Tumour-infiltrating Lymphocytes: A Prognostic Factor of PSA-free Survival in Patients with Local Prostate Carcinoma Treated by Radical Prostatectomy. V. KÄRJÄ, S. AALTOOMAA, P. LIPPONEN, T. ISOTALO, M. TALJA, R. MOKKA (<i>Kuopio; Lahti, Finland</i>)	4435
Comparison between Whole-body Positron Emission Tomography and Bone Scintigraphy in Evaluating Bony Metastases of Esophageal Carcinomas. H. KATO, T. MIYAZAKI, M. NAKAJIMA, J. TAKITA, H. KIMURA, A. FARIED, M. SOHDA, Y. FUKAI, N. MASUDA, M. FUKUCHI, R. MANDA, H. OJIMA, K. TSUKADA, H. KUWANO, N. ORIUCHI, K. ENDO (<i>Gunma, Japan</i>)	4439
Carboplatin in Combination with Raltitrexed in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: A Multicentre Phase II Study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.). D. GALETTA, F. GIOTTA, G. ROSATI, V. GEBBIA, L. MANZIONE, M. DI BISCEGLIE, N. BORSELLINO, G. COLUCCI (<i>Bari; Potenza; Palermo, Italy</i>)	4445
Concurrent Chemo-radiotherapy with Taxotere and Cisplatin in Head and Neck Cancer: A Feasibility Study. M. MENCOBONI, L. REBELLA, S. TREDICI, R. GHIO, D. SCARPATI, M. BAVAZZANO, B. JANKOWSKA, M. DELLE PIANE (<i>Genoa, Italy</i>).....	4451
Prognostic Significance of the Polymorphisms in Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene in Lung Cancer. A. TAKEHARA, K. KAWAKAMI, N. OHTA, K. OYAMA, Y. OTA, M. ODA, G. WATANABE (<i>Kanazawa, Japan</i>).....	4455
Treatment of Metastatic Neuroendocrine Carcinomas Based on WHO Classification. S. ARTALE, L. GIANNETTA, G. CEREÀ, P. PEDRAZZOLI, I. SCHIAVETTO, M. NAPOLITANO, S. VERONESE, E. BRAMERIO, M. GAMBACORTA, A. VANZULLI, S. PISCONTI, R. PUGLIESE, S. SIENA (<i>Milan; Taranto, Italy</i>)	4463

Nitric Oxide-releasing Medications and Colorectal Cancer Risk: The Framingham Study. J.E. MUSCAT, A.-M. DYER, R.E. ROSENBAUM, B. RIGAS (<i>Hershey, PA; Stony Brook, NY, USA</i>)	4471
Feasibility of 21-day Continuous Infusion of Epirubicin in Hormone-refractory Prostate Cancer Patients. A. BERRUTI, A. MOSCA, R. BITOSSI, G. GORZEGNO, S. GUERCIO, M. POGGIO, M. TAMPELLINI, F. PORPIGLIA, O. OSTELLINO, R.M.SCARPA, L. DOGLIOTTI (<i>Orbassano; Alba e Bra, Italy</i>)	4475
Docetaxel, Estramustine and Prednisone for Hormone-refractory Prostate Cancer: A Single-center Experience. A. BOEHMER, A.G. ANASTASIADIS, S. FEYERABEND, U. NAGELE, M. KUCZYK, D. SCHILLING, S. CORVIN, A.S. MERSEBURGER, A. STENZL (<i>Tuebingen, Germany</i>)	4481
Excretion of Hydroxylated Metabolites of Tamoxifen in Human Bile and Urine. E.R. KISANGA, G. MELLGREN, E.A. LIEN (<i>Bergen, Norway; Kilimanjaro, Tanzania</i>)	4487
First-line Chemotherapy with Fluorouracil-Epirubicin-Navelbine (FEN) Combination in Advanced Breast Cancer. A. ARDAVANIS, D. TRYFONOPOULOS, G. ORPHANOS, G. IOANNIDIS, M. KARAMOUZIS, G. RIGATOS (<i>Athens, Greece</i>)	4493
Chemosensitivity Testing of a Novel Platinum Analog, Nedaplatin (254-S), in Human Gynecological Carcinomas: a Comparison with Cisplatin. M. KOSHIYAMA, M. KINEZAKI, T. UCHIDA, M. SUMITOMO (<i>Hyogo; Nara, Japan</i>)	4499
* Lymphangiogenesis, Inflammation and Metastasis. S.F. SCHOPPMANN (<i>Vienna, Austria</i>)	4503
Mitomycin C and Capecitabine Combination (MiXe) in Heavily Pretreated Metastatic Breast Cancer Patients. A Dose-finding Study. R. MAISANO, N. CARISTI, M. MARE, A. MAFODDA, R. CARBONI, E. MONTALTO, M. IORFIDA, M. NARDI (<i>Reggio Calabria; Messina; Viagrande, Italy</i>)	4513
* Biological Prognostic Factors in Adult Soft Tissue Sarcomas. A. OTTAIANO, A. DE CHIARA, F. FAZIOLI, A. AIELLO TALAMANCA, S. MORI, GERARDO BOTTI, A. MILANO, G. APICE (<i>Naples, Italy</i>)	4519
* Prostate Cancer in the Elderly. K.N. SYRIGOS, E. KARAPANAGIOTOU, K.J. HARRINGTON (<i>Athens, Greece; London, UK</i>)	4527
Expression of BRCA1, HER-1 (EGFR) and HER-2 in Sporadic Breast Cancer and Relationships to Other Clinicopathological Prognostic Features. Y. ANSQUER, L. MANDELBROT, T. LEHY, L. SALOMON, C. DHAINAUT, P. MADELENAT, G. FELDMANN, F. WALKER (<i>Colombes Cedex; Paris, France</i>)	4535
Cyclooxygenase-2 Protein Expression in Relation to Apoptotic Potential and its Prognostic Significance in Bladder Urothelial Carcinoma. K. DIAMANTOPOULOU, A. LAZARIS, E. MYLONA, A. ZERVAS, K. STRAVODIMOS, I. NIKOLAOU, S. ATHANASSIADOU, L. NAKOPOULOU (<i>Athens, Greece</i>)	4543
Neoplasias of the Colorectal Crypts. C.A. RUBIO (<i>Stockholm, Sweden</i>)	4551
Role and Cost-effectiveness of Adrenal Imaging and Image-guided FNA Cytology in the Management of Incidentally Discovered Adrenal Tumours. F. LUMACHI, S.M.M. BASSO, S. BORSATO, A. TREGNAGHI, P. ZUCCHETTA, M.C. MARZOLA, D. CECCHIN, F. BUI, G. FABIA (<i>Padova; Perugia, Italy</i>)	4559
Increased Survival of Tumor-bearing Mice by the Delta Opioid SNC 80. R. GOMEZ-FLORES, D. CABALLERO-HERNÁNDEZ, R. TAMEZ-GUERRA, C. RODRÍGUEZ-PADILLA, P. TAMEZ-GUERRA, K.C. RICE, M.E. HICKS, R.J. WEBER (<i>San Nicolas de los Garza, NL, México; Bethesda, MD; Peoria, IL, USA</i>)	4563
	4909

Des- γ -carboxy Prothrombin (PIVKA-II)-producing Mediastinal Embryonal Carcinoma with Features of Hepatoid Differentiation. Y. HASEGAWA, K. TOMITA, K. HASHIMOTO, Y. SHIGEOKA, M. WATANABE, A. YAMASAKI, E. SHIMIZU (<i>Yonago, Japan</i>)	4569
Extrarenal Malignant Rhabdoid Tumour of the Heel – A Case Report. M. MAZZOCCHI, S. CHIUMMARELLO, G. BISTONI, F. MARCHETTI, C. ALFANO (<i>Rome; Perugia, Italy</i>)	4573
Computer-aided Diagnosis of Melanocytic Lesions. I. STANGANELLI, A. BRUCALE, L. CALORI, R. GORI, A. LOVATO, S. MAGI, B. KOPF, R. BACCHILEGA, V. RAPISARDA, A. TESTORI, P.A. ASCIERTO, E. SIMEONE, M. FERRI (<i>Ravenna; Milan; Bologna; Napoli, Italy</i>)	4577
Perioperative Application of the <i>Viscum album</i> Extract Isorel in Digestive Tract Cancer Patients. M.B. ENESEL, I. ACALOVSKI, V. GROSU, A. SBARCEA, C. RUSU, A. DOBRE, T. WEISS, N. ZARKOVIC (<i>Tg. Mures; Cluj Napoca; Bucharest, Romania; Poertschach, Austria; Zagreb, Croatia</i>)	4583
Very Early Detection of Response to Imatinib Mesylate Therapy of Gastrointestinal Stromal Tumours Using ¹⁸ Fluoro-Deoxyglucose-Positron Emission Tomography. T. HEINICKE, E. WARDELMANN, T. SAUERBRUCH, H.J. TSCHAMPA, A. GLASMACHER, H. PALMEDO (<i>Bonn, Germany</i>)	4591
Interleukin-4 in Patients with Prostate Cancer. T. UEDA, M.D. SADAR, H. SUZUKI, K. AKAKURA, S. SAKAMOTO, M. SHIMBO, T. SUYAMA, T. IMAMOTO, A. KOMIYA, N. YUKIO, T. ICHIKAWA (<i>Chiba; Tokyo, Japan; Vancouver, BC, Canada</i>)	4595
* Perspectives of Immunotherapy in Metastatic Breast Cancer. D. LÜFTNER, D. POLLMANN, S. SCHILDHAUER, J. SEHOULI, K. POSSINGER (<i>Berlin, Germany</i>)	4599
Treatment of Unresectable Glioblastoma Multiforme. C. NIEDER, A.L. GROSU, S. ASTNER, M. MOLLS (<i>Munich, Germany</i>)	4605
Weekly Paclitaxel as Second/Third-line Treatment in Advanced Non-small Cell Lung Cancer Patients: Efficacy and Tolerability C. CAMPS, C. CABALLERO, A. BLASCO, M.J. SAFONT, A. BERROCAL, J. GARDE, A. JUAREZ, R. SIRERA, R.M. BREMNES (<i>Valencia, Spain; Tromso, Norway</i>).....	4611
Predictive Biological Markers for Response of Invasive Breast Cancer to Anthracycline / Cyclophosphamide-based Primary (Radio-) Chemotherapy. H.-B. PRISACK, C. KARREMAN, O. MODLICH, W. AUDRETSCH, M. DANAE, M. REZAI, H. BOJAR (<i>Düsseldorf, Germany</i>).....	4615
Coping and Defending as Risk Factors for Breast Cancer in Patients with Breast Disease; a Prospective Case-control Study in Kuopio, Finland. P. OLLONEN, J. LEHTONEN, M. ESKELINEN (<i>Kuopio, Finland</i>)	4623
Expression of Caveolin-1 in Pleomorphic Carcinoma of the Lung is Correlated with a Poor Prognosis. K.C. MOON, G.K. LEE, S.-H. YOO, Y.K. JEON, J.-H. CHUNG, J. HAN, D.H. CHUNG (<i>Goyang; Seoul, South Korea</i>)	4631
Evaluation of Tartrate-resistant Acid Phosphatase (TRACP) 5b as Bone Resorption Marker in Irradiated Bone Metastases S. MOSE, C. MENZEL, A.A. KURTH, K. OBERT, U. RAMM, K. EBERLEIN, H.-D. BOETTCHER, U. PICHLMEIER (<i>Frankfurt/Main; Hamburg; Villingen Schwenningen, Germany</i>)	4639
Prevalence, Changes in and Correlates of Fatigue in the First Year after Diagnosis of Testicular Cancer. J. FLEER, D.T. SLEIJFER, H.J. HOEKSTRA, M.A. TUINMAN, J.E.H.M. HOEKSTRA-WEEBERS (<i>Groningen, The Netherlands</i>).....	4647
Tumour Control Probability of Stage III Inoperable Non-small Cell Lung Tumours after Sequential Chemoradiotherapy. S.Y. EL SHAROUNI, H.B. KAL, J.J. BATTERMANN (<i>Utrecht, The Netherlands</i>).....	4655

Concurrent Radiotherapy and Tumor Targeting with ¹¹¹ In-HMFG1-F(ab') ₂ in Patients with MUC1-positive Non-small Cell Lung Cancer. M. GARKAVIJ, M. SAMARZIJA, S.B. EWERS, M. JAKOPOVIC, S. TEZAK, J. TENNVALL (<i>Lund, Sweden; Zagreb, Croatia</i>)	4663
Impact of Radiotherapy with and without Concurrent Cisplatin on Lymphocyte Subpopulations in Cervical Cancer Patients. B. BACHTIARY, I. HERBACEK, T. ZIDECK, T.-H. KNOCKE, J. DIMOPOULOS, R. POETTER, M. MICKSCHE (<i>Vienna, Austria</i>).....	4673
Real-time RT-PCR: A Complementary Method to Detect HER-2 Status in Breast Carcinoma. C. BOSSARD, I. BIECHE, V.E LE DOUSSAL, R. LIDEREAU, J.C. SABOURIN (<i>Saint-Cloud; Paris, France</i>).....	4679
Weekly Chemotherapy with Cisplatin and Paclitaxel in Inoperable Non-small Cell Lung Cancer: An Extended Phase II Study. D. FERRIGNO, G. BUCCHERI (<i>Cuneo, Italy</i>)	4685
Combined Overexpression of EGFR and Estrogen Receptor α Correlates with a Poor Outcome in Lung Cancer. H. KAWAI, A. ISHII, K. WASHIYA, T. KONNO, H. KON, C. YAMAYA, I. ONO, J. OGAWA (<i>Akita, Japan</i>)	4693
Expression of p53, Cyclin D1 and Ki-67 in Pre-malignant and Malignant Oral Lesions: Association with Clinicopathological Parameters. B. RAJU, R. MEHROTRA, G. ØIJORDSBAKKEN, A.K. AL-SHARABI, E.N. VASSTRAND, S.O. IBRAHIM (<i>Bergen, Norway; Allahabad, India; Sana'a, Yemen</i>)	4699
Reduced α - and β -catenin Expression Predicts Shortened Survival in Local Prostate Cancer. S. AALTOOMAA, V. KÄRJÄ, P. LIPPONEN, T. ISOTALO, J.-P. KANKKUNEN, M. TALJA, R. MOKKA (<i>Kuopio; Lahti, Finland</i>)	4707
Docetaxel Administered Every Two Weeks as Second-line Chemotherapy for Advanced Non-small Cell Lung Cancer: A Phase II Study. L. DE PETRIS, M.R. MIGLIORINO, A. CERIBELLI, O. MARTELLI, M. DI MOLFETTA, A. MANCUSO, S. DE SANTIS, R. DI SALVIA, F. DE MARINIS (<i>Rome, Italy</i>).....	4713
Utility of FDG-PET for Investigating Unexplained Serum AFP Elevation in Patients with Suspected Hepatocellular Carcinoma Recurrence. Y.-K. CHEN, D.-S. HSIEH, C.-S. LIAO, C.-H. BAI, C.-T. SU, Y.-Y. SHEN, J.-F. HSIEH, A.C. LIAO, C.-H. KAO (<i>Taichung; Taipei; Tainan, Taiwan, ROC</i>).....	4719
Biochemical Nature and Mapping of PSMA Epitopes Recognized by Human Antibodies Induced after Immunization with Gene-based Vaccines. K. TODOROVA, S. ZOUBAK, M. MINCHEFF, S. KYURKCHIEV (<i>Sofia, Bulgaria; Washington, DC, USA</i>)	4727
Adjuvant Intravesical Treatment with a Standardized Mistletoe Extract to Prevent Recurrence of Superficial Urinary Bladder Cancer. U. ELSÄSSER-BEILE, C. LEIBER, U. WETTERAUER, P. BÜHLER, P. WOLF, M. LUCHT, U. MENGS (<i>Freiburg; Köln, Germany</i>).....	4733
Comparison of Tc-99m Sestamibi and F-18 FDG-PET in the Assessment of Multiple Myeloma. G.-U. HUNG, C.-C. TSAI, S.-C. TSAI, W.-Y. LIN (<i>Changhua; Tainan; Taichung, Taiwan, ROC</i>)	4737
Serum Levels of Soluble Syndecan-1 in Hodgkin's Lymphoma. T.P. VASSILAKOPOULOS, M.-C. KYRTSONIS, A. PAPAIOGIANNIS, G. NADALI, M.K. ANGELOPOULOU, T. TZENOU, M.N. DIMOPOULOU, M.P. SIAKANTARIS, F.N. KONTOPIDOU, C. KALPADAKIS, S.I. KOKORIS, E.M. DIMITRIADOU, P. TSAFTARIDIS, G. PIZZOLO, G.A. PANGALIS (<i>Athens, Greece; Verona, Italy</i>)	4743
Low-dose Leucovorin and 5-Fluorouracil for Unresectable Multiple Liver Metastasis from Colorectal Cancer. K. ISHIBASHI, K. YOSHIMATSU, H. YOKOMIZO, A. UMEHARA, K. YOSHIDA, T. FUJIMOTO, K. WATANABE, T. KATSUBE, Y. NARITAKA, K. OGAWA (<i>Tokyo, Japan</i>)	4747

Prevention of Surgery-induced Suppression of Granulocyte Function by Intravenous Application of a Fermented Extract from <i>Viscum album</i> L. in Breast Cancer Patients. A. BÜSSING, M. BISCHOF, W. HATZMANN, F. BARTSCH, D. SOTO-VERA, E.-M. FRONK, M. GMEINDL, G.M. STEIN (<i>Herdecke; Witten; Berlin, Germany</i>)	4753
Inhibition of EGFR Tyrosine-kinase in NSCLC Treatment: the Hungarian Experience with Gefitinib in the Context of an Expanded Access Programme. G. OSTOROS, R. HARISI, G. KOVACS, J. HORTI, L. GECZI, K. SZONDY, M. OROSZ, E. FERENCZI, E. RUBY, B. DOME (<i>Budapest; Kecskemet; Torokbalint, Hungary</i>)	4759
Relationship between Eradication of <i>Helicobacter pylori</i> and Gastric Mucosal Superoxide Dismutase Activity. R. FARKAS, L. PRONAI, Z. TULASSAY, L. SELMECI (<i>Budapest, Hungary</i>)	4763
Retroperitoneal Liposarcoma with Metastasis to both Orbits: an Unusual Metastatic Site. A. FABI, N. SALESI, A. VIDIRI, A. MIRRI, V. FERRARESI, F. COGNETTI (<i>Rome, Italy</i>)	4769

Book Reviews

* Reviews (pages 4503, 4519, 4527, 4599)

Number 6D

Abstracts of the 13th International Hamburg Symposium on Tumor Markers November 27 - 29, 2004, Hamburg, Germany. Special Issue Edited by R. Klapdor	4773-4848
Index 2005	4849-4992

Subject Index

(Figures refer to page numbers)

- A. archangelica*, essential oils, cytotoxicity, CrI, 1877
 A431 cells, bisphosphonate, alendronate, squamous cell carcinoma, proliferation, invasion, 2655
 ABC transporter, chemosensitivity, conjugated bilirubin, renal cell carcinoma, MRP2, 2729
 Aberrant crypt foci, PPAR β/δ , cyclin D1, multiple intestinal neoplasia, azoxymethane, ApcMin/+ mice, β -catenin, Wnt signalling pathway, 3781
 Abort placenta, Thomsen-Friedenreich, tumor antigen, 1675
 ACE inhibitor, angiogenesis, hepatocarcinogenesis, renin-angiotensin system, 3335
 N-Acetyl-2-aminofluorene, N-acetyltransferase, wogonin, human leukemia cells, 2-aminofluorene, 127
 Acetyl-L-carnitine, oxaliplatin, neurotoxicity, 2681
 N-Acetyl-L-cysteine, hydroquinone, apoptosis, HL-60 cells, Cu/Zn and Mn superoxide dismutase mRNA, caspases, 161
 N-Acetyltransferase (NAT), berberine, leukemia cell line (HL-60), 2-aminofluorene (AF), flow cytometry, 4149
 N-Acetyltransferase, wogonin, human leukemia cells, N-acetyl-2-aminofluorene, 2-aminofluorene, 127
 Acinar cell carcinoma, alpha-fetoprotein, AFP, pancreatic carcinoma, 1671
 Aclarubicin, lung cancer, acute leukemia, gefitinib, cytarabine, 2579
 ACNU, MGMT, hMLH1, alkylating agents, gallbladder carcinoma, 4021
 Acridine orange, musculoskeletal sarcoma, photodynamic therapy, limb salvage surgery, radiation, 1225
 Acridine orange, photodynamic therapy, xenon, excitation, illuminance, osteosarcoma, 3979
 Actin cytoskeleton, fenretinide, 4-HPR, ovarian cancer, OVCAR-5, angiogenesis, endothelial cells, HUVEC, FAK, 249
 Activated lymphocytes, dendritic cells, vaccine, autologous tumor cells, 3771
 Activin, invasive mole, gestational trophoblastic disease, inhibin, Sialyl Lewis A, glycodelin, immunohistochemistry, 1725
 Acute leukemia, lung cancer, gefitinib, cytarabine, aclarubicin, 2579
 Acute leukemia, *MLL* gene, chromosomal band 11q23, 1931
 Acute liver damage, hepatocellular carcinoma, transarterial chemo-embolization, Lipiodol, ICG-R15, 2551
 Acute myeloid leukemia, WP1034, apoptosis, signal transduction, Jak-Stat, 1841
 ADCC, HER2, trastuzumab, LAK, 827
 Adenocarcinoma of the lung, aviscumine, recombinant mistletoe lectin, prognostic factors, non-small cell lung cancer, 3303
 Adenocarcinoma, allelic imbalance, Barrett's oesophagus, gastric cardia, D7S483, 7q36, 913
 Adenocarcinoma, sirolimus, liver, rat, sarcoma, hepatoma, 789
 Adenoid cystic carcinoma, breast, 455
 Adenoid cystic carcinoma, imatinib, salivary gland, 3659
 Adenoid cystic carcinoma, neutron therapy, dedifferentiation, histological subtype, salivary glands, head and neck, 1321
 Adenoma, serrated, pancreas, intraductal, 3099
 Adenomas, colon, rectum, progression, invasive carcinoma, 2503
 Adenomas, cystatins, cysteine cathepsins, intracranial tumours, invasion, stefin A, 587
 Adenomas, serrated, microtubular, colon, rectum, 1353
 Adenovirus, gene therapy, bladder cancer, recombinant IL-2, 2757
 Adhesion molecule, NK cell, paclitaxel, 735
 Adhesion molecules, selectins, SCCHN, metastasis, 4141
 Adhesive molecules, ICAM-1, VCAM-1, colorectal cancer, diagnosis, 1597
 Adjuvant chemotherapy, gastric cancer, advanced, chemosensitivity, MTT assay, extended surgery, superextended lymphadenectomy, 3453
 Adjuvant intravesical treatment, superficial bladder cancer, mistletoe extract, mistletoe lectin, 4733
 Adjuvant radiotherapy, vulvar cancer, exclusive radiotherapy, surgery, 3089
 Adjuvant therapy, 2C4, HER2/neu, Herceptin™, metastatic breast cancer, pertuzumab, trastuzumab, review, 1483
 Adjuvant therapy, aromatase inhibitors, breast cancer, tamoxifen, review, 2497
 Adjuvant therapy, nuclear morphometry, nuclear area, colorectal cancer, prognosis, 3083
 Adoptive immunotherapy (AIT), peptide-pulsed dendritic cell-activated killer (PDAK) cells, T-cell receptor (TCR), lung metastasis, 2407
 Adoptive immunotherapy, immunocell therapy, melanoma, dendritic cells, lymphocytes, mixed response, 3741
 ADPRT, lung cancer, DNA repair, single nucleotide polymorphism, APEX1, XRCC1, LIG3, 537
 Adrenal FNA cytology, adrenal incidentalomas, adrenal tumours, adrenal scintigraphy, MRI, 4559
 Adrenal incidentalomas, adrenal tumours, adrenal scintigraphy, adrenal FNA cytology, MRI, 4559
 Adrenal scintigraphy, adrenal incidentalomas, adrenal tumours, adrenal FNA cytology, MRI, 4559
 Adrenal tumours, adrenal incidentalomas, adrenal scintigraphy, adrenal FNA cytology, MRI, 4559

- Advanced breast cancer, sequential chemotherapy, docetaxel, epirubicin, vinorelbine, 1309
- Advanced cervical cancer, cisplatin, vinorelbine, 2489
- Advanced gastric cancer, cisplatin, docetaxel, TS-1, phase II study, second-line chemotherapy, 2973
- Advanced gastric cancer, irinotecan, cisplatin, phase I/II trial, 1257
- Advanced, gastric cancer, chemosensitivity, adjuvant chemotherapy, MTT assay, extended surgery, superextended lymphadenectomy, 3453
- Adverse effect, SELDI TOF-MS, protein expression profile, ProteinChip System, HMW kininogen, apolipoprotein A-II, 1197
- AFP, alpha-fetoprotein, pancreatic carcinoma, acinar cell carcinoma, 1671
- AFP-producing Barrett's esophageal cancer, hepatoid adenocarcinoma, liver metastasis, paclitaxel, cisplatin, 2965
- African-American, benign human prostate cells, hTERT, androgen, androgen receptor antagonist, 1
- African-American, cyclin D1, breast cancer, estrogen receptor, 273
- Afterloading, PSA, prostate, radiotherapy, 1555
- Age, canine, prostatic cells, ER β , 4081
- Aged, esophageal cancer, combined modality therapy, 3055
- Aged, prostate cancer, prevention, detection, review, 4527
- Ageing, sodium fluoride, human oral cells, cytotoxicity, apoptosis, mitochondrial function, 2085
- Ageing, telomere length, telomere shortening, review, 3011
- Aging, carcinogenesis, stem cells, dedifferentiation, 1385
- AgNORs, MIB-1, breast cancer, 3957
- Ah receptor, gastric tumour, hamartoma, dioxin, 903
- AIN, immunosuppression, macrophage, VEGF, angiogenesis, 693
- Akt, p38 MAPK, apoptosis, gemcitabine, pancreatic cancer, 3347
- ALCL, transgenic mice, NPM-ALK, lymphoma, 3191
- Alendronate, bisphosphonate, A431 cells, squamous cell carcinoma, proliferation, invasion, 2655
- Alkaline phosphatase, bone remodelling markers, N-terminal telopeptide of collagen type I, bone metastases, bisphosphonates, zoledronic acid, 1457
- Alkylating agents, MGMT, hMLH1, gallbladder carcinoma, ACNU, 4021
- All-*trans* retinoic acid (ATRA), N-(4-hydroxyphenyl) retinamide, apoptosis, reactive oxygen species, glutathione, tissue transglutaminase, BSO, 1945
- Allelic imbalance, Barrett's oesophagus, gastric cardia, adenocarcinoma, D7S483, 7q36, 913
- Alpha particle emitter, folate receptor, folate conjugate, targeted radiotherapy, 9
- Alpha-fetoprotein, AFP, pancreatic carcinoma, acinar cell carcinoma, 1671
- Alpha-fetoprotein, positron emission tomography, 18F-fluorodeoxyglucose, hepatocellular carcinoma, 4719
- Alpha-hederin, *Nigella sativa*, thymoquinone, 2199
- Alpha-hederin, thymoquinone, apoptosis, glutathione, *Nigella sativa*, 4255
- Alpha-N-acetylgalactosaminidase, Gc protein, Gc protein-derived macrophage activating factor (GcMAF), review, 3689
- Alternative splicing, angiogenesis, cartilaginous tumors, VEGF, 955
- Alvaradoin E, alvaradoin F, annexin V-FITC, anthracenone C-glycosides, apoptosis, DAPI, DiOC₆, hollow fiber test, mitochondrial membrane potential analysis, propidium iodide, TUNEL assay, 779
- Alvaradoin F, alvaradoin E, annexin V-FITC, anthracenone C-glycosides, apoptosis, DAPI, DiOC₆, hollow fiber test, mitochondrial membrane potential analysis, propidium iodide, TUNEL assay, 779
- Alveolar macrophage, LPS, Coley's toxin, Toll-like receptor, innate immunity, immune therapy, lung carcinoma, co-cultivation, 3747
- 2-Aminofluorene (AF), N-acetyltransferase (NAT), berberine, leukemia cell line (HL-60), flow cytometry, 4149
- 2-Aminofluorene, N-acetyltransferase, wogonin, human leukemia cells, N-acetyl-2-aminofluorene, 127
- Amphotericin B, ⁸⁶Rb⁺, potassium ion flux, mesothelioma, ionophores, small cell lung cancer, 2609
- Amrubicin, irinotecan, non-small cell lung cancer, phase I study, non-platinum regimen, topoisomerase inhibitor, 2429
- Anaplastic oligodendroglioma, procarbazine, ranimustine, vincristine, 3715
- Androgen receptor antagonist, benign human prostate cells, African-American, hTERT, androgen, 1
- Androgen receptor, prostate cancer, interleukin-4, interleukin-6, 4595
- Androgen receptor, prostate cancer, PC-EW, PC-OR, mutation screening, 1611
- Androgen, benign human prostate cells, African-American, hTERT, androgen receptor antagonist, 1
- Anemia, epoetin alfa, 669
- Anemia, erythropoietin, quality of life, 3495
- Anemia, testicular cancer, cancer-related fatigue, testosterone, trait anxiety, 4647
- Anesthesia, radiation therapy, chemotherapy, 2815
- ANG-1, cytoplasm, fibroblast, angiopoietin, ANG-2, 171
- ANG-2, cytoplasm, fibroblast, angiopoietin, ANG-1, 171
- Angiogenesis models, tumor endothelial cells, angiogenic phenotype, antiangiogenesis, review, 3799
- Angiogenesis, ACE inhibitor, hepatocarcinogenesis, renin-angiotensin system, 3335

- Angiogenesis, alternative splicing, cartilaginous tumors, VEGF, 955
- Angiogenesis, CD105, TGF- β 1, endothelial cells, 1851
- Angiogenesis, cervix, cancer, EMD 55, 900, CD 31, 4261
- Angiogenesis, chorioallantoic membrane, irradiation, nitric oxide, 1059
- Angiogenesis, COX-2, endometrial cancer, apoptosis, cell growth, metastatic potential, immunomodulation, review, 3679
- Angiogenesis, digoxin, mice, neuroblastoma, tumor, 207
- Angiogenesis, fenretinide, 4-HPR, ovarian cancer, OVCAR-5, endothelial cells, HUVEC, actin cytoskeleton, FAK, 249
- Angiogenesis, hollow fibre assay, anti-vascular effects, H460 non-small cell lung carcinoma cell line, VEGF, 1889
- Angiogenesis, imaging, liposomes, matrix metallo-proteinases, phage display, 33
- Angiogenesis, immunosuppression, macrophage, VEGF, AIN, 693
- Angiogenesis, inositol hexaphosphate, prostate cancer, mitogenic signaling, cell survival signaling, cell cycle progression, apoptosis, review, 2891
- Angiogenesis, lung cancer, VEGF, iNOS, oncoprotein, risk model, 497
- Angiogenesis, metastatic cascade, cell adhesion, local proteolysis, cell migration, review, 3327
- Angiogenesis, ovarian endometriosis, MVD, VEGF, survivin, 4313
- Angiogenesis, renal cell carcinoma, bone metastasis, fibroblast growth factor-2, antisense oligodeoxynucleotide, 1109
- Angiogenesis, roxithromycin (RXM), VEGF, HepG2, 133
- Angiogenesis, soft tissue sarcoma, VEGF, Flk-1, MVD, 3591
- Angiogenesis, tenascin (Tn-C)-C, vascular endothelial growth factor (VEGF), microvessel density (MVD), non-small cell lung cancer (NSCLC), 489
- Angiogenesis, VEGF-D, cell proliferation, breast cancer, cyclin, 701
- Angiogenesis, $\alpha\beta$ 3 integrin antagonist, anticancer, antiangiogenesis, 197
- Angiogenic phenotype, tumor endothelial cells, antiangiogenesis, angiogenesis models, review, 3799
- Angiopoietin, cytoplasm, fibroblast, ANG-1, ANG-2, 171
- Angiosarcoma, intravascular papillary endothelial hyperplasia, Masson's hemangioma, soft-tissue sarcoma, 1409
- Angiostatic proteins, herpesvirus, lung cancer cells, 2049
- Animal model, bladder cancer, carboxyamido-triazole, apoptosis, proliferation, 725
- Animal model, canine mammary tumors, Cox-2, inflammatory mammary carcinoma, enzyme immunoassay, 4269
- Annexin V-FITC, alvaradoin E, alvaradoin F, anthracenone C-glycosides, apoptosis, DAPI, DiOC₆, hollow fiber test, mitochondrial membrane potential analysis, propidium iodide, TUNEL assay, 779
- Annexin-V-FITC, prostate cancer cells, black cohosh extract, apoptosis, M30 antibody, 139
- Anthocyanins, chemoprevention, genotoxicity, apoptosis, lymphocytes, 2837
- Anthracenone C-glycosides, alvaradoin E, alvaradoin F, annexin V-FITC, apoptosis, DAPI, DiOC₆, hollow fiber test, mitochondrial membrane potential analysis, propidium iodide, TUNEL assay, 779
- Anthracycline derivatives, antiproliferative activity, toxicity, cardiotoxicity, 2043
- Anthracyclines, cardiotoxicity, chest wall irradiation, breast cancer, natriuretic peptides, 3651
- Anthracyclines, topo II poison, apoptosis, 2193
- Anti-adherence therapy, anticancer cell adherence agent, peritoneal metastasis, dextran sulfate, peritoneal metastasis, 895
- Anti-angiogenesis, chemokine, platelet factor 4 (PF4), 847
- Anti-angiogenesis, protease inhibitor, ionizing radiation, 4357
- Anti-apoptosis, gastric cancer cell, IAP, inhibitor of apoptosis protein, 2713
- Anti-*Helicobacter pylori* activity, *Capsicum annuum* L. var. angulosum Mill. extracts, cytotoxicity, MDR reversal, anti-HIV activity, urease inhibition, 1991
- Anti-Her2/neu, monoclonal antibody, bispecific antibody, extracellular glycoproteins, prostate cancer, immunotherapy, 43
- Anti-HIV activity, *Capsicum annuum* L. var. angulosum Mill. extracts, cytotoxicity, MDR reversal, anti-*Helicobacter pylori* activity, urease inhibition, 1991
- Anti-metastasis, VGA1155, vascular endothelial growth factor, 3973
- Anti-proliferative activity, bisphosphonate, tumor cells, structure-activity, 1139
- Anti-PSMA antibodies, prostate cancer, gene-based PSMA vaccination, LNCaP cells, carbohydrate cleaving enzyme, proteases, 4727
- Anti-tumor, Bcl-2, Bcl-2 phosphorylation, sesquiterpenelactones, taxol, apoptotic proteins, 313
- Anti-vascular effects, hollow fibre assay, angiogenesis, H460 non-small cell lung carcinoma cell line, VEGF, 1889
- Antiangiogenesis, angiogenesis, $\alpha\beta$ 3 integrin antagonist, anticancer, 197
- Antiangiogenesis, tumor endothelial cells, angiogenic phenotype, angiogenesis models, review, 3799
- Antibody-based therapy, immunotherapy, cytotoxic T lymphocytes, natural killer cells, tumor antigen, carcinoembryonic antigen, review, 3725

- Anticancer cell adherence agent, anti-adherence therapy, peritoneal metastasis, dextran sulfate, peritoneal metastasis, 895
- Anticancer drugs, codeinone, α , β -unsaturated ketones, apoptosis, caspase-3, DNA fragmentation, 4037
- Anticancer drugs, gastric cancer, chemosensitivity, chemotherapy, 931
- Anticancer, angiogenesis, $\alpha\beta$ integrin antagonist, antiangiogenesis, 197
- Antigen presentation, dendritic cell, human, CTL, tumor immunity, 2177
- Antigen-presenting cell, IL-12, CD83, CD68, dendritic cell, macrophage, colorectal cancer, 3541
- Antimicrobial, indolo[2, 3-b]quinoline, cell cycle, topoisomerase II, MDR, DNA-binding, cytotoxicity, lipophilicity, 2857
- Antioxidant, Cu plate, cytotoxicity, radical, SOD, ESR, 283
- Antioxidants, apoptosis, γ -irradiation, macrophages, reactive oxygen species, caspase inhibitors, 4091
- Antioxidants, eradication treatment, gastric mucosa, gastritis, *Helicobacter pylori*, reactive oxygen metabolites, superoxide dismutase, 4763
- Antiproliferation, cancer, vitamin D, $24(\text{OH})_2\text{D}_2$, bisphosphonate, 1909
- Antiproliferation, cancer, vitamin D, BCI-210, 27-OH-BCI-210, 4333
- Antiproliferative activity, anthracycline derivatives, toxicity, cardiotoxicity, 2043
- Antiproliferative effect, apoptosis, Bcl-2, *Eurycoma longifolia*, MCF-7, 2205
- Antisense oligodeoxynucleotide, renal cell carcinoma, bone metastasis, fibroblast growth factor-2, angiogenesis, 1109
- Antisense oligonucleotides, Mcl-1, Bcl-2, ionizing radiation, apoptosis, melanoma, 2697
- Antisense, human papillomavirus, raft cultures, replication, oncogenes, 765
- Antitelomerase drug PIPER, cytotoxic effect, TRAP assay, 3341
- Antitumor activity, fibrinogen, methotrexate, conjugates, glycation, 2229
- Antitumor target, pituitary tumor-transforming gene, PTTG, 121
- Antitumour activity, pancreatic cancer, mistletoe extract, mistletoe lectin, *Viscum album*, Gemcitabine, intratumoral injection, human cancer xenograft, 1969
- Anxiety, breast symptoms, depression, breast cancer, 2527
- ApcMin/+ mice, PPAR β/δ , cyclin D1, multiple intestinal neoplasia, aberrant crypt foci, azoxymethane, β -catenin, Wnt signalling pathway, 3781
- APEX1, lung cancer, DNA repair, single nucleotide polymorphism, XRCC1, ADPRT, LIG3, 537
- Apolipoprotein A-II, SELDI TOF-MS, protein expression profile, adverse effect, ProteinChip System, HMW kininogen, 1197
- Apoptin gene, e4orf4 gene, cancer gene therapy, apoptosis, 1087
- Apoptosis, γ -irradiation, macrophages, reactive oxygen species, antioxidants, caspase inhibitors, 4091
- Apoptosis, alpha-hederin, thymoquinone, glutathione, *Nigella sativa*, 4255
- Apoptosis, alvaradoin E, alvaradoin F, annexin V-FITC, anthracenone C-glycosides, DAPI, DiOC₆, hollow fiber test, mitochondrial membrane potential analysis, propidium iodide, TUNEL assay, 779
- Apoptosis, anthracyclines, topo II poison, 2193
- Apoptosis, antiproliferative effect, Bcl-2, *Eurycoma longifolia*, MCF-7, 2205
- Apoptosis, antisense oligonucleotides, Mcl-1, Bcl-2, ionizing radiation, melanoma, 2697
- Apoptosis, apoptin gene, e4orf4 gene, cancer gene therapy, 1087
- Apoptosis, azulenequinones, caspase, DNA fragmentation, apoptosis-related protein expression, 305
- Apoptosis, baicalein, lung squamous carcinoma cell line CH27, cell cycle regulatory molecules, Bcl-2, caspase-3, 959
- Apoptosis, benign prostatic hyperplasia, bcl-2, bax, fas, c-myc, 3937
- Apoptosis, bisphenol A, hydroquinone, thiols, cytotoxicity, caspases, 2241
- Apoptosis, bladder cancer, carboxyamido-triazole, proliferation, animal model, 725
- Apoptosis, bladder cancer, flavopiridol, cyclin-dependent kinase, cell cycle arrest, 4341
- Apoptosis, bladder cancer, Superantigen, staphylococcal enterotoxin B, Fas-ligand, 3565
- Apoptosis, bladder urothelial carcinoma, cyclooxygenase-2, 4543
- Apoptosis, brain tumor, T11TS / S-LFA-3, immunotherapy, 2905
- Apoptosis, BRCA1, progesterone, cell cycle, MCF7 cell line, 243
- Apoptosis, breast cancer cells, arabinoxylan rice bran, 859
- Apoptosis, cancer, chemoresistance, glutaminase, glutamine, 3315
- Apoptosis, cervical carcinoma, Ck19, Rhenium-188, radioimmunotherapy, 2719
- Apoptosis, chemoprevention, anthocyanins, genotoxicity, lymphocytes, 2837
- Apoptosis, codeinone, α , β -unsaturated ketones, anticancer drugs, caspase-3, DNA fragmentation, 4037
- Apoptosis, COX-2, endometrial cancer, angiogenesis, cell growth, metastatic potential, immunomodulation, review, 3679

- Apoptosis, curcumin, α -diisoeugenol, COX-2 inhibition, 4029
- Apoptosis, cyclic dipeptides, cancer cells, HT-29, poly(ADP-ribose)polymerase (PARP), caspase-3, 4197
- Apoptosis, cyclin cdk's, PKC, phosphoinositol 3-kinase, deoxyadenosine resistance, p53, flavopiridol, LY294002, roscovitine, wortmannin, UCN-01, leukemia cells, 101
- Apoptosis, diffuse large B-cell lymphomas, differentiation, proliferation, 347
- Apoptosis, diterpene, trachylobane, HL-60, cytotoxicity, *Croton zambesicus*, 363
- Apoptosis, ellagic acid, cell cycle arrest, p53, p21, caspase-3, 971
- Apoptosis, enterolactone, COLO 201, colon cancer, 2269
- Apoptosis, eugenol-related compounds, cytotoxicity, HL-60 cells, LPS, COX-2, RAW cells, 3263
- Apoptosis, FAK, FRNK, SCCHN cells, paclitaxel, etoposide, 5-fluorouracil, 4349
- Apoptosis, focal hyperthermia, liver, colorectal liver metastases, 1413
- Apoptosis, galectin-1, MCF7 cells, BeWo cells, mycoplasma, 1575
- Apoptosis, GL331, glioma, cell cycle, topoisomerase II inhibitor, 4203
- Apoptosis, glycyrrhetic acid, glycyrrhizin, G1 arrest, Bcl-2 family, hepatocellular carcinoma, 4043
- Apoptosis, green tea, polyphenol, EGCG, oral cancer, p21^{WAF1}, 63
- Apoptosis, heavy water (deuterium oxide, D₂O), cell cycle distribution, pancreatic cancer, AsPC-1, BxPC-3 and PANC-1 cells, 3407
- Apoptosis, high hydrostatic pressure, tumor cells, orthopedic surgery, chondrosarcoma, chondrocytes, 1977
- Apoptosis, hRFI, chemotherapy, cisplatin, irinotecan, 5-fluorouracil, colorectal cancer, 2737
- Apoptosis, hydroquinone, N-acetyl-L-cysteine, HL-60 cells, Cu/Zn and Mn superoxide dismutase mRNA, caspases, 161
- Apoptosis, inositol hexaphosphate, prostate cancer, mitogenic signaling, cell survival signaling, cell cycle progression, angiogenesis, review, 2891
- Apoptosis, isothiocyanates, multidrug resistance, cell cycle, mitochondrial transmembrane potential, HL60 cell line, 3375
- Apoptosis, lipoxygenase, carotenoid, lipid peroxidation, phytochemical, 3871
- Apoptosis, lung cancer, NF κ B, VEGF, p53, 69
- Apoptosis, melanoma, MHC class II, CIITA, 3889
- Apoptosis, monolayer MCF-7 cells, phagocytosis, *S. cerevisiae*, MGN-3, 4187
- Apoptosis, myeloid leukemia, TSP-1, peptides, differentiation, 757
- Apoptosis, N-(4-hydroxyphenyl) retinamide, reactive oxygen species, glutathione, tissue transglutaminase, BSO, all-*trans* retinoic acid (ATRA), 1945
- Apoptosis, p38 MAPK, Akt, gemcitabine, pancreatic cancer, 3347
- Apoptosis, P8, breast carcinoma, immunohistochemistry, ssDNA, 833
- Apoptosis, p8, medullary thyroid carcinoma, 3419
- Apoptosis, phagocytosis, *S. cerevisiae*, SCC-4, Caco-2, oxidative burst, 981
- Apoptosis, prostate cancer cells, black cohosh extract, annexin-V-FITC, M30 antibody, 139
- Apoptosis, retinoids, lymphoma, ATRA, 4HPR, 4179
- Apoptosis, sodium fluoride, human oral cells, ageing, cytotoxicity, mitochondrial function, 2085
- Apoptosis, sodium fluorosilicate, cytotoxicity, osteosarcoma (HOS) cells, 391
- Apoptosis, tumor rejection antigen, SART-1, cell cycle, 1983
- Apoptosis, tumor specificity, doxorubicin, DNA fragmentation, mdr1, 877
- Apoptosis, WP1034, acute myeloid leukemia, signal transduction, Jak-Stat, 1841
- Apoptosis, xanthorrhizol, *C. xanthorrhiza*, HeLa, 2221
- Apoptosis-related protein expression, azulenequinones, apoptosis, caspase, DNA fragmentation, 305
- Apoptotic DNA fragmentation, NF-kappaB activation, Sabarubicin, paclitaxel, parthenolide, colon cancer cells, 2119
- Apoptotic genes, curcumin, breast cancer, 3293
- Apoptotic proteins, Bcl-2, Bcl-2 phosphorylation, sesquiterpenelactones, taxol, anti-tumor, 313
- 1- β -D-Arabinofuranosylcytosine, L1210 cells, thymidylate synthase, thymidine kinase, 157
- Arabinoxylan rice bran, breast cancer cells, apoptosis, 859
- Area under the plasma concentration-time curve (AUC), nedaplatin, pharmacokinetics, pharmacodynamics, toxicodynamics, thrombocytopenia, 1273
- Aromatase inhibitors, adjuvant therapy, breast cancer, tamoxifen, review, 2497
- Arsenic trioxide, glutathione, multidrug-resistance, buthionine-sulfoximine, reactive oxygen species, 991
- Artemisinin, butyric acid, Molt-4 cells, lymphocytes, 4325
- Arterial infusion, macrocytic anemia, hepatobiliary malignancy, 5-FU, 1243
- Asbestos, mesothelioma-malignant, prolymphocytic leukemia, SV40, 429
- Ascites, P-glycoprotein, multidrug resistance, ovarian cancer, functional assay, 1187
- Ascitic fluid, collagen gel droplet-embedded culture drug sensitivity test (CD-DST), ovarian cancer, pleural fluid, neoadjuvant chemotherapy, 3547

- AsPC-1, heavy water (deuterium oxide, D₂O), apoptosis, cell cycle distribution, pancreatic cancer, BxPC-3 and PANC-1 cells, 3407
- Aspirin, nitric oxide, colorectal cancer, 4471
- Astrocytoma, doppel, prion, protein interaction, 4369
- ATRA, retinoids, apoptosis, lymphoma, 4HPR, 4179
- Atrophic gastritis, carcinoid, hypergastrinemia, 4417
- Atypical antibodies, paraneoplastic neurological syndromes, Western blot, rat cerebellum, 3211
- AUC, pharmacokinetics, pharmacodynamics, nedaplatin, optimal sampling, limited sampling, platelet, 1283
- Autoantibodies, ELISA, prostatesome, prostate cancer, prostate specific antigen, 4399
- Autoimmune thyroiditis, Tc1, Tc2, papillary carcinoma, thyroid nodule, 2483
- Autologous tumor cell cultures, medullary thyroid carcinoma, drug resistance, immunotherapy, dendritic cells, 4225
- Autologous tumor cells, dendritic cells, activated lymphocytes, vaccine, 3771
- Automated diagnosis, computer-aided diagnosis, melanoma, melanocytic nevi, digital epiluminescence microscopy, dermoscopy, 4577
- Autopsy changes, prostate specific antigen, prostate, 1263
- Autoradiography, peritoneal metastases, radioimmunotherapy, Norbormide, 5-fluorouracil, 917
- Aviscumine, adenocarcinoma of the lung, recombinant mistletoe lectin, prognostic factors, non-small cell lung cancer, 3303
- Azoxymethane, PPAR β/δ , cyclin D1, multiple intestinal neoplasia, aberrant crypt foci, ApcMin/+ mice, β -catenin, Wnt signalling pathway, 3781
- Azulenequinones, apoptosis, caspase, DNA fragmentation, apoptosis-related protein expression, 305
- Azulenequinones, Raw 264.7 cells, NO, iNOS, ESR, radicals, 4157
- Azygos vein, esophageal carcinoma, serum p53 antibody, 3231
- B7, SCCHN, IL-2, immunotherapy, gene therapy, 3917
- B7-H1, sPD-1, hepatocarcinoma, immunotherapy, 3309
- Bad, 3, 5-dibenzoyl-1, 4-dihydropyridines, tumor-specificity, DNA fragmentation, caspase, Bcl-2, Bax, radical, 2033
- Bad, berberine, tumor specificity, DNA fragmentation, caspase, Bcl-2, 4053
- Bad, stilbenes, flavonoids, oral tumor cells, DNA fragmentation, caspase, Bcl-2, Bax, 2055
- Baicalein, lung squamous carcinoma cell line CH27, apoptosis, cell cycle regulatory molecules, Bcl-2, caspase-3, 959
- Barrett's oesophagus, allelic imbalance, gastric cardia, adenocarcinoma, D7S483, 7q36, 913
- Basal cell carcinoma, skin tumors, facial surgery, clinical study, basal cell carcinoma-histological subtypes, 1693
- Basal cell carcinoma-histological subtypes, basal cell carcinoma, skin tumors, facial surgery, clinical study, 1693
- Bax, 3, 5-dibenzoyl-1, 4-dihydropyridines, tumor-specificity, DNA fragmentation, caspase, Bcl-2, Bad, radical, 2033
- Bax, Bcl-2, caspase, etoposide, hydroxyurea, interleukin, lymphoma, p53, 999
- Bax, benign prostatic hyperplasia, apoptosis, bcl-2, fas, c-myc, 3937
- Bax, esophageal squamous cell carcinoma, chemoradiotherapy, Hsp27, Hsp70, p21, p53, bcl2, 2749
- Bax, pancreatic cancer, retinoblastoma, p53, p21^{WAF1/CIP1}, 1361
- Bax, stilbenes, flavonoids, oral tumor cells, DNA fragmentation, caspase, Bcl-2, Bad, 2055
- BCG therapy, urinary bladder, carcinoma *in situ*, ImmunoCyt/uCyt+™, 3641
- BCI-210, cancer, vitamin D, 27-OH-BCI-210, antiproliferation, 4333
- Bcl-2 family, glycyrrhetic acid, glycyrrhizin, G1 arrest, apoptosis, hepatocellular carcinoma, 4043
- Bcl-2 phosphorylation, Bcl-2, sesquiterpenelactones, taxol, apoptotic proteins, anti-tumor, 313
- Bcl-2 protein, p53 protein, gastric cancer, immunohistochemistry, prognosis, 3629
- Bcl-2, 3, 5-dibenzoyl-1, 4-dihydropyridines, tumor-specificity, DNA fragmentation, caspase, Bax, Bad, radical, 2033
- Bcl-2, antiproliferative effect, apoptosis, *Eurycoma longifolia*, MCF-7, 2205
- Bcl-2, antisense oligonucleotides, Mcl-1, ionizing radiation, apoptosis, melanoma, 2697
- Bcl-2, baicalein, lung squamous carcinoma cell line CH27, apoptosis, cell cycle regulatory molecules, caspase-3, 959
- Bcl-2, bax, caspase, etoposide, hydroxyurea, interleukin, lymphoma, p53, 999
- Bcl-2, Bcl-2 phosphorylation, sesquiterpenelactones, taxol, apoptotic proteins, anti-tumor, 313
- Bcl-2, benign prostatic hyperplasia, apoptosis, bax, fas, c-myc, 3937
- Bcl-2, berberine, tumor specificity, DNA fragmentation, caspase, Bad, 4053
- Bcl-2, ER α , PgR, proliferation, Her-2/neu, p53, EGF-R, 4615
- Bcl-2, stilbenes, flavonoids, oral tumor cells, DNA fragmentation, caspase, Bax, Bad, 2055
- Bcl-xL, breast cancer, NF- κ B, c-FLIP, paclitaxel, docetaxel, 2367
- Bcl2, clinically localized prostate cancer, p53, PAR4, biochemical failure, 3123
- Bcl2, esophageal squamous cell carcinoma, chemoradiotherapy, Hsp27, Hsp70, p21, p53, bax, 2749
- Benign human prostate cells, African-American, hTERT, androgen, androgen receptor antagonist, 1

- Benign prostatic hyperplasia, apoptosis, bcl-2, bax, fas, c-myc, 3937
- Berberine, N-acetyltransferase (NAT), leukemia cell line (HL-60), 2-aminofluorene (AF), flow cytometry, 4149
- Berberine, tumor specificity, DNA fragmentation, caspase, Bad, Bcl-2, 4053
- Betamethasone, glucocorticoids, cortivazol, prednisolone, dexamethasone, resistance, 2253
- Betulinic acid, cytotoxicity, semi-empirical molecular-orbital method, 3951
- Bevacizumab, colorectal cancer, VEGF, 3619
- Bevacizumab, pancreatic neoplasms, gemcitabine, cisplatin, irinotecan, fluorouracil, 3637
- BeWo cells, galectin-1, apoptosis, MCF7 cells, mycoplasma, 1575
- BFGF, malignant melanoma, microenvironment, PDEGF, 4299
- Bicalutamide, LNCaP cells, 4-OH tamoxifen, 4277
- Bile duct carcinomas, carcinoma of the gallbladder, razoxane, radiosensitizing agents, 3613
- Biliary tract and pancreatic cancer, hepatic arterial infusion chemotherapy, reservoir port, liver metastasis, 5-fluorouracil, cisplatin, 477
- Biochanin A, phytoestrogens, lignans, flaxseed, matairesinol, trophoblast tumour cells, 1817
- Biochemical failure, clinically localized prostate cancer, bcl2, p53, PAR4, 3123
- Biodegradable polymer, doxorubicin, brain tumor, interstitial chemotherapy, 3825
- Biodistribution, lung cancer, ¹¹¹InHMFG1-F(ab')₂, radiotherapy, lysine, 4663
- Biological markers, chemotherapy control, colorectal cancer, breast cancer, ovarian cancer, 1655
- Biotherapy, neuroendocrine carcinomas, 4463
- Biotherapy, ultrasound, cavitation, drug delivery, transfection, gene therapy, 149
- Biotherapy, *Viscum album*, mistletoe, immune-suppression, Isorel, immunomodulation, NK cells, T-helper cells, 4583
- Bisbenzylisoquinoline alkaloids, multidrug resistance, MDR modifiers, P-glycoprotein, xenograft, 1953
- Bispecific antibody, monoclonal antibody, anti-Her2/neu, extracellular glycoproteins, prostate cancer, immunotherapy, 43
- Bisphenol A, hydroquinone, thiols, cytotoxicity, apoptosis, caspases, 2241
- Bisphosphonate, alendronate, A431 cells, squamous cell carcinoma, proliferation, invasion, 2655
- Bisphosphonate, anti-proliferative activity, tumor cells, structure-activity, 1139
- Bisphosphonate, cancer, vitamin D, 24(OH)₂D₂, antiproliferation, 1909
- Bisphosphonates, bone remodelling markers, N-terminal telopeptide of collagen type I, alkaline phosphatase, bone metastases, zoledronic acid, 1457
- Bisphosphonates, hypercalcemia, osteoprotegerin, RANKL, 3607
- BKV, JCV, DNA sequences, colon rectal tumors, 1079
- Black cohosh extract, prostate cancer cells, apoptosis, annexin-V-FITC, M30 antibody, 139
- Bladder cancer, carboxyamido-triazole, apoptosis, proliferation, animal model, 725
- Bladder cancer, flavopiridol, cyclin-dependent kinase, apoptosis, cell cycle arrest, 4341
- Bladder cancer, gemcitabine, hypoxia, 3413
- Bladder cancer, gene therapy, adenovirus, recombinant IL-2, 2757
- Bladder cancer, hTERT, hTEP-1, p53, caspase-3, survival, immunohistochemistry, 3109
- Bladder cancer, prostate cancer, doxazosin, serotonin, 4281
- Bladder cancer, radiochemotherapy, transurethral resection, 1623
- Bladder cancer, Superantigen, staphylococcal enterotoxin B, apoptosis, Fas-ligand, 3565
- Bladder cancer, TPA, HER-2/neu, uPAR, tumour marker, TP53, 635
- Bladder carcinoma, topoisomerase 2 α , HER2, p53, FISH, multitissue array, prognosis, 263
- Bladder neoplasms, DNA cytometry, image analysis, survival analysis, 3243
- Bladder urothelial carcinoma, cyclooxygenase-2, apoptosis, 4543
- Bleomycin, dogs, cancer, chemotherapy, cisplatin, electroporation, 839
- Bone marrow involvement, FDG-PET, MIBI scan, multiple myeloma, soft tissue lesions, skeletal lesions, 4737
- Bone marrow, breast cancer, disseminated tumor cells, cytokeratin, her2, micrometastases, 2171
- Bone metastases, bone remodelling markers, N-terminal telopeptide of collagen type I, alkaline phosphatase, bisphosphonates, zoledronic acid, 1457
- Bone metastases, PINP, osteocalcin, crosslaps, breast cancer, 1491
- Bone metastases, prostate cancer, COX-2, osteolytic lesions, osteoblastic, 107
- Bone metastases, TRACP 5b, radiotherapy, breast cancer, 4639
- Bone metastasis, breast cancer, integrins, osteoclasts, osteoclast activation, 79
- Bone metastasis, breast cancer, PTHrP, humanized monoclonal antibody, 3817
- Bone metastasis, microvessel density, breast cancer, lung cancer, renal cell cancer, 3075
- Bone metastasis, prostate cancer, vision loss, 3521

- Bone metastasis, renal cell carcinoma, fibroblast growth factor-2, angiogenesis, antisense oligodeoxynucleotide, 1109
- Bone mineral content, retinoids, retinoid glucuronides, breast cancer, cancer chemotherapy, mammary tumors, retinol, triglycerides, 2391
- Bone remodelling markers, N-terminal telopeptide of collagen type I, alkaline phosphatase, bone metastases, bisphosphonates, zoledronic acid, 1457
- Bone scintigraphy, 18-F-Fluorodeoxyglucose (FDG), positron emission tomography (PET), esophageal carcinoma, bony metastasis, 4439
- Bony metastasis, 18-F-Fluorodeoxyglucose (FDG), positron emission tomography (PET), esophageal carcinoma, bone scintigraphy, 4439
- Book reviews (after page-) 682, 2600, 3676, 4772
- Boot strap statistics, magnetic resonance imaging, texture analysis, carcinoma, 3399
- Brachytherapy, prostate cancer, therapy, radical prostatectomy, cryotherapy, high intensity focused ultrasound, watchful waiting, chemotherapy, 551
- Brain metastases, chemotherapy, breast cancer, primary cell culture, cytotoxicity assay, 1531
- Brain metastases, ovarian cancer, central nervous system, 3553
- Brain metastasis, COX-2, necrosis, radiation, 2969
- Brain metastasis, small cell lung cancer, right lung, left lung, upper lobe, lower lobe, gender, smoking, epidemiology, 1101
- Brain tumor, doxorubicin, biodegradable polymer, interstitial chemotherapy, 3825
- Brain tumor, T11TS / S-LFA-3, immunotherapy, apoptosis, 2905
- Brain tumour, paediatric, medulloblastoma, NG2, 3855
- BRCA1, BRCA2, hMSH2 mRNA, colorectal cancer, Lieberkühnien adenocarcinomas, 2009
- BRCA1, HER-1, HER-2, immunohistochemistry, breast cancer, 4535
- BRCA1, progesterone, apoptosis, cell cycle, MCF7 cell line, 243
- BRCA2, BRCA1, hMSH2 mRNA, colorectal cancer, Lieberkühnien adenocarcinomas, 2009
- Breast cancer cells, arabinoxylan rice bran, apoptosis, 859
- Breast cancer cells, cell death, paclitaxel, docetaxel, DNA fragmentation, caspase activation, cytochrome c release, 4215
- Breast cancer incidence, epidemiology, upper outer quadrant, underarm cosmetics, cancer prevention, 2543
- Breast cancer xenograft, chitinase, MCF-7 cells, lysis, 3167
- Breast cancer, 5-fluorouracil, epirubicin, vinorelbine, 4493
- Breast cancer, adjuvant therapy, aromatase inhibitors, tamoxifen, review, 2497
- Breast cancer, AgNORs, MIB-1, 3957
- Breast cancer, apoptotic genes, curcumin, 3293
- Breast cancer, bone metastasis, integrins, osteoclasts, osteoclast activation, 79
- Breast cancer, bone metastasis, microvessel density, lung cancer, renal cell cancer, 3075
- Breast cancer, bone metastasis, PTHrP, humanized monoclonal antibody, 3817
- Breast cancer, BRCA1, HER-1, HER-2, immunohistochemistry, 4535
- Breast cancer, breast disease, coping and defending, 4623
- Breast cancer, breast symptoms, depression, anxiety, 2527
- Breast cancer, cardiotoxicity, anthracyclines, chest wall irradiation, natriuretic peptides, 3651
- Breast cancer, caveolin-1, estrogen receptor, estrogen signaling, 369
- Breast cancer, chemotherapy control, biological markers, colorectal cancer, ovarian cancer, 1655
- Breast cancer, chemotherapy, primary cell culture, cytotoxicity assay, brain metastases, 1531
- Breast cancer, chromogenic *in situ* hybridization, HER2, chromosome 17 polysomy, immunohistochemistry, 939
- Breast cancer, CLA, VEGF-A, linoleic acid, 4061
- Breast cancer, cyclin D1, African-American, estrogen receptor, 273
- Breast cancer, diagnostic accuracy, mammotome, vacuum biopsy, FNAC, ultrasound, 2465
- Breast cancer, disseminated tumor cells, cytokeratin, bone marrow, her2, micrometastases, 2171
- Breast cancer, ductal breast cancer, E-cadherin, fibronectin, prognosis, 2879
- Breast cancer, elongation factor-1, mRNA expression, RT-PCR, 2573
- Breast cancer, enkephalin, enkephalinase, N-methylnitrosourea, 193
- Breast cancer, epirubicin, paclitaxel, sequence, 1211
- Breast cancer, epirubicin, vinorelbine, 1343
- Breast cancer, exosomes, HER2/neu, dendritic cells, Herceptin (Trastuzumab), 3703
- Breast cancer, genetic polymorphism, SULT1A1, SNP, 2515
- Breast cancer, glycodeilin, metastasis, 1761
- Breast cancer, heat shock protein, hsp27, prognosis, immuno-histochemistry, 1649
- Breast cancer, Her-2/neu, real-time PCR, 1895
- Breast cancer, Her2/neu, steroid receptors, Ki67, p53, DCIS, 1719
- Breast cancer, high-dose chemotherapy, trastuzumab, ERBB2, 663
- Breast cancer, hormones, tumor markers, 451
- Breast cancer, IGF-I, cattle, 871
- Breast cancer, immunohistochemistry, estrogen and progesterone receptors, cutpoint analysis, prognosis, 2535
- Breast cancer, MDA-MB-231, fibroblast growth factor receptor, Grb14, *Xenopus* oocyte, 3877

- Breast cancer, mucinous carcinoma, MUC1, MUC1-core, Thomsen-Friedenreich, CA19-9, CA50, CA242, immuno-histochemistry, 1755
- Breast cancer, nail disorders, ixabepilone, 3531
- Breast cancer, neoadjuvant chemotherapy, mammography, sonography, 2519
- Breast cancer, NF- κ B, Bcl-xL, c-FLIP, paclitaxel, docetaxel, 2367
- Breast cancer, phytoestrogens, cancer prevention, isoflavones, review, 2357
- Breast cancer, PINP, osteocalcin, crosslaps, bone metastases, 1491
- Breast cancer, platelets, VEGF, thrombospondin, tissue factor, 3963
- Breast cancer, RARRES3, TIG3, RIG1, estrogen receptor, progesterone receptor, tumor suppressor gene, 2453
- Breast cancer, retinoids, retinoid glucuronides, cancer chemotherapy, mammary tumors, retinol, triglycerides, bone mineral content, 2391
- Breast cancer, Sialyl Lewis X, Sialyl Lewis A, E-cadherin, cathepsin-D, 1615
- Breast cancer, sulfatase, progestins, nomegestrol acetate, 2827
- Breast cancer, TRACP 5b, radiotherapy, bone metastases, 4639
- Breast cancer, VEGF-D, cell proliferation, cyclin, angiogenesis, 701
- Breast cancer, vitamin D, VDR, xenograft, 24(OH)₂D₂, 235
- Breast carcinoma, Doppler ultrasound, ultrasound contrast media, neoadjuvant chemotherapy, 595
- Breast carcinoma, P8, apoptosis, immunohistochemistry, ssDNA, 833
- Breast carcinomas, primary cultures of carcinoma cells, cyclin D1 and HER2/neu by FISH, 1051
- Breast disease, breast cancer, coping and defending, 4623
- Breast ductal carcinoma, HIF-1 α , VEGF-C, VEGF-D, 3003
- Breast neoplasms, HER-2, circulating extracellular domains, immunohistochemistry, 1433
- Breast sarcoma, malignant fibrous histiocytoma, 505
- Breast symptoms, depression, anxiety, breast cancer, 2527
- Breast symptoms, psychosocial stress, 531
- Breast, adenoid cystic carcinoma, 455
- Breast, hyperbaric oxygenation, mammary neoplasms, epithelial cells, 3833
- Breast, invasion, metastasis, lung, 3905
- Breast, rhabdomyosarcoma, metastatic, 527
- Breast, wnt5a, cancer, suppressor, survival, 731
- Breast-conserving surgery, nipple resection, surgical margin and breast cancer, 2957
- Bronchial carcinoma, pregnancy protein 1, placental-specific tissue protein 10, α 1-fetoprotein, 1667
- Bronchial pre-invasive lesions, c-erbB-2, Her-2, preneoplastic lesions, early invasive lesions, carcinogenesis, lung cancer, 2005
- BSO, N-(4-hydroxyphenyl) retinamide, apoptosis, reactive oxygen species, glutathione, tissue transglutaminase, all-trans retinoic acid (ATRA), 1945
- Budesonide, inflammatory polyps, pseudopolyps, ulcerative colitis, hepatitis, 2961
- Burkitt lymphoma, LCL, p16^{INK4A}, p14^{ARF}, promoter methylation, genetic change, 2153
- Buthionine-sulfoximine, arsenic trioxide, glutathione, multidrug-resistance, reactive oxygen species, 991
- Butyric acid, artemisinin, Molt-4 cells, lymphocytes, 4325
- BxPC-3 and PANC-1 cells, heavy water (deuterium oxide, D₂O), apoptosis, cell cycle distribution, pancreatic cancer, AsPC-1, 3407
- Bystander effect, herpes simplex virus thymidine kinase, ganciclovir, gap junctional intercellular communication, multidrug resistance, 255
- C-erbB-2, Her-2, preneoplastic lesions, bronchial pre-invasive lesions, early invasive lesions, carcinogenesis, lung cancer, 2005
- C-erbB-2, vulvar carcinoma, TGF- α , neoangiogenesis, immunohistology, prognosis, 1731
- C-FLIP, breast cancer, NF- κ B, Bcl-xL, paclitaxel, docetaxel, 2367
- C-kit, dedifferentiated liposarcomas, well-differentiated liposarcomas, imatinib-mesylate, GISTs, polymorphism, 2215
- C-kit, gastrointestinal stromal tumour, positron emission tomography, imatinib mesylate, receptor protein-tyrosine kinase, 4591
- C-kit, TGF- β 1, pancreatic cancer, immunohistochemistry, tyrosine kinase, 3523
- C-MYC amplification, fluorescence *in situ* hybridization, chromosome 8 aneuploidy, gastric adenocarcinoma, 4069
- C-myc, benign prostatic hyperplasia, apoptosis, bcl-2, bax, fas, 3937
- C. xanthorrhiza*, xanthorrhizol, apoptosis, HeLa, 2221
- CA 125, small cell lung cancer, tumor marker, ProGRP, NSE, lung cancer, CEA, CYFRA 21-1, SCC, 1773
- CA 19-9, CEA, rectal carcinoma, tumor marker, overall survival, prognostic factor, 1787
- CA 19-9, pancreatic adenocarcinoma, tumor markers, differentiation, 3625
- CA 19-9, pancreatic cancer, radiochemotherapy, gemcitabine, toxicity, 1523
- CA125, ovarian cancer, vaginal ultrasound, CT scan, 1551
- CA19-9, mucinous carcinoma, breast cancer, MUC1, MUC1-core, Thomsen-Friedenreich, CA50, CA242, immuno-histochemistry, 1755
- CA19-9, pancreatic cancer, polychemotherapy, CEA, 1687

- CA242, mucinous carcinoma, breast cancer, MUC1, MUC1-core, Thomsen-Friedenreich, CA19-9, CA50, immuno-histochemistry, 1755
- CA50, mucinous carcinoma, breast cancer, MUC1, MUC1-core, Thomsen-Friedenreich, CA19-9, CA242, immuno-histochemistry, 1755
- Caco-2, phagocytosis, *S. cerevisiae*, SCC-4, oxidative burst, apoptosis, 981
- Cadherin-6, circulating cancer cells, renal cell carcinoma, tumor marker, 377
- CAFC cells, fractionated radiotherapy, hematopoietic, stromal cells, 2801
- Caffeine, chemotherapy, metastatic tumor, musculoskeletal sarcoma, 2399
- Calcitonin, CD44, G-protein, invasion, paracrine, prostate cancer, signal transduction, 2075
- Calcitriol, vitamin D analogue, combined treatment, VDR, *in vitro* assay, cancer, 2235
- Calcitriol, vitamin D, vitamin D analog, seocalcitol, medium-chain triglyceride, canine transitional cell carcinoma, growth inhibition, cell cycle, VDR, 2689
- Camptothecin, CPT-11, SN-38, liposome, drug delivery, 331
- Cancer cells, cyclic dipeptides, HT-29, poly(ADP-ribose)polymerase (PARP), caspase-3, apoptosis, 4197
- Cancer chemotherapy, retinoids, retinoid glucuronides, breast cancer, mammary tumors, retinol, triglycerides, bone mineral content, 2391
- Cancer gene therapy, apoptin gene, e4orf4 gene, apoptosis, 1087
- Cancer metastasis, surgical stress, urinary trypsin inhibitor (UTI), murine colon carcinoma cell, 815
- Cancer patients, questionnaires, religion and medicine, spirituality and religion, 1449
- Cancer prevention, breast cancer incidence, epidemiology, upper outer quadrant, underarm cosmetics, 2543
- Cancer prevention, phytoestrogens, breast cancer, isoflavones, review, 2357
- Cancer screening, thyroid incidentaloma, thyroid carcinoma, PET, FDG, 1421
- Cancer treatment, SCCHN, EGFR, signal transduction, 1871
- Cancer, apoptosis, chemoresistance, glutaminase, glutamine, 3315
- Cancer, calcitriol, vitamin D analogue, combined treatment, VDR, *in vitro* assay, 2235
- Cancer, cervix, EMD 55, 900, CD 31, angiogenesis, 4261
- Cancer, dogs, chemotherapy, cisplatin, bleomycin, electroporation, 839
- Cancer, esophageal, p63, 3533
- Cancer, microarray expression profiling, metastases, prostate, 1477
- Cancer, proenzyme therapy, protease inhibitors, 1157
- Cancer, SCC antigen, uterine cervix, radiotherapy, 1663
- Cancer, vitamin D, 24(OH)₂D₂, antiproliferation, bisphosphonate, 1909
- Cancer, vitamin D, BCI-210, 27-OH-BCI-210, antiproliferation, 4333
- Cancer, wnt5a, breast, suppressor, survival, 731
- Cancer-bearing host, tumor specific antigens, immunogens, tumor markers, review, 2345
- Cancer-related fatigue, testicular cancer, anemia, testosterone, trait anxiety, 4647
- Canine mammary tumors, animal model, Cox-2, inflammatory mammary carcinoma, enzyme immunoassay, 4269
- Canine transitional cell carcinoma, vitamin D, calcitriol, vitamin D analog, seocalcitol, medium-chain triglyceride, growth inhibition, cell cycle, VDR, 2689
- Canine, prostatic cells, age, ERβ, 4081
- Canis familiaris*, cytogenetics, lymphoma, 3995
- Capecitabine, irinotecan, pharmacokinetics, metabolism, 2985
- Capecitabine, mitomycin, metastatic breast cancer, 4513
- Capecitabine, rectal cancer, phase I study, oxaliplatin, 629
- Capillary blood, PSA, prostate cancer, test strip, 1659
- Capsaicin, mutagenesis, phytochemicals, chemoprevention, 117
- Capsicum annuum* L. var. *angulosum* Mill. extracts, cytotoxicity, MDR reversal, anti-HIV activity, anti-*Helicobacter pylori* activity, urease inhibition, 1991
- Carbohydrate cleaving enzyme, prostate cancer, gene-based PSMA vaccination, LNCaP cells, anti-PSMA antibodies, proteases, 4727
- Carbonic anhydrase IX (CA IX), gene therapy, MN protein, renal cell carcinoma, 881
- Carboplatin, head and neck squamous cell carcinoma, raltitrexed, 4445
- Carboplatin, NSCLC, triple chemotherapy, paclitaxel, vinorelbine, 1333
- Carboxyamido-triazole, bladder cancer, apoptosis, proliferation, animal model, 725
- Carcinoembryonic antigen, colon cancer, receptor, heterogeneous RNA binding protein, 23
- Carcinoembryonic antigen, immunotherapy, cytotoxic T lymphocytes, natural killer cells, antibody-based therapy, tumor antigen, review, 3725
- Carcinoembryonic antigen, lung cancer, pN1, 3601
- Carcinoembryonic antigen, lung cancer, von Willebrand antigen, 403
- Carcinogenesis, aging, stem cells, dedifferentiation, 1385
- Carcinogenesis, c-erbB-2, Her-2, preneoplastic lesions, bronchial pre-invasive lesions, early invasive lesions, lung cancer, 2005
- Carcinogenesis, tumour-promoting factors, fat, colon, caroverine, ubiquinone, 2793

- Carcinogenesis, vulvar cancer, vin, *Lichen sclerosus*, squamous cell hyperplasia, p53, immunohistology, prognosis, 1739
- Carcinoid, atrophic gastritis, hypergastrinemia, 4417
- Carcinoma *in situ*, urinary bladder, ImmunoCyt/uCyt+™, BCG therapy, 3641
- Carcinoma of the gallbladder, bile duct carcinomas, razoxane, radiosensitizing agents, 3613
- Carcinoma, magnetic resonance imaging, texture analysis, boot strap statistics, 3399
- Cardiotoxicity, anthracycline derivatives, antiproliferative activity, toxicity, 2043
- Cardiotoxicity, anthracyclines, chest wall irradiation, breast cancer, natriuretic peptides, 3651
- Carotenoid, apoptosis, lipoxygenase, lipid peroxidation, phytochemical, 3871
- Carotid body, paraganglioma, *SDHD* mutations, 2449
- Caroverine, tumour-promoting factors, fat, colon, carcinogenesis, ubiquinone, 2793
- Cartilaginous tumors, alternative splicing, angiogenesis, VEGF, 955
- CAS200, melanoma metastases, cytokeratins, image cytophotometry, 2789
- Caspase activation, cell death, paclitaxel, docetaxel, breast cancer cells, DNA fragmentation, cytochrome c release, 4215
- Caspase inhibitors, apoptosis, γ -irradiation, macrophages, reactive oxygen species, antioxidants, 4091
- Caspase, 3, 5-dibenzoyl-1, 4-dihydropyridines, tumor-specificity, DNA fragmentation, Bcl-2, Bax, Bad, radical, 2033
- Caspase, azulenequinones, apoptosis, DNA fragmentation, apoptosis-related protein expression, 305
- Caspase, bax, Bcl-2, etoposide, hydroxyurea, interleukin, lymphoma, p53, 999
- Caspase, berberine, tumor specificity, DNA fragmentation, Bad, Bcl-2, 4053
- Caspase, stilbenes, flavonoids, oral tumor cells, DNA fragmentation, Bcl-2, Bax, Bad, 2055
- Caspase-3, 2, 3, 7, 8-tetrachlorodibenzo-*p*-dioxin, ERK, JNK, p38, RAW 264.7 cells, 2831
- Caspase-3, baicalein, lung squamous carcinoma cell line CH27, apoptosis, cell cycle regulatory molecules, Bcl-2, 959
- Caspase-3, codeinone, α , β -unsaturated ketones, anticancer drugs, apoptosis, DNA fragmentation, 4037
- Caspase-3, cyclic dipeptides, cancer cells, HT-29, poly(ADP-ribose)polymerase (PARP), apoptosis, 4197
- Caspase-3, ellagic acid, cell cycle arrest, apoptosis, p53, p21, 971
- Caspase-3, hTERT, hTEP-1, p53, survival, bladder cancer, immunohistochemistry, 3109
- Caspases, bisphenol A, hydroquinone, thiols, cytotoxicity, apoptosis, 2241
- Caspases, hydroquinone, N-acetyl-L-cysteine, apoptosis, HL-60 cells, Cu/Zn and Mn superoxide dismutase mRNA, 161
- Catecholamines, chromaffin cell, chromogranin A, pheochromocytoma, metaiodobenzylguanidine (MIBG), iodine-123 (123I), 1547
- α -Catenin, β -catenin, prostate neoplasm, prognosis, 4707
- β -Catenin, gallbladder carcinoma, cholecystitis, gallbladder tissue, E-cadherin, 4249
- β -Catenin, gastric cancer, cell proliferation, E-cadherin, family history, 2567
- β -Catenin, PPAR β/δ , cyclin D1, multiple intestinal neoplasia, aberrant crypt foci, azoxymethane, ApcMin/+ mice, Wnt signalling pathway, 3781
- β -Catenin, α -catenin, prostate neoplasm, prognosis, 4707
- Cathepsin, hypoxia, cystatin, oral carcinoma, 2841
- Cathepsin-D, Sialyl Lewis X, Sialyl Lewis A, E-cadherin, breast cancer, 1615
- Catheters, prophylaxis, warfarin, thrombosis, chemotherapy, 3143
- Cattle, breast cancer, IGF-I, 871
- Caveolin-1, estrogen receptor, breast cancer, estrogen signaling, 369
- Caveolin-1, pleomorphic carcinoma, lung, prognosis, 4631
- Cavitation, ultrasound, drug delivery, transfection, gene therapy, biotherapy, 149
- CCL2 (MCP-1), chemokines, colorectal cancer, CCL5 (RANTES), CXCL8, IL-8, 3581
- CCl₄, hepatic cirrhosis, diagnosis of cirrhosis, 1029
- CCL5 (RANTES), chemokines, colorectal cancer, CCL2 (MCP-1), CXCL8, IL-8, 3581
- CD 31, cervix, cancer, EMD 55, 900, angiogenesis, 4261
- CD105, TGF- β 1, endothelial cells, angiogenesis, 1851
- CD20, CD4, CD8, prostate carcinoma, PSA, tumour-infiltrating lymphocytes, 4435
- CD3-LAK, immuno-cell therapy, dendritic cell (DC), pancreatic carcinoma, gemcitabine, 3709
- CD4+, ultraviolet rays, immunocompromised host, 1963
- CD4, CD8, CD20, prostate carcinoma, PSA, tumour-infiltrating lymphocytes, 4435
- CD44, calcitonin, G-protein, invasion, paracrine, prostate cancer, signal transduction, 2075
- CD44, laryngeal carcinoma, survival analysis, 1115
- CD44v6, cervical carcinoma, prognostic factors, 617
- CD44v6, soluble CD44, neoplasm, squamous cell carcinoma of the head and neck, SCCHN, serum tumor marker, clinical prognostic factor, 2821
- CD62L, gastric cancer, spleen, TGF-beta, regulatory T cells, 643
- CD68, IL-12, CD83, dendritic cell, macrophage, antigen-presenting cell, colorectal cancer, 3541
- CD8, CD4, CD20, prostate carcinoma, PSA, tumour-infiltrating lymphocytes, 4435

- CD83, IL-12, CD68, dendritic cell, macrophage, antigen-presenting cell, colorectal cancer, 3541
- CDNA array, reference RNA, 1397
- CDNA microarray, *in vitro*, gene expression, chemotherapy, resistance, 2661
- CEA mRNA, TaqMan PCR, colorectal liver metastasis, recurrence, 1327
- CEA, CA 19-9, rectal carcinoma, tumor marker, overall survival, prognostic factor, 1787
- CEA, head and neck cancer, lymphatic metastasis, SCC, CYFRA 21-1, 1539
- CEA, pancreatic cancer, polychemotherapy, CA19-9, 1687
- CEA, PPD, immunochemotherapy, PSK, 5-fluorouracil, 1377
- CEA, SCC, cervical cancer, tumor markers, prognosis, 1765
- CEA, small cell lung cancer, tumor marker, ProGRP, NSE, lung cancer, CA 125, CYFRA 21-1, SCC, 1773
- Celiac axis infusion, pancreatic cancer, microembolization, isolated abdominal perfusion, 4407
- Cell adhesion inhibition, fibronectin, fucoidan, integrins, MDA-MB-231 breast cell, 2129
- Cell adhesion inhibition, hCG, E-selectin, 1811
- Cell adhesion molecules, Sialyl Lewis A, Sialyl Lewis X, X-ray irradiation, colon cancer, 875
- Cell adhesion, metastatic cascade, local proteolysis, cell migration, angiogenesis, review, 3327
- Cell adhesion, non-small cell lung cancers, focal adhesion, metastatic potential, 4135
- Cell cycle analysis, DSB, mitotic delay, signaling proteins, 1123
- Cell cycle arrest, bladder cancer, flavopiridol, cyclin-dependent kinase, apoptosis, 4341
- Cell cycle arrest, ellagic acid, apoptosis, p53, p21, caspase-3, 971
- Cell cycle distribution, heavy water (deuterium oxide, D₂O), apoptosis, pancreatic cancer, AsPC-1, BxPC-3 and PANC-1 cells, 3407
- Cell cycle progression, inositol hexaphosphate, prostate cancer, mitogenic signaling, cell survival signaling, apoptosis, angiogenesis, review, 2891
- Cell cycle regulatory molecules, baicalein, lung squamous carcinoma cell line CH27, apoptosis, Bcl-2, caspase-3, 959
- Cell cycle, apoptosis, GL331, glioma, topoisomerase II inhibitor, 4203
- Cell cycle, BRCA1, progesterone, apoptosis, MCF7 cell line, 243
- Cell cycle, indolo[2, 3-b]quinoline, topoisomerase II, MDR, DNA-binding, cytotoxicity, lipophilicity, antimicrobial, 2857
- Cell cycle, isothiocyanates, multidrug resistance, apoptosis, mitochondrial transmembrane potential, HL60 cell line, 3375
- Cell cycle, MCI-186, epidermal growth factor, EGFR phosphorylation, 1131
- Cell cycle, tumor rejection antigen, SART-1, apoptosis, 1983
- Cell cycle, vitamin D, calcitriol, vitamin D analog, seocalcitol, medium-chain triglyceride, canine transitional cell carcinoma, growth inhibition, VDR, 2689
- Cell death, paclitaxel, docetaxel, breast cancer cells, DNA fragmentation, caspase activation, cytochrome c release, 4215
- Cell growth, COX-2, endometrial cancer, angiogenesis, apoptosis, metastatic potential, immunomodulation, review, 3679
- Cell line, poorly-differentiated carcinoma, lymph node, metastasis, SKY, CGH, 683
- Cell lines, cytokeratins, RT-PCR, HNSCC, 2675
- Cell migration, metastatic cascade, cell adhesion, local proteolysis, angiogenesis, review, 3327
- Cell morphology, millimeter waves, wide-band irradiation mode, monochromatic irradiation mode, RPMI 7932, 1023
- Cell proliferation, conjugated linoleic acid isomers, CLA derivatives, fatty acids, 3943
- Cell proliferation, D-allose, ovarian carcinoma, 2639
- Cell proliferation, gastric cancer, E-cadherin, β -catenin, family history, 2567
- Cell proliferation, osteosarcoma, glycosaminoglycans, 2851
- Cell proliferation, VEGF-D, breast cancer, cyclin, angiogenesis, 701
- Cell shape, erythrocyte membrane, detergent, multidrug resistance protein (MRP), phospholipid translocation, haemolysis, 3173
- Cell survival signaling, inositol hexaphosphate, prostate cancer, mitogenic signaling, cell cycle progression, apoptosis, angiogenesis, review, 2891
- Cell ultrastructure, MCF-7 human breast carcinoma cell line, wide-band low-power millimeter waves irradiation, 1009
- Cellular response, DNA immunization, mouse models of breast cancer, MUC1, spontaneous tumors, 3893
- Central nervous system, ovarian cancer, brain metastases, 3553
- Cervical cancer, cisplatin, vinorelbine, 2489
- Cervical cancer, familial cervical cancer, Latin America, 1219
- Cervical cancer, HPV, Organotypic raft culture, interferon, 1091
- Cervical cancer, pRb2/p130, p107, p53, HPV, immunohistochemistry, 2187
- Cervical cancer, radiotherapy, radio-chemotherapy, lymphocyte subpopulations, 4673
- Cervical cancer, SCC, CEA, tumor markers, prognosis, 1765

- Cervical cancer, smoking, oral contraceptives, steroid hormones, review, 3041
- Cervical cancer, squamous cell, estradiol/progesterone ratio, 611
- Cervical cancer, TIMP-4, 623
- Cervical carcinoma, CD44v6, prognostic factors, 617
- Cervical carcinoma, Ck19, Rhenium-188, apoptosis, radioimmunotherapy, 2719
- Cervical carcinoma, nedaplatin, MTT assay, ovarian carcinoma, endometrial carcinoma, 4499
- Cervicography, screening, HPV, HPV testing, colposcopy, liquid-based cytology, 3469
- Cervix, cancer, EMD 55, 900, CD 31, angiogenesis, 4261
- CGH, poorly-differentiated carcinoma, lymph node, metastasis, cell line, SKY, 683
- Chemo-radiotherapy, esophageal squamous cell carcinoma, Hsp27, Hsp70, p21, p53, bax, bcl2, 2749
- Chemo-radiotherapy, NSCLC inoperable stage III, TCP, 4655
- Chemo-radiotherapy, taxotere, cisplatin, head and neck cancer, 4451
- Chemokine, platelet factor 4 (PF4), anti-angiogenesis, 847
- Chemokines, colorectal cancer, CCL2 (MCP-1), CCL5 (RANTES), CXCL8, IL-8, 3581
- Chemoprevention, anthocyanins, genotoxicity, apoptosis, lymphocytes, 2837
- Chemoprevention, capsaicin, mutagenesis, phytochemicals, 117
- Chemoprevention, green tea, epigallocatechin-3-gallate, EGCG analog, VEGF, 397
- Chemoresistance, apoptosis, cancer, glutaminase, glutamine, 3315
- Chemoresistance, testicular germ-cell tumor, hMLH1 methylation, MMR, MSI, 4319
- Chemosensitivity *in vitro*, vinflunine, head and neck squamous cell carcinoma, clonogenic assay, 4363
- Chemosensitivity, ABC transporter, conjugated bilirubin, renal cell carcinoma, MRP2, 2729
- Chemosensitivity, gastric cancer, advanced, adjuvant chemotherapy, MTT assay, extended surgery, superextended lymphadenectomy, 3453
- Chemosensitivity, gastric cancer, anticancer drugs, chemotherapy, 931
- Chemotherapy control, biological markers, colorectal cancer, breast cancer, ovarian cancer, 1655
- Chemotherapy control, thymidine kinase, colorectal cancer, 1831
- Chemotherapy, breast cancer, primary cell culture, cytotoxicity assay, brain metastases, 1531
- Chemotherapy, caffeine, metastatic tumor, musculoskeletal sarcoma, 2399
- Chemotherapy, catheters, prophylaxis, warfarin, thrombosis, 3143
- Chemotherapy, colorectal cancer, liver metastasis, gene, 1237
- Chemotherapy, colorectal cancer, monitoring, prediction, DNA, nucleosomes, cytokeratin 19-fragments, CYFRA 21-1, serum, 1795
- Chemotherapy, dogs, cancer, cisplatin, bleomycin, electroporation, 839
- Chemotherapy, fibrosarcoma, cisplatin, 2777
- Chemotherapy, gastric cancer, anticancer drugs, chemosensitivity, 931
- Chemotherapy, Glioblastoma multiforme, radiotherapy, 4605
- Chemotherapy, hRFI, apoptosis, cisplatin, irinotecan, 5-fluorouracil, colorectal cancer, 2737
- Chemotherapy, *in vitro*, gene expression, cDNA microarray, resistance, 2661
- Chemotherapy, mesothelioma, survival, 3671
- Chemotherapy, metastases, colorectal cancer, review, 563
- Chemotherapy, neutropenic enterocolitis, ovarian cancer, paclitaxel, 2509
- Chemotherapy, non-small cell lung cancer (NSCLC), targeted therapy, 1501
- Chemotherapy, non-small cell lung cancer, Paclitaxel, 2555
- Chemotherapy, osteosarcoma, stem cell, osteoblast, 947
- Chemotherapy, ovarian cancer, cisplatin, taxol, topotecan, 2113
- Chemotherapy, ovarian cancer, mucinous, 3501
- Chemotherapy, prostate cancer, therapy, radical prostatectomy, brachytherapy, cryotherapy, high intensity focused ultrasound, watchful waiting, 551
- Chemotherapy, radiation therapy, anesthesia, 2815
- Chest wall irradiation, cardiotoxicity, anthracyclines, breast cancer, natriuretic peptides, 3651
- Children, methotrexate, high-grade gliomas, preradiation chemotherapy, 2583
- Chitinase, MCF-7 cells, breast cancer xenograft, lysis, 3167
- Cholecystitis, gallbladder carcinoma, gallbladder tissue, E-cadherin, β -catenin, 4249
- Chondrocytes, high hydrostatic pressure, tumor cells, orthopedic surgery, apoptosis, chondrosarcoma, 1977
- Chondrosarcoma, high hydrostatic pressure, tumor cells, orthopedic surgery, apoptosis, chondrocytes, 1977
- Chorioallantoic membrane, angiogenesis, irradiation, nitric oxide, 1059
- Choroid plexus tumors, 4429
- Crohn's disease, colorectal cancer, DNA-aneuploidy, 4393
- Chromaffin cell, catecholamines, chromogranin A, pheochromocytoma, metaiodobenzylguanidine (MIBG), iodine-123 (^{123}I), 1547
- Chromogenic *in situ* hybridization, breast cancer, HER2, chromosome 17 polysomy, immunohistochemistry, 939
- Chromogranin A, chromaffin cell, catecholamines, pheochromocytoma, metaiodobenzylguanidine (MIBG), iodine-123 (^{123}I), 1547

- Chromogranin-A, primary neuroendocrine carcinoma, Merkel cell carcinoma, neuroendocrine differentiation, prognosis, 853
- Chromosomal band 11q23, *MLL* gene, acute leukemia, 1931
- Chromosome 17 polysomy, breast cancer, chromogenic *in situ* hybridization, HER2, immunohistochemistry, 939
- Chromosome 8 aneuploidy, fluorescence *in situ* hybridization, C-MYC amplification, gastric adenocarcinoma, 4069
- Chromosome abnormalities, karyotype, molecular cytogenetics, hematologic malignancies, review, 2979
- Chronic dysphagia, rehabilitation, head and neck cancer, 2929
- CIITA, melanoma, apoptosis, MHC class II, 3889
- Circulating cancer cells, cadherin-6, renal cell carcinoma, tumor marker, 377
- Circulating extracellular domains, breast neoplasms, HER-2, immunohistochemistry, 1433
- Circulating HER-2/neu, metastatic breast cancer, immunotherapy, trastuzumab, Herceptin, review, 4599
- Circulating nucleic acids, K-ras mutations, TGGE (temperature gradient electrophoresis), colorectal carcinoma, 657
- Circulating tumor cells, Ep-CAM, micrometastasis, colorectal cancer, 319
- Cisplatin combination, NSCLC, 2991
- Cisplatin resistance, docetaxel, irinotecan, ovarian cancer, 3559
- Cisplatin resistance, K⁺ channels, ion homeostasis, microarray, confocal microscopy, 4113
- Cisplatin, advanced cervical cancer, vinorelbine, 2489
- Cisplatin, advanced gastric cancer, docetaxel, TS-1, phase II study, second-line chemotherapy, 2973
- Cisplatin, bevacizumab, pancreatic neoplasms, gemcitabine, irinotecan, fluorouracil, 3637
- Cisplatin, chemo-radiotherapy, taxotere, head and neck cancer, 4451
- Cisplatin, dogs, cancer, chemotherapy, bleomycin, electroporation, 839
- Cisplatin, fibrosarcoma, chemotherapy, 2777
- Cisplatin, gemcitabine, non-small cell lung cancer, 471
- Cisplatin, hepatic arterial infusion chemotherapy, reservoir port, liver metastasis, biliary tract and pancreatic cancer, 5-fluorouracil, 477
- Cisplatin, hepatoid adenocarcinoma, AFP-producing Barrett's esophageal cancer, liver metastasis, paclitaxel, 2965
- Cisplatin, hepatoma, methotrexate, telomeres, telomerase, drug resistance, dynamics, gene amplification, 3279
- Cisplatin, hRFI, apoptosis, chemotherapy, irinotecan, 5-fluorouracil, colorectal cancer, 2737
- Cisplatin, hyperthermia, XP cells, 2649
- Cisplatin, irinotecan, advanced gastric cancer, phase I/II trial, 1257
- Cisplatin, lipoplatin, tumor targeting, gastric cancer, colon cancer, hepatocellular cancer, 3031
- Cisplatin, melanoma, temozolomide, interferon-alpha, 1441
- Cisplatin, non-small cell lung cancer, paclitaxel, 4685
- Cisplatin, ovarian cancer, chemotherapy, taxol, topotecan, 2113
- Cisplatin, oxaliplatin, teratocarcinoma cell line 2102EP, drug resistance, 1147
- Cisplatin, phase II, multicentric trial, S-1, gastric cancer, 1297
- Cisplatin, procainamide hydrochloride, tissue morphology, 4123
- Cisplatin, radiation, DNA repair, mutants, recombination repair, 53
- Cisplatin, SPI-077, STEALTH[®] liposomes, TNF- α , rat sarcoma, systemic treatment, 743
- Cisplatin, vascular disrupting agent, MN-029, radiation, 3899
- Cisplatin, ZD 1839, SCCHN, 3985
- Ck19, cervical carcinoma, Rhenium-188, apoptosis, radioimmunotherapy, 2719
- CLA derivatives, conjugated linoleic acid isomers, fatty acids, cell proliferation, 3943
- CLA, breast cancer, VEGF-A, linoleic acid, 4061
- Clasto- β -lactone, nocodazole, etoposide, MG-132, HSP70, 3321
- Clear cell sarcoma, sentinel lymph node, 4413
- Clinical prognosis, renal cell cancer, EGFR, tissue microarray, survival, 1901
- Clinical prognostic factor, soluble CD44, CD44v6, neoplasm, squamous cell carcinoma of the head and neck, SCCHN, serum tumor marker, 2821
- Clinical study, basal cell carcinoma, skin tumors, facial surgery, basal cell carcinoma-histological subtypes, 1693
- Clinical study, pleomorphic adenoma, salivary glands, head and neck tumors, parotid, salivary gland carcinoma, 1703
- Clinically localized prostate cancer, bcl2, p53, PAR4, biochemical failure, 3123
- Clonogenic assay, vinflunine, head and neck squamous cell carcinoma, chemosensitivity *in vitro*, 4363
- Co-cultivation, LPS, Coley's toxin, Toll-like receptor, innate immunity, immune therapy, lung carcinoma, alveolar macrophage, 3747
- Codeinone, α , β -unsaturated ketones, anticancer drugs, apoptosis, caspase-3, DNA fragmentation, 4037
- Codeinone, β -unsaturated ketones, anticancer drugs, apoptosis, caspase-3, DNA fragmentation, 4037
- Coley's toxin, LPS, Toll-like receptor, innate immunity, immune therapy, lung carcinoma, alveolar macrophage, co-cultivation, 3747
- Collagen gel droplet-embedded culture drug sensitivity test (CD-DST), ovarian cancer, ascitic fluid, pleural fluid, neoadjuvant chemotherapy, 3547

- COLO 201, enterolactone, colon cancer, apoptosis, 2269
- Colon cancer cells, NF-kappaB activation, Sabarubicin, paclitaxel, apoptotic DNA fragmentation, parthenolide, 2119
- Colon cancer, carcinoembryonic antigen, receptor, heterogeneous RNA binding protein, 23
- Colon cancer, enterolactone, COLO 201, apoptosis, 2269
- Colon cancer, lipoplatin, cisplatin, tumor targeting, gastric cancer, hepatocellular cancer, 3031
- Colon cancer, osteoprotegerin, RANKL, TNF, IL-1 β , immunohistochemistry, 3809
- Colon cancer, p53, intron 6, 2767
- Colon cancer, real-time PCR, cytokines, TH1, H2, 2135
- Colon cancer, Sialyl Lewis A, Sialyl Lewis X, X-ray irradiation, cell adhesion molecules, 875
- Colon carcinogenesis, dimethylhydrazine, scanning electron microscopy, F433 rat, 3883
- Colon rectal tumors, BKV, JCV, DNA sequences, 1079
- Colon, crypts, colorectal cancer, ulcerative colitis, 4551
- Colon, rectum, adenomas, progression, invasive carcinoma, 2503
- Colon, serrated, microtubular, adenomas, rectum, 1353
- Colon, tumour-promoting factors, fat, carcinogenesis, caroverine, ubiquinone, 2793
- Colorectal adenomas, cyclooxygenase-2, colorectal cancer, 2065
- Colorectal cancer, adhesive molecules, ICAM-1, VCAM-1, diagnosis, 1597
- Colorectal cancer, bevacizumab, VEGF, 3619
- Colorectal cancer, BRCA1, BRCA2, hMSH2 mRNA, Lieberkühnien adenocarcinomas, 2009
- Colorectal cancer, chemokines, CCL2 (MCP-1), CCL5 (RANTES), CXCL8, IL-8, 3581
- Colorectal cancer, chemotherapy control, biological markers, breast cancer, ovarian cancer, 1655
- Colorectal cancer, chemotherapy control, thymidinekinase, 1831
- Colorectal cancer, chemotherapy, metastases, review, 563
- Colorectal cancer, chemotherapy, monitoring, prediction, DNA, nucleosomes, cytokeratin 19-fragments, CYFRA 21-1, serum, 1795
- Colorectal cancer, colon, crypts, ulcerative colitis, 4551
- Colorectal cancer, COX-2, COX-1, NSAIDs, proliferation, 225
- Colorectal cancer, Crohn's disease, DNA-aneuploidy, 4393
- Colorectal cancer, cyclooxygenase-2, colorectal adenomas, 2065
- Colorectal cancer, Ep-CAM, circulating tumor cells, micrometastasis, 319
- Colorectal cancer, galectin-3 expression, prognosis, immunohistochemistry, 3117
- Colorectal cancer, genetic polymorphisms, NAD(P)H oxidase p22phox, paraoxonase, 1465
- Colorectal cancer, hRFI, apoptosis, chemotherapy, cisplatin, irinotecan, 5-fluorouracil, 2737
- Colorectal cancer, IL-12, CD83, CD68, dendritic cell, macrophage, antigen-presenting cell, 3541
- Colorectal cancer, irinotecan, raltitrexed, first-line chemotherapy, phase II study, 1391
- Colorectal cancer, liver metastasis, chemotherapy, gene, 1237
- Colorectal cancer, liver metastasis, leucovorin, 4747
- Colorectal cancer, mevalonate pathway, 3393
- Colorectal cancer, mRNA, MMP-2, MMP-7, TIMP-1, TIMP-2, 3387
- Colorectal cancer, nitric oxide, aspirin, 4471
- Colorectal cancer, nuclear morphometry, nuclear area, prognosis, adjuvant therapy, 3083
- Colorectal cancer, RUNX3, methylation-specific PCR, 2627
- Colorectal cancer, tumor colony forming assay, regional chemotherapy, liver metastases, 795
- Colorectal carcinoma (CRC), liver metastasis, staging system, prognostic factors, 1251
- Colorectal carcinoma, coregulators, estrogen receptor α , estrogen receptor β , estrogen receptor-related receptor α , 4287
- Colorectal carcinoma, K-ras mutations, TGGE (temperature gradient electrophoresis), circulating nucleic acids, 657
- Colorectal carcinoma, thymidine phosphorylase, dihydropyrimidine dehydrogenase, gastric carcinoma, 3755
- Colorectal liver metastases, focal hyperthermia, apoptosis, liver, 1413
- Colorectal liver metastasis, TaqMan PCR, CEA mRNA, recurrence, 1327
- Colposcopy, screening, HPV, HPV testing, liquid-based cytology, cervicography, 3469
- Combined modality therapy, esophageal cancer, aged, 3055
- Combined treatment, calcitriol, vitamin D analogue, VDR, *in vitro* assay, cancer, 2235
- Combretastatin A-4, microtubules, β -tubulin isotypes, resistance, 3865
- Comet assay, vitamin C, zinc, DNA damage, 3197
- Complexed PSA (c PSA), PSA, free PSA (f PSA), prostate cancer, 1591
- Computed tomography, gastrointestinal tumor, endoscopic ultrasonography, volumetry, diagnosis, 3-D structure, 2935
- Computed tomography, occult, tracheal carcinoma, positron emission tomography, image fusion, 459
- Computer-aided diagnosis (CAD) system, lung cancer, screening, helical computed tomography (CT) scan, 483
- Computer-aided diagnosis, automatic diagnosis, melanoma, melanocytic nevi, digital epiluminescence microscopy, dermoscopy, 4577

- Concurrent chemoradiotherapy, in NK/ T cell lymphoma, 4403
- Confocal microscopy, cisplatin resistance, K⁺ channels, ion homeostasis, microarray, 4113
- Confocal microscopy, multidrug resistance (MDR), MDR modulators, P-glycoprotein, sarcoma, flow cytometry, 383
- Congenital anomalies, spleen, 4385
- Conjugated bilirubin, ABC transporter, chemosensitivity, renal cell carcinoma, MRP2, 2729
- Conjugated linoleic acid isomers, CLA derivatives, fatty acids, cell proliferation, 3943
- Conjugates, fibrinogen, methotrexate, glycation, antitumor activity, 2229
- Coping and defending, breast disease, breast cancer, 4623
- Coregulators, estrogen receptor α , estrogen receptor β , estrogen receptor-related receptor α , colorectal carcinoma, 4287
- Corticosteroids, *pneumocystis carinii*, pneumonia, lymphopenia, radiation of thoracic duct, 651
- Cortivazol, glucocorticoids, prednisolone, dexamethasone, betamethasone, resistance, 2253
- COX-1, COX-2, colorectal cancer, NSAIDs, proliferation, 225
- COX-2 inhibition, curcumin, α -diisoeugenol, apoptosis, 4029
- COX-2, animal model, canine mammary tumors, inflammatory mammary carcinoma, enzyme immunoassay, 4269
- COX-2, brain metastasis, necrosis, radiation, 2969
- COX-2, COX-1, colorectal cancer, NSAIDs, proliferation, 225
- COX-2, endometrial cancer, angiogenesis, apoptosis, cell growth, metastatic potential, immunomodulation, review, 3679
- COX-2, eugenol-related compounds, cytotoxicity, apoptosis, HL-60 cells, LPS, RAW cells, 3263
- COX-2, hesperetin, hesperidin, radical-scavenging activity, inhibition rate constants, 3367
- COX-2, prostate cancer, osteolytic lesions, osteoblastic, bone metastases, 107
- COX-2, STS, immunohistochemistry, soft tissue sarcomas, epithelial differentiation, 2669
- CPT-11, camptothecin, SN-38, liposome, drug delivery, 331
- Craniospinal irradiation, fertility, ovarian position, MR, 3481
- CrI, *A. archangelica*, essential oils, cytotoxicity, 1877
- Crosslaps, PINP, osteocalcin, breast cancer, bone metastases, 1491
- Croton zambesicus*, diterpene, trachylobane, HL-60, apoptosis, cytotoxicity, 363
- Cryopreserved ovarian tissue, ovary, transplantation, sex cord stromal tumors, 4107
- Cryotherapy, prostate cancer, therapy, radical prostatectomy, brachytherapy, high intensity focused ultrasound, watchful waiting, chemotherapy, 551
- Crypts, colon, colorectal cancer, ulcerative colitis, 4551
- CT scan, CA125, ovarian cancer, vaginal ultrasound, 1551
- CTL, dendritic cell, human, tumor immunity, antigen presentation, 2177
- CTL, lymph node, dendritic cell, immunotherapy, lung cancer, sentinel node, 85
- CTL-adoptive immunotherapy, SCCHN tumor cell culture, MHC-restricted immune response, 4075
- Cu plate, cytotoxicity, antioxidant, radical, SOD, ESR, 283
- Cu/Zn and Mn superoxide dismutase mRNA, hydroquinone, N-acetyl-L-cysteine, apoptosis, HL-60 cells, caspases, 161
- Curcumin, apoptotic genes, breast cancer, 3293
- Curcumin, α -diisoeugenol, apoptosis, COX-2 inhibition, 4029
- Cutpoint analysis, immunohistochemistry, breast cancer, estrogen and progesterone receptors, prognosis, 2535
- CXCL8, chemokines, colorectal cancer, CCL2 (MCP-1), CCL5 (RANTES), IL-8, 3581
- Cyclic dipeptides, cancer cells, HT-29, poly(ADP-ribose)polymerase (PARP), caspase-3, apoptosis, 4197
- Cyclin cdk's, PKC, phosphoinositol 3-kinase, apoptosis, deoxyadenosine resistance, p53, flavopiridol, LY294002, roscovitine, wortmannin, UCN-01, leukemia cells, 101
- Cyclin D1 and HER2/neu by FISH, breast carcinomas, primary cultures of carcinoma cells, 1051
- Cyclin D1, breast cancer, African-American, estrogen receptor, 273
- Cyclin D1, oral cancer, p53, qat, Yemen, India, 4699
- Cyclin D1, PPAR β/δ , multiple intestinal neoplasia, aberrant crypt foci, azoxymethane, ApcMin/+ mice, β -catenin, Wnt signalling pathway, 3781
- Cyclin, VEGF-D, cell proliferation, breast cancer, angiogenesis, 701
- Cyclin-dependent kinase, bladder cancer, flavopiridol, apoptosis, cell cycle arrest, 4341
- Cyclooxygenase-2 enzyme, Glioblastoma multiforme, 675
- Cyclooxygenase-2, bladder urothelial carcinoma, apoptosis, 4543
- Cyclooxygenase-2, colorectal adenomas, colorectal cancer, 2065
- Cyclooxygenase-2, interleukin-1 α , gastric cancer, 3225
- CYFRA 21-1, colorectal cancer, chemotherapy, monitoring, prediction, DNA, nucleosomes, cytokeratin 19-fragments, serum, 1795
- CYFRA 21-1, head and neck cancer, lymphatic metastasis, SCC, CEA, 1539
- CYFRA 21-1, small cell lung cancer, tumor marker, ProGRP, NSE, lung cancer, CEA, CA 125, SCC, 1773
- CYP17, familial prostate cancer, polymorphism, association, 1303

- Cystatin, hypoxia, cathepsin, oral carcinoma, 2841
- Cystatins, adenomas, cysteine cathepsins, intracranial tumours, invasion, stefin A, 587
- Cysteine cathepsins, adenomas, cystatins, intracranial tumours, invasion, stefin A, 587
- Cytarabine, lung cancer, acute leukemia, gefitinib, aclarubicin, 2579
- Cytochrome c release, cell death, paclitaxel, docetaxel, breast cancer cells, DNA fragmentation, caspase activation, 4215
- Cytogenetics, *Canis familiaris*, lymphoma, 3995
- Cytokeratin 19-fragments, colorectal cancer, chemotherapy, monitoring, prediction, DNA, nucleosomes, CYFRA 21-1, serum, 1795
- Cytokeratin, breast cancer, disseminated tumor cells, bone marrow, her2, micrometastases, 2171
- Cytokeratin, gastric cancer, Epstein-Barr virus, 3183
- Cytokeratins, cell lines, RT-PCR, HNSCC, 2675
- Cytokeratins, melanoma metastases, CAS200, image cytophotometry, 2789
- Cytokine, IL-1, IL-6, gastric carcinoma, 709
- Cytokines, colon cancer, real-time PCR, TH1, H2, 2135
- Cytokines, PSK, Th1/Th2, DC1/DC2, 443
- Cytoplasm, fibroblast, angiopoietin, ANG-1, ANG-2, 171
- Cytoprotection, melatonin, hematopoietic stem cell, doxorubicin, hematopoiesis, 4245
- Cytosol, thymidine kinase, TPS, VEGF, endostatin, thyroid gland, 1517
- Cytotoxic effect, antitelomerase drug PIPER, TRAP assay, 3341
- Cytotoxic T lymphocyte (CTL), gastric cancer, tumor-associated macrophages (TAM), Fas ligand (FasL), immunomodulation, prognosis, 463
- Cytotoxic T lymphocytes, immunotherapy, natural killer cells, antibody-based therapy, tumor antigen, carcinoembryonic antigen, review, 3725
- Cytotoxicity assay, chemotherapy, breast cancer, primary cell culture, brain metastases, 1531
- Cytotoxicity, *A. archangelica*, essential oils, CrI, 1877
- Cytotoxicity, betulinic acid, semi-empirical molecular-orbital method, 3951
- Cytotoxicity, bisphenol A, hydroquinone, thiols, apoptosis, caspases, 2241
- Cytotoxicity, *Capsicum annuum* L. var. *angulosum* Mill. extracts, MDR reversal, anti-HIV activity, anti-*Helicobacter pylori* activity, urease inhibition, 1991
- Cytotoxicity, Cu plate, antioxidant, radical, SOD, ESR, 283
- Cytotoxicity, diterpene, trachylobane, HL-60, apoptosis, *Croton zambesicus*, 363
- Cytotoxicity, eugenol-related compounds, apoptosis, HL-60 cells, LPS, COX-2, RAW cells, 3263
- Cytotoxicity, indolo[2, 3-b]quinoline, cell cycle, topoisomerase II, MDR, DNA-binding, lipophilicity, antimicrobial, 2857
- Cytotoxicity, sodium fluoride, human oral cells, ageing, apoptosis, mitochondrial function, 2085
- Cytotoxicity, sodium fluorosilicate, apoptosis, osteosarcoma (HOS) cells, 391
- D-allose, cell proliferation, ovarian carcinoma, 2639
- D₂O (heavy water, deuterium oxide), apoptosis, cell cycle distribution, pancreatic cancer, AsPC-1, BxPC-3 and PANC-1 cells, 3407
- D7S483, allelic imbalance, Barrett's oesophagus, gastric cardia, adenocarcinoma, 7q36, 913
- Daidzein, endometrial cells, genistein, estrogen receptor, RT-PCR, 1713
- DAPI, alvaradoin E, alvaradoin F, annexin V-FITC, anthracenone C-glycosides, apoptosis, DiOC₆, hollow fiber test, mitochondrial membrane potential analysis, propidium iodide, TUNEL assay, 779
- Daurorubicin, folate receptor, drug targeting, liposomes, leukemia, 343
- DC1/DC2, PSK, Th1/Th2, cytokines, 443
- DCIS, breast cancer, Her2/neu, steroid receptors, Ki67, p53, 1719
- Dedifferentiated liposarcomas, c-kit, well-differentiated liposarcomas, imatinib-mesylate, GISTs, polymorphism, 2215
- Dedifferentiation, carcinogenesis, aging, stem cells, 1385
- Dedifferentiation, neutron therapy, adenoid cystic carcinoma, histological subtype, salivary glands, head and neck, 1321
- Dendritic cell (DC), immuno-cell therapy, CD3-LAK, pancreatic carcinoma, gemcitabine, 3709
- Dendritic cell, human, CTL, tumor immunity, antigen presentation, 2177
- Dendritic cell, IL-12, CD83, CD68, macrophage, antigen-presenting cell, colorectal cancer, 3541
- Dendritic cell, lymph node, immunotherapy, lung cancer, CTL, sentinel node, 85
- Dendritic cells, activated lymphocytes, vaccine, autologous tumor cells, 3771
- Dendritic cells, endometrial cancer, S100 protein, prognostic factor, 1747
- Dendritic cells, exosomes, HER2/neu, Herceptin (Trastuzumab), breast cancer, 3703
- Dendritic cells, FasL, vaccine, TGF- β , 299
- Dendritic cells, human, tumor immunity, 3445
- Dendritic cells, immunocell therapy, melanoma, lymphocytes, adoptive immunotherapy, mixed response, 3741
- Dendritic cells, medullary thyroid carcinoma, drug resistance, immunotherapy, autologous tumor cell cultures, 4225

- Dendritic cells, OK-432, tumor immunity, Toll-like receptor, TLR-4, 4231
- Deoxyadenosine resistance, cyclin cdk's, PKC, phosphoinositol 3-kinase, apoptosis, p53, flavopiridol, LY294002, roscovitine, wortmannin, UCN-01, leukemia cells, 101
- Depression, breast symptoms, anxiety, breast cancer, 2527
- Dermoscopy, computer-aided diagnosis, automatic diagnosis, melanoma, melanocytic nevi, digital epiluminescence microscopy, 4577
- Des- γ -carboxy prothrombin (PIVKA-II), mediastinal embryonal carcinoma, hepatoid differentiation, 4569
- Detection, prostate cancer, aged, prevention, review, 4527
- Detergent, erythrocyte membrane, multidrug resistance protein (MRP), cell shape, phospholipid translocation, haemolysis, 3173
- Dexamethasone, glucocorticoids, cortivazol, prednisolone, betamethasone, resistance, 2253
- Dextran sulfate, anti-adherence therapy, anticancer cell adherence agent, peritoneal metastasis, peritoneal metastasis, 895
- DHPLC, RET, sequencing, MEN 2, 2091
- DHX32, RNA helicase, lymphocyte, differentiation, 2645
- Diagnosis of cirrhosis, hepatic cirrhosis, CCl₄, 1029
- Diagnosis, adhesive molecules, ICAM-1, VCAM-1, colorectal cancer, 1597
- Diagnosis, gastrointestinal tumor, computed tomography, endoscopic ultrasonography, volumetry, 3-D structure, 2935
- Diagnostic accuracy, breast cancer, mammotome, vacuum biopsy, FNAC, ultrasound, 2465
- Diagnostic and prognostic markers, nuclear matrix, prostate cancer, review, 3999
- 5-Dibenzoyl-1, 3, 4-dihydropyridines, tumor-specificity, DNA fragmentation, caspase, Bcl-2, Bax, Bad, radical, 2033
- Differential diagnosis, epithelial splenic cysts, immunohistochemistry, 515
- Differentiation, diffuse large B-cell lymphomas, apoptosis, proliferation, 347
- Differentiation, myeloid leukemia, TSP-1, peptides, apoptosis, 757
- Differentiation, pancreatic adenocarcinoma, tumor markers, CA 19-9, 3625
- Differentiation, RNA helicase, DHX32, lymphocyte, 2645
- Diffuse large B-cell lymphomas, differentiation, apoptosis, proliferation, 347
- Digital epiluminescence microscopy, computer-aided diagnosis, automatic diagnosis, melanoma, melanocytic nevi, dermoscopy, 4577
- Digoxin, angiogenesis, mice, neuroblastoma, tumor, 207
- Dihydropyrimidine dehydrogenase (DPD), gastric scirrhus carcinoma, S-1, DPD inhibitory fluoropyrimidines (DIF), 2997
- Dihydropyrimidine dehydrogenase (DPD), thymidylate synthase (TS), non-small cell lung cancer, RT-PCR, 923
- Dihydropyrimidine dehydrogenase, thymidine phosphorylase, gastric carcinoma, colorectal carcinoma, 3755
- 4-Dihydropyridines, 3, 5-dibenzoyl-1, tumor-specificity, DNA fragmentation, caspase, Bcl-2, Bax, Bad, radical, 2033
- α -Diisoeugenol, curcumin, apoptosis, COX-2 inhibition, 4029
- Dimensions, fractal, laryngeal cancer, prognostic factors, image analysis, 2141
- Dimethylhydrazine, colon carcinogenesis, scanning electron microscopy, F433 rat, 3883
- DiOC₆, alvaradoin E, alvaradoin F, annexin V-FITC, anthracenone C-glycosides, apoptosis, DAPI, hollow fiber test, mitochondrial membrane potential analysis, propidium iodide, TUNEL assay, 779
- Dioxin, gastric tumour, hamartoma, Ah receptor, 903
- Disseminated tumor cells, breast cancer, cytokeratin, bone marrow, her2, micrometastases, 2171
- Disseminated tumor cells, immunomagnetic selection, multiplex RT-PCR, 1803
- Distant metastasis, malignant fibrous histiocytoma, vascular invasion, 1337
- Diterpene, trachylobane, HL-60, apoptosis, cytotoxicity, *Croton zambesicus*, 363
- Diterpenes, helioscopinolides, *Euphorbia*, multidrug resistance, 3259
- DMXAA, FAA, TNF- α , LPS, murine macrophages, 1179
- DNA analysis, HNPCC, microsatellite instability, multiplex PCR, 3251
- DNA cytometry, bladder neoplasms, image analysis, survival analysis, 3243
- DNA damage, vitamin C, zinc, Comet assay, 3197
- DNA double-strand break, radiosensitization, interferon- α , reactive oxygen species, p21Cip1/WAF1, 2631
- DNA fragmentation, 3, 5-dibenzoyl-1, 4-dihydropyridines, tumor-specificity, caspase, Bcl-2, Bax, Bad, radical, 2033
- DNA fragmentation, azulenequinones, apoptosis, caspase, apoptosis-related protein expression, 305
- DNA fragmentation, berberine, tumor specificity, caspase, Bad, Bcl-2, 4053
- DNA fragmentation, cell death, paclitaxel, docetaxel, breast cancer cells, caspase activation, cytochrome c release, 4215
- DNA fragmentation, codeinone, α , β -unsaturated ketones, anticancer drugs, apoptosis, caspase-3, 4037
- DNA fragmentation, stilbenes, flavonoids, oral tumor cells, caspase, Bcl-2, Bax, Bad, 2055
- DNA fragmentation, tumor specificity, apoptosis, doxorubicin, mdr1, 877
- DNA immunization, cellular response, mouse models of breast cancer, MUC1, spontaneous tumors, 3893

- DNA methylation, glutathione S-transferase pi, human herpes virus 4, stomach neoplasms, 4013
- DNA methylation, tumor antigen, reverse transcriptase polymerase chain reaction, stomach neoplasms, immunohistochemistry, survival analysis, 2105
- DNA microarray, interferon receptor gene, interferon-stimulated genes, 3271
- DNA mismatch repair, microsatellite instability, ovarian clear-cell carcinoma, p53, 2785
- DNA repair, cisplatin, radiation, mutants, recombination repair, 53
- DNA repair, lung cancer, single nucleotide polymorphism, APEX1, XRCC1, ADPRT, LIG3, 537
- DNA sequences, BKV, JCV, colon rectal tumors, 1079
- DNA topoisomerase I, (-)-Menthofol, topoisomerase II α , topoisomerase II β , gastric cancer, 2069
- DNA, colorectal cancer, chemotherapy, monitoring, prediction, nucleosomes, cytokeratin 19-fragments, CYFRA 21-1, serum, 1795
- DNA-aneuploidy, Crohn's disease, colorectal cancer, 4393
- DNA-binding, indolo[2, 3-b]quinoline, cell cycle, topoisomerase II, MDR, cytotoxicity, lipophilicity, antimicrobial, 2857
- DNA-cytophotometry, prostate cancer, PSA, 1783
- Docetaxel, advanced gastric cancer, cisplatin, TS-1, phase II study, second-line chemotherapy, 2973
- Docetaxel, breast cancer, NF- κ B, Bcl-xL, c-FLIP, paclitaxel, 2367
- Docetaxel, cell death, paclitaxel, breast cancer cells, DNA fragmentation, caspase activation, cytochrome c release, 4215
- Docetaxel, gemcitabine, proximal muscle weakness, myalgias, edema, 523
- Docetaxel, irinotecan, cisplatin resistance, ovarian cancer, 3559
- Docetaxel, non-small cell lung cancer, 4713
- Docetaxel, NSCLC, gemcitabine, liposomal doxorubicin, 1427
- Docetaxel, sequential chemotherapy, epirubicin, vinorelbine, advanced breast cancer, 1309
- Dogs, cancer, chemotherapy, cisplatin, bleomycin, electroporation, 839
- Doppel, prion, astrocytoma, protein interaction, 4369
- Doppler ultrasound, breast carcinoma, ultrasound contrast media, neoadjuvant chemotherapy, 595
- Doppler ultrasound, ultrasound contrast media, salivary gland tumor, 2477
- Doxazosin, prostate cancer, bladder cancer, serotonin, 4281
- Doxifluridine, paclitaxel, gastric cancer, thymidine phosphorylase, 1291
- Doxorubicin, biodegradable polymer, brain tumor, interstitial chemotherapy, 3825
- Doxorubicin, melatonin, hematopoietic stem cell, hematopoiesis, cytoprotection, 4245
- Doxorubicin, proliferation, migration, osteosarcoma, extracellular matrix, matrix-metalloproteinase, β 1 integrin, topoisomerase II, 805
- Doxorubicin, tumor specificity, apoptosis, DNA fragmentation, mdr1, 877
- DPD inhibitory fluoropyrimidines (DIF), gastric scirrhus carcinoma, S-1, dihydropyrimidine dehydrogenase (DPD), 2997
- Drug allergy, interstitial lung disease (ILD), gefitinib, Iressa, 415
- Drug delivery, camptothecin, CPT-11, SN-38, liposome, 331
- Drug delivery, ultrasound, cavitation, transfection, gene therapy, biotherapy, 149
- Drug resistance, cisplatin, oxaliplatin, teratocarcinoma cell line 2102EP, 1147
- Drug resistance, Gn-RH agonist, prostate cancer, leuprorelin, triptorelin, 577
- Drug resistance, hepatoma, methotrexate, cisplatin, telomeres, telomerase, dynamics, gene amplification, 3279
- Drug resistance, medullary thyroid carcinoma, immunotherapy, autologous tumor cell cultures, dendritic cells, 4225
- Drug targeting, folate receptor, liposomes, daunorubicin, leukemia, 343
- DSB, mitotic delay, signaling proteins, cell cycle analysis, 1123
- DU 145, prostate cancer, xenograft, radiotherapy, testis, estramustine, 2873
- Ductal breast cancer, breast cancer, E-cadherin, fibronectin, prognosis, 2879
- Ductal breast carcinoma. FNAB, telomerase, Her-2 /neu, ER, 1927
- Dynamics, hepatoma, methotrexate, cisplatin, telomeres, telomerase, drug resistance, gene amplification, 3279
- E-cadherin, breast cancer, ductal breast cancer, fibronectin, prognosis, 2879
- E-cadherin, gallbladder carcinoma, cholecystitis, gallbladder tissue, β -catenin, 4249
- E-cadherin, gastric cancer, cell proliferation, β -catenin, family history, 2567
- E-cadherin, Sialyl Lewis X, Sialyl Lewis A, cathepsin-D, breast cancer, 1615
- E-selectin, hCG, cell adhesion inhibition, 1811
- E4orf4 gene, apoptin gene, cancer gene therapy, apoptosis, 1087
- Early invasive lesions, c-erbB-2, Her-2, preneoplastic lesions, bronchial pre-invasive lesions, carcinogenesis, lung cancer, 2005
- Early-stage colorectal carcinoma, myofibroblast, microvessel density, podoplanin, lymphangiogenesis, lymph node metastasis, 2705

- Ebselen, radical-scavenging activity, inhibition rate constants, 3989
- Edema, gemcitabine, docetaxel, proximal muscle weakness, myalgias, 523
- Efficacy, weekly paclitaxel, toxicity, non-small cell lung cancer, NSCLC, 4611
- EGCG analog, green tea, epigallocatechin-3-gallate, chemoprevention, VEGF, 397
- EGCG, green tea, polyphenol, oral cancer, p21^{WAF1}, apoptosis, 63
- EGF-R, ER α , PgR, proliferation, Bcl-2, Her-2/neu, p53, 4615
- EGFR phosphorylation, MCI-186, epidermal growth factor, cell cycle, 1131
- EGFR, estrogen receptor α , lung cancer, prognostic factor, 4693
- EGFR, HER-2, metastatic, squamous cell carcinoma, skin, immunohistochemistry, 1205
- EGFR, renal cell cancer, clinical prognosis, tissue microarray, survival, 1901
- EGFR, SCCHN, signal transduction, cancer treatment, 1871
- Elastin, melanoma, matrikines, galectin-3, review, 2617
- Electroporation, dogs, cancer, chemotherapy, cisplatin, bleomycin, 839
- ELISA, autoantibodies, prostasome, prostate cancer, prostate specific antigen, 4399
- ELISA, glycodelin, monoclonal antibodies, ovarian cancer, 1581
- Ellagic acid, cell cycle arrest, apoptosis, p53, p21, caspase-3, 971
- Elongation factor-1, breast cancer, mRNA expression, RT-PCR, 2573
- EMD 55, cervix, cancer, 900, CD 31, angiogenesis, 4261
- EMR, group III, tubular adenoma, tubular adenocarcinoma, 3513
- Endometrial cancer, COX-2, angiogenesis, apoptosis, cell growth, metastatic potential, immunomodulation, review, 3679
- Endometrial cancer, dendritic cells, S100 protein, prognostic factor, 1747
- Endometrial cancer, endometrium, immunohistochemistry, parathyroid hormone-related peptide (PTH-rp), 1633
- Endometrial cancer, endometrium, immunohistochemistry, estrogen receptor alpha (ER- α), estrogen receptor beta (ER- β), progesterone receptor (PR), 1679
- Endometrial cancer, estrogen receptors, progesterone receptors, hormone dependency, HER-2/neu, 2921
- Endometrial cancer, matrix metalloproteinases, MMP-2, prognostic factors, 4101
- Endometrial carcinoma, nedaplatin, MTT assay, ovarian carcinoma, cervical carcinoma, 4499
- Endometrial carcinoma, surgery, laparoscopy, hysterectomy, recurrence, 2423
- Endometrial cells, genistein, daidzein, estrogen receptor, RT-PCR, 1713
- Endometrium, endometrial cancer, immunohistochemistry, parathyroid hormone-related peptide (PTH-rp), 1633
- Endometrium, endometrial cancer, immunohistochemistry, estrogen receptor alpha (ER- α), estrogen receptor beta (ER- β), progesterone receptor (PR), 1679
- Endometrium, small cell carcinoma, neuroendocrine tumours, 1823
- Endoscopic ultrasonography, gastrointestinal tumor, computed tomography, volumetry, diagnosis, 3-D structure, 2935
- Endostatin, thymidine kinase, TPS, VEGF, thyroid gland, cytosol, 1517
- Endothelial cells, CD105, TGF- β 1, angiogenesis, 1851
- Endothelial cells, fenretinide, 4-HPR, ovarian cancer, OVCAR-5, angiogenesis, HUVEC, actin cytoskeleton, FAK, 249
- Endothelial-breast cancer interaction, p21^{WAF1/Cip1}, 2743
- Endoxifen, tamoxifen, 4-hydroxy-N-desmethyltamoxifen, 4-hydroxytamoxifen, 4487
- Enkephalin, breast cancer, enkephalinase, N-methylnitrosourea, 193
- Enkephalinase, enkephalin, breast cancer, N-methylnitrosourea, 193
- Enterolactone, COLO 201, colon cancer, apoptosis, 2269
- Enzyme immunoassay, animal model, canine mammary tumors, Cox-2, inflammatory mammary carcinoma, 4269
- Ep-CAM, circulating tumor cells, micrometastasis, colorectal cancer, 319
- Ep-CAM, human monoclonal antibody, MK-1, tumor targeting, 3733
- EphA2, EphrinA-1, oesophageal squamous cell carcinoma, tissue array, immunohistochemistry, RT-PCR, laser capture microdissection, 2943
- EphA2, esophageal cancer, KAI1, focal adhesion kinase, Ki-67, 4005
- EphrinA-1, EphA2, oesophageal squamous cell carcinoma, tissue array, immunohistochemistry, RT-PCR, laser capture microdissection, 2943
- Epidemiology, brain metastasis, small cell lung cancer, right lung, left lung, upper lobe, lower lobe, gender, smoking, 1101
- Epidemiology, breast cancer incidence, upper outer quadrant, underarm cosmetics, cancer prevention, 2543
- Epidermal growth factor receptor tyrosine kinase inhibitor, hypertrophic osteoarthropathy, lung adenocarcinoma, 2435
- Epidermal growth factor receptor, focal adhesion kinase, invasion, migration, flavonoids, siRNA, 2017

- Epidermal growth factor, MCI-186, cell cycle, EGFR phosphorylation, 1131
- Epigallocatechin-3-gallate, green tea, EGCG analog, chemoprevention, VEGF, 397
- Epirubicin, 5-Fluorouracil, vinorelbine, breast cancer, 4493
- Epirubicin, breast cancer, paclitaxel, sequence, 1211
- Epirubicin, prostate cancer, hormone-refractory, 4475
- Epirubicin, sequential chemotherapy, docetaxel, vinorelbine, advanced breast cancer, 1309
- Epirubicin, vinorelbine, breast cancer, 1343
- Epithelial cells, hyperbaric oxygenation, breast, mammary neoplasms, 3833
- Epithelial differentiation, Cox-2, STS, immunohistochemistry, soft tissue sarcomas, 2669
- Epithelial ovarian cancer, spleen, metastasis, recurrence, 1471
- Epithelial splenic cysts, differential diagnosis, immunohistochemistry, 515
- Epithelial-mesenchymal transition (EMT), oral keratinocyte, $\alpha\beta6$, squamous cell carcinoma, 751
- Epoetin alfa, anemia, 669
- Epstein-Barr virus, gastric cancer, cytokeratin, 3183
- ER, telomerase, Her-2 /neu, ductal breast carcinoma. FNAB, 1927
- Eradication treatment, antioxidants, gastric mucosa, gastritis, *Helicobacter pylori*, reactive oxygen metabolites, superoxide dismutase, 4763
- ERBB2, high-dose chemotherapy, trastuzumab, breast cancer, 663
- ERK, 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin, JNK, p38, caspase-3, RAW 264.7 cells, 2831
- Erythrocyte membrane, detergent, multidrug resistance protein (MRP), cell shape, phospholipid translocation, haemolysis, 3173
- Erythropoietin, quality of life, anemia, 3495
- ER α , PgR, proliferation, Bcl-2, Her-2/neu, p53, EGF-R, 4615
- ER β , canine, prostatic cells, age, 4081
- Esophageal cancer classification, esophagectomy, 3461
- Esophageal cancer, combined modality therapy, aged, 3055
- Esophageal cancer, KAI1, EphA2, focal adhesion kinase, Ki-67, 4005
- Esophageal cancer, oral health, Iran, 543
- Esophageal cancer, polycyclic hydrocarbons, Iran, 425
- Esophageal carcinoma, 18-F-Fluorodeoxyglucose (FDG), positron emission tomography (PET), bony metastasis, bone scintigraphy, 4439
- Esophageal carcinoma, serum p53 antibody, azygos vein, 3231
- Esophageal squamous cell carcinoma, chemo-radiotherapy, Hsp27, Hsp70, p21, p53, bax, bcl2, 2749
- Esophageal squamous cell carcinoma, S100A2, Δ Np63, 1247
- Esophageal, cancer, p63, 3533
- Esophagectomy, esophageal cancer classification, 3461
- ESR, azulenequinones, Raw 264.7 cells, NO, iNOS, radicals, 4157
- ESR, Cu plate, cytotoxicity, antioxidant, radical, SOD, 283
- Essential oils, *A. archangelica*, cytotoxicity, CrI, 1877
- Estradiol/progesterone ratio, cervical cancer, squamous cell, 611
- Estramustine, prostate cancer, DU 145, xenograft, radiotherapy, testis, 2873
- Estrogen and progesterone receptors, immunohistochemistry, breast cancer, cutpoint analysis, prognosis, 2535
- Estrogen receptor alpha (ER- α), endometrium, endometrial cancer, immunohistochemistry, estrogen receptor beta (ER- β), progesterone receptor (PR), 1679
- Estrogen receptor beta (ER- β), endometrium, endometrial cancer, immunohistochemistry, estrogen receptor alpha (ER- α), progesterone receptor (PR), 1679
- Estrogen receptor α , coregulators, estrogen receptor β , estrogen receptor-related receptor α , colorectal carcinoma, 4287
- Estrogen receptor α , EGFR, lung cancer, prognostic factor, 4693
- Estrogen receptor β , coregulators, estrogen receptor α , estrogen receptor-related receptor α , colorectal carcinoma, 4287
- Estrogen receptor, caveolin-1, breast cancer, estrogen signaling, 369
- Estrogen receptor, cyclin D1, breast cancer, African-American, 273
- Estrogen receptor, endometrial cells, genistein, daidzein, RT-PCR, 1713
- Estrogen receptor, RARRES3, TIG3, RIG1, breast cancer, progesterone receptor, tumor suppressor gene, 2453
- Estrogen receptor-related receptor α , coregulators, estrogen receptor α , estrogen receptor β , colorectal carcinoma, 4287
- Estrogen receptors, endometrial cancer, progesterone receptors, hormone dependency, HER-2/neu, 2921
- Estrogen signaling, caveolin-1, estrogen receptor, breast cancer, 369
- ET-18-OCH₃, ether lipids, MCF-7 cells, p70 S6 kinase, 95
- Ether lipids, ET-18-OCH₃, MCF-7 cells, p70 S6 kinase, 95
- Etoposide, bax, Bcl-2, caspase, hydroxyurea, interleukin, lymphoma, p53, 999
- Etoposide, FAK, FRNK, apoptosis, SCCHN cells, paclitaxel, 5-fluorouracil, 4349
- Etoposide, nocodazole, MG-132, clasto- β -lactone, HSP70, 3321
- Eugenol-related compounds, cytotoxicity, apoptosis, HL-60 cells, LPS, COX-2, RAW cells, 3263

- Euphorbia*, diterpenes, helioscopinolides, multidrug resistance, 3259
- Euphorbia*, jatrophone diterpenes, multidrug resistance, HTB-26 cell line, 4173
- Eurycoma longifolia*, antiproliferative effect, apoptosis, Bcl-2, MCF-7, 2205
- Excitation, photodynamic therapy, acridine orange, xenon, illuminance, osteosarcoma, 3979
- Exclusive radiotherapy, vulvar cancer, adjuvant radiotherapy, surgery, 3089
- Exosomes, HER2/neu, dendritic cells, Herceptin (Trastuzumab), breast cancer, 3703
- Expanded Access Programme, gefitinib, non-small cell lung cancer, 4759
- Extended surgery, gastric cancer, advanced, chemosensitivity, adjuvant chemotherapy, MTT assay, superextended lymphadenectomy, 3453
- Extracellular glycoproteins, monoclonal antibody, bispecific antibody, anti-Her2/neu, prostate cancer, immunotherapy, 43
- Extracellular matrix, proliferation, migration, osteosarcoma, doxorubicin, matrix-metalloproteinase, β 1 integrin, topoisomerase II, 805
- Extrarenal rhabdoid tumour, heel, 4573
- F433 rat, dimethylhydrazine, colon carcinogenesis, scanning electron microscopy, 3883
- FAA, DMXAA, TNF- α , LPS, murine macrophages, 1179
- Facial surgery, basal cell carcinoma, skin tumors, clinical study, basal cell carcinoma-histological subtypes, 1693
- Factor V, prothrombin, oral cancer, oncogenesis, thrombophilia, 2561
- FAK, fenretinide, 4-HPR, ovarian cancer, OVCAR-5, angiogenesis, endothelial cells, HUVEC, actin cytoskeleton, 249
- FAK, FRNK, apoptosis, SCCHN cells, paclitaxel, etoposide, 5-fluorouracil, 4349
- Familial cervical cancer, cervical cancer, Latin America, 1219
- Familial prostate cancer, CYP17, polymorphism, association, 1303
- Family history, gastric cancer, cell proliferation, E-cadherin, β -catenin, 2567
- Farnesyltransferase inhibitor, R115777, Ras, 3215
- Fas ligand (FasL), gastric cancer, tumor-associated macrophages (TAM), cytotoxic T lymphocyte (CTL), immunomodulation, prognosis, 463
- Fas, benign prostatic hyperplasia, apoptosis, bcl-2, bax, c-myc, 3937
- Fas-ligand, bladder cancer, Superantigen, staphylococcal enterotoxin B, apoptosis, 3565
- FasL, vaccine, TGF- β , dendritic cells, 299
- Fat, tumour-promoting factors, colon, carcinogenesis, caroverine, ubiquinone, 2793
- Fatty acids, conjugated linoleic acid isomers, CLA derivatives, cell proliferation, 3943
- FDG, thyroid incidentaloma, thyroid carcinoma, cancer screening, PET, 1421
- FDG-PET, MIBI scan, multiple myeloma, bone marrow involvement, soft tissue lesions, skeletal lesions, 4737
- Fenretinide, 4-HPR, ovarian cancer, OVCAR-5, angiogenesis, endothelial cells, HUVEC, actin cytoskeleton, FAK, 249
- Fertility, ovarian position, craniospinal irradiation, MR, 3481
- α 1-fetoprotein, pregnancy protein 1, placental-specific tissue protein 10, bronchial carcinoma, 1667
- Fibrinogen, methotrexate, conjugates, glycation, antitumor activity, 2229
- Fibroblast growth factor receptor, MDA-MB-231, Grb14, breast cancer, *Xenopus* oocyte, 3877
- Fibroblast growth factor-2, renal cell carcinoma, bone metastasis, angiogenesis, antisense oligodeoxynucleotide, 1109
- Fibroblast, cytoplasm, angiopoietin, ANG-1, ANG-2, 171
- Fibronectin, breast cancer, ductal breast cancer, E-cadherin, prognosis, 2879
- Fibronectin, cell adhesion inhibition, fucoidan, integrins, MDA-MB-231 breast cell, 2129
- Fibronectin, ovarian cancer, invasion markers, matrix metallo- proteinase, prognosis, 2885
- Fibrosarcoma, chemotherapy, cisplatin, 2777
- Fibrothecoma, melanoma, ovarian tumor, 1603
- First-line chemotherapy, colorectal cancer, irinotecan, raltitrexed, phase II study, 1391
- FISH, non-Hodgkin's lymphoma, IGH rearrangement, recurrent translocation, 3179
- FISH, non-small cell lung cancer, HER2, immunohistochemistry, 3061
- FISH, topoisomerase 2 α , HER2, p53, bladder carcinoma, multitissue array, prognosis, 263
- Flavonoids, epidermal growth factor receptor, focal adhesion kinase, invasion, migration, siRNA, 2017
- Flavonoids, stilbenes, oral tumor cells, DNA fragmentation, caspase, Bcl-2, Bax, Bad, 2055
- Flavopiridol, bladder cancer, cyclin-dependent kinase, apoptosis, cell cycle arrest, 4341
- Flavopiridol, cyclin cdk's, PKC, phosphoinositol 3-kinase, apoptosis, deoxyadenosine resistance, p53, LY294002, roscovitine, wortmannin, UCN-01, leukemia cells, 101
- Flaxseed, phytoestrogens, lignans, matairesinol, Biochanin A, trophoblast tumour cells, 1817
- Flk-1, soft tissue sarcoma, VEGF, MVD, angiogenesis, 3591
- Flow cytometry, mucoepidermoid carcinoma, salivary gland neoplasms, ploidy, Ki-67, grading, 2589
- Flow cytometry, multidrug resistance (MDR), MDR modulators, P-glycoprotein, sarcoma, confocal microscopy, 383

- Flow cytometry, N-acetyltransferase (NAT), berberine, leukemia cell line (HL-60), 2-aminofluorene (AF), 4149
- Flow cytometry, quantitative fluorescence *in situ* hybridisation, telomeres, flow-FISH, 1039
- Flow-FISH, flow cytometry, quantitative fluorescence *in situ* hybridisation, telomeres, 1039
- Fluorescence *in situ* hybridization, chromosome 8 aneuploidy, C-MYC amplification, gastric adenocarcinoma, 4069
- Fluorescent microspheres, sentinel node detection, 821
- 18-F-Fluorodeoxyglucose (FDG), positron emission tomography (PET), esophageal carcinoma, bony metastasis, bone scintigraphy, 4439
- 18-F-Fluorodeoxyglucose, positron emission tomography, hepatocellular carcinoma, alpha-fetoprotein, 4719
- Fluorouracil, bevacizumab, pancreatic neoplasms, gemcitabine, cisplatin, irinotecan, 3637
- 5-Fluorouracil, CEA, PPD, immunochemotherapy, PSK, 1377
- 5-Fluorouracil, epirubicin, vinorelbine, breast cancer, 4493
- 5-Fluorouracil, FAK, FRNK, apoptosis, SCCHN cells, paclitaxel, etoposide, 4349
- 5-Fluorouracil, hepatic arterial infusion chemotherapy, reservoir port, liver metastasis, biliary tract and pancreatic cancer, cisplatin, 477
- 5-Fluorouracil, hRFI, apoptosis, chemotherapy, cisplatin, irinotecan, colorectal cancer, 2737
- 5-Fluorouracil, NLCQ-1, paclitaxel, 2161
- 5-Fluorouracil, peritoneal metastases, radioimmunotherapy, Norbormide, autoradiography, 917
- 5-Fluorouracil, VEGF, IP-10, pancreatic carcinoma, irinotecan, oxaliplatin, leucovorin, gemcitabine, 3287
- FNAC, breast cancer, diagnostic accuracy, mammotome, vacuum biopsy, ultrasound, 2465
- Focal adhesion kinase, epidermal growth factor receptor, invasion, migration, flavonoids, siRNA, 2017
- Focal adhesion kinase, esophageal cancer, KAI1, EphA2, Ki-67, 4005
- Focal adhesion, non-small cell lung cancers, cell adhesion, metastatic potential, 4135
- Focal hyperthermia, apoptosis, liver, colorectal liver metastases, 1413
- Folate conjugate, folate receptor, targeted radiotherapy, alpha particle emitter, 9
- Folate receptor, drug targeting, liposomes, daunorubicin, leukemia, 343
- Folate receptor, folate conjugate, targeted radiotherapy, alpha particle emitter, 9
- Follicular carcinoma, HBME-1, thyroid, immunohistochemistry, 179
- Follicular tumor, hTERT, immunohistochemistry, 509
- Fractal, dimensions, laryngeal cancer, prognostic factors, image analysis, 2141
- Fractionated radiotherapy, hematopoietic, CAFC cells, stromal cells, 2801
- Fraxiparine, heparin, metastasis, mouse, tumors, 2869
- Free prostate specific antigen, prostate cancer, prostate specific antigen, 2439
- Free PSA (f PSA), PSA, complexed PSA (c PSA), prostate cancer, 1591
- FRNK, FAK, apoptosis, SCCHN cells, paclitaxel, etoposide, 5-fluorouracil, 4349
- 5-FU, macrocytic anemia, arterial infusion, hepatobiliary malignancy, 1243
- Fucoidan, cell adhesion inhibition, fibronectin, integrins, MDA-MB-231 breast cell, 2129
- Functional assay, P-glycoprotein, multidrug resistance, ascites, ovarian cancer, 1187
- Fuzzy logic, tumor markers, gastro-intestinal cancer, 1507
- G-protein, calcitonin, CD44, invasion, paracrine, prostate cancer, signal transduction, 2075
- G1 arrest, glycyrrhetic acid, glycyrrhizin, apoptosis, Bcl-2 family, hepatocellular carcinoma, 4043
- Galectin-1, apoptosis, MCF7 cells, BeWo cells, mycoplasma, 1575
- Galectin-3 expression, colorectal cancer, prognosis, immunohistochemistry, 3117
- Galectin-3, elastin, melanoma, matrikines, review, 2617
- Gallbladder carcinoma, cholecystitis, gallbladder tissue, E-cadherin, β -catenin, 4249
- Gallbladder carcinoma, MGMT, hMLH1, alkylating agents, ACNU, 4021
- Gallbladder tissue, gallbladder carcinoma, cholecystitis, E-cadherin, β -catenin, 4249
- Ganciclovir, herpes simplex virus thymidine kinase, bystander effect, gap junctional intercellular communication, multidrug resistance, 255
- Gap junctional intercellular communication, herpes simplex virus thymidine kinase, ganciclovir, bystander effect, multidrug resistance, 255
- Gastrectomy with spleen preservation / splenectomy, gastric cancer, recurrence, survival, 3023
- Gastric adenocarcinoma, fluorescence *in situ* hybridization, chromosome 8 aneuploidy, C-MYC amplification, 4069
- Gastric cancer cell, anti-apoptosis, IAP, inhibitor of apoptosis protein, 2713
- Gastric cancer, (-)-Menthol, DNA topoisomerase I, topoisomerase II α , topoisomerase II β , 2069
- Gastric cancer, advanced, chemosensitivity, adjuvant chemotherapy, MTT assay, extended surgery, superextended lymphadenectomy, 3453
- Gastric cancer, anticancer drugs, chemosensitivity, chemotherapy, 931
- Gastric cancer, cell proliferation, E-cadherin, β -catenin, family history, 2567
- Gastric cancer, Epstein-Barr virus, cytokeratin, 3183

- Gastric cancer, gastrectomy with spleen preservation / splenectomy, recurrence, survival, 3023
- Gastric cancer, interleukin-1 α , cyclooxygenase-2, 3225
- Gastric cancer, lipoplatin, cisplatin, tumor targeting, colon cancer, hepatocellular cancer, 3031
- Gastric cancer, lymph node, metastasis, sentinel node concept, 1349
- Gastric cancer, metastatic lymph node ratio, lymph node dissection, prognostic factor, 1369
- Gastric cancer, p53 protein, bcl-2 protein, immunohistochemistry, prognosis, 3629
- Gastric cancer, paclitaxel, doxifluridine, thymidine phosphorylase, 1291
- Gastric cancer, phase II, multicentric trial, S-1, cisplatin, 1297
- Gastric cancer, spleen, CD62L, TGF-beta, regulatory T cells, 643
- Gastric cancer, SU6668, vascular endothelial growth factor, peritoneal dissemination, 17
- Gastric cancer, tumor-associated macrophages (TAM), Fas ligand (FasL), cytotoxic T lymphocyte (CTL), immunomodulation, prognosis, 463
- Gastric carcinoma, cytokine, IL-1, IL-6, 709
- Gastric carcinoma, thymidine phosphorylase, dihydropyrimidine dehydrogenase, colorectal carcinoma, 3755
- Gastric cardia, allelic imbalance, Barrett's oesophagus, adenocarcinoma, D7S483, 7q36, 913
- Gastric mucosa, antioxidants, eradication treatment, gastritis, *Helicobacter pylori*, reactive oxygen metabolites, superoxide dismutase, 4763
- Gastric scirrhous carcinoma, S-1, dihydropyrimidine dehydrogenase (DPD), DPD inhibitory fluoropyrimidines (DIF), 2997
- Gastric tumour, hamartoma, dioxin, Ah receptor, 903
- Gastritis, antioxidants, eradication treatment, gastric mucosa, *Helicobacter pylori*, reactive oxygen metabolites, superoxide dismutase, 4763
- Gastro-intestinal cancer, fuzzy logic, tumor markers, 1507
- Gastrointestinal stromal tumour, positron emission tomography, imatinib mesylate, c-kit, receptor protein-tyrosine kinase, 4591
- Gastrointestinal tumor, computed tomography, endoscopic ultrasonography, volumetry, diagnosis, 3-D structure, 2935
- Gc protein, Gc protein-derived macrophage activating factor (GcMAF), alpha-N-acetylgalactosaminidase, review, 3689
- Gc protein-derived macrophage activating factor (GcMAF), Gc protein, alpha-N-acetylgalactosaminidase, review, 3689
- Gefitinib ('Iressa', ZD1839), non-small cell lung cancer (NSCLC), vinorelbine, 547
- Gefitinib, expanded Access Programme, non-small cell lung cancer, 4759
- Gefitinib, interstitial lung disease (ILD), Iressa, drug allergy, 415
- Gefitinib, lung cancer, acute leukemia, cytarabine, aclarubicin, 2579
- Gefitinib, non-small cell lung cancer, 435
- Gemcitabine, bevacizumab, pancreatic neoplasms, cisplatin, irinotecan, fluorouracil, 3637
- Gemcitabine, bladder cancer, hypoxia, 3413
- Gemcitabine, cisplatin, non-small cell lung cancer, 471
- Gemcitabine, docetaxel, proximal muscle weakness, myalgias, edema, 523
- Gemcitabine, immuno-cell therapy, CD3-LAK, dendritic cell (DC), pancreatic carcinoma, 3709
- Gemcitabine, intravesical chemotherapy, phase II study, pharmacokinetics, 2493
- Gemcitabine, low performance status, non-small cell lung cancer, paclitaxel, 409
- Gemcitabine, NSCLC, docetaxel, liposomal doxorubicin, 1427
- Gemcitabine, p38 MAPK, Akt, apoptosis, pancreatic cancer, 3347
- Gemcitabine, paclitaxel, leukemia cells, 4165
- Gemcitabine, pancreatic cancer, mistletoe extract, mistletoe lectin, *Viscum album*, intratumoral injection, antitumour activity, human cancer xenograft, 1969
- Gemcitabine, pancreatic cancer, radiochemotherapy, CA 19-9, toxicity, 1523
- Gemcitabine, pegylated liposomal doxorubicin, ovarian cancer, 3103
- Gemcitabine, superficial bladder cancer, intravesical chemotherapy, 2381
- Gemcitabine, VEGF, IP-10, pancreatic carcinoma, irinotecan, oxaliplatin, 5-fluorouracil, leucovorin, 3287
- Gender, brain metastasis, small cell lung cancer, right lung, left lung, upper lobe, lower lobe, smoking, epidemiology, 1101
- Gene amplification, hepatoma, methotrexate, cisplatin, telomeres, telomerase, drug resistance, dynamics, 3279
- Gene expression, *in vitro*, cDNA microarray, chemotherapy, resistance, 2661
- Gene therapy, bladder cancer, adenovirus, recombinant IL-2, 2757
- Gene therapy, carbonic anhydrase IX (CA IX), MN protein, renal cell carcinoma, 881
- Gene therapy, murine polyomavirus, VLPs, immune therapy, vaccines, review, 2601
- Gene therapy, photochemical internalization, gene transfer, Glioblastoma multiforme, 291
- Gene therapy, SCCHN, IL-2, B7, immunotherapy, 3917
- Gene therapy, ultrasound, cavitation, drug delivery, transfection, biotherapy, 149

- Gene transfer, photochemical internalization, gene therapy, Glioblastoma multiforme, 291
- Gene, colorectal cancer, liver metastasis, chemotherapy, 1237
- Gene-based PSMA vaccination, prostate cancer, LNCaP cells, anti-PSMA antibodies, carbohydrate cleaving enzyme, proteases, 4727
- Genetic change, Burkitt lymphoma, LCL, p16^{INK4A}, p14^{ARF}, promoter methylation, 2153
- Genetic polymorphism, SULT1A1, SNP, breast cancer, 2515
- Genetic polymorphisms, NAD(P)H oxidase p22phox, paraoxonase, colorectal cancer, 1465
- Genetic profiling, prostate cancer cell lines, microarray, metastasis-associated genes, 183
- Genistein, endometrial cells, daidzein, estrogen receptor, RT-PCR, 1713
- Genotoxicity, chemoprevention, anthocyanins, apoptosis, lymphocytes, 2837
- Gestational trophoblastic disease, invasive mole, inhibin, activin, Sialyl Lewis A, glycodelin, immunohistochemistry, 1725
- Giant intramuscular hemangioma, multistep approach, timing, 2417
- GISTs, c-kit, dedifferentiated liposarcomas, well-differentiated liposarcomas, imatinib-mesylate, polymorphism, 2215
- GL331, apoptosis, glioma, cell cycle, topoisomerase II inhibitor, 4203
- Glioblastoma multiforme, cyclooxygenase-2 enzyme, 675
- Glioblastoma multiforme, photochemical internalization, gene transfer, gene therapy, 291
- Glioblastoma multiforme, radiotherapy, chemotherapy, 4605
- Glioblastoma, 20S proteasome, peptidase activity, 3203
- Glioma, apoptosis, GL331, cell cycle, topoisomerase II inhibitor, 4203
- Glioma, p53, transcriptional activation, phosphorylation, 213
- Glomus tumours, *SDHD*-, *SDHB*-, *SDHC*-gene, succinate dehydrogenase (SDH) enzyme activity, loss of heterozygosity (LOH), 2809
- Glucocorticoids, cortivazol, prednisolone, dexamethasone, betamethasone, resistance, 2253
- Glucose consumption, GLUT1, protein synthesis, tumour proliferation, 3431
- GLUT1, glucose consumption, protein synthesis, tumour proliferation, 3431
- Glutaminase, apoptosis, cancer, chemoresistance, glutamine, 3315
- Glutamine, apoptosis, cancer, chemoresistance, glutaminase, 3315
- Glutathione S-transferase pi, human herpes virus 4, stomach neoplasms, DNA methylation, 4013
- Glutathione, alpha-hederin, thymoquinone, apoptosis, *Nigella sativa*, 4255
- Glutathione, arsenic trioxide, multidrug-resistance, buthionine-sulfoximine, reactive oxygen species, 991
- Glutathione, N-(4-hydroxyphenyl) retinamide, apoptosis, reactive oxygen species, tissue transglutaminase, BSO, all-trans retinoic acid (ATRA), 1945
- Glycation, fibrinogen, methotrexate, conjugates, antitumor activity, 2229
- Glycodelin A, ovarian cancer, ovarian cysts, 1639
- Glycodelin, breast cancer, metastasis, 1761
- Glycodelin, invasive mole, gestational trophoblastic disease, inhibin, activin, Sialyl Lewis A, immunohistochemistry, 1725
- Glycodelin, monoclonal antibodies, ELISA, ovarian cancer, 1581
- Glycosaminoglycans, osteosarcoma, cell proliferation, 2851
- Glycyrrhetic acid, glycyrrhizin, G1 arrest, apoptosis, Bcl-2 family, hepatocellular carcinoma, 4043
- Glycyrrhizin, glycyrrhetic acid, G1 arrest, apoptosis, Bcl-2 family, hepatocellular carcinoma, 4043
- Gn-RH agonist, prostate cancer, leuprorelin, triptorelin, drug resistance, 577
- Grading, MFH, prognosis, 4293
- Grading, mucoepidermoid carcinoma, salivary gland neoplasms, flow cytometry, ploidy, Ki-67, 2589
- Granulocyte function, immunomodulation, surgical stress, mistletoe therapy, *Viscum album*, oxidative burst, 4753
- Grb14, MDA-MB-231, fibroblast growth factor receptor, breast cancer, *Xenopus* oocyte, 3877
- Green tea, epigallocatechin-3-gallate, EGCG analog, chemoprevention, VEGF, 397
- Green tea, polyphenol, EGCG, oral cancer, p21^{WAF1}, apoptosis, 63
- Group III, EMR, tubular adenoma, tubular adenocarcinoma, 3513
- Growth inhibition, vitamin D, calcitriol, vitamin D analog, seocalcitol, medium-chain triglyceride, canine transitional cell carcinoma, cell cycle, VDR, 2689
- H2, colon cancer, real-time PCR, cytokines, TH1, 2135
- H460 non-small cell lung carcinoma cell line, hollow fibre assay, anti-vascular effects, angiogenesis, VEGF, 1889
- Haemolysis, erythrocyte membrane, detergent, multidrug resistance protein (MRP), cell shape, phospholipid translocation, 3173
- Hamartoma, gastric tumour, dioxin, Ah receptor, 903
- HBME-1, follicular carcinoma, thyroid, immunohistochemistry, 179
- HCG, cell adhesion inhibition, E-selectin, 1811
- β-HCG, stage I seminoma, testicular cancer, radiotherapy, 1543
- HCV RNA PCR, hepatitis C, interferon-alpha, ribavirin, signal transduction, 1315

- Head and neck cancer, chemo-radiotherapy, taxotere, cisplatin, 4451
- Head and neck cancer, chronic dysphagia, rehabilitation, 2929
- Head and neck cancer, lymphatic metastasis, SCC, CYFRA 21-1, CEA, 1539
- Head and neck cancer, microsatellite analyses, recurrence, second primary tumours, 2771
- Head and neck cancer, serum selenium, resectability, 1711
- Head and neck squamous cell carcinoma, carboplatin, raltitrexed, 4445
- Head and neck squamous cell carcinoma, interleukin-6, serum level, 2761
- Head and neck squamous cell carcinoma, vinflunine, clonogenic assay, chemosensitivity *in vitro*, 4363
- Head and neck tumors, pleomorphic adenoma, salivary glands, parotid, salivary gland carcinoma, clinical study, 1703
- Head and neck, neutron therapy, adenoid cystic carcinoma, dedifferentiation, histological subtype, salivary glands, 1321
- Heat shock protein, hsp27, prognosis, immuno-histochemistry, breast cancer, 1649
- Heavy water (deuterium oxide, D₂O), apoptosis, cell cycle distribution, pancreatic cancer, AsPC-1, BxPC-3 and PANC-1 cells, 3407
- Hedgehog signaling pathway, thymus, thymoma, 3697
- Heel, extrarenal rhabdoid tumour, 4573
- HeLa, xanthorrhizol, *C. xanthorrhiza*, apoptosis, 2221
- Helical computed tomography (CT) scan, lung cancer, screening, computer-aided diagnosis (CAD) system, 483
- Helicobacter pylori*, antioxidants, eradication treatment, gastric mucosa, gastritis, reactive oxygen metabolites, superoxide dismutase, 4763
- Helioscopinolides, diterpenes, *Euphorbia*, multidrug resistance, 3259
- Helix pomatia* agglutinin, metastases, 1829
- Hematologic malignancies, chromosome abnormalities, karyotype, molecular cytogenetics, review, 2979
- Hematopoiesis, melatonin, hematopoietic stem cell, doxorubicin, cytoprotection, 4245
- Hematopoietic stem cell, melatonin, doxorubicin, hematopoiesis, cytoprotection, 4245
- Hematopoietic, fractionated radiotherapy, CAFC cells, stromal cells, 2801
- Heparin, Fraxiparine, metastasis, mouse, tumors, 2869
- Hepatotomy, hepatocellular carcinoma, prognosis, 3067
- Hepatic arterial infusion chemotherapy, reservoir port, liver metastasis, biliary tract and pancreatic cancer, 5-fluorouracil, cisplatin, 477
- Hepatic cirrhosis, diagnosis of cirrhosis, CCl₄, 1029
- Hepatitis C, HCV RNA PCR, interferon-alpha, ribavirin, signal transduction, 1315
- Hepatitis, inflammatory polyps, pseudopolyps, ulcerative colitis, budesonide, 2961
- Hepatobiliary malignancy, macrocytic anemia, arterial infusion, 5-FU, 1243
- Hepatocarcinogenesis, angiogenesis, ACE inhibitor, renin-angiotensin system, 3335
- Hepatocarcinoma, sPD-1, B7-H1, immunotherapy, 3309
- Hepatocellular cancer, lipoplatin, cisplatin, tumor targeting, gastric cancer, colon cancer, 3031
- Hepatocellular carcinoma, glycyrrhetic acid, glycyrrhizin, G1 arrest, apoptosis, Bcl-2 family, 4043
- Hepatocellular carcinoma, hepatectomy, prognosis, 3067
- Hepatocellular carcinoma, positron emission tomography, 18F-fluorodeoxyglucose, alpha-fetoprotein, 4719
- Hepatocellular carcinoma, transarterial chemo-embolization, acute liver damage, Lipiodol, ICG-R15, 2551
- Hepatoid adenocarcinoma, AFP-producing Barrett's esophageal cancer, liver metastasis, paclitaxel, cisplatin, 2965
- Hepatoid differentiation, Des-γ-carboxy prothrombin (PIVKA-II), mediastinal embryonal carcinoma, 4569
- Hepatoma, methotrexate, cisplatin, telomeres, telomerase, drug resistance, dynamics, gene amplification, 3279
- Hepatoma, sirolimus, liver, rat, adenocarcinoma, sarcoma, 789
- HepG2, roxithromycin (RXM), VEGF, angiogenesis, 133
- HER-1, BRCA1, HER-2, immunohistochemistry, breast cancer, 4535
- Her-2 /neu, telomerase, ER, ductal breast carcinoma. FNAB, 1927
- HER-2 status, invasive breast carcinoma, real-time quantitative RT-PCR, 4679
- HER-2, BRCA1, HER-1, immunohistochemistry, breast cancer, 4535
- HER-2, breast neoplasms, circulating extracellular domains, immunohistochemistry, 1433
- Her-2, c-erbB-2, preneoplastic lesions, bronchial pre-invasive lesions, early invasive lesions, carcinogenesis, lung cancer, 2005
- HER-2, EGFR, metastatic, squamous cell carcinoma, skin, immunohistochemistry, 1205
- HER-2, influenza virus, tumor antigen, memory CTL, IL-15, 715
- HER-2/neu, bladder cancer, TPA, uPAR, tumour marker, TP53, 635
- HER-2/neu, endometrial cancer, estrogen receptors, progesterone receptors, hormone dependency, 2921
- Her-2/neu, ERα, PgR, proliferation, Bcl-2, p53, EGF-R, 4615
- Her-2/neu, real-time PCR, breast cancer, 1895
- HER2, breast cancer, chromogenic *in situ* hybridization, chromosome 17 polysomy, immunohistochemistry, 939

- HER2, breast cancer, disseminated tumor cells, cytokeratin, bone marrow, micrometastases, 2171
- HER2, non-small cell lung cancer, immuno-histochemistry, FISH, 3061
- HER2, topoisomerase 2 α , p53, bladder carcinoma, FISH, multitissue array, prognosis, 263
- HER2, trastuzumab, LAK, ADCC, 827
- HER2/neu, 2C4, adjuvant therapy, Herceptin™, metastatic breast cancer, pertuzumab, trastuzumab, review, 1483
- HER2/neu, breast cancer, steroid receptors, Ki67, p53, DCIS, 1719
- HER2/neu, exosomes, dendritic cells, Herceptin (Trastuzumab), breast cancer, 3703
- Herbal medicine, *Psidium guajava*, T regulatory cell, tumor vaccine, Th1/Th2 balance, 3763
- Herceptin (Trastuzumab), exosomes, HER2/neu, dendritic cells, breast cancer, 3703
- Herceptin, metastatic breast cancer, immunotherapy, trastuzumab, circulating HER-2/neu, review, 4599
- Herceptin™, 2C4, adjuvant therapy, HER2/neu, metastatic breast cancer, pertuzumab, trastuzumab, review, 1483
- Herpes simplex virus thymidine kinase, ganciclovir, bystander effect, gap junctional intercellular communication, multidrug resistance, 255
- Herpesvirus, angiostatic proteins, lung cancer cells, 2049
- Hesperetin, hesperidin, radical-scavenging activity, inhibition rate constants, COX-2, 3367
- Hesperidin, hesperetin, radical-scavenging activity, inhibition rate constants, COX-2, 3367
- Heterogeneous RNA binding protein, carcinoembryonic antigen, colon cancer, receptor, 23
- HGF, NK4, peritoneal implantation, milky spots, 3847
- HIF-1 α , VEGF-C, VEGF-D, breast ductal carcinoma, 3003
- High hydrostatic pressure, tumor cells, orthopedic surgery, apoptosis, chondrosarcoma, chondrocytes, 1977
- High intensity focused ultrasound, prostate cancer, therapy, radical prostatectomy, brachytherapy, cryotherapy, watchful waiting, chemotherapy, 551
- High-dose chemotherapy, metastatic breast cancer, stem-cell transplantation, trifunctional antibody, T-cell reinfusion, 3047
- High-dose chemotherapy, trastuzumab, breast cancer, ERBB2, 663
- High-grade gliomas, methotrexate, children, preradiation chemotherapy, 2583
- Histological subtype, neutron therapy, adenoid cystic carcinoma, dedifferentiation, salivary glands, head and neck, 1321
- HL-60 cells, eugenol-related compounds, cytotoxicity, apoptosis, LPS, COX-2, RAW cells, 3263
- HL-60 cells, hydroquinone, N-acetyl-L-cysteine, apoptosis, Cu/Zn and Mn superoxide dismutase mRNA, caspases, 161
- HL-60, diterpene, trachylobane, apoptosis, cytotoxicity, *Croton zambesicus*, 363
- HL60 cell line, isothiocyanates, multidrug resistance, cell cycle, apoptosis, mitochondrial transmembrane potential, 3375
- HMLH1 methylation, testicular germ-cell tumor, MMR, MSI, chemoresistance, 4319
- HMLH1, MGMT, alkylating agents, gallbladder carcinoma, ACNU, 4021
- HMSH2 mRNA, BRCA1, BRCA2, colorectal cancer, Lieberkühnien adenocarcinomas, 2009
- HMW kininogen, SELDI TOF-MS, protein expression profile, adverse effect, ProteinChip System, apolipoprotein A-II, 1197
- HNPCC, microsatellite instability, multiplex PCR, DNA analysis, 3251
- HNSCC, cytokeratins, cell lines, RT-PCR, 2675
- Hodgkin's, lymphoma, syndecan-1, serum levels, 4743
- Hollow fiber test, alvaradoin E, alvaradoin F, annexin V-FITC, anthracenone C-glycosides, apoptosis, DAPI, DiOC₆, mitochondrial membrane potential analysis, propidium iodide, TUNEL assay, 779
- Hollow fibre assay, anti-vascular effects, angiogenesis, H460 non-small cell lung carcinoma cell line, VEGF, 1889
- Hormone dependence, hormone independence, insulin growth factor receptor type-1, mammary carcinogenesis, mammary tumors, N-nitroso-N-methylurea, protein tyrosine kinase activities, 4305
- Hormone dependency, endometrial cancer, estrogen receptors, progesterone receptors, HER-2/neu, 2921
- Hormone independence, hormone dependence, insulin growth factor receptor type-1, mammary carcinogenesis, mammary tumors, N-nitroso-N-methylurea, protein tyrosine kinase activities, 4305
- Hormone resistance, prostate cancer, tamoxifen, 3597
- Hormone-refractory prostate cancer, taxanes, 4481
- Hormone-refractory, epirubicin, prostate cancer, 4475
- Hormones, breast cancer, tumor markers, 451
- Hospital mortality, oesophageal surgery, surgical volume, 419
- HPLC, methionine-dependent cancer, methionine-depletion therapy, high resolution, sensitivity, 59
- 4-HPR, fenretinide, ovarian cancer, OVCAR-5, angiogenesis, endothelial cells, HUVEC, actin cytoskeleton, FAK, 249
- 4-HPR, retinoids, apoptosis, lymphoma, ATRA, 4179
- HPV ISH, HPV, tonsillar carcinoma, p16, radiotherapy, L1 capsid, prognosis, 4375
- HPV testing, screening, HPV, colposcopy, liquid-based cytology, cervicography, 3469
- HPV, cervical cancer, Organotypic raft culture, interferon, 1091

- HPV, pRb2/p130, p107, p53, cervical cancer, immunohistochemistry, 2187
- HPV, screening, HPV testing, colposcopy, liquid-based cytology, cervicography, 3469
- HPV, tonsillar carcinoma, p16, radiotherapy, L1 capsid, HPV ISH, prognosis, 4375
- HRFI, apoptosis, chemotherapy, cisplatin, irinotecan, 5-fluorouracil, colorectal cancer, 2737
- Hsp27, esophageal squamous cell carcinoma, chemo-radiotherapy, Hsp70, p21, p53, bax, bcl2, 2749
- Hsp27, heat shock protein, prognosis, immuno-histochemistry, breast cancer, 1649
- Hsp70, esophageal squamous cell carcinoma, chemo-radiotherapy, Hsp27, p21, p53, bax, bcl2, 2749
- HSP70, nocodazole, etoposide, MG-132, clasto- β -lactone, 3321
- HT-29, cyclic dipeptides, cancer cells, poly(ADP-ribose)polymerase (PARP), caspase-3, apoptosis, 4197
- HTB-26 cell line, jatrophone diterpenes, *Euphorbia*, multidrug resistance, 4173
- HTEP-1, hTERT, p53, caspase-3, survival, bladder cancer, immunohistochemistry, 3109
- HTERT, benign human prostate cells, African-American, androgen, androgen receptor antagonist, 1
- HTERT, follicular tumor, immunohistochemistry, 509
- HTERT, hTEP-1, p53, caspase-3, survival, bladder cancer, immunohistochemistry, 3109
- Human cancer xenograft, pancreatic cancer, mistletoe extract, mistletoe lectin, *Viscum album*, Gemcitabine, intratumoral injection, antitumour activity, 1969
- Human gliomas, NLCQ-1, radiation, hypoxia, 1865
- Human herpes virus 4, glutathione S-transferase pi, stomach neoplasms, DNA methylation, 4013
- Human leukemia cells, N-acetyltransferase, wogonin, N-acetyl-2-aminofluorene, 2-aminofluorene, 127
- Human monoclonal antibody, MK-1, Ep-CAM, tumor targeting, 3733
- Human oral cells, sodium fluoride, ageing, cytotoxicity, apoptosis, mitochondrial function, 2085
- Human papillomavirus, antisense, raft cultures, replication, oncogenes, 765
- Human retina, p27(KIP1), retinoblastoma, 3843
- Human, dendritic cell, CTL, tumor immunity, antigen presentation, 2177
- Human, dendritic cells, tumor immunity, 3445
- Humanized monoclonal antibody, breast cancer, bone metastasis, PTHrP, 3817
- HUVEC, fenretinide, 4-HPR, ovarian cancer, OVCAR-5, angiogenesis, endothelial cells, actin cytoskeleton, FAK, 249
- Hybridoma, tumor-infiltrating B lymphocyte, monoclonal antibody, lung cancer, 3791
- Hydroquinone, bisphenol A, thiols, cytotoxicity, apoptosis, caspases, 2241
- Hydroquinone, N-acetyl-L-cysteine, apoptosis, HL-60 cells, Cu/Zn and Mn superoxide dismutase mRNA, caspases, 161
- 4-Hydroxy-N-desmethyltamoxifen, tamoxifen, endoxifen, 4-hydroxytamoxifen, 4487
- N-(4-Hydroxyphenyl) retinamide, apoptosis, reactive oxygen species, glutathione, tissue transglutaminase, BSO, all-*trans* retinoic acid (ATRA), 1945
- 4-Hydroxytamoxifen, tamoxifen, 4-hydroxy-N-desmethyltamoxifen, endoxifen, 4487
- Hydroxyurea, bax, Bcl-2, caspase, etoposide, interleukin, lymphoma, p53, 999
- Hyperbaric oxygenation, breast, mammary neoplasms, epithelial cells, 3833
- Hypercalcemia, osteoprotegerin, RANKL, bisphosphonates, 3607
- Hyperfractionated irradiation, radiotherapy, oral squamous cell carcinoma, vital tumor cells, 1707
- Hypergastrinemia, carcinoid, atrophic gastritis, 4417
- Hyperthermia, cisplatin, XP cells, 2649
- Hypertrophic osteoarthropathy, lung adenocarcinoma, epidermal growth factor receptor tyrosine kinase inhibitor, 2435
- Hypoglycemia, malignant solitary fibrous tumor, soft tissue tumor, insulin-like growth factor II, 2461
- Hypoxia, bladder cancer, gemcitabine, 3413
- Hypoxia, cathepsin, cystatin, oral carcinoma, 2841
- Hypoxia, interleukin-12, vasculature, perfusion, proliferation, ICAM-1, 1015
- Hypoxia, NLCQ-1, radiation, human gliomas, 1865
- Hypoxia, p27, pRb, oxygen-dependent checkpoint, 2259
- Hysterectomy, endometrial carcinoma, surgery, laparoscopy, recurrence, 2423
- IAP, gastric cancer cell, anti-apoptosis, inhibitor of apoptosis protein, 2713
- Ibuprofen, prostate cancer, LNCaP cells, vitamin D, NSAID, 3425
- ICAM-1, adhesive molecules, VCAM-1, colorectal cancer, diagnosis, 1597
- ICAM-1, interleukin-12, vasculature, hypoxia, perfusion, proliferation, 1015
- ICG-R15, hepatocellular carcinoma, transarterial chemo-embolization, acute liver damage, Lipiodol, 2551
- IGF II, JIP-1, testicular tumours, 1075
- IGF-I, breast cancer, cattle, 871
- IGH rearrangement, non-Hodgkin's lymphoma, FISH, recurrent translocation, 3179
- IL-1, cytokine, IL-6, gastric carcinoma, 709
- IL-12, CD83, CD68, dendritic cell, macrophage, antigen-presenting cell, colorectal cancer, 3541
- IL-15, HER-2, influenza virus, tumor antigen, memory CTL, 715
- IL-1 β , colon cancer, osteoprotegerin, RANKL, TNF, immunohistochemistry, 3809

- IL-2, maintenance therapy, 13-*cis* retinoic acid, solid tumors, 3149
- IL-2, SCCHN, B7, immunotherapy, gene therapy, 3917
- IL-6, cytokine, IL-1, gastric carcinoma, 709
- IL-8, chemokines, colorectal cancer, CCL2 (MCP-1), CCL5 (RANTES), CXCL8, 3581
- Illuminance, photodynamic therapy, acridine orange, xenon, excitation, osteosarcoma, 3979
- Image analysis, bladder neoplasms, DNA cytometry, survival analysis, 3243
- Image analysis, fractal, dimensions, laryngeal cancer, prognostic factors, 2141
- Image cytophotometry, melanoma metastases, cytokeratins, CAS200, 2789
- Image fusion, occult, tracheal carcinoma, positron emission tomography, computed tomography, 459
- Imaging, angiogenesis, liposomes, matrix metallo-proteinases, phage display, 33
- Imatinib mesylate, gastrointestinal stromal tumour, positron emission tomography, c-kit, receptor protein-tyrosine kinase, 4591
- Imatinib, adenoid cystic carcinoma, salivary gland, 3659
- Imatinib-mesylate, c-kit, dedifferentiated liposarcomas, well-differentiated liposarcomas, GISTs, polymorphism, 2215
- Immune modulation, oncology, microcirculation, standardized mistletoe extract, 601
- Immune therapy, LPS, Coley's toxin, Toll-like receptor, innate immunity, lung carcinoma, alveolar macrophage, co-cultivation, 3747
- Immune therapy, murine polyomavirus, VLPs, gene therapy, vaccines, review, 2601
- Immune therapy, trifunctional bispecific antibody, multicellular tumor spheroids, 4239
- Immune-suppression, *Viscum album*, mistletoe, biotherapy, Isorel, immunomodulation, NK cells, T-helper cells, 4583
- Immuno-histochemistry, non-small cell lung cancer, HER2, FISH, 3061
- Immuno-histochemistry, p53 protein, bcl-2 protein, gastric cancer, prognosis, 3629
- Immuno-cell therapy, CD3-LAK, dendritic cell (DC), pancreatic carcinoma, gemcitabine, 3709
- Immuno-histochemistry, endometrium, endometrial cancer, parathyroid hormone-related peptide (PTH-rp), 1633
- Immuno-histochemistry, epithelial splenic cysts, differential diagnosis, 515
- Immuno-histochemistry, HBME-1, follicular carcinoma, thyroid, 179
- Immuno-histochemistry, heat shock protein, hsp27, prognosis, breast cancer, 1649
- Immuno-histochemistry, mucinous carcinoma, breast cancer, MUC1, MUC1-core, Thomsen-Friedenreich, CA19-9, CA50, CA242, 1755
- Immunocell therapy, melanoma, dendritic cells, lymphocytes, adoptive immunotherapy, mixed response, 3741
- Immunochemotherapy, CEA, PPD, PSK, 5-fluorouracil, 1377
- Immunocompromised host, ultraviolet rays, CD4+ , 1963
- ImmunoCyt/uCyt+™, urinary bladder, carcinoma *in situ*, BCG therapy, 3641
- Immunogens, tumor specific antigens, tumor markers, cancer-bearing host, review, 2345
- Immunohistochemistry, BRCA1, HER-1, HER-2, breast cancer, 4535
- Immunohistochemistry, breast cancer, chromogenic *in situ* hybridization, HER2, chromosome 17 polysomy, 939
- Immunohistochemistry, breast cancer, estrogen and progesterone receptors, cutpoint analysis, prognosis, 2535
- Immunohistochemistry, breast neoplasms, HER-2, circulating extracellular domains, 1433
- Immunohistochemistry, c-kit, TGF-β1, pancreatic cancer, tyrosine kinase, 3523
- Immunohistochemistry, colon cancer, osteoprotegerin, RANKL, TNF, IL-1β, 3809
- Immunohistochemistry, colorectal cancer, galectin-3 expression, prognosis, 3117
- Immunohistochemistry, Cox-2, STS, soft tissue sarcomas, epithelial differentiation, 2669
- Immunohistochemistry, EGFR, HER-2, metastatic, squamous cell carcinoma, skin, 1205
- Immunohistochemistry, endometrium, endometrial cancer, estrogen receptor alpha (ER-α), estrogen receptor beta (ER-β), progesterone receptor (PR), 1679
- Immunohistochemistry, EphA2, EphrinA-1, oesophageal squamous cell carcinoma, tissue array, RT-PCR, laser capture microdissection, 2943
- Immunohistochemistry, hTERT, follicular tumor, 509
- Immunohistochemistry, hTERT, hTEP-1, p53, caspase-3, survival, bladder cancer, 3109
- Immunohistochemistry, invasive mole, gestational trophoblastic disease, inhibin, activin, Sialyl Lewis A, glycodefin, 1725
- Immunohistochemistry, leiomyoma, leiomyoblastoma, leiomyoma of uncertain malignant potential, leiomyosarcoma, 1559
- Immunohistochemistry, P8, apoptosis, breast carcinoma, ssDNA, 833
- Immunohistochemistry, pRb2/p130, p107, p53, HPV, cervical cancer, 2187
- Immunohistochemistry, Skp2, UFT, radiation, prognosis, 2471
- Immunohistochemistry, tumor antigen, DNA methylation, reverse transcriptase polymerase chain reaction, stomach neoplasms, survival analysis, 2105

- Immunohistology, vulvar cancer, vin, *Lichen sclerosus*, squamous cell hyperplasia, p53, carcinogenesis, prognosis, 1739
- Immunohistology, vulvar carcinoma, TGF- α , c-erbB-2, neoangiogenesis, prognosis, 1731
- Immunomagnetic selection, disseminated tumor cells, multiplex RT-PCR, 1803
- Immunomodulation, COX-2, endometrial cancer, angiogenesis, apoptosis, cell growth, metastatic potential, review, 3679
- Immunomodulation, gastric cancer, tumor-associated macrophages (TAM), Fas ligand (FasL), cytotoxic T lymphocyte (CTL), prognosis, 463
- Immunomodulation, surgical stress, mistletoe therapy, *Viscum album*, granulocyte function, oxidative burst, 4753
- Immunomodulation, *Viscum album*, mistletoe, immune-suppression, biotherapy, Isorel, NK cells, T-helper cells, 4583
- Immunosuppression, macrophage, VEGF, angiogenesis, AIN, 693
- Immunotherapy, brain tumor, T11TS / S-LFA-3, apoptosis, 2905
- Immunotherapy, cytotoxic T lymphocytes, natural killer cells, antibody-based therapy, tumor antigen, carcinoembryonic antigen, review, 3725
- Immunotherapy, lymph node, dendritic cell, lung cancer, CTL, sentinel node, 85
- Immunotherapy, medullary thyroid carcinoma, drug resistance, autologous tumor cell cultures, dendritic cells, 4225
- Immunotherapy, metastatic breast cancer, trastuzumab, Herceptin, circulating HER-2/neu, review, 4599
- Immunotherapy, monoclonal antibody, bispecific antibody, anti-Her2/neu, extracellular glycoproteins, prostate cancer, 43
- Immunotherapy, SCCHN, IL-2, B7, gene therapy, 3917
- Immunotherapy, SPD-1, B7-H1, hepatocarcinoma, 3309
- In vitro* assay, calcitriol, vitamin D analogue, combined treatment, VDR, cancer, 2235
- In vitro*, gene expression, cDNA microarray, chemotherapy, resistance, 2661
- In vitro*, TCC, paclitaxel, MMP, invasion, 2097
- India, oral cancer, cyclin D1, p53, qat, Yemen, 4699
- Indolo[2, 3-b]quinoline, cell cycle, topoisomerase II, MDR, DNA-binding, cytotoxicity, lipophilicity, antimicrobial, 2857
- Inflammation, metastasis, lymphangiogenesis, TAMs, VEGF-C, invasion, review, 4503
- Inflammatory mammary carcinoma, animal model, canine mammary tumors, Cox-2, enzyme immunoassay, 4269
- Inflammatory polyps, pseudopolyps, ulcerative colitis, hepatitis, budesonide, 2961
- Influenza virus, HER-2, tumor antigen, memory CTL, IL-15, 715
- Inhibin, invasive mole, gestational trophoblastic disease, activin, Sialyl Lewis A, glycodelin, immunohistochemistry, 1725
- Inhibition rate constants, ebselen, radical-scavenging activity, 3989
- Inhibition rate constants, hesperetin, hesperidin, radical-scavenging activity, COX-2, 3367
- Inhibition rate constants, polyamines, stoichiometric factors (n), 965
- Inhibitor of apoptosis protein, gastric cancer cell, anti-apoptosis, IAP, 2713
- ¹¹¹InHMFG1-F(ab')₂, lung cancer, radiotherapy, biodistribution, lysine, 4663
- Innate immunity, LPS, Coley's toxin, Toll-like receptor, immune therapy, lung carcinoma, alveolar macrophage, co-cultivation, 3747
- INOS, azulenequinones, Raw 264.7 cells, NO, ESR, radicals, 4157
- INOS, lung cancer, angiogenesis, VEGF, oncoprotein, risk model, 497
- Inositol hexaphosphate, prostate cancer, mitogenic signaling, cell survival signaling, cell cycle progression, apoptosis, angiogenesis, review, 2891
- Insulin growth factor receptor type-1, hormone dependence, hormone independence, mammary carcinogenesis, mammary tumors, N-nitroso-N-methylurea, protein tyrosine kinase activities, 4305
- Insulin-like growth factor II, malignant solitary fibrous tumor, soft tissue tumor, hypoglycemia, 2461
- $\alpha\beta 3$ Integrin antagonist, angiogenesis, anticancer, antiangiogenesis, 197
- $\alpha\beta 6$ Integrin oral keratinocyte, squamous cell carcinoma, epithelial-mesenchymal transition (EMT), 751
- $\beta 1$ Integrin, proliferation, migration, osteosarcoma, extracellular matrix, doxorubicin, matrix-metalloproteinase, topoisomerase II, 805
- Integrins, bone metastasis, breast cancer, osteoclasts, osteoclast activation, 79
- Integrins, cell adhesion inhibition, fibronectin, fucoidan, MDA-MB-231 breast cell, 2129
- Interferon receptor gene, DNA microarray, interferon-stimulated genes, 3271
- Interferon, cervical cancer, HPV, Organotypic raft culture, 1091
- Interferon-alpha, hepatitis C, HCV RNA PCR, ribavirin, signal transduction, 1315
- Interferon-alpha, melanoma, temozolomide, cisplatin, 1441
- Interferon-stimulated genes, DNA microarray, interferon receptor gene, 3271
- Interferon- α , radiosensitization, reactive oxygen species, DNA double-strand break, p21Cip1/WAF1, 2631
- Interleukin, bax, Bcl-2, caspase, etoposide, hydroxyurea, lymphoma, p53, 999

- Interleukin-12, vasculature, hypoxia, perfusion, proliferation, ICAM-1, 1015
- Interleukin-1 α , cyclooxygenase-2, gastric cancer, 3225
- Interleukin-4, prostate cancer, interleukin-6, androgen receptor, 4595
- Interleukin-6, prostate cancer, interleukin-4, androgen receptor, 4595
- Interleukin-6, serum level, head and neck squamous cell carcinoma, 2761
- Internet, surgical and medical oncology, professional updating, 3095
- Interstitial chemotherapy, doxorubicin, biodegradable polymer, brain tumor, 3825
- Interstitial lung disease (ILD), gefitinib, Iressa, drug allergy, 415
- Intra-osseous application, osteoblastic bone metastases, rat, 1067
- Intracranial tumours, adenomas, cystatins, cysteine cathepsins, invasion, stefin A, 587
- Intraductal, serrated, adenoma, pancreas, 3099
- Intratumoral injection, pancreatic cancer, mistletoe extract, mistletoe lectin, *Viscum album*, Gemcitabine, antitumour activity, human cancer xenograft, 1969
- Intravascular papillary endothelial hyperplasia, Masson's hemangioma, soft-tissue sarcoma, angiosarcoma, 1409
- Intravesical chemotherapy, gemcitabine, phase II study, pharmacokinetics, 2493
- Intravesical chemotherapy, superficial bladder cancer, gemcitabine, 2381
- Intron 6, p53, colon cancer, 2767
- Invasion markers, ovarian cancer, matrix metalloproteinase, fibronectin, prognosis, 2885
- Invasion, adenomas, cystatins, cysteine cathepsins, intracranial tumours, stefin A, 587
- Invasion, bisphosphonate, alendronate, A431 cells, squamous cell carcinoma, proliferation, 2655
- Invasion, calcitonin, CD44, G-protein, paracrine, prostate cancer, signal transduction, 2075
- Invasion, epidermal growth factor receptor, focal adhesion kinase, migration, flavonoids, siRNA, 2017
- Invasion, metastasis, breast, lung, 3905
- Invasion, metastasis, lymphangiogenesis, inflammation, TAMs, VEGF-C, review, 4503
- Invasion, TCC, paclitaxel, MMP, *in vitro*, 2097
- Invasion, tumour budding, rectal carcinoma, 1269
- Invasive breast carcinoma, HER-2 status, real-time quantitative RT-PCR, 4679
- Invasive carcinoma, colon, rectum, adenomas, progression, 2503
- Invasive mole, gestational trophoblastic disease, inhibin, activin, Sialyl Lewis A, glycodelin, immunohistochemistry, 1725
- Iodine-123 (123I), chromaffin cell, catecholamines, chromogranin A, pheochromocytoma, metaiodobenzylguanidine (MIBG), 1547
- Ion homeostasis, cisplatin resistance, K⁺ channels, microarray, confocal microscopy, 4113
- Ionizing radiation, antisense oligonucleotides, Mcl-1, Bcl-2, apoptosis, melanoma, 2697
- Ionizing radiation, protease inhibitor, anti-angiogenesis, 4357
- Ionophores, ⁸⁶Rb⁺, potassium ion flux, mesothelioma, small cell lung cancer, amphotericin B, 2609
- IP-10, VEGF, pancreatic carcinoma, irinotecan, oxaliplatin, 5-fluorouracil, leucovorin, gemcitabine, 3287
- Iran, esophageal cancer, oral health, 543
- Iran, esophageal cancer, polycyclic hydrocarbons, 425
- Iressa, interstitial lung disease (ILD), gefitinib, drug allergy, 415
- Irinotecan, amrubicin, non-small cell lung cancer, phase I study, non-platinum regimen, topoisomerase inhibitor, 2429
- Irinotecan, bevacizumab, pancreatic neoplasms, gemcitabine, cisplatin, fluorouracil, 3637
- Irinotecan, cisplatin, advanced gastric cancer, phase I/II trial, 1257
- Irinotecan, colorectal cancer, raltitrexed, first-line chemotherapy, phase II study, 1391
- Irinotecan, docetaxel, cisplatin resistance, ovarian cancer, 3559
- Irinotecan, hRFI, apoptosis, chemotherapy, cisplatin, 5-fluorouracil, colorectal cancer, 2737
- Irinotecan, pharmacokinetics, metabolism, capecitabine, 2985
- Irinotecan, VEGF, IP-10, pancreatic carcinoma, oxaliplatin, 5-fluorouracil, leucovorin, gemcitabine, 3287
- Irradiation, angiogenesis, chorioallantoic membrane, nitric oxide, 1059
- γ -Irradiation, apoptosis, macrophages, reactive oxygen species, antioxidants, caspase inhibitors, 4091
- Isoflavones, phytoestrogens, cancer prevention, breast cancer, review, 2357
- Isolated abdominal perfusion, pancreatic cancer, celiac axis infusion, microembolization, 4407
- Isorel, *Viscum album*, mistletoe, immune-suppression, biotherapy, immunomodulation, NK cells, T-helper cells, 4583
- Isothiocyantes, multidrug resistance, cell cycle, apoptosis, mitochondrial transmembrane potential, HL60 cell line, 3375
- Ixabepilone, nail disorders, breast cancer, 3531
- Jak-Stat, WP1034, acute myeloid leukemia, apoptosis, signal transduction, 1841
- Jatrophane diterpenes, *Euphorbia*, multidrug resistance, HTB-26 cell line, 4173

- JCV, BKV, DNA sequences, colon rectal tumors, 1079
 JIP-1, IGF II, testicular tumours, 1075
 JNK, 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin, ERK, p38, caspase-3, RAW 264.7 cells, 2831
 K⁺ channels, cisplatin resistance, ion homeostasis, microarray, confocal microscopy, 4113
 K-ras mutations, TGGE (temperature gradient electrophoresis), colorectal carcinoma, circulating nucleic acids, 657
 KAI1, esophageal cancer, EphA2, focal adhesion kinase, Ki-67, 4005
 Karyotype, chromosome abnormalities, molecular cytogenetics, hematologic malignancies, review, 2979
 KB-V1, P-glycoprotein, multidrug resistance, plasma membrane vesicles, phosphorylation, reconstitution, proteo-liposomes, octyl-glucoside, 3925
 Ki-67 (MIB-1) antigen, proliferative tumor marker, topoisomerase II- α , thyroid tumors, 1835
 Ki-67, breast cancer, Her2/neu, steroid receptors, p53, DCIS, 1719
 Ki-67, esophageal cancer, KAI1, EphA2, focal adhesion kinase, 4005
 Ki-67, mucoepidermoid carcinoma, salivary gland neoplasms, flow cytometry, ploidy, grading, 2589
 L1 capsid, HPV, tonsillar carcinoma, p16, radiotherapy, HPV ISH, prognosis, 4375
 L1210 cells, 1- β -D-arabinofuranosylcytosine, thymidylate synthase, thymidine kinase, 157
 L5178Y-R lymphoma, SNC 80, non-peptide opioids, δ -opioid agonist, murine tumor cells, tumor mouse model, 4563
 LAK, HER2, trastuzumab, ADCC, 827
 Laparoscopy, endometrial carcinoma, surgery, hysterectomy, recurrence, 2423
 Laryngeal cancer, fractal, dimensions, prognostic factors, image analysis, 2141
 Laryngeal carcinoma, CD44, survival analysis, 1115
 Laser capture microdissection, EphA2, EphrinA-1, oesophageal squamous cell carcinoma, tissue array, immunohistochemistry, RT-PCR, 2943
 Latin America, cervical cancer, familial cervical cancer, 1219
 LCL, Burkitt lymphoma, p16^{INK4A}, p14^{ARF}, promoter methylation, genetic change, 2153
 Left lung, brain metastasis, small cell lung cancer, right lung, upper lobe, lower lobe, gender, smoking, epidemiology, 1101
 Leiomyoblastoma, leiomyoma, leiomyoma of uncertain malignant potential, leiomyosarcoma, immunohistochemistry, 1559
 Leiomyoma of uncertain malignant potential, leiomyoma, leiomyoblastoma, leiomyosarcoma, immunohistochemistry, 1559
 Leiomyoma, leiomyoblastoma, leiomyoma of uncertain malignant potential, leiomyosarcoma, immunohistochemistry, 1559
 Leiomyosarcoma, leiomyoma, leiomyoblastoma, leiomyoma of uncertain malignant potential, immunohistochemistry, 1559
 Leucovorin, colorectal cancer, liver metastasis, 4747
 Leucovorin, VEGF, IP-10, pancreatic carcinoma, irinotecan, oxaliplatin, 5-fluorouracil, gemcitabine, 3287
 Leukemia cell line (HL-60), N-acetyltransferase (NAT), berberine, 2-aminofluorene (AF), flow cytometry, 4149
 Leukemia cells, cyclin cdk's, PKC, phosphoinositol 3-kinase, apoptosis, deoxyadenosine resistance, p53, flavopiridol, LY294002, roscovitine, wortmannin, UCN-01, 101
 Leukemia cells, gemcitabine, paclitaxel, 4165
 Leukemia model, TT-232, somatostatin analog, 325
 Leukemia, folate receptor, drug targeting, liposomes, daunorubicin, 343
 Leuprorelin, Gn-RH agonist, prostate cancer, triptorelin, drug resistance, 577
Lichen sclerosis, vulvar cancer, vin, squamous cell hyperplasia, p53, immunohistology, carcinogenesis, prognosis, 1739
 Lieberkühnien adenocarcinomas, BRCA1, BRCA2, hMSH2 mRNA, colorectal cancer, 2009
 LIG3, lung cancer, DNA repair, single nucleotide polymorphism, APEX1, XRCC1, ADPRT, 537
 Ligand, 12-O-retinoylphorbol-13-acetate (RPA), retinol-binding-protein (RBP), 3355
 Lignans, phytoestrogens, flaxseed, matairesinol, Biochanin A, trophoblast tumour cells, 1817
 Limb salvage surgery, musculoskeletal sarcoma, photodynamic therapy, acridine orange, radiation, 1225
 Limited sampling, pharmacokinetics, pharmacodynamics, nedaplatin, AUC, optimal sampling, platelet, 1283
 Linoleic acid, breast cancer, CLA, VEGF-A, 4061
 Lipid peroxidation, apoptosis, lipoxygenase, carotenoid, phytochemical, 3871
 Lipiodol, hepatocellular carcinoma, transarterial chemo-embolization, acute liver damage, ICG-R15, 2551
 Lipophilicity, indolo[2, 3-b]quinoline, cell cycle, topoisomerase II, MDR, DNA-binding, cytotoxicity, antimicrobial, 2857
 Lipoplatin, cisplatin, tumor targeting, gastric cancer, colon cancer, hepatocellular cancer, 3031
 Liposomal doxorubicin, NSCLC, docetaxel, gemcitabine, 1427
 Liposome, camptothecin, CPT-11, SN-38, drug delivery, 331
 Liposomes, angiogenesis, imaging, matrix metalloproteinases, phage display, 33
 Liposomes, folate receptor, drug targeting, daunorubicin, leukemia, 343

- Lipoxygenase, apoptosis, carotenoid, lipid peroxidation, phytochemical, 3871
- Liquid-based cytology, screening, HPV, HPV testing, colposcopy, cervicography, 3469
- Liver metastases, tumor colony forming assay, regional chemotherapy, colorectal cancer, 795
- Liver metastasis, colorectal cancer, chemotherapy, gene, 1237
- Liver metastasis, colorectal cancer, leucovorin, 4747
- Liver metastasis, colorectal carcinoma (CRC), staging system, prognostic factors, 1251
- Liver metastasis, hepatic arterial infusion chemotherapy, reservoir port, biliary tract and pancreatic cancer, 5-fluorouracil, cisplatin, 477
- Liver metastasis, hepatoid adenocarcinoma, AFP-producing Barrett's esophageal cancer, paclitaxel, cisplatin, 2965
- Liver, focal hyperthermia, apoptosis, colorectal liver metastases, 1413
- Liver, sirolimus, rat, adenocarcinoma, sarcoma, hepatoma, 789
- LNCaP cells, bicalutamide, 4-OH tamoxifen, 4277
- LNCaP cells, prostate cancer, gene-based PSMA vaccination, anti-PSMA antibodies, carbohydrate cleaving enzyme, proteases, 4727
- LNCaP cells, prostate cancer, vitamin D, ibuprofen, NSAID, 3425
- Local proteolysis, metastatic cascade, cell adhesion, cell migration, angiogenesis, review, 3327
- LOH, urine, microsatellites, 4049
- Loss of heterozygosity (LOH), glomus tumours, *SDHD*-, *SDHB*-, *SDHC*-gene, succinate dehydrogenase (SDH) enzyme activity, 2809
- Low performance status, non-small cell lung cancer, paclitaxel, gemcitabine, 409
- Lower lobe, brain metastasis, small cell lung cancer, right lung, left lung, upper lobe, gender, smoking, epidemiology, 1101
- LPS, Coley's toxin, Toll-like receptor, innate immunity, immune therapy, lung carcinoma, alveolar macrophage, co-cultivation, 3747
- LPS, eugenol-related compounds, cytotoxicity, apoptosis, HL-60 cells, COX-2, RAW cells, 3263
- LPS, FAA, DMXAA, TNF- α , murine macrophages, 1179
- Lung adenocarcinoma, hypertrophic osteoarthropathy, epidermal growth factor receptor tyrosine kinase inhibitor, 2435
- Lung cancer cells, herpesvirus, angiostatic proteins, 2049
- Lung cancer, $^{111}\text{InHMF}G1\text{-F(ab')}_2$, radiotherapy, biodistribution, lysine, 4663
- Lung cancer, acute leukemia, gefitinib, cytarabine, aclarubicin, 2579
- Lung cancer, angiogenesis, VEGF, iNOS, oncoprotein, risk model, 497
- Lung cancer, bone metastasis, microvessel density, breast cancer, renal cell cancer, 3075
- Lung cancer, c-erbB-2, Her-2, preneoplastic lesions, bronchial pre-invasive lesions, early invasive lesions, carcinogenesis, 2005
- Lung cancer, DNA repair, single nucleotide polymorphism, APEX1, XRCC1, ADPRT, LIG3, 537
- Lung cancer, EGFR, estrogen receptor α , prognostic factor, 4693
- Lung cancer, lymph node, dendritic cell, immunotherapy, CTL, sentinel node, 85
- Lung cancer, NF κ B, apoptosis, VEGF, p53, 69
- Lung cancer, pN1, carcinoembryonic antigen, 3601
- Lung cancer, screening, helical computed tomography (CT) scan, computer-aided diagnosis (CAD) system, 483
- Lung cancer, small cell lung cancer, tumor marker, ProGRP, NSE, CEA, CA 125, CYFRA 21-1, SCC, 1773
- Lung cancer, survival, prognosis, 3517
- Lung cancer, tumor immunity, Th1, Tc1, Th2, Tc2, 2027
- Lung cancer, tumor-infiltrating B lymphocyte, monoclonal antibody, hybridoma, 3791
- Lung cancer, vaginal metastasis, 1645
- Lung cancer, von Willebrand antigen, carcinoembryonic antigen, 403
- Lung cancer, YB-1, PCNA, p53, 3437
- Lung carcinoma, LPS, Coley's toxin, Toll-like receptor, innate immunity, immune therapy, alveolar macrophage, co-cultivation, 3747
- Lung metastasis, adoptive immunotherapy (AIT), peptide-pulsed dendritic cell-activated killer (PDAK) cells, T-cell receptor (TCR), 2407
- Lung squamous carcinoma cell line CH27, baicalein, apoptosis, cell cycle regulatory molecules, Bcl-2, caspase-3, 959
- Lung, caveolin-1, pleomorphic carcinoma, prognosis, 4631
- Lung, invasion, metastasis, breast, 3905
- LY294002, cyclin cdk's, PKC, phosphoinositol 3-kinase, apoptosis, deoxyadenosine resistance, p53, flavopiridol, roscovitine, wortmannin, UCN-01, leukemia cells, 101
- Lymph node dissection, gastric cancer, metastatic lymph node ratio, prognostic factor, 1369
- Lymph node metastasis, myofibroblast, microvessel density, early-stage colorectal carcinoma, podoplanin, lymphangiogenesis, 2705
- Lymph node staging in head and neck cancers, MR lymphography, Sinerem MRI, 3665
- Lymph node, dendritic cell, immunotherapy, lung cancer, CTL, sentinel node, 85
- Lymph node, gastric cancer, metastasis, sentinel node concept, 1349
- Lymph node, poorly-differentiated carcinoma, metastasis, cell line, SKY, CGH, 683

- Lymphangiogenesis, metastasis, inflammation, TAMs, VEGF-C, invasion, review, 4503
- Lymphangiogenesis, myofibroblast, microvessel density, early-stage colorectal carcinoma, podoplanin, lymph node metastasis, 2705
- Lymphatic metastasis, head and neck cancer, SCC, CYFRA 21-1, CEA, 1539
- Lymphocyte subpopulations, cervical cancer, radiotherapy, radio-chemotherapy, 4673
- Lymphocyte, RNA helicase, DHX32, differentiation, 2645
- Lymphocytes, artemisinin, butyric acid, Molt-4 cells, 4325
- Lymphocytes, chemoprevention, anthocyanins, genotoxicity, apoptosis, 2837
- Lymphocytes, immunocell therapy, melanoma, dendritic cells, adoptive immunotherapy, mixed response, 3741
- Lymphoma, bax, Bcl-2, caspase, etoposide, hydroxyurea, interleukin, p53, 999
- Lymphoma, *Canis familiaris*, cytogenetics, 3995
- Lymphoma, Hodgkin's, syndecan-1, serum levels, 4743
- Lymphoma, retinoids, apoptosis, ATRA, 4HPR, 4179
- Lymphoma, transgenic mice, NPM-ALK, ALCL, 3191
- Lymphopenia, *pneumocystis carinii*, pneumonia, corticosteroids, radiation of thoracic duct, 651
- Lysine, lung cancer, ¹¹¹InHMFG1-F(ab')₂, radiotherapy, biodistribution, 4663
- Lysis, chitinase, MCF-7 cells, breast cancer xenograft, 3167
- M30 antibody, prostate cancer cells, black cohosh extract, apoptosis, annexin-V-FITC, 139
- Macrocytic anemia, arterial infusion, hepatobiliary malignancy, 5-FU, 1243
- Macrophage, IL-12, CD83, CD68, dendritic cell, antigen-presenting cell, colorectal cancer, 3541
- Macrophage, immunosuppression, VEGF, angiogenesis, AIN, 693
- Macrophages, apoptosis, γ -irradiation, reactive oxygen species, antioxidants, caspase inhibitors, 4091
- Magnetic resonance images, neurofibromatosis, neurofibromatosis type 1, malignant peripheral nerve sheath tumor, mpnst, mutation, 1699
- Magnetic resonance imaging, texture analysis, carcinoma, boot strap statistics, 3399
- Maintenance therapy, IL-2, 13-*cis* retinoic acid, solid tumors, 3149
- Malignant fibrous histiocytoma, breast sarcoma, 505
- Malignant fibrous histiocytoma, postradiation sarcoma, osteosarcoma, telomerase activity, telomere length, 2951
- Malignant fibrous histiocytoma, vascular invasion, distant metastasis, 1337
- Malignant glioma, nitrosourea, 3585
- Malignant melanoma, microenvironment, PDEGF, bFGF, 4299
- Malignant melanoma, S-100, MIA, tumor marker, prognostic factors, 1779
- Malignant peripheral nerve sheath tumor, neurofibromatosis, neurofibromatosis type 1, mpnst, mutation, magnetic resonance images, 1699
- Malignant solitary fibrous tumor, soft tissue tumor, hypoglycemia, insulin-like growth factor II, 2461
- Mammary carcinogenesis, hormone dependence, hormone independence, insulin growth factor receptor type-1, mammary tumors, *N*-nitroso-*N*-methylurea, protein tyrosine kinase activities, 4305
- Mammary neoplasms, hyperbaric oxygenation, breast, epithelial cells, 3833
- Mammary tumors, hormone dependence, hormone independence, insulin growth factor receptor type-1, mammary carcinogenesis, *N*-nitroso-*N*-methylurea, protein tyrosine kinase activities, 4305
- Mammary tumors, retinoids, retinoid glucuronides, breast cancer, cancer chemotherapy, retinol, triglycerides, bone mineral content, 2391
- Mammography, neoadjuvant chemotherapy, breast cancer, sonography, 2519
- Mammotome, breast cancer, diagnostic accuracy, vacuum biopsy, FNAC, ultrasound, 2465
- Margins, nephron sparing surgery, NSS, RCC, survival, 1629
- Masson's hemangioma, intravascular papillary endothelial hyperplasia, soft-tissue sarcoma, angiosarcoma, 1409
- Matairesinol, phytoestrogens, lignans, flaxseed, Biochanin A, trophoblast tumour cells, 1817
- Matrikines, elastin, melanoma, galectin-3, review, 2617
- Matrix metallo-proteinase, ovarian cancer, invasion markers, fibronectin, prognosis, 2885
- Matrix metallo-proteinases, angiogenesis, imaging, liposomes, phage display, 33
- Matrix metalloproteinases, endometrial cancer, MMP-2, prognostic factors, 4101
- Matrix metalloproteinases, squamous cell carcinoma, oropharynx, prognostic markers, 4129
- Matrix-metalloproteinase, proliferation, migration, osteosarcoma, extracellular matrix, doxorubicin, β 1 integrin, topoisomerase II, 805
- MCF-7 cells, chitinase, breast cancer xenograft, lysis, 3167
- MCF-7 cells, ether lipids, ET-18-OCH₃, p70 S6 kinase, 95
- MCF-7 human breast carcinoma cell line, wide-band low-power millimeter waves irradiation, cell ultrastructure, 1009
- MCF-7, antiproliferative effect, apoptosis, Bcl-2, *Eurycoma longifolia*, 2205
- MCF7 cell line, BRCA1, progesterone, apoptosis, cell cycle, 243
- MCF7 cells, galectin-1, apoptosis, BeWo cells, mycoplasma, 1575
- MCI-186, epidermal growth factor, cell cycle, EGFR phosphorylation, 1131

- Mcl-1, antisense oligonucleotides, Bcl-2, ionizing radiation, apoptosis, melanoma, 2697
- MDA-MB-231 breast cell, cell adhesion inhibition, fibronectin, fucoidan, integrins, 2129
- MDA-MB-231, fibroblast growth factor receptor, Grb14, breast cancer, *Xenopus* oocyte, 3877
- MDR modifiers, multidrug resistance, P-glycoprotein, bisbenzylisoquinoline alkaloids, xenograft, 1953
- MDR modulators, multidrug resistance (MDR), P-glycoprotein, sarcoma, flow cytometry, confocal microscopy, 383
- MDR reversal, *Capsicum annuum* L. var. *angulosum* Mill. extracts, cytotoxicity, anti-HIV activity, anti-*Helicobacter pylori* activity, urease inhibition, 1991
- MDR, indolo[2, 3-b]quinoline, cell cycle, topoisomerase II, DNA-binding, cytotoxicity, lipophilicity, antimicrobial, 2857
- Mdr1, tumor specificity, apoptosis, doxorubicin, DNA fragmentation, 877
- Mediastinal embryonal carcinoma, Des- γ -carboxy prothrombin (PIVKA-II), hepatoid differentiation, 4569
- Medium-chain triglyceride, vitamin D, calcitriol, vitamin D analog, seocalcitol, canine transitional cell carcinoma, growth inhibition, cell cycle, VDR, 2689
- Medullary thyroid carcinoma, drug resistance, immunotherapy, autologous tumor cell cultures, dendritic cells, 4225
- Medullary thyroid carcinoma, p8, apoptosis, 3419
- Medulloblastoma, brain tumour, paediatric, NG2, 3855
- Melanocytic nevi, computer-aided diagnosis, automatic diagnosis, melanoma, digital epiluminescence microscopy, dermoscopy, 4577
- Melanoma metastases, cytokeratins, CAS200, image cytophotometry, 2789
- Melanoma of the vagina, vulvar melanoma, uterine cervix melanoma, ovarian melanoma, 1567
- Melanoma, antisense oligonucleotides, Mcl-1, Bcl-2, ionizing radiation, apoptosis, 2697
- Melanoma, apoptosis, MHC class II, CIITA, 3889
- Melanoma, computer-aided diagnosis, automatic diagnosis, melanocytic nevi, digital epiluminescence microscopy, dermoscopy, 4577
- Melanoma, elastin, matrikines, galectin-3, review, 2617
- Melanoma, fibrothecoma, ovarian tumor, 1603
- Melanoma, immunocell therapy, dendritic cells, lymphocytes, adoptive immunotherapy, mixed response, 3741
- Melanoma, temozolomide, cisplatin, interferon-alpha, 1441
- Melatonin, hematopoietic stem cell, doxorubicin, hematopoiesis, cytoprotection, 4245
- Memory CTL, HER-2, influenza virus, tumor antigen, IL-15, 715
- MEN 2, RET, DHPLC, sequencing, 2091
- (-)-Menthol, DNA topoisomerase I, topoisomerase II α , topoisomerase II β , gastric cancer, 2069
- Merkel cell carcinoma, primary neuroendocrine carcinoma, neuroendocrine differentiation, prognosis, chromogranin-A, 853
- Mesothelioma, $^{86}\text{Rb}^+$, potassium ion flux, ionophores, small cell lung cancer, amphotericin B, 2609
- Mesothelioma, chemotherapy, survival, 3671
- Mesothelioma-malignant, prolymphocytic leukemia, SV40, asbestos, 429
- Metabolism, irinotecan, pharmacokinetics, capecitabine, 2985
- Metaiodobenzylguanidine (MIBG), chromaffin cell, catecholamines, chromogranin A, pheochromocytoma, iodine-123 (123I), 1547
- Metastases model, VX2, squamous cell carcinoma, tumor resection, 4209
- Metastases, chemotherapy, colorectal cancer, review, 563
- Metastases, *Helix pomatia* agglutinin, 1829
- Metastases, microarray expression profiling, cancer, prostate, 1477
- Metastasis, epithelial ovarian cancer, spleen, recurrence, 1471
- Metastasis, gastric cancer, lymph node, sentinel node concept, 1349
- Metastasis, glycodefin, breast cancer, 1761
- Metastasis, heparin, Fraxiparine, mouse, tumors, 2869
- Metastasis, invasion, breast, lung, 3905
- Metastasis, lymphangiogenesis, inflammation, TAMs, VEGF-C, invasion, review, 4503
- Metastasis, poorly-differentiated carcinoma, lymph node, cell line, SKY, CGH, 683
- Metastasis, selectins, SCCHN, adhesion molecules, 4141
- Metastasis-associated genes, prostate cancer cell lines, microarray, genetic profiling, 183
- Metastasizing thyroid cancer, sternal metastasis, resection, 4389
- Metastatic breast cancer, 2C4, adjuvant therapy, HER2/neu, HerceptinTM, pertuzumab, trastuzumab, review, 1483
- Metastatic breast cancer, high-dose chemotherapy, stem-cell transplantation, trifunctional antibody, T-cell reinfusion, 3047
- Metastatic breast cancer, immunotherapy, trastuzumab, Herceptin, circulating HER-2/neu, review, 4599
- Metastatic breast cancer, mitomycin, capecitabine, 4513
- Metastatic cascade, cell adhesion, local proteolysis, cell migration, angiogenesis, review, 3327
- Metastatic lymph node ratio, gastric cancer, lymph node dissection, prognostic factor, 1369
- Metastatic potential, COX-2, endometrial cancer, angiogenesis, apoptosis, cell growth, immunomodulation, review, 3679

- Metastatic potential, non-small cell lung cancers, cell adhesion, focal adhesion, 4135
- Metastatic tumor, chemotherapy, caffeine, musculoskeletal sarcoma, 2399
- Metastatic, EGFR, HER-2, squamous cell carcinoma, skin, immunohistochemistry, 1205
- Metastatic, rhabdomyosarcoma, breast, 527
- Methionine-dependent cancer, methionine-depletion therapy, HPLC, high resolution, sensitivity, 59
- Methionine-depletion therapy, methionine-dependent cancer, HPLC, high resolution, sensitivity, 59
- Methotrexate, fibrinogen, conjugates, glycation, antitumor activity, 2229
- Methotrexate, hepatoma, cisplatin, telomeres, telomerase, drug resistance, dynamics, gene amplification, 3279
- Methotrexate, high-grade gliomas, children, preradiation chemotherapy, 2583
- N-Methyl-nitrosourea, enkephalin, breast cancer, enkephalinase, 193
- Methylation-specific PCR, RUNX3, colorectal cancer, 2627
- Mevalonate pathway, colorectal cancer, 3393
- MFH, grading, prognosis, 4293
- MG-132, nocodazole, etoposide, clasto- β -lactone, HSP70, 3321
- MGMT, hMLH1, alkylating agents, gallbladder carcinoma, ACNU, 4021
- MGN-3, monolayer MCF-7 cells, apoptosis, phagocytosis, *S. cerevisiae*, 4187
- MHC class II, melanoma, apoptosis, CIITA, 3889
- MHC-restricted immune response, SCCHN tumor cell culture, CTL-adoptive immunotherapy, 4075
- MIA, S-100, tumor marker, malignant melanoma, prognostic factors, 1779
- MIB-1, AgNORs, breast cancer, 3957
- MIBI scan, FDG-PET, multiple myeloma, bone marrow involvement, soft tissue lesions, skeletal lesions, 4737
- Mice, angiogenesis, digoxin, neuroblastoma, 207
- Microarray expression profiling, cancer, metastases, prostate, 1477
- Microarray, cisplatin resistance, K⁺ channels, ion homeostasis, confocal microscopy, 4113
- Microarray, prostate cancer cell lines, metastasis-associated genes, genetic profiling, 183
- Microcirculation, oncology, immune modulation, standardized mistletoe extract, 601
- Microembolization, pancreatic cancer, celiac axis infusion, isolated abdominal perfusion, 4407
- Microenvironment, malignant melanoma, PDEGF, bFGF, 4299
- Micrometastases, breast cancer, disseminated tumor cells, cytokeratin, bone marrow, her2, 2171
- Micrometastasis, Ep-CAM, circulating tumor cells, colorectal cancer, 319
- Microsatellite analyses, recurrence, second primary tumours, head and neck cancer, 2771
- Microsatellite instability, HNPCC, multiplex PCR, DNA analysis, 3251
- Microsatellite instability, ovarian clear-cell carcinoma, DNA mismatch repair, p53, 2785
- Microsatellites, LOH, urine, 4049
- Microtubular, serrated, adenomas, colon, rectum, 1353
- Microtubules, β -tubulin isotypes, resistance, combretastatin A-4, 3865
- Microvessel density (MVD), tenascin (Tn-C)-C, vascular endothelial growth factor (VEGF), angiogenesis, non-small cell lung cancer (NSCLC), 489
- Microvessel density, bone metastasis, breast cancer, lung cancer, renal cell cancer, 3075
- Microvessel density, myofibroblast, early-stage colorectal carcinoma, podoplanin, lymphangiogenesis, lymph node metastasis, 2705
- Midbody, taxol, taxotere, mitotic spindle, mitotic catastrophe, multinucleation, 1919
- Migration, epidermal growth factor receptor, focal adhesion kinase, invasion, flavonoids, siRNA, 2017
- Migration, proliferation, osteosarcoma, extracellular matrix, doxorubicin, matrix-metalloproteinase, β 1 integrin, topoisomerase II, 805
- Milky spots, NK4, HGF, peritoneal implantation, 3847
- Millimeter waves, wide-band irradiation mode, monochromatic irradiation mode, RPMI 7932, cell morphology, 1023
- Mistletoe extract, pancreatic cancer, mistletoe lectin, *Viscum album*, Gemcitabine, intratumoral injection, antitumour activity, human cancer xenograft, 1969
- Mistletoe extract, superficial bladder cancer, adjuvant intravesical treatment, mistletoe lectin, 4733
- Mistletoe lectin, pancreatic cancer, mistletoe extract, *Viscum album*, Gemcitabine, intratumoral injection, antitumour activity, human cancer xenograft, 1969
- Mistletoe lectin, superficial bladder cancer, adjuvant intravesical treatment, mistletoe extract, 4733
- Mistletoe therapy, immunomodulation, surgical stress, *Viscum album*, granulocyte function, oxidative burst, 4753
- Mistletoe, *Viscum album*, immune-suppression, biotherapy, Isorel, immunomodulation, NK cells, T-helper cells, 4583
- Mitochondrial function, sodium fluoride, human oral cells, ageing, cytotoxicity, apoptosis, 2085
- Mitochondrial membrane potential analysis, alvaradoin E, alvaradoin F, annexin V-FITC, anthracenone C-glycosides, apoptosis, DAPI, DiOC₆, hollow fiber test, propidium iodide, TUNEL assay, 779
- Mitochondrial transmembrane potential, isothiocyanates, multidrug resistance, cell cycle, apoptosis, HL60 cell line, 3375

- Mitogenic signaling, inositol hexaphosphate, prostate cancer, cell survival signaling, cell cycle progression, apoptosis, angiogenesis, review, 2891
- Mitomycin, capecitabine, metastatic breast cancer, 4513
- Mitotic catastrophe, taxol, taxotere, mitotic spindle, midbody, multinucleation, 1919
- Mitotic delay, DSB, signaling proteins, cell cycle analysis, 1123
- Mitotic spindle, taxol, taxotere, mitotic catastrophe, midbody, multinucleation, 1919
- Mixed response, immunocell therapy, melanoma, dendritic cells, lymphocytes, adoptive immunotherapy, 3741
- MK-1, human monoclonal antibody, Ep-CAM, tumor targeting, 3733
- MLL* gene, chromosomal band 11q23, acute leukemia, 1931
- MMP, TCC, paclitaxel, invasion, *in vitro*, 2097
- MMP-2, endometrial cancer, matrix metalloproteinases, prognostic factors, 4101
- MMP-2, mRNA, MMP-7, TIMP-1, TIMP-2, colorectal cancer, 3387
- MMP-7, mRNA, MMP-2, TIMP-1, TIMP-2, colorectal cancer, 3387
- MMR, testicular germ-cell tumor, hMLH1 methylation, MSI, chemoresistance, 4319
- MN protein, carbonic anhydrase IX (CA IX), gene therapy, renal cell carcinoma, 881
- MN-029, vascular disrupting agent, radiation, cisplatin, 3899
- Molecular cytogenetics, chromosome abnormalities, karyotype, hematologic malignancies, review, 2979
- Molecular genetic tumor marker, non-small cell lung cancer, review, 1193
- Molecular imaging, radiotracer development, 1827
- Molt-4 cells, artemisinin, butyric acid, lymphocytes, 4325
- Monitoring, colorectal cancer, chemotherapy, prediction, DNA, nucleosomes, cytokeratin 19-fragments, CYFRA 21-1, serum, 1795
- Monochromatic irradiation mode, millimeter waves, wide-band irradiation mode, RPMI 7932, cell morphology, 1023
- Monoclonal antibodies, glycodelin, ELISA, ovarian cancer, 1581
- Monoclonal antibodies, pharmacokinetics, oncology, review, 2327
- Monoclonal antibody, bispecific antibody, anti-Her2/neu, extracellular glycoproteins, prostate cancer, immunotherapy, 43
- Monoclonal antibody, tumor-infiltrating B lymphocyte, lung cancer, hybridoma, 3791
- Monolayer MCF-7 cells, apoptosis, phagocytosis, *S. cerevisiae*, MGN-3, 4187
- Mouse models of breast cancer, DNA immunization, cellular response, MUC1, spontaneous tumors, 3893
- Mouse, heparin, Fraxiparine, metastasis, tumors, 2869
- Mpnst, neurofibromatosis, neurofibromatosis type 1, malignant peripheral nerve sheath tumor, mutation, magnetic resonance images, 1699
- MR lymphography, Sinerem MRI, lymph node staging in head and neck cancers, 3665
- MR, fertility, ovarian position, craniospinal irradiation, 3481
- MRI, adrenal incidentalomas, adrenal tumours, adrenal scintigraphy, adrenal FNA cytology, 4559
- MRNA expression, breast cancer, elongation factor-1, RT-PCR, 2573
- MRNA, MMP-2, MMP-7, TIMP-1, TIMP-2, colorectal cancer, 3387
- MRP2, ABC transporter, chemosensitivity, conjugated bilirubin, renal cell carcinoma, 2729
- MSI, testicular germ-cell tumor, hMLH1 methylation, MMR, chemoresistance, 4319
- MTHFR polymorphism, TS polymorphism, prognosis, non-small cell lung cancer, 4455
- MTHFR, stomach cancer, polymorphism, 2249
- MTT assay, gastric cancer, advanced, chemosensitivity, adjuvant chemotherapy, extended surgery, superextended lymphadenectomy, 3453
- MTT assay, nedaplatin, ovarian carcinoma, cervical carcinoma, endometrial carcinoma, 4499
- MUC1, DNA immunization, cellular response, mouse models of breast cancer, spontaneous tumors, 3893
- MUC1, mucinous carcinoma, breast cancer, MUC1-core, Thomsen-Friedenreich, CA19-9, CA50, CA242, immunohistochemistry, 1755
- MUC1, peptide, vaccine, pancreas cancer, 3575
- MUC1-core, mucinous carcinoma, breast cancer, MUC1, Thomsen-Friedenreich, CA19-9, CA50, CA242, immunohistochemistry, 1755
- Mucinous carcinoma, breast cancer, MUC1, MUC1-core, Thomsen-Friedenreich, CA19-9, CA50, CA242, immunohistochemistry, 1755
- Mucinous, ovarian cancer, chemotherapy, 3501
- Mucoepidermoid carcinoma, salivary gland neoplasms, flow cytometry, ploidy, Ki-67, grading, 2589
- Multicellular tumor spheroids, trifunctional bispecific antibody, immune therapy, 4239
- Multicentric trial, phase II, S-1, cisplatin, gastric cancer, 1297
- Multidrug resistance (MDR), MDR modulators, P-glycoprotein, sarcoma, flow cytometry, confocal microscopy, 383
- Multidrug resistance protein (MRP), erythrocyte membrane, detergent, cell shape, phospholipid translocation, haemolysis, 3173
- Multidrug resistance, diterpenes, helioscopinolides, *Euphorbia*, 3259

- Multidrug resistance, herpes simplex virus thymidine kinase, ganciclovir, bystander effect, gap junctional intercellular communication, 255
- Multidrug resistance, isothiocyanates, cell cycle, apoptosis, mitochondrial transmembrane potential, HL60 cell line, 3375
- Multidrug resistance, jatrophone diterpenes, *Euphorbia*, HTB-26 cell line, 4173
- Multidrug resistance, MDR modifiers, P-glycoprotein, bisbenzylisoquinoline alkaloids, xenograft, 1953
- Multidrug resistance, P-glycoprotein, ascites, ovarian cancer, functional assay, 1187
- Multidrug resistance, P-glycoprotein, KB-V1, plasma membrane vesicles, phosphorylation, reconstitution, proteo-liposomes, octyl-glucoside, 3925
- Multidrug-resistance, arsenic trioxide, glutathione, buthionine-sulfoximine, reactive oxygen species, 991
- Multinucleation, taxol, taxotere, mitotic spindle, mitotic catastrophe, midbody, 1919
- Multiple intestinal neoplasia, PPAR β/δ , cyclin D1, aberrant crypt foci, azoxymethane, ApcMin/+ mice, β -catenin, Wnt signalling pathway, 3781
- Multiple myeloma, FDG-PET, MIBI scan, bone marrow involvement, soft tissue lesions, skeletal lesions, 4737
- Multiplex PCR, HNPCC, microsatellite instability, DNA analysis, 3251
- Multiplex RT-PCR, disseminated tumor cells, immunomagnetic selection, 1803
- Multistep approach, giant intramuscular hemangioma, timing, 2417
- Multitissue array, topoisomerase 2 α , HER2, p53, bladder carcinoma, FISH, prognosis, 263
- Murine colon carcinoma cell, surgical stress, cancer metastasis, urinary trypsin inhibitor (UTI), 815
- Murine macrophages, FAA, DMXAA, TNF- α , LPS, 1179
- Murine polyomavirus, VLPs, gene therapy, immune therapy, vaccines, review, 2601
- Murine tumor cells, SNC 80, non-peptide opioids, δ -opioid agonist, L5178Y-R lymphoma, tumor mouse model, 4563
- Musculoskeletal sarcoma, chemotherapy, caffeine, metastatic tumor, 2399
- Musculoskeletal sarcoma, photodynamic therapy, acridine orange, limb salvage surgery, radiation, 1225
- Mutagenesis, capsaicin, phytochemicals, chemoprevention, 117
- Mutants, cisplatin, radiation, DNA repair, recombination repair, 53
- Mutation screening, prostate cancer, androgen receptor, PC-EW, PC-OR, 1611
- Mutation, neurofibromatosis, neurofibromatosis type 1, malignant peripheral nerve sheath tumor, mpnst, magnetic resonance images, 1699
- MVD, ovarian endometriosis, angiogenesis, VEGF, survivin, 4313
- MVD, soft tissue sarcoma, VEGF, Flk-1, angiogenesis, 3591
- Myalgias, gemcitabine, docetaxel, proximal muscle weakness, edema, 523
- Mycoplasma, galectin-1, apoptosis, MCF7 cells, BeWo cells, 1575
- Myeloid leukemia, TSP-1, peptides, differentiation, apoptosis, 757
- Myo-inositol hexakisphosphate, 2593
- Myofibroblast, microvessel density, early-stage colorectal carcinoma, podoplanin, lymphangiogenesis, lymph node metastasis, 2705
- NAD(P)H oxidase p22phox, genetic polymorphisms, paraoxonase, colorectal cancer, 1465
- Nail disorders, ixabepilone, breast cancer, 3531
- Natriuretic peptides, cardiotoxicity, anthracyclines, chest wall irradiation, breast cancer, 3651
- Natural killer cells, immunotherapy, cytotoxic T lymphocytes, antibody-based therapy, tumor antigen, carcinoembryonic antigen, review, 3725
- Necrosis, COX-2, brain metastasis, radiation, 2969
- Nedaplatin, MTT assay, ovarian carcinoma, cervical carcinoma, endometrial carcinoma, 4499
- Nedaplatin, pharmacokinetics, pharmacodynamics, AUC, optimal sampling, limited sampling, platelet, 1283
- Nedaplatin, pharmacokinetics, pharmacodynamics, toxicodynamics, area under the plasma concentration-time curve (AUC), thrombocytopenia, 1273
- Neoadjuvant chemotherapy, breast cancer, mammography, sonography, 2519
- Neoadjuvant chemotherapy, breast carcinoma, Doppler ultrasound, ultrasound contrast media, 595
- Neoadjuvant chemotherapy, collagen gel droplet-embedded culture drug sensitivity test (CD-DST), ovarian cancer, ascitic fluid, pleural fluid, 3547
- Neoangiogenesis, vulvar carcinoma, TGF- α , c-erbB-2, immunohistology, prognosis, 1731
- Neoplasm, soluble CD44, CD44v6, squamous cell carcinoma of the head and neck, SCCHN, serum tumor marker, clinical prognostic factor, 2821
- Nephron sparing surgery, margins, NSS, RCC, survival, 1629
- Neuroblastoma, angiogenesis, digoxin, mice, tumor, 207
- Neuroendocrine carcinomas, biotherapy, 4463
- Neuroendocrine differentiation, primary neuroendocrine carcinoma, Merkel cell carcinoma, prognosis, chromogranin-A, 853
- Neuroendocrine tumours, endometrium, small cell carcinoma, 1823
- Neurofibromatosis type 1, neurofibromatosis, malignant peripheral nerve sheath tumor, mpnst, mutation, magnetic resonance images, 1699

- Neurofibromatosis, neurofibromatosis type 1, malignant peripheral nerve sheath tumor, mpnst, mutation, magnetic resonance images, 1699
- Neurotoxicity, acetyl-L-carnitine, oxaliplatin, 2681
- Neutron therapy, adenoid cystic carcinoma, dedifferentiation, histological subtype, salivary glands, head and neck, 1321
- Neutropenia – leukopenia, pegfilgrastim, 2445
- Neutropenic enterocolitis, ovarian cancer, chemotherapy, paclitaxel, 2509
- NF- κ B, breast cancer, Bcl-xL, c-FLIP, paclitaxel, docetaxel, 2367
- NF-kappaB activation, Sabarubicin, paclitaxel, apoptotic DNA fragmentation, parthenolide, colon cancer cells, 2119
- NF κ B, lung cancer, apoptosis, VEGF, p53, 69
- NG2, brain tumour, paediatric, medulloblastoma, 3855
- Nigella sativa*, alpha-hederin, thymoquinone, 2199
- Nigella sativa*, alpha-hederin, thymoquinone, apoptosis, glutathione, 4255
- Nipple resection, breast-conserving surgery, surgical margin and breast cancer, 2957
- Nitric oxide, angiogenesis, chorioallantoic membrane, irradiation, 1059
- Nitric oxide, aspirin, colorectal cancer, 4471
- Nitroimidazole, radiosensitizer, 2145
- N*-Nitroso-*N*-methyleurea, hormone dependence, hormone independence, insulin growth factor receptor type-1, mammary carcinogenesis, mammary tumors, protein tyrosine kinase activities, 4305
- Nitrosourea, malignant glioma, 3585
- NK cell, adhesion molecule, paclitaxel, 735
- NK cells, *Viscum album*, mistletoe, immune-suppression, biotherapy, Isorel, immunomodulation, T-helper cells, 4583
- NK/ T cell lymphoma, concurrent chemoradiotherapy, 4403
- NK4, HGF, peritoneal implantation, milky spots, 3847
- NLCQ-1, 5-fluorouracil, paclitaxel, 2161
- NLCQ-1, radiation, human gliomas, hypoxia, 1865
- NO, azulenequinones, Raw 264.7 cells, iNOS, ESR, radicals, 4157
- Nocodazole, etoposide, MG-132, clasto- β -lactone, HSP70, 3321
- Nomegestrol acetate, breast cancer, sulfatase, progestins, 2827
- Non-Hodgkin's lymphoma, FISH, IGH rearrangement, recurrent translocation, 3179
- Non-peptide opioids, SNC 80, δ -opioid agonist, murine tumor cells, L5178Y-R lymphoma, tumor mouse model, 4563
- Non-platinum regimen, irinotecan, amrubicin, non-small cell lung cancer, phase I study, topoisomerase inhibitor, 2429
- Non-platinum regimen, NSCLC, first-line chemotherapy, 3489
- Non-small cell lung cancer (NSCLC), chemotherapy, targeted therapy, 1501
- Non-small cell lung cancer (NSCLC), gefitinib ('Iressa', ZD1839), vinorelbine, 547
- Non-small cell lung cancer (NSCLC), tenascin (Tn-C)-C, vascular endothelial growth factor (VEGF), microvessel density (MVD), angiogenesis, 489
- Non-small cell lung cancer, adenocarcinoma of the lung, aviscumine, recombinant mistletoe lectin, prognostic factors, 3303
- Non-small cell lung cancer, chemotherapy, Paclitaxel, 2555
- Non-small cell lung cancer, cisplatin, paclitaxel, 4685
- Non-small cell lung cancer, docetaxel, 4713
- Non-small cell lung cancer, expanded Access Programme, gefitinib, 4759
- Non-small cell lung cancer, gefitinib, 435
- Non-small cell lung cancer, gemcitabine, cisplatin, 471
- Non-small cell lung cancer, HER2, immuno-histochemistry, FISH, 3061
- Non-small cell lung cancer, irinotecan, amrubicin, phase I study, non-platinum regimen, topoisomerase inhibitor, 2429
- Non-small cell lung cancer, low performance status, paclitaxel, gemcitabine, 409
- Non-small cell lung cancer, molecular genetic tumor marker, review, 1193
- Non-small cell lung cancer, p53, staging, prognostic factors, 2385
- Non-small cell lung cancer, thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), RT-PCR, 923
- Non-small cell lung cancer, TS polymorphism, MTHFR polymorphism, prognosis, 4455
- Non-small cell lung cancer, weekly paclitaxel, efficacy, toxicity, NSCLC, 4611
- Non-small cell lung cancers, cell adhesion, focal adhesion, metastatic potential, 4135
- Norbormide, peritoneal metastases, radioimmunotherapy, 5-fluorouracil, autoradiography, 917
- NPM-ALK, transgenic mice, lymphoma, ALCL, 3191
- NSAID, prostate cancer, LNCaP cells, vitamin D, ibuprofen, 3425
- NSAIDs, COX-2, COX-1, colorectal cancer, proliferation, 225
- NSCLC inoperable stage III, chemo-radiotherapy, TCP, 4655
- NSCLC, cisplatin combination, 2991
- NSCLC, docetaxel, gemcitabine, liposomal doxorubicin, 1427
- NSCLC, first-line chemotherapy, non-platinum regimen, 3489
- NSCLC, triple chemotherapy, carboplatin, paclitaxel, vinorelbine, 1333

- NSCLC, weekly paclitaxel, efficacy, toxicity, non-small cell lung cancer, 4611
- NSE, small cell lung cancer, tumor marker, ProGRP, lung cancer, CEA, CA 125, CYFRA 21-1, SCC, 1773
- NSS, margins, nephron sparing surgery, RCC, survival, 1629
- Nuclear area, nuclear morphometry, colorectal cancer, prognosis, adjuvant therapy, 3083
- Nuclear matrix, prostate cancer, diagnostic and prognostic markers, review, 3999
- Nuclear morphometry, nuclear area, colorectal cancer, prognosis, adjuvant therapy, 3083
- Nucleosomes, colorectal cancer, chemotherapy, monitoring, prediction, DNA, cytokeratin 19-fragments, CYFRA 21-1, serum, 1795
- Nucleus, phospholipase C, signaling, 2039
- Occult, tracheal carcinoma, positron emission tomography, computed tomography, image fusion, 459
- Octyl-glucoside, P-glycoprotein, multidrug resistance, KB-V1, plasma membrane vesicles, phosphorylation, reconstitution, proteo-liposomes, 3925
- Oesophageal squamous cell carcinoma, EphA2, EphrinA-1, tissue array, immunohistochemistry, RT-PCR, laser capture microdissection, 2943
- Oesophageal surgery, surgical volume, hospital mortality, 419
- OK-432, dendritic cells, tumor immunity, Toll-like receptor, TLR-4, 4231
- Oncogenes, human papillomavirus, antisense, raft cultures, replication, 765
- Oncogenesis, factor V, prothrombin, oral cancer, thrombophilia, 2561
- Oncology, immune modulation, microcirculation, standardized mistletoe extract, 601
- Oncology, monoclonal antibodies, pharmacokinetics, review, 2327
- Oncoprotein, lung cancer, angiogenesis, VEGF, iNOS, risk model, 497
- δ -Opioid agonist, SNC 80, non-peptide opioids, murine tumor cells, L5178Y-R lymphoma, tumor mouse model, 4563
- Optimal sampling, pharmacokinetics, pharmacodynamics, nedaplatin, AUC, limited sampling, platelet, 1283
- Oral cancer, cyclin D1, p53, qat, Yemen, India, 4699
- Oral cancer, factor V, prothrombin, oncogenesis, thrombophilia, 2561
- Oral cancer, green tea, polyphenol, EGCG, p21^{WAF1}, apoptosis, 63
- Oral carcinoma, hypoxia, cathepsin, cystatin, 2841
- Oral contraceptives, cervical cancer, smoking, steroid hormones, review, 3041
- Oral health, esophageal cancer, Iran, 543
- Oral keratinocyte, $\alpha\beta$ 6, squamous cell carcinoma, epithelial-mesenchymal transition (EMT), 751
- Oral squamous cell carcinoma, radiotherapy, hyperfractionated irradiation, vital tumor cells, 1707
- Oral tumor cells, stilbenes, flavonoids, DNA fragmentation, caspase, Bcl-2, Bax, Bad, 2055
- Orbit metastasis, retroperitoneal liposarcoma, 4769
- Organotypic raft culture, cervical cancer, HPV, interferon, 1091
- Oropharynx, matrix metalloproteinases, squamous cell carcinoma, prognostic markers, 4129
- Orthopedic surgery, high hydrostatic pressure, tumor cells, apoptosis, chondrosarcoma, chondrocytes, 1977
- Osteoblast, osteosarcoma, chemotherapy, stem cell, 947
- Osteoblastic bone metastases, intra-osseous application, rat, 1067
- Osteoblastic, prostate cancer, COX-2, osteolytic lesions, bone metastases, 107
- Osteocalcin, PINP, crosslaps, breast cancer, bone metastases, 1491
- Osteoclast activation, bone metastasis, breast cancer, integrins, osteoclasts, 79
- Osteoclasts, bone metastasis, breast cancer, integrins, osteoclast activation, 79
- Osteolytic lesions, prostate cancer, COX-2, osteoblastic, bone metastases, 107
- Osteoprotegerin, colon cancer, RANKL, TNF, IL-1 β , immunohistochemistry, 3809
- Osteoprotegerin, hypercalcemia, RANKL, bisphosphonates, 3607
- Osteosarcoma (HOS) cells, sodium fluorosilicate, cytotoxicity, apoptosis, 391
- Osteosarcoma, chemotherapy, stem cell, osteoblast, 947
- Osteosarcoma, glycosaminoglycans, cell proliferation, 2851
- Osteosarcoma, photodynamic therapy, acridine orange, xenon, excitation, illuminance, 3979
- Osteosarcoma, postradiation sarcoma, malignant fibrous histiocytoma, telomerase activity, telomere length, 2951
- Osteosarcoma, proliferation, migration, extracellular matrix, doxorubicin, matrix-metalloproteinase, β 1 integrin, topoisomerase II, 805
- Ovarian cancer, brain metastases, central nervous system, 3553
- Ovarian cancer, CA125, vaginal ultrasound, CT scan, 1551
- Ovarian cancer, chemotherapy control, biological markers, colorectal cancer, breast cancer, 1655
- Ovarian cancer, chemotherapy, cisplatin, taxol, topotecan, 2113
- Ovarian cancer, collagen gel droplet-embedded culture drug sensitivity test (CD-DST), ascitic fluid, pleural fluid, neoadjuvant chemotherapy, 3547
- Ovarian cancer, docetaxel, irinotecan, cisplatin resistance, 3559

- Ovarian cancer, fenretinide, 4-HPR, OVCAR-5, angiogenesis, endothelial cells, HUVEC, actin cytoskeleton, FAK, 249
- Ovarian cancer, glycodelin A, ovarian cysts, 1639
- Ovarian cancer, glycodelin, monoclonal antibodies, ELISA, 1581
- Ovarian cancer, invasion markers, matrix metalloproteinase, fibronectin, prognosis, 2885
- Ovarian cancer, mucinous, chemotherapy, 3501
- Ovarian cancer, neutropenic enterocolitis, chemotherapy, paclitaxel, 2509
- Ovarian cancer, P-glycoprotein, multidrug resistance, ascites, functional assay, 1187
- Ovarian cancer, pegylated liposomal doxorubicin, Gemcitabine, 3103
- Ovarian carcinoma, D-allose, cell proliferation, 2639
- Ovarian carcinoma, nedaplatin, MTT assay, cervical carcinoma, endometrial carcinoma, 4499
- Ovarian clear-cell carcinoma, microsatellite instability, DNA mismatch repair, p53, 2785
- Ovarian cysts, glycodelin A, ovarian cancer, 1639
- Ovarian endometriosis, angiogenesis, MVD, VEGF, survivin, 4313
- Ovarian melanoma, vulvar melanoma, melanoma of the vagina, uterine cervix melanoma, 1567
- Ovarian position, fertility, craniospinal irradiation, MR, 3481
- Ovarian tumor, melanoma, fibrothecoma, 1603
- Ovary, transplantation, sex cord stromal tumors, cryopreserved ovarian tissue, 4107
- OVCAR-5, fenretinide, 4-HPR, ovarian cancer, angiogenesis, endothelial cells, HUVEC, actin cytoskeleton, FAK, 249
- Overall survival, CEA, CA 19-9, rectal carcinoma, tumor marker, prognostic factor, 1787
- Oxaliplatin, acetyl-L-carnitine, neurotoxicity, 2681
- Oxaliplatin, capecitabine, rectal cancer, phase I study, 629
- Oxaliplatin, cisplatin, teratocarcinoma cell line 2102EP, drug resistance, 1147
- Oxaliplatin, VEGF, IP-10, pancreatic carcinoma, irinotecan, 5-fluorouracil, leucovorin, gemcitabine, 3287
- Oxidative burst, immunomodulation, surgical stress, mistletoe therapy, *Viscum album*, granulocyte function, 4753
- Oxidative burst, phagocytosis, *S. cerevisiae*, SCC-4, Caco-2, apoptosis, 981
- Oxygen-dependent checkpoint, p27, pRb, hypoxia, 2259
- P-glycoprotein, multidrug resistance (MDR), MDR modulators, sarcoma, flow cytometry, confocal microscopy, 383
- P-glycoprotein, multidrug resistance, ascites, ovarian cancer, functional assay, 1187
- P-glycoprotein, multidrug resistance, KB-V1, plasma membrane vesicles, phosphorylation, reconstitution, proteo-liposomes, octyl-glucoside, 3925
- P-glycoprotein, multidrug resistance, MDR modifiers, bisbenzylisoquinoline alkaloids, xenograft, 1953
- P107, pRb2/p130, p53, HPV, cervical cancer, immunohistochemistry, 2187
- P14^{ARF}, Burkitt lymphoma, LCL, p16^{INK4A}, promoter methylation, genetic change, 2153
- P16, HPV, tonsillar carcinoma, radiotherapy, L1 capsid, HPV ISH, prognosis, 4375
- P16^{INK4A}, Burkitt lymphoma, LCL, p14^{ARF}, promoter methylation, genetic change, 2153
- P21, ellagic acid, cell cycle arrest, apoptosis, p53, caspase-3, 971
- P21, esophageal squamous cell carcinoma, chemoradiotherapy, Hsp27, Hsp70, p53, bax, bcl2, 2749
- P21^{Cip1/WAF1}, radiosensitization, interferon- α , reactive oxygen species, DNA double-strand break, 2631
- P21^{WAF1}, green tea, polyphenol, EGCG, oral cancer, apoptosis, 63
- P21^{WAF1/Cip1}, endothelial-breast cancer interaction, 2743
- P21^{WAF1/CIP1}, pancreatic cancer, retinoblastoma, p53, Bax, 1361
- P27(KIP1), human retina, retinoblastoma, 3843
- P27, phenylacetate, prostate cancer, Skp2, 1881
- P27, pRb, hypoxia, oxygen-dependent checkpoint, 2259
- P38 MAPK, Akt, apoptosis, gemcitabine, pancreatic cancer, 3347
- P38, 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin, ERK, JNK, caspase-3, RAW 264.7 cells, 2831
- P53 protein, bcl-2 protein, gastric cancer, immunohistochemistry, prognosis, 3629
- P53, bax, Bcl-2, caspase, etoposide, hydroxyurea, interleukin, lymphoma, 999
- P53, breast cancer, Her2/neu, steroid receptors, Ki67, DCIS, 1719
- P53, clinically localized prostate cancer, bcl2, PAR4, biochemical failure, 3123
- P53, cyclin cdk's, PKC, phosphoinositol 3-kinase, apoptosis, deoxyadenosine resistance, flavopiridol, LY294002, roscovitine, wortmannin, UCN-01, leukemia cells, 101
- P53, ellagic acid, cell cycle arrest, apoptosis, p21, caspase-3, 971
- P53, ER α , PgR, proliferation, Bcl-2, Her-2/neu, EGF-R, 4615
- P53, esophageal squamous cell carcinoma, chemoradiotherapy, Hsp27, Hsp70, p21, bax, bcl2, 2749
- P53, glioma, transcriptional activation, phosphorylation, 213
- P53, hTERT, hTEP-1, caspase-3, survival, bladder cancer, immunohistochemistry, 3109
- P53, intron 6, colon cancer, 2767

- P53, lung cancer, NF κ B, apoptosis, VEGF, 69
P53, microsatellite instability, ovarian clear-cell carcinoma, DNA mismatch repair, 2785
P53, non-small cell lung cancer, staging, prognostic factors, 2385
P53, oral cancer, cyclin D1, qat, Yemen, India, 4699
P53, pancreatic cancer, retinoblastoma, p21^{WAF1/CIP1}, Bax, 1361
P53, pRb2/p130, p107, HPV, cervical cancer, immunohistochemistry, 2187
P53, topoisomerase 2 α , HER2, bladder carcinoma, FISH, multitissue array, prognosis, 263
P53, urinary bladder, small cell carcinoma, prognosis, survival, 2001
P53, vulvar cancer, vin, *Lichen sclerosus*, squamous cell hyperplasia, immunohistology, carcinogenesis, prognosis, 1739
P53, YB-1, PCNA, lung cancer, 3437
P63, esophageal, cancer, 3533
P70 S6 kinase, ether lipids, ET-18-OCH₃, MCF-7 cells, 95
P8, apoptosis, breast carcinoma, immunohistochemistry, ssDNA, 833
P8, medullary thyroid carcinoma, apoptosis, 3419
Paclitaxel, breast cancer, epirubicin, sequence, 1211
Paclitaxel, breast cancer, NF- κ B, Bcl-xL, c-FLIP, docetaxel, 2367
Paclitaxel, cell death, docetaxel, breast cancer cells, DNA fragmentation, caspase activation, cytochrome c release, 4215
Paclitaxel, doxifluridine, gastric cancer, thymidine phosphorylase, 1291
Paclitaxel, FAK, FRNK, apoptosis, SCCHN cells, etoposide, 5-fluorouracil, 4349
Paclitaxel, gemcitabine, leukemia cells, 4165
Paclitaxel, hepatoid adenocarcinoma, AFP-producing Barrett's esophageal cancer, liver metastasis, cisplatin, 2965
Paclitaxel, low performance status, non-small cell lung cancer, gemcitabine, 409
Paclitaxel, neutropenic enterocolitis, ovarian cancer, chemotherapy, 2509
Paclitaxel, NF-kappaB activation, Sabarubicin, apoptotic DNA fragmentation, parthenolide, colon cancer cells, 2119
Paclitaxel, NK cell, adhesion molecule, 735
Paclitaxel, NLCQ-1, 5-fluorouracil, 2161
Paclitaxel, non-small cell lung cancer, chemotherapy, 2555
Paclitaxel, non-small cell lung cancer, cisplatin, 4685
Paclitaxel, NSCLC, triple chemotherapy, carboplatin, vinorelbine, 1333
Paclitaxel, solid tumors, 4423
Paclitaxel, TCC, MMP, invasion, *in vitro*, 2097
Paediatric, brain tumour, medulloblastoma, NG2, 3855
Pancreas cancer, MUC1, peptide, vaccine, 3575
Pancreas, serrated, adenoma, intraductal, 3099
Pancreatic adenocarcinoma, tumor markers, differentiation, CA 19-9, 3625
Pancreatic cancer cells, survivin, small inhibitory RNA, 3967
Pancreatic cancer, c-kit, TGF- β 1, immunohistochemistry, tyrosine kinase, 3523
Pancreatic cancer, celiac axis infusion, microembolization, isolated abdominal perfusion, 4407
Pancreatic cancer, heavy water (deuterium oxide, D₂O), apoptosis, cell cycle distribution, AsPC-1, BxPC-3 and PANC-1 cells, 3407
Pancreatic cancer, mistletoe extract, mistletoe lectin, *Viscum album*, Gemcitabine, intratumoral injection, antitumour activity, human cancer xenograft, 1969
Pancreatic cancer, p38 MAPK, Akt, apoptosis, gemcitabine, 3347
Pancreatic cancer, polychemotherapy, CA19-9, CEA, 1687
Pancreatic cancer, radiochemotherapy, CA 19-9, gemcitabine, toxicity, 1523
Pancreatic cancer, retinoblastoma, p53, p21^{WAF1/CIP1}, Bax, 1361
Pancreatic carcinoma, alpha-fetoprotein, AFP, acinar cell carcinoma, 1671
Pancreatic carcinoma, immuno-cell therapy, CD3-LAK, dendritic cell (DC), gemcitabine, 3709
Pancreatic carcinoma, VEGF, IP-10, irinotecan, oxaliplatin, 5-fluorouracil, leucovorin, gemcitabine, 3287
Pancreatic neoplasms, bevacizumab, gemcitabine, cisplatin, irinotecan, fluorouracil, 3637
Papillary carcinoma, Tc1, Tc2, autoimmune thyroiditis, thyroid nodule, 2483
Papillary renal cell carcinoma, synchronous collecting duct carcinoma, 579
PAR4, clinically localized prostate cancer, bcl2, p53, biochemical failure, 3123
Paracrine, calcitonin, CD44, G-protein, invasion, prostate cancer, signal transduction, 2075
Paraganglioma, carotid body, *SDHD* mutations, 2449
Paraneoplastic neurological syndromes, atypical antibodies, Western blot, rat cerebellum, 3211
Paraoxonase, genetic polymorphisms, NAD(P)H oxidase p22phox, colorectal cancer, 1465
Parathyroid hormone related peptide (PTH-rp), endometrium, endometrial cancer, immunohistochemistry, 1633
Parotid, pleomorphic adenoma, salivary glands, head and neck tumors, salivary gland carcinoma, clinical study, 1703
Parthenolide, NF-kappaB activation, Sabarubicin, paclitaxel, apoptotic DNA fragmentation, colon cancer cells, 2119

- Patterns of Care Study, prostate cancer, radical external beam radiotherapy, 3507
- PC-EW, prostate cancer, androgen receptor, PC-OR, mutation screening, 1611
- PC-EW, prostate cancer, progesterone receptor, PC-OR, PROGINS, 1607
- PC-OR, prostate cancer, androgen receptor, PC-EW, mutation screening, 1611
- PC-OR, prostate cancer, progesterone receptor, PC-EW, PROGINS, 1607
- PCNA, YB-1, p53, lung cancer, 3437
- PDEGF, malignant melanoma, microenvironment, bFGF, 4299
- Pegfilgrastim, neutropenia – leukopenia, 2445
- Pegylated liposomal doxorubicin, Gemcitabine, ovarian cancer, 3103
- Peptidase activity, Glioblastoma, 20S proteasome, 3203
- Peptide, MUC1, vaccine, pancreas cancer, 3575
- Peptide-pulsed dendritic cell-activated killer (PDAK) cells, adoptive immunotherapy (AIT), T-cell receptor (TCR), lung metastasis, 2407
- Peptides, myeloid leukemia, TSP-1, differentiation, apoptosis, 757
- Perfusion, interleukin-12, vasculature, hypoxia, proliferation, ICAM-1, 1015
- Peritoneal dissemination, SU6668, gastric cancer, vascular endothelial growth factor, 17
- Peritoneal implantation, NK4, HGF, milky spots, 3847
- Peritoneal metastases, radioimmunotherapy, Norbormide, 5-fluorouracil, autoradiography, 917
- Peritoneal metastasis, anti-adherence therapy, anticancer cell adherence agent, dextran sulfate, peritoneal metastasis, 895
- Peritoneal metastasis, anti-adherence therapy, anticancer cell adherence agent, peritoneal metastasis, dextran sulfate, 895
- Pertuzumab, 2C4, adjuvant therapy, HER2/neu, Herceptin™, metastatic breast cancer, trastuzumab, review, 1483
- PET, thyroid incidentaloma, thyroid carcinoma, cancer screening, FDG, 1421
- PgR, ERα, proliferation, Bcl-2, Her-2/neu, p53, EGF-R, 4615
- Phage display, angiogenesis, imaging, liposomes, matrix metallo-proteinases, 33
- Phagocytosis, monolayer MCF-7 cells, apoptosis, *S. cerevisiae*, MGN-3, 4187
- Phagocytosis, *S. cerevisiae*, SCC-4, Caco-2, oxidative burst, apoptosis, 981
- Pharmacodynamics, nedaplatin, pharmacokinetics, toxicodynamics, area under the plasma concentration-time curve (AUC), thrombocytopenia, 1273
- Pharmacodynamics, pharmacokinetics, nedaplatin, AUC, optimal sampling, limited sampling, platelet, 1283
- Pharmacokinetics, intravesical chemotherapy, gemcitabine, phase II study, 2493
- Pharmacokinetics, irinotecan, metabolism, capecitabine, 2985
- Pharmacokinetics, monoclonal antibodies, oncology, review, 2327
- Pharmacokinetics, nedaplatin, pharmacodynamics, toxicodynamics, area under the plasma concentration-time curve (AUC), thrombocytopenia, 1273
- Pharmacokinetics, pharmacodynamics, nedaplatin, AUC, optimal sampling, limited sampling, platelet, 1283
- Phase I study, capecitabine, rectal cancer, oxaliplatin, 629
- Phase I study, irinotecan, amrubicin, non-small cell lung cancer, non-platinum regimen, topoisomerase inhibitor, 2429
- Phase I/II trial, irinotecan, cisplatin, advanced gastric cancer, 1257
- Phase II study, advanced gastric cancer, cisplatin, docetaxel, TS-1, second-line chemotherapy, 2973
- Phase II study, colorectal cancer, irinotecan, raltitrexed, first-line chemotherapy, 1391
- Phase II study, intravesical chemotherapy, gemcitabine, pharmacokinetics, 2493
- Phase II, multicentric trial, S-1, cisplatin, gastric cancer, 1297
- Phenylacetate, prostate cancer, Skp2, p27, 1881
- Pheochromocytoma, chromaffin cell, catecholamines, chromogranin A, metaiodobenzylguanidine (MIBG), iodine-123 (123I), 1547
- Phosphoinositol 3-kinase, cyclin cdk's, PKC, apoptosis, deoxyadenosine resistance, p53, flavopiridol, LY294002, roscovitine, wortmannin, UCN-01, leukemia cells, 101
- Phospholipase C, signaling, nucleus, 2039
- Phospholipid translocation, erythrocyte membrane, detergent, multidrug resistance protein (MRP), cell shape, haemolysis, 3173
- Phosphorylation, glioma, p53, transcriptional activation, 213
- Phosphorylation, P-glycoprotein, multidrug resistance, KB-V1, plasma membrane vesicles, reconstitution, proteo-liposomes, octyl-glucoside, 3925
- Photochemical internalization, gene transfer, gene therapy, Glioblastoma multiforme, 291
- Photodynamic therapy, acridine orange, xenon, excitation, illuminance, osteosarcoma, 3979
- Photodynamic therapy, musculoskeletal sarcoma, acridine orange, limb salvage surgery, radiation, 1225
- Phytochemical, apoptosis, lipoxygenase, carotenoid, lipid peroxidation, 3871
- Phytochemicals, capsaicin, mutagenesis, chemoprevention, 117
- Phytoestrogens, cancer prevention, breast cancer, isoflavones, review, 2357

- Phytoestrogens, lignans, flaxseed, matairesinol, Biochanin A, trophoblast tumour cells, 1817
- PINP, osteocalcin, crosslaps, breast cancer, bone metastases, 1491
- Pituitary tumor-transforming gene, PTTG, antitumor target, 121
- PKC, cyclin cdk's, phosphoinositol 3-kinase, apoptosis, deoxyadenosine resistance, p53, flavopiridol, LY294002, roscovitine, wortmannin, UCN-01, leukemia cells, 101
- Placental-specific tissue protein 10, pregnancy protein 1, α 1-fetoprotein, bronchial carcinoma, 1667
- Plasma membrane vesicles, P-glycoprotein, multidrug resistance, KB-V1, phosphorylation, reconstitution, proteo-liposomes, octyl-glucoside, 3925
- Platelet factor 4 (PF4), chemokine, anti-angiogenesis, 847
- Platelet, pharmacokinetics, pharmacodynamics, nedaplatin, AUC, optimal sampling, limited sampling, 1283
- Platelets, breast cancer, VEGF, thrombospondin, tissue factor, 3963
- Pleomorphic adenoma, salivary glands, head and neck tumors, parotid, salivary gland carcinoma, clinical study, 1703
- Pleomorphic carcinoma, caveolin-1, lung, prognosis, 4631
- Pleural fluid, collagen gel droplet-embedded culture drug sensitivity test (CD-DST), ovarian cancer, ascitic fluid, neoadjuvant chemotherapy, 3547
- Ploidy, mucoepidermoid carcinoma, salivary gland neoplasms, flow cytometry, Ki-67, grading, 2589
- PN1, lung cancer, carcinoembryonic antigen, 3601
- Pneumonia, *pneumocystis carinii*, lymphopenia, corticosteroids, radiation of thoracic duct, 651
- Pneumocystis carinii*, pneumonia, lymphopenia, corticosteroids, radiation of thoracic duct, 651
- Podoplanin, myofibroblast, microvessel density, early-stage colorectal carcinoma, lymphangiogenesis, lymph node metastasis, 2705
- Poly(ADP-ribose)polymerase (PARP), cyclic dipeptides, cancer cells, HT-29, caspase-3, apoptosis, 4197
- Polyamines, stoichiometric factors (n), inhibition rate constants, 965
- Polychemotherapy, pancreatic cancer, CA19-9, CEA, 1687
- Polycyclic hydrocarbons, esophageal cancer, Iran, 425
- Polymorphism, c-kit, dedifferentiated liposarcomas, well-differentiated liposarcomas, imatinib-mesylate, GISTs, 2215
- Polymorphism, CYP17, familial prostate cancer, association, 1303
- Polymorphism, MTHFR, stomach cancer, 2249
- Polyphenol, green tea, EGCG, oral cancer, p21^{WAF1}, apoptosis, 63
- Poorly-differentiated carcinoma, lymph node, metastasis, cell line, SKY, CGH, 683
- Positron emission tomography (PET), 18-F-Fluorodeoxyglucose (FDG), esophageal carcinoma, bony metastasis, bone scintigraphy, 4439
- Positron emission tomography, ¹⁸F-fluorodeoxyglucose, hepatocellular carcinoma, alpha-fetoprotein, 4719
- Positron emission tomography, gastrointestinal stromal tumour, imatinib mesylate, c-kit, receptor protein-tyrosine kinase, 4591
- Positron emission tomography, occult, tracheal carcinoma, computed tomography, image fusion, 459
- Postradiation sarcoma, malignant fibrous histiocytoma, osteosarcoma, telomerase activity, telomere length, 2951
- Potassium ion flux, ⁸⁶Rb+, mesothelioma, ionophores, small cell lung cancer, amphotericin B, 2609
- PPAR β/δ , cyclin D1, multiple intestinal neoplasia, aberrant crypt foci, azoxymethane, ApcMin/+ mice, β -catenin, Wnt signalling pathway, 3781
- PPD, CEA, immunochemotherapy, PSK, 5-fluorouracil, 1377
- PRb, p27, hypoxia, oxygen-dependent checkpoint, 2259
- PRb2/p130, p107, p53, HPV, cervical cancer, immunohistochemistry, 2187
- Prediction, colorectal cancer, chemotherapy, monitoring, DNA, nucleosomes, cytokeratin 19-fragments, CYFRA 21-1, serum, 1795
- Prednisolone, glucocorticoids, cortivazol, dexamethasone, betamethasone, resistance, 2253
- Pregnancy protein 1, placental-specific tissue protein 10, α 1-fetoprotein, bronchial carcinoma, 1667
- Preneoplastic lesions, c-erbB-2, Her-2, bronchial pre-invasive lesions, early invasive lesions, carcinogenesis, lung cancer, 2005
- Preradiation chemotherapy, methotrexate, high-grade gliomas, children, 2583
- Prevention, prostate cancer, aged, detection, review, 4527
- Primary cell culture, chemotherapy, breast cancer, cytotoxicity assay, brain metastases, 1531
- Primary cultures of carcinoma cells, breast carcinomas, cyclin D1 and HER2/neu by FISH, 1051
- Primary neuroendocrine carcinoma, Merkel cell carcinoma, neuroendocrine differentiation, prognosis, chromogranin-A, 853
- Prion, doppel, astrocytoma, protein interaction, 4369
- Procainamide hydrochloride, cisplatin, tissue morphology, 4123
- Procarbazine, anaplastic oligodendroglioma, ranimustine, vincristine, 3715
- Proenzyme therapy, cancer, protease inhibitors, 1157
- Professional updating, internet, surgical and medical oncology, 3095
- Progesterone receptor (PR), endometrium, endometrial cancer, immunohistochemistry, estrogen receptor alpha (ER- α), estrogen receptor beta (ER- β), 1679

- Progesterone receptor, prostate cancer, PC-EW, PC-OR, PROGINS, 1607
- Progesterone receptor, RARRES3, TIG3, RIG1, breast cancer, estrogen receptor, tumor suppressor gene, 2453
- Progesterone receptors, endometrial cancer, estrogen receptors, hormone dependency, HER-2/neu, 2921
- Progesterone, BRCA1, apoptosis, cell cycle, MCF7 cell line, 243
- Proggestins, breast cancer, sulfatase, nomegestrol acetate, 2827
- PROGINS, prostate cancer, progesterone receptor, PC-EW, PC-OR, 1607
- Prognosis, breast cancer, ductal breast cancer, E-cadherin, fibronectin, 2879
- Prognosis, caveolin-1, pleomorphic carcinoma, lung, 4631
- Prognosis, colorectal cancer, galectin-3 expression, immunohistochemistry, 3117
- Prognosis, gastric cancer, tumor-associated macrophages (TAM), Fas ligand (FasL), cytotoxic T lymphocyte (CTL), immunomodulation, 463
- Prognosis, heat shock protein, hsp27, immuno-histochemistry, breast cancer, 1649
- Prognosis, hepatocellular carcinoma, hepatectomy, 3067
- Prognosis, HPV, tonsillar carcinoma, p16, radiotherapy, L1 capsid, HPV ISH, 4375
- Prognosis, immunohistochemistry, breast cancer, estrogen and progesterone receptors, cutpoint analysis, 2535
- Prognosis, lung cancer, survival, 3517
- Prognosis, MFH, grading, 4293
- Prognosis, nuclear morphometry, nuclear area, colorectal cancer, adjuvant therapy, 3083
- Prognosis, ovarian cancer, invasion markers, matrix metallo- proteinase, fibronectin, 2885
- Prognosis, p53 protein, bcl-2 protein, gastric cancer, immuno-histochemistry, 3629
- Prognosis, primary neuroendocrine carcinoma, Merkel cell carcinoma, neuroendocrine differentiation, chromogranin-A, 853
- Prognosis, SCC, CEA, cervical cancer, tumor markers, 1765
- Prognosis, Skp2, UFT, radiation, immunohistochemistry, 2471
- Prognosis, topoisomerase 2 α , HER2, p53, bladder carcinoma, FISH, multitissue array, 263
- Prognosis, TS polymorphism, MTHFR polymorphism, non-small cell lung cancer, 4455
- Prognosis, urinary bladder, small cell carcinoma, p53, survival, 2001
- Prognosis, vulvar cancer, vin, *Lichen sclerosus*, squamous cell hyperplasia, p53, immunohistology, carcinogenesis, 1739
- Prognosis, vulvar carcinoma, TGF- α , c-erbB-2, neoangiogenesis, immunohistology, 1731
- Prognosis, α -catenin, β -catenin, prostate neoplasm, 4707
- Prognostic factor, CEA, CA 19-9, rectal carcinoma, tumor marker, overall survival, 1787
- Prognostic factor, EGFR, estrogen receptor α , lung cancer, 4693
- Prognostic factor, endometrial cancer, dendritic cells, S100 protein, 1747
- Prognostic factor, gastric cancer, metastatic lymph node ratio, lymph node dissection, 1369
- Prognostic factors, adenocarcinoma of the lung, aviscumine, recombinant mistletoe lectin, non-small cell lung cancer, 3303
- Prognostic factors, CD44v6, cervical carcinoma, 617
- Prognostic factors, colorectal carcinoma (CRC), liver metastasis, staging system, 1251
- Prognostic factors, endometrial cancer, matrix metalloproteinases, MMP-2, 4101
- Prognostic factors, fractal, dimensions, laryngeal cancer, image analysis, 2141
- Prognostic factors, p53, non-small cell lung cancer, staging, 2385
- Prognostic factors, S-100, MIA, tumor marker, malignant melanoma, 1779
- Prognostic factors, soft tissue sarcomas, review, 4519
- Prognostic markers, matrix metalloproteinases, squamous cell carcinoma, oropharynx, 4129
- Progression, colon, rectum, adenomas, invasive carcinoma, 2503
- ProGRP, small cell lung cancer, tumor marker, NSE, lung cancer, CEA, CA 125, CYFRA 21-1, SCC, 1773
- Proliferation, bisphosphonate, alendronate, A431 cells, squamous cell carcinoma, invasion, 2655
- Proliferation, bladder cancer, carboxyamido-triazole, apoptosis, animal model, 725
- Proliferation, COX-2, COX-1, colorectal cancer, NSAIDs, 225
- Proliferation, diffuse large B-cell lymphomas, differentiation, apoptosis, 347
- Proliferation, ER α , PgR, Bcl-2, Her-2/neu, p53, EGF-R, 4615
- Proliferation, interleukin-12, vasculature, hypoxia, perfusion, ICAM-1, 1015
- Proliferation, migration, osteosarcoma, extracellular matrix, doxorubicin, matrix-metalloproteinase, β 1 integrin, topoisomerase II, 805
- Proliferative tumor marker, Ki-67 (MIB-1) antigen, topoisomerase II- α , thyroid tumors, 1835
- Prolymphocytic leukemia, mesothelioma-malignant, SV40, asbestos, 429
- Promoter methylation, Burkitt lymphoma, LCL, p16^{INK4A}, p14^{ARF}, genetic change, 2153
- Prophylaxis, catheters, warfarin, thrombosis, chemotherapy, 3143

- Propidium iodide, alvaradoin E, alvaradoin F, annexin V-FITC, anthracenone C-glycosides, apoptosis, DAPI, DiOC₆, hollow fiber test, mitochondrial membrane potential analysis, TUNEL assay, 779
- Prostasome, autoantibodies, ELISA, prostate cancer, prostate specific antigen, 4399
- Prostate cancer cell lines, microarray, metastasis-associated genes, genetic profiling, 183
- Prostate cancer cells, black cohosh extract, apoptosis, annexin-V-FITC, M30 antibody, 139
- Prostate cancer, aged, prevention, detection, review, 4527
- Prostate cancer, androgen receptor, PC-EW, PC-OR, mutation screening, 1611
- Prostate cancer, autoantibodies, ELISA, prostasome, prostate specific antigen, 4399
- Prostate cancer, bladder cancer, doxazosin, serotonin, 4281
- Prostate cancer, bone metastasis, vision loss, 3521
- Prostate cancer, calcitonin, CD44, G-protein, invasion, paracrine, signal transduction, 2075
- Prostate cancer, COX-2, osteolytic lesions, osteoblastic, bone metastases, 107
- Prostate cancer, DU 145, xenograft, radiotherapy, testis, estramustine, 2873
- Prostate cancer, epirubicin, hormone-refractory, 4475
- Prostate cancer, gene-based PSMA vaccination, LNCaP cells, anti-PSMA antibodies, carbohydrate cleaving enzyme, proteases, 4727
- Prostate cancer, Gn-RH agonist, leuprorelin, triptorelin, drug resistance, 577
- Prostate cancer, hormone resistance, tamoxifen, 3597
- Prostate cancer, inositol hexaphosphate, mitogenic signaling, cell survival signaling, cell cycle progression, apoptosis, angiogenesis, review, 2891
- Prostate cancer, interleukin-4, interleukin-6, androgen receptor, 4595
- Prostate cancer, LNCaP cells, vitamin D, ibuprofen, NSAID, 3425
- Prostate cancer, monoclonal antibody, bispecific antibody, anti-Her2/neu, extracellular glycoproteins, immunotherapy, 43
- Prostate cancer, nuclear matrix, diagnostic and prognostic markers, review, 3999
- Prostate cancer, Patterns of Care Study, radical external beam radiotherapy, 3507
- Prostate cancer, phenylacetate, Skp2, p27, 1881
- Prostate cancer, progesterone receptor, PC-EW, PC-OR, PROGINS, 1607
- Prostate cancer, prostate specific antigen, free prostate specific antigen, 2439
- Prostate cancer, PSA, capillary blood, test strip, 1659
- Prostate cancer, PSA, complexed PSA (c PSA), free PSA (f PSA), 1591
- Prostate cancer, PSA, DNA-cytophotometry, 1783
- Prostate cancer, therapy, radical prostatectomy, brachytherapy, cryotherapy, high intensity focused ultrasound, watchful waiting, chemotherapy, 551
- Prostate cancer, urine, VEGF, 3645
- Prostate carcinoma, CD4, CD8, CD20, PSA, tumour-infiltrating lymphocytes, 4435
- Prostate neoplasm, α -catenin, β -catenin, prognosis, 4707
- Prostate specific antigen, autopsy changes, prostate, 1263
- Prostate specific antigen, prostate cancer, free prostate specific antigen, 2439
- Prostate specific antigen, autoantibodies, ELISA, prostasome, prostate cancer, 4399
- Prostate, microarray expression profiling, cancer, metastases, 1477
- Prostate, prostate specific antigen, autopsy changes, 1263
- Prostate, PSA, radiotherapy, afterloading, 1555
- Prostatic cells, canine, age, ER β , 4081
- Protease inhibitor, ionizing radiation, anti-angiogenesis, 4357
- Protease inhibitors, proenzyme therapy, cancer, 1157
- Proteases, prostate cancer, gene-based PSMA vaccination, LNCaP cells, anti-PSMA antibodies, carbohydrate cleaving enzyme, 4727
- 20S Proteasome, glioblastoma, peptidase activity, 3203
- Protein expression profile, SELDI TOF-MS, adverse effect, ProteinChip System, HMW kininogen, apolipoprotein A-II, 1197
- Protein interaction, Doppel, prion, astrocytoma, 4369
- Protein synthesis, GLUT1, glucose consumption, tumour proliferation, 3431
- Protein tyrosine kinase activities, hormone dependence, hormone independence, insulin growth factor receptor type-1, mammary carcinogenesis, mammary tumors, *N*-nitroso-*N*-methylurea, 4305
- ProteinChip System, SELDI TOF-MS, protein expression profile, adverse effect, HMW kininogen, apolipoprotein A-II, 1197
- Proteo-liposomes, P-glycoprotein, multidrug resistance, KB-V1, plasma membrane vesicles, phosphorylation, reconstitution, octyl-glucoside, 3925
- Prothrombin, factor V, oral cancer, oncogenesis, thrombophilia, 2561
- Proximal muscle weakness, gemcitabine, docetaxel, myalgias, edema, 523
- PSA, CD4, CD8, CD20, prostate carcinoma, tumour-infiltrating lymphocytes, 4435
- PSA, complexed PSA (c PSA), free PSA (f PSA), prostate cancer, 1591
- PSA, prostate cancer, capillary blood, test strip, 1659
- PSA, prostate cancer, DNA-cytophotometry, 1783
- PSA, prostate, radiotherapy, afterloading, 1555
- Pseudopolyps, inflammatory polyps, ulcerative colitis, hepatitis, budesonide, 2961

- Psidium guajava*, T regulatory cell, tumor vaccine, Th1/Th2 balance, herbal medicine, 3763
- PSK, CEA, PPD, immunochemotherapy, 5-fluorouracil, 1377
- PSK, Th1/Th2, DC1/DC2, cytokines, 443
- Psychosocial stress, breast symptoms, 531
- PTHrP, breast cancer, bone metastasis, humanized monoclonal antibody, 3817
- PTTG, pituitary tumor-transforming gene, antitumor target, 121
- Qat, oral cancer, cyclin D1, p53, Yemen, India, 4699
- Quality of life, erythropoietin, anemia, 3495
- Quantitative fluorescence *in situ* hybridisation, flow cytometry, telomeres, flow-FISH, 1039
- Questionnaires, religion and medicine, spirituality and religion, cancer patients, 1449
- Quinoline, indolo[2, 3-b] cell cycle, topoisomerase II, MDR, DNA-binding, cytotoxicity, lipophilicity, antimicrobial, 2857
- R115777, farnesyltransferase inhibitor, Ras, 3215
- Radiation of thoracic duct, *Pneumocystis carinii*, pneumonia, lymphopenia, corticosteroids, 651
- Radiation therapy, chemotherapy, anesthesia, 2815
- Radiation, cisplatin, DNA repair, mutants, recombination repair, 53
- Radiation, COX-2, brain metastasis, necrosis, 2969
- Radiation, musculoskeletal sarcoma, photodynamic therapy, acridine orange, limb salvage surgery, 1225
- Radiation, NLCQ-1, human gliomas, hypoxia, 1865
- Radiation, Skp2, UFT, prognosis, immunohistochemistry, 2471
- Radiation, vascular disrupting agent, MN-029, cisplatin, 3899
- Radical external beam radiotherapy, Patterns of Care Study, prostate cancer, 3507
- Radical prostatectomy, prostate cancer, therapy, brachytherapy, cryotherapy, high intensity focused ultrasound, watchful waiting, chemotherapy, 551
- Radical, 3, 5-dibenzoyl-1, 4-dihydropyridines, tumor-specificity, DNA fragmentation, caspase, Bcl-2, Bax, Bad, 2033
- Radical, Cu plate, cytotoxicity, antioxidant, SOD, ESR, 283
- Radical-scavenging activity, ebselen, inhibition rate constants, 3989
- Radical-scavenging activity, hesperetin, hesperidin, inhibition rate constants, COX-2, 3367
- Radicals, azulenequinones, Raw 264.7 cells, NO, iNOS, ESR, 4157
- Radio-chemotherapy, cervical cancer, radiotherapy, lymphocyte subpopulations, 4673
- Radiochemotherapy, bladder cancer, transurethral resection, 1623
- Radiochemotherapy, pancreatic cancer, CA 19-9, gemcitabine, toxicity, 1523
- Radioimmunotherapy, cervical carcinoma, Ck19, Rhenium-188, apoptosis, 2719
- Radioimmunotherapy, peritoneal metastases, Norbormide, 5-fluorouracil, autoradiography, 917
- Radiosensitization, interferon- α , reactive oxygen species, DNA double-strand break, p21^{Cip1/WAF1}, 2631
- Radiosensitizer, nitroimidazole, 2145
- Radiosensitizing agents, bile duct carcinomas, carcinoma of the gallbladder, razoxane, 3613
- Radiotherapy, cervical cancer, radio-chemotherapy, lymphocyte subpopulations, 4673
- Radiotherapy, Glioblastoma multiforme, chemotherapy, 4605
- Radiotherapy, HPV, tonsillar carcinoma, p16, L1 capsid, HPV ISH, prognosis, 4375
- Radiotherapy, lung cancer, ¹¹¹InHMFG1-F(ab')₂, biodistribution, lysine, 4663
- Radiotherapy, oral squamous cell carcinoma, hyperfractionated irradiation, vital tumor cells, 1707
- Radiotherapy, prostate cancer, DU 145, xenograft, testis, estramustine, 2873
- Radiotherapy, PSA, prostate, afterloading, 1555
- Radiotherapy, SCC antigen, cancer, uterine cervix, 1663
- Radiotherapy, stage I seminoma, β -hCG, testicular cancer, 1543
- Radiotherapy, TRACP 5b, bone metastases, breast cancer, 4639
- Radiotracer development, molecular imaging, 1827
- Raft cultures, human papillomavirus, antisense, replication, oncogenes, 765
- Raltitrexed, colorectal cancer, irinotecan, first-line chemotherapy, phase II study, 1391
- Raltitrexed, head and neck squamous cell carcinoma, carboplatin, 4445
- Ranimustine, anaplastic oligodendroglioma, procarbazine, vincristine, 3715
- RANKL, colon cancer, osteoprotegerin, TNF, IL-1 β , immunohistochemistry, 3809
- RANKL, hypercalcemia, osteoprotegerin, bisphosphonates, 3607
- RARRES3, TIG3, RIG1, breast cancer, estrogen receptor, progesterone receptor, tumor suppressor gene, 2453
- Ras, farnesyltransferase inhibitor, R115777, 3215
- Rat cerebellum, paraneoplastic neurological syndromes, atypical antibodies, Western blot, 3211
- Rat sarcoma, SPI-077, STEALTH[®] liposomes, cisplatin, TNF- α , systemic treatment, 743
- Rat, osteoblastic bone metastases, intra-osseous application, 1067
- Rat, sirolimus, liver, adenocarcinoma, sarcoma, hepatoma, 789
- RAW 264.7 cells, 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin, ERK, JNK, p38, caspase-3, 2831

- Raw 264.7 cells, azulenequinones, NO, iNOS, ESR, radicals, 4157
- RAW cells, eugenol-related compounds, cytotoxicity, apoptosis, HL-60 cells, LPS, COX-2, 3263
- Razoxane, bile duct carcinomas, carcinoma of the gallbladder, radiosensitizing agents, 3613
- ⁸⁶Rb+, potassium ion flux, mesothelioma, ionophores, small cell lung cancer, amphotericin B, 2609
- RCC, margins, nephron sparing surgery, NSS, survival, 1629
- Reactive oxygen metabolites, antioxidants, eradication treatment, gastric mucosa, gastritis, *Helicobacter pylori*, superoxide dismutase, 4763
- Reactive oxygen species, apoptosis, γ -irradiation, macrophages, antioxidants, caspase inhibitors, 4091
- Reactive oxygen species, arsenic trioxide, glutathione, multidrug-resistance, buthionine-sulfoximine, 991
- Reactive oxygen species, N-(4-hydroxyphenyl) retinamide, apoptosis, glutathione, tissue transglutaminase, BSO, all-*trans* retinoic acid (ATRA), 1945
- Reactive oxygen species, radiosensitization, interferon- α , DNA double-strand break, p21^{Cip1/WAF1}, 2631
- Real-time PCR, colon cancer, cytokines, TH1, H2, 2135
- Real-time PCR, Her-2/neu, breast cancer, 1895
- Real-time quantitative RT-PCR, invasive breast carcinoma, HER-2 status, 4679
- Receptor protein-tyrosine kinase, gastrointestinal stromal tumour, positron emission tomography, imatinib mesylate, c-kit, 4591
- Receptor, carcinoembryonic antigen, colon cancer, heterogeneous RNA binding protein, 23
- Recombinant IL-2, gene therapy, bladder cancer, adenovirus, 2757
- Recombinant mistletoe lectin, adenocarcinoma of the lung, aviscumine, prognostic factors, non-small cell lung cancer, 3303
- Recombination repair, cisplatin, radiation, DNA repair, mutants, 53
- Reconstitution, P-glycoprotein, multidrug resistance, KB-V1, plasma membrane vesicles, phosphorylation, proteo-liposomes, octyl-glucoside, 3925
- Rectal cancer, capecitabine, phase I study, oxaliplatin, 629
- Rectal cancer, α -tubulin, β -tubulin, tumorigenesis, 3237
- Rectal carcinoma, CEA, CA 19-9, tumor marker, overall survival, prognostic factor, 1787
- Rectal carcinoma, tumour budding, invasion, 1269
- Rectum, colon, adenomas, progression, invasive carcinoma, 2503
- Rectum, serrated, microtubular, adenomas, colon, 1353
- Recurrence, endometrial carcinoma, surgery, laparoscopy, hysterectomy, 2423
- Recurrence, epithelial ovarian cancer, spleen, metastasis, 1471
- Recurrence, gastric cancer, gastrectomy with spleen preservation / splenectomy, survival, 3023
- Recurrence, microsatellite analyses, second primary tumours, head and neck cancer, 2771
- Recurrence, TaqMan PCR, CEA mRNA, colorectal liver metastasis, 1327
- Recurrent translocation, non-Hodgkin's lymphoma, FISH, IGH rearrangement, 3179
- Reference RNA, cDNA array, 1397
- Regional chemotherapy, tumor colony forming assay, liver metastases, colorectal cancer, 795
- Regulatory T cells, gastric cancer, spleen, CD62L, TGF-beta, 643
- Rehabilitation, chronic dysphagia, head and neck cancer, 2929
- Religion and medicine, questionnaires, spirituality and religion, cancer patients, 1449
- Renal cell cancer, bone metastasis, microvessel density, breast cancer, lung cancer, 3075
- Renal cell cancer, EGFR, clinical prognosis, tissue microarray, survival, 1901
- Renal cell carcinoma, ABC transporter, chemosensitivity, conjugated bilirubin, MRP2, 2729
- Renal cell carcinoma, bone metastasis, fibroblast growth factor-2, angiogenesis, antisense oligodeoxynucleotide, 1109
- Renal cell carcinoma, cadherin-6, circulating cancer cells, tumor marker, 377
- Renal cell carcinoma, carbonic anhydrase IX (CA IX), gene therapy, MN protein, 881
- Renin-angiotensin system, angiogenesis, ACE inhibitor, hepatocarcinogenesis, 3335
- Replication, human papillomavirus, antisense, raft cultures, oncogenes, 765
- Resectability, head and neck cancer, serum selenium, 1711
- Resection, metastasizing thyroid cancer, sternal metastasis, 4389
- Reservoir port, hepatic arterial infusion chemotherapy, liver metastasis, biliary tract and pancreatic cancer, 5-fluorouracil, cisplatin, 477
- Resistance, glucocorticoids, cortivazol, prednisolone, dexamethasone, betamethasone, 2253
- Resistance, *in vitro*, gene expression, cDNA microarray, chemotherapy, 2661
- Resistance, microtubules, β -tubulin isotypes, combretastatin A-4, 3865
- RET, DHPLC, sequencing, MEN 2, 2091
- Retinoblastoma, p27(KIP1), human retina, 3843
- Retinoblastoma, pancreatic cancer, p53, p21^{WAF1/CIP1}, Bax, 1361
- 13-*cis* Retinoic acid, maintenance therapy, IL-2, solid tumors, 3149

- Retinoid glucuronides, retinoids, breast cancer, cancer chemotherapy, mammary tumors, retinol, triglycerides, bone mineral content, 2391
- Retinoids, apoptosis, lymphoma, ATRA, 4HPR, 4179
- Retinoids, retinoid glucuronides, breast cancer, cancer chemotherapy, mammary tumors, retinol, triglycerides, bone mineral content, 2391
- Retinol, retinoids, retinoid glucuronides, breast cancer, cancer chemotherapy, mammary tumors, triglycerides, bone mineral content, 2391
- Retinol-binding-protein (RBP), 12-O-retinoylphorbol-13-acetate (RPA), ligand, 3355
- 12-O-Retinoylphorbol-13-acetate (RPA), ligand, retinol-binding-protein (RBP), 3355
- Retroperitoneal liposarcoma, orbit metastasis, 4769
- Reverse transcriptase polymerase chain reaction, tumor antigen, DNA methylation, stomach neoplasms, immunohistochemistry, survival analysis, 2105
- Review, 2C4, adjuvant therapy, HER2/neu, Herceptin™, metastatic breast cancer, pertuzumab, trastuzumab, 1483
- Review, adjuvant therapy, aromatase inhibitors, breast cancer, tamoxifen, 2497
- Review, cervical cancer, smoking, oral contraceptives, steroid hormones, 3041
- Review, chemotherapy, metastases, colorectal cancer, 563
- Review, chromosome abnormalities, karyotype, molecular cytogenetics, hematologic malignancies, 2979
- Review, COX-2, endometrial cancer, angiogenesis, apoptosis, cell growth, metastatic potential, immunomodulation, 3679
- Review, elastin, melanoma, matrikines, galectin-3, 2617
- Review, Gc protein, Gc protein-derived macrophage activating factor (GcMAF), alpha-N-acetylgalactosaminidase, 3689
- Review, immunotherapy, cytotoxic T lymphocytes, natural killer cells, antibody-based therapy, tumor antigen, carcinoembryonic antigen, 3725
- Review, inositol hexaphosphate, prostate cancer, mitogenic signaling, cell survival signaling, cell cycle progression, apoptosis, angiogenesis, 2891
- Review, metastasis, lymphangiogenesis, inflammation, TAMs, VEGF-C, invasion, 4503
- Review, metastatic breast cancer, immunotherapy, trastuzumab, Herceptin, circulating HER-2/neu, 4599
- Review, metastatic cascade, cell adhesion, local proteolysis, cell migration, angiogenesis, 3327
- Review, molecular genetic tumor marker, non-small cell lung cancer, 1193
- Review, monoclonal antibodies, pharmacokinetics, oncology, 2327
- Review, murine polyomavirus, VLPs, gene therapy, immune therapy, vaccines, 2601
- Review, nuclear matrix, prostate cancer, diagnostic and prognostic markers, 3999
- Review, phytoestrogens, cancer prevention, breast cancer, isoflavones, 2357
- Review, prostate cancer, aged, prevention, detection, 4527
- Review, soft tissue sarcomas, prognostic factors, 4519
- Review, telomere length, telomere shortening, ageing, 3011
- Review, tumor endothelial cells, angiogenic phenotype, antiangiogenesis, angiogenesis models, 3799
- Review, tumor specific antigens, immunogens, tumor markers, cancer-bearing host, 2345
- Rhabdomyosarcoma, breast, metastatic, 527
- Rhenium-188, cervical carcinoma, Ck19, apoptosis, radioimmunotherapy, 2719
- Ribavirin, hepatitis C, HCV RNA PCR, interferon-alpha, signal transduction, 1315
- RIG1, RARRES3, TIG3, breast cancer, estrogen receptor, progesterone receptor, tumor suppressor gene, 2453
- Right lung, brain metastasis, small cell lung cancer, left lung, upper lobe, lower lobe, gender, smoking, epidemiology, 1101
- Risk model, lung cancer, angiogenesis, VEGF, iNOS, oncoprotein, 497
- RNA helicase, DHX32, lymphocyte, differentiation, 2645
- Roscovitine, cyclin cdk's, PKC, phosphoinositol 3-kinase, apoptosis, deoxyadenosine resistance, p53, flavopiridol, LY294002, wortmannin, UCN-01, leukemia cells, 101
- Roxithromycin (RXM), VEGF, angiogenesis, HepG2, 133
- RPMI 7932, millimeter waves, wide-band irradiation mode, monochromatic irradiation mode, cell morphology, 1023
- RT-PCR, breast cancer, elongation factor-1, mRNA expression, 2573
- RT-PCR, cytokeratins, cell lines, HNSCC, 2675
- RT-PCR, endometrial cells, genistein, daidzein, estrogen receptor, 1713
- RT-PCR, EphA2, EphrinA-1, oesophageal squamous cell carcinoma, tissue array, immunohistochemistry, laser capture microdissection, 2943
- RT-PCR, thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), non-small cell lung cancer, 923
- RT-PCR, thyroglobulin, thyroid cancer, 3135
- RUNX3, colorectal cancer, methylation-specific PCR, 2627
- S. cerevisiae*, monolayer MCF-7 cells, apoptosis, phagocytosis, MGN-3, 4187
- S. cerevisiae*, phagocytosis, SCC-4, Caco-2, oxidative burst, apoptosis, 981
- S-1, gastric scirrhus carcinoma, dihydropyrimidine dehydrogenase (DPD), DPD inhibitory fluoropyrimidines (DIF), 2997
- S-1, phase II, multicentric trial, cisplatin, gastric cancer, 1297
- S-100, MIA, tumor marker, malignant melanoma, prognostic factors, 1779

- S100 protein, endometrial cancer, dendritic cells, prognostic factor, 1747
- S100A2, esophageal squamous cell carcinoma, Δ Np63, 1247
- Sabarubicin, NF-kappaB activation, paclitaxel, apoptotic DNA fragmentation, parthenolide, colon cancer cells, 2119
- Salivary gland carcinoma, pleomorphic adenoma, salivary glands, head and neck tumors, parotid, clinical study, 1703
- Salivary gland neoplasms, mucoepidermoid carcinoma, flow cytometry, ploidy, Ki-67, grading, 2589
- Salivary gland tumor, Doppler ultrasound, ultrasound contrast media, 2477
- Salivary gland, imatinib, adenoid cystic carcinoma, 3659
- Salivary glands, neutron therapy, adenoid cystic carcinoma, dedifferentiation, histological subtype, head and neck, 1321
- Salivary glands, pleomorphic adenoma, head and neck tumors, parotid, salivary gland carcinoma, clinical study, 1703
- Sarcoma, multidrug resistance (MDR), MDR modulators, P-glycoprotein, flow cytometry, confocal microscopy, 383
- Sarcoma, sirolimus, liver, rat, adenocarcinoma, hepatoma, 789
- SART-1, tumor rejection antigen, cell cycle, apoptosis, 1983
- Scanning electron microscopy, dimethylhydrazine, colon carcinogenesis, F433 rat, 3883
- SCC antigen, cancer, uterine cervix, radiotherapy, 1663
- SCC, CEA, cervical cancer, tumor markers, prognosis, 1765
- SCC, head and neck cancer, lymphatic metastasis, CYFRA 21-1, CEA, 1539
- SCC, small cell lung cancer, tumor marker, ProGRP, NSE, lung cancer, CEA, CA 125, CYFRA 21-1, 1773
- SCC-4, phagocytosis, *S. cerevisiae*, Caco-2, oxidative burst, apoptosis, 981
- SCCHN cells, FAK, FRNK, apoptosis, paclitaxel, etoposide, 5-fluorouracil, 4349
- SCCHN tumor cell culture, MHC-restricted immune response, CTL-adoptive immunotherapy, 4075
- SCCHN, cisplatin, ZD 1839, 3985
- SCCHN, EGFR, signal transduction, cancer treatment, 1871
- SCCHN, IL-2, B7, immunotherapy, gene therapy, 3917
- SCCHN, selectins, adhesion molecules, metastasis, 4141
- SCCHN, soluble CD44, CD44v6, neoplasm, squamous cell carcinoma of the head and neck, serum tumor marker, clinical prognostic factor, 2821
- Screening, HPV, HPV testing, colposcopy, liquid-based cytology, cervicography, 3469
- Screening, lung cancer, helical computed tomography (CT) scan, computer-aided diagnosis (CAD) system, 483
- SDHB*-, glomus tumours, *SDHD*-, *SDHC*-gene, succinate dehydrogenase (SDH) enzyme activity, loss of heterozygosity (LOH), 2809
- SDHC*-gene, glomus tumours, *SDHD*-, *SDHB*-, succinate dehydrogenase (SDH) enzyme activity, loss of heterozygosity (LOH), 2809
- SDHD* mutations, carotid body, paraganglioma, 2449
- SDHD*-, glomus tumours, *SDHB*-, *SDHC*-gene, succinate dehydrogenase (SDH) enzyme activity, loss of heterozygosity (LOH), 2809
- Second primary tumours, microsatellite analyses, recurrence, head and neck cancer, 2771
- Second-line chemotherapy, advanced gastric cancer, cisplatin, docetaxel, TS-1, phase II study, 2973
- SELDI TOF-MS, protein expression profile, adverse effect, ProteinChip System, HMW kininogen, apolipoprotein A-II, 1197
- Selectins, SCCHN, adhesion molecules, metastasis, 4141
- Semi-empirical molecular-orbital method, betulinic acid, cytotoxicity, 3951
- Sensitivity, methionine-dependent cancer, methionine-depletion therapy, HPLC, high resolution, 59
- Sentinel lymph node, clear cell sarcoma, 4413
- Sentinel node concept, gastric cancer, lymph node, metastasis, 1349
- Sentinel node detection, fluorescent microspheres, 821
- Sentinel node, lymph node, dendritic cell, immunotherapy, lung cancer, CTL, 85
- Seocalcitol, vitamin D, calcitriol, vitamin D analog, medium-chain triglyceride, canine transitional cell carcinoma, growth inhibition, cell cycle, VDR, 2689
- Sequencing, RET, DHPLC, MEN 2, 2091
- Sequential chemotherapy, docetaxel, epirubicin, vinorelbine, advanced breast cancer, 1309
- Serotonin, prostate cancer, bladder cancer, doxazosin, 4281
- Serrated, adenoma, pancreas, intraductal, 3099
- Serrated, microtubular, adenomas, colon, rectum, 1353
- Serum level, interleukin-6, head and neck squamous cell carcinoma, 2761
- Serum levels, Hodgkin's, lymphoma, syndecan-1, 4743
- Serum p53 antibody, esophageal carcinoma, azygos vein, 3231
- Serum selenium, head and neck cancer, resectability, 1711
- Serum tumor marker, soluble CD44, CD44v6, neoplasm, squamous cell carcinoma of the head and neck, SCCHN, clinical prognostic factor, 2821
- Serum, colorectal cancer, chemotherapy, monitoring, prediction, DNA, nucleosomes, cytokeratin 19-fragments, CYFRA 21-1, 1795
- Sesquiterpenelactones, Bcl-2, Bcl-2 phosphorylation, taxol, apoptotic proteins, anti-tumor, 313
- Sex cord stromal tumors, ovary, transplantation, cryopreserved ovarian tissue, 4107

- Sialyl Lewis A, invasive mole, gestational trophoblastic disease, inhibin, activin, glycodelin, immunohistochemistry, 1725
- Sialyl Lewis A, Sialyl Lewis X, E-cadherin, cathepsin-D, breast cancer, 1615
- Sialyl Lewis A, Sialyl Lewis X, X-ray irradiation, colon cancer, cell adhesion molecules, 875
- Sialyl Lewis X, Sialyl Lewis A, E-cadherin, cathepsin-D, breast cancer, 1615
- Sialyl Lewis X, Sialyl Lewis A, X-ray irradiation, colon cancer, cell adhesion molecules, 875
- Signal transduction, calcitonin, CD44, G-protein, invasion, paracrine, prostate cancer, 2075
- Signal transduction, hepatitis C, HCV RNA PCR, interferon-alpha, ribavirin, 1315
- Signal transduction, SCCHN, EGFR, cancer treatment, 1871
- Signal transduction, WP1034, acute myeloid leukemia, apoptosis, Jak-Stat, 1841
- Signaling proteins, DSB, mitotic delay, cell cycle analysis, 1123
- Signaling, phospholipase C, nucleus, 2039
- Sinerem MRI, MR lymphography, lymph node staging in head and neck cancers, 3665
- Single nucleotide polymorphism, lung cancer, DNA repair, APEX1, XRCC1, ADPRT, LIG3, 537
- SiRNA, epidermal growth factor receptor, focal adhesion kinase, invasion, migration, flavonoids, 2017
- Sirolimus, liver, rat, adenocarcinoma, sarcoma, hepatoma, 789
- Skeletal lesions, FDG-PET, MIBI scan, multiple myeloma, bone marrow involvement, soft tissue lesions, 4737
- Skin tumors, basal cell carcinoma, facial surgery, clinical study, basal cell carcinoma-histological subtypes, 1693
- Skin, EGFR, HER-2, metastatic, squamous cell carcinoma, immunohistochemistry, 1205
- Skp2, phenylacetate, prostate cancer, p27, 1881
- Skp2, UFT, radiation, prognosis, immunohistochemistry, 2471
- SKY, poorly-differentiated carcinoma, lymph node, metastasis, cell line, CGH, 683
- Small cell carcinoma, endometrium, neuroendocrine tumours, 1823
- Small cell carcinoma, urinary bladder, p53, prognosis, survival, 2001
- Small cell lung cancer, ⁸⁶Rb+, potassium ion flux, mesothelioma, ionophores, amphotericin B, 2609
- Small cell lung cancer, brain metastasis, right lung, left lung, upper lobe, lower lobe, gender, smoking, epidemiology, 1101
- Small cell lung cancer, tumor marker, ProGRP, NSE, lung cancer, CEA, CA 125, CYFRA 21-1, SCC, 1773
- Small inhibitory RNA, survivin, pancreatic cancer cells, 3967
- Smoking, brain metastasis, small cell lung cancer, right lung, left lung, upper lobe, lower lobe, gender, epidemiology, 1101
- Smoking, cervical cancer, oral contraceptives, steroid hormones, review, 3041
- SN-38, camptothecin, CPT-11, liposome, drug delivery, 331
- SNC 80, non-peptide opioids, δ -opioid agonist, murine tumor cells, L5178Y-R lymphoma, tumor mouse model, 4563
- SNP, genetic polymorphism, SULT1A1, breast cancer, 2515
- SOD, Cu plate, cytotoxicity, antioxidant, radical, ESR, 283
- Sodium fluoride, human oral cells, ageing, cytotoxicity, apoptosis, mitochondrial function, 2085
- Sodium fluorosilicate, cytotoxicity, apoptosis, osteosarcoma (HOS) cells, 391
- Soft tissue lesions, FDG-PET, MIBI scan, multiple myeloma, bone marrow involvement, skeletal lesions, 4737
- Soft tissue sarcoma, VEGF, Flk-1, MVD, angiogenesis, 3591
- Soft tissue sarcomas, Cox-2, STS, immunohistochemistry, epithelial differentiation, 2669
- Soft tissue sarcomas, prognostic factors, review, 4519
- Soft tissue tumor, malignant solitary fibrous tumor, hypoglycemia, insulin-like growth factor II, 2461
- Soft-tissue sarcoma, intravascular papillary endothelial hyperplasia, Masson's hemangioma, angiosarcoma, 1409
- Solid tumors, maintenance therapy, IL-2, 13-*cis* retinoic acid, 3149
- Solid tumors, paclitaxel, 4423
- Soluble CD44, CD44v6, neoplasm, squamous cell carcinoma of the head and neck, SCCHN, serum tumor marker, clinical prognostic factor, 2821
- Somatostatin analog, TT-232, leukemia model, 325
- Sonography, neoadjuvant chemotherapy, breast cancer, mammography, 2519
- SPD-1, B7-H1, hepatocarcinoma, immunotherapy, 3309
- SPI-077, STEALTH[®] liposomes, cisplatin, TNF- α , rat sarcoma, systemic treatment, 743
- Spirituality and religion, questionnaires, religion and medicine, cancer patients, 1449
- Spleen, congenital anomalies, 4385
- Spleen, epithelial ovarian cancer, metastasis, recurrence, 1471
- Spleen, gastric cancer, CD62L, TGF-beta, regulatory T cells, 643
- Spontaneous tumors, DNA immunization, cellular response, mouse models of breast cancer, MUC1, 3893
- Squamous cell carcinoma of the head and neck, soluble CD44, CD44v6, neoplasm, SCCHN, serum tumor marker, clinical prognostic factor, 2821
- Squamous cell carcinoma, bisphosphonate, alendronate, A431 cells, proliferation, invasion, 2655

- Squamous cell carcinoma, EGFR, HER-2, metastatic, skin, immunohistochemistry, 1205
- Squamous cell carcinoma, matrix metalloproteinases, oropharynx, prognostic markers, 4129
- Squamous cell carcinoma, oral keratinocyte, $\alpha\beta 6$, epithelial-mesenchymal transition (EMT), 751
- Squamous cell carcinoma, VX2, metastases model, tumor resection, 4209
- Squamous cell hyperplasia, vulvar cancer, vin, *Lichen sclerosus*, p53, immunohistology, carcinogenesis, prognosis, 1739
- Squamous cell, cervical cancer, estradiol/progesterone ratio, 611
- SsDNA, P8, apoptosis, breast carcinoma, immunohistochemistry, 833
- Stage I seminoma, β -hCG, testicular cancer, radiotherapy, 1543
- Staging system, colorectal carcinoma (CRC), liver metastasis, prognostic factors, 1251
- Staging, p53, non-small cell lung cancer, prognostic factors, 2385
- Standardized mistletoe extract, oncology, immune modulation, microcirculation, 601
- Staphylococcal enterotoxin B, bladder cancer, Superantigen, apoptosis, Fas-ligand, 3565
- STEALTH® liposomes, SPI-077, cisplatin, TNF- α , rat sarcoma, systemic treatment, 743
- Stefin A, adenomas, cystatins, cysteine cathepsins, intracranial tumours, invasion, 587
- Stem cell, osteosarcoma, chemotherapy, osteoblast, 947
- Stem cells, carcinogenesis, aging, dedifferentiation, 1385
- Stem-cell transplantation, high-dose chemotherapy, metastatic breast cancer, trifunctional antibody, T-cell reinfusion, 3047
- Sternal metastasis, metastasizing thyroid cancer, resection, 4389
- Steroid hormones, cervical cancer, smoking, oral contraceptives, review, 3041
- Steroid receptors, breast cancer, Her2/neu, Ki67, p53, DCIS, 1719
- Stilbenes, flavonoids, oral tumor cells, DNA fragmentation, caspase, Bcl-2, Bax, Bad, 2055
- Stoichiometric factors (n), polyamines, inhibition rate constants, 965
- Stomach cancer, MTHFR, polymorphism, 2249
- Stomach neoplasms, glutathione S-transferase pi, human herpes virus 4, DNA methylation, 4013
- Stomach neoplasms, tumor antigen, DNA methylation, reverse transcriptase polymerase chain reaction, immunohistochemistry, survival analysis, 2105
- Stromal cells, fractionated radiotherapy, hematopoietic, CAFC cells, 2801
- Structure-activity, bisphosphonate, anti-proliferative activity, tumor cells, 1139
- STS, Cox-2, immunohistochemistry, soft tissue sarcomas, epithelial differentiation, 2669
- SU6668, gastric cancer, vascular endothelial growth factor, peritoneal dissemination, 17
- Succinate dehydrogenase (SDH) enzyme activity, glomus tumours, *SDHD*-, *SDHB*-, *SDHC*-gene, loss of heterozygosity (LOH), 2809
- Sulfatase, breast cancer, progestins, nomegestrol acetate, 2827
- SULT1A1, genetic polymorphism, SNP, breast cancer, 2515
- Superantigen, bladder cancer, staphylococcal enterotoxin B, apoptosis, Fas-ligand, 3565
- Superextended lymphadenectomy, gastric cancer, advanced, chemosensitivity, adjuvant chemotherapy, MTT assay, extended surgery, 3453
- Superficial bladder cancer, adjuvant intravesical treatment, mistletoe extract, mistletoe lectin, 4733
- Superficial bladder cancer, intravesical chemotherapy, gemcitabine, 2381
- Superoxide dismutase, antioxidants, eradication treatment, gastric mucosa, gastritis, *Helicobacter pylori*, reactive oxygen metabolites, 4763
- Suppressor, wnt5a, breast, cancer, survival, 731
- Surgery, endometrial carcinoma, laparoscopy, hysterectomy, recurrence, 2423
- Surgery, vulvar cancer, exclusive radiotherapy, adjuvant radiotherapy, 3089
- Surgical and medical oncology, internet, professional updating, 3095
- Surgical margin and breast cancer, breast-conserving surgery, nipple resection, 2957
- Surgical stress, cancer metastasis, urinary trypsin inhibitor (UTI), murine colon carcinoma cell, 815
- Surgical stress, immunomodulation, mistletoe therapy, *Viscum album*, granulocyte function, oxidative burst, 4753
- Surgical volume, oesophageal surgery, hospital mortality, 419
- Survival analysis, bladder neoplasms, DNA cytometry, image analysis, 3243
- Survival analysis, CD44, laryngeal carcinoma, 1115
- Survival analysis, tumor antigen, DNA methylation, reverse transcriptase polymerase chain reaction, stomach neoplasms, immunohistochemistry, 2105
- Survival, gastric cancer, gastrectomy with spleen preservation / splenectomy, recurrence, 3023
- Survival, hTERT, hTEP-1, p53, caspase-3, bladder cancer, immunohistochemistry, 3109
- Survival, lung cancer, prognosis, 3517
- Survival, margins, nephron sparing surgery, NSS, RCC, 1629
- Survival, mesothelioma, chemotherapy, 3671

- Survival, renal cell cancer, EGFR, clinical prognosis, tissue microarray, 1901
- Survival, urinary bladder, small cell carcinoma, p53, prognosis, 2001
- Survival, wnt5a, breast, cancer, suppressor, 731
- Survivin, ovarian endometriosis, angiogenesis, MVD, VEGF, 4313
- Survivin, pancreatic cancer cells, small inhibitory RNA, 3967
- SV40, mesothelioma-malignant, prolymphocytic leukemia, asbestos, 429
- Synchronous collecting duct carcinoma, papillary renal cell carcinoma, 579
- Syndecan-1, Hodgkin's, lymphoma, serum levels, 4743
- Systemic treatment, SPI-077, STEALTH[®] liposomes, cisplatin, TNF- α , rat sarcoma, 743
- T regulatory cell, *Psidium guajava*, tumor vaccine, Th1/Th2 balance, herbal medicine, 3763
- T-cell receptor (TCR), adoptive immunotherapy (AIT), peptide-pulsed dendritic cell-activated killer (PDAK) cells, lung metastasis, 2407
- T-cell reinfusion, high-dose chemotherapy, metastatic breast cancer, stem-cell transplantation, trifunctional antibody, 3047
- T-helper cells, *Viscum album*, mistletoe, immune-suppression, biotherapy, Isorel, immunomodulation, NK cells, 4583
- T11TS / S-LFA-3, brain tumor, immunotherapy, apoptosis, 2905
- tamoxifen, 4-hydroxy-N-desmethyltamoxifen, endoxifen, 4-hydroxytamoxifen, 4487
- tamoxifen, adjuvant therapy, aromatase inhibitors, breast cancer, review, 2497
- tamoxifen, hormone resistance, prostate cancer, 3597
- 4-OH tamoxifen, LNCaP cells, bicalutamide, 4277
- TAMs, metastasis, lymphangiogenesis, inflammation, VEGF-C, invasion, review, 4503
- TaqMan PCR, CEA mRNA, colorectal liver metastasis, recurrence, 1327
- Targeted radiotherapy, folate receptor, folate conjugate, alpha particle emitter, 9
- Targeted therapy, non-small cell lung cancer (NSCLC), chemotherapy, 1501
- Taxanes, hormone-refractory prostate cancer, 4481
- Taxol, Bcl-2, Bcl-2 phosphorylation, sesquiterpenelactones, apoptotic proteins, anti-tumor, 313
- Taxol, ovarian cancer, chemotherapy, cisplatin, topotecan, 2113
- Taxol, taxotere, mitotic spindle, mitotic catastrophe, midbody, multinucleation, 1919
- Taxotere, chemo-radiotherapy, cisplatin, head and neck cancer, 4451
- Taxotere, taxol, mitotic spindle, mitotic catastrophe, midbody, multinucleation, 1919
- Tc1, lung cancer, tumor immunity, Th1, Th2, Tc2, 2027
- Tc1, Tc2, papillary carcinoma, autoimmune thyroiditis, thyroid nodule, 2483
- Tc2, lung cancer, tumor immunity, Th1, Tc1, Th2, 2027
- Tc2, Tc1, papillary carcinoma, autoimmune thyroiditis, thyroid nodule, 2483
- TCC, paclitaxel, MMP, invasion, *in vitro*, 2097
- TCP, NSCLC inoperable stage III, chemo-radiotherapy, 4655
- Telomerase activity, postradiation sarcoma, malignant fibrous histiocytoma, osteosarcoma, telomere length, 2951
- Telomerase, hepatoma, methotrexate, cisplatin, telomeres, drug resistance, dynamics, gene amplification, 3279
- Telomerase, Her-2 /neu, ER, ductal breast carcinoma. FNAB, 1927
- Telomere length, postradiation sarcoma, malignant fibrous histiocytoma, osteosarcoma, telomerase activity, 2951
- Telomere length, telomere shortening, ageing, review, 3011
- Telomere shortening, telomere length, ageing, review, 3011
- Telomeres, flow cytometry, quantitative fluorescence *in situ* hybridisation, flow-FISH, 1039
- Telomeres, hepatoma, methotrexate, cisplatin, telomerase, drug resistance, dynamics, gene amplification, 3279
- Temozolomide, melanoma, cisplatin, interferon-alpha, 1441
- Tenascin (Tn-C)-C, vascular endothelial growth factor (VEGF), microvessel density (MVD), angiogenesis, non-small cell lung cancer (NSCLC), 489
- Teratocarcinoma cell line 2102EP, cisplatin, oxaliplatin, drug resistance, 1147
- N-Terminal telopeptide of collagen type I, bone remodelling markers, alkaline phosphatase, bone metastases, bisphosphonates, zoledronic acid, 1457
- Test strip, PSA, prostate cancer, capillary blood, 1659
- Testicular cancer, cancer-related fatigue, anemia, testosterone, trait anxiety, 4647
- Testicular cancer, stage I seminoma, β -hCG, radiotherapy, 1543
- Testicular germ-cell tumor, hMLH1 methylation, MMR, MSI, chemoresistance, 4319
- Testicular tumours, IGF II, JIP-1, 1075
- Testis, prostate cancer, DU 145, xenograft, radiotherapy, estramustine, 2873
- Testosterone, testicular cancer, cancer-related fatigue, anemia, trait anxiety, 4647
- 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin, ERK, JNK, p38, caspase-3, RAW 264.7 cells, 2831
- Texture analysis, magnetic resonance imaging, carcinoma, boot strap statistics, 3399
- TGF-beta, gastric cancer, spleen, CD62L, regulatory T cells, 643
- TGF- α , vulvar carcinoma, c-erbB-2, neoangiogenesis, immunohistology, prognosis, 1731

- TGF- β , FasL, vaccine, dendritic cells, 299
- TGF- β 1, c-kit, pancreatic cancer, immunohistochemistry, tyrosine kinase, 3523
- TGF- β 1, CD105, endothelial cells, angiogenesis, 1851
- TGGE (temperature gradient electrophoresis), K-ras mutations, colorectal carcinoma, circulating nucleic acids, 657
- TH1, colon cancer, real-time PCR, cytokines, H2, 2135
- Th1, lung cancer, tumor immunity, Tc1, Th2, Tc2, 2027
- Th1/Th2 balance, *Psidium guajava*, T regulatory cell, tumor vaccine, herbal medicine, 3763
- Th1/Th2, PSK, DC1/DC2, cytokines, 443
- Th2, lung cancer, tumor immunity, Th1, Tc1, Tc2, 2027
- Thiols, bisphenol A, hydroquinone, cytotoxicity, apoptosis, caspases, 2241
- Thomsen-Friedenreich, mucinous carcinoma, breast cancer, MUC1, MUC1-core, CA19-9, CA50, CA242, immunohistochemistry, 1755
- Thomsen-Friedenreich, tumor antigen, abort placenta, 1675
- Thrombocytopenia, nedaplatin, pharmacokinetics, pharmacodynamics, toxicodynamics, area under the plasma concentration-time curve (AUC), 1273
- Thrombophilia, factor V, prothrombin, oral cancer, oncogenesis, 2561
- Thrombosis, catheters, prophylaxis, warfarin, chemotherapy, 3143
- Thrombospondin, platelets, breast cancer, VEGF, tissue factor, 3963
- Thymidine kinase, 1- β -D-arabinofuranosylcytosine, L1210 cells, thymidylate synthase, 157
- Thymidine kinase, TPS, VEGF, endostatin, thyroid gland, cytosol, 1517
- Thymidine phosphorylase, dihydropyrimidine dehydrogenase, gastric carcinoma, colorectal carcinoma, 3755
- Thymidine phosphorylase, paclitaxel, doxifluridine, gastric cancer, 1291
- Thymidinekinase, chemotherapy control, colorectal cancer, 1831
- Thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), non-small cell lung cancer, RT-PCR, 923
- Thymidylate synthase, 1- β -D-arabinofuranosylcytosine, L1210 cells, thymidine kinase, 157
- Thymoma, hedgehog signaling pathway, thymus, 3697
- Thymoquinone, alpha-hederin, apoptosis, glutathione, *Nigella sativa*, 4255
- Thymoquinone, *Nigella sativa*, alpha-hederin, 2199
- Thymus, hedgehog signaling pathway, thymoma, 3697
- Thyroglobulin, RT-PCR, thyroid cancer, 3135
- Thyroid cancer, thyroglobulin, RT-PCR, 3135
- Thyroid carcinoma, thyroid incidentaloma, cancer screening, PET, FDG, 1421
- Thyroid gland, thymidine kinase, TPS, VEGF, endostatin, cytosol, 1517
- Thyroid incidentaloma, thyroid carcinoma, cancer screening, PET, FDG, 1421
- Thyroid nodule, Tc1, Tc2, papillary carcinoma, autoimmune thyroiditis, 2483
- Thyroid tumors, proliferative tumor marker, Ki-67 (MIB-1) antigen, topoisomerase II- α , 1835
- Thyroid, HBME-1, follicular carcinoma, immunohistochemistry, 179
- TIG3, RARRES3, RIG1, breast cancer, estrogen receptor, progesterone receptor, tumor suppressor gene, 2453
- Timing, giant intramuscular hemangioma, multistep approach, 2417
- TIMP-1, mRNA, MMP-2, MMP-7, TIMP-2, colorectal cancer, 3387
- TIMP-2, mRNA, MMP-2, MMP-7, TIMP-1, colorectal cancer, 3387
- TIMP-4, cervical cancer, 623
- Tissue array, EphA2, EphrinA-1, oesophageal squamous cell carcinoma, immunohistochemistry, RT-PCR, laser capture microdissection, 2943
- Tissue factor, platelets, breast cancer, VEGF, thrombospondin, 3963
- Tissue microarray, renal cell cancer, EGFR, clinical prognosis, survival, 1901
- Tissue morphology, procainamide hydrochloride, cisplatin, 4123
- Tissue transglutaminase, N-(4-hydroxyphenyl) retinamide, apoptosis, reactive oxygen species, glutathione, BSO, all-*trans* retinoic acid (ATRA), 1945
- TLR-4, dendritic cells, OK-432, tumor immunity, Toll-like receptor, 4231
- TNF, colon cancer, osteoprotegerin, RANKL, IL-1 β , immunohistochemistry, 3809
- TNF- α , FAA, DMXAA, LPS, murine macrophages, 1179
- TNF- α , SPI-077, STEALTH[®] liposomes, cisplatin, rat sarcoma, systemic treatment, 743
- Toll-like receptor, dendritic cells, OK-432, tumor immunity, TLR-4, 4231
- Toll-like receptor, LPS, Coley's toxin, innate immunity, immune therapy, lung carcinoma, alveolar macrophage, co-cultivation, 3747
- Tonsillar carcinoma, HPV, p16, radiotherapy, L1 capsid, HPV ISH, prognosis, 4375
- Topo II poison, anthracyclines, apoptosis, 2193
- Topoisomerase 2 α , HER2, p53, bladder carcinoma, FISH, multitissue array, prognosis, 263
- Topoisomerase II inhibitor, apoptosis, GL331, glioma, cell cycle, 4203
- Topoisomerase II, indolo[2,3-b]quinoline, cell cycle, MDR, DNA-binding, cytotoxicity, lipophilicity, antimicrobial, 2857

- Topoisomerase II, proliferation, migration, osteosarcoma, extracellular matrix, doxorubicin, matrix-metalloproteinase, $\beta 1$ integrin, 805
- Topoisomerase II α , (-)-Menthol, DNA topoisomerase I, topoisomerase II β , gastric cancer, 2069
- Topoisomerase II- α , proliferative tumor marker, Ki-67 (MIB-1) antigen, thyroid tumors, 1835
- Topoisomerase II β , (-)-Menthol, DNA topoisomerase I, topoisomerase II α , gastric cancer, 2069
- Topoisomerase inhibitor, irinotecan, amrubicin, non-small cell lung cancer, phase I study, non-platinum regimen, 2429
- Topotecan, ovarian cancer, chemotherapy, cisplatin, taxol, 2113
- Toxicity, anthracycline derivatives, antiproliferative activity, cardiotoxicity, 2043
- Toxicity, pancreatic cancer, radiochemotherapy, CA 19-9, gemcitabine, 1523
- Toxicity, weekly paclitaxel, efficacy, non-small cell lung cancer, NSCLC, 4611
- Toxicodynamics, nedaplatin, pharmacokinetics, pharmacodynamics, area under the plasma concentration-time curve (AUC), thrombocytopenia, 1273
- TP53, bladder cancer, TPA, HER-2/neu, uPAR, tumour marker, 635
- TPA, bladder cancer, HER-2/neu, uPAR, tumour marker, TP53, 635
- TPS, thymidine kinase, VEGF, endostatin, thyroid gland, cytosol, 1517
- Tracheal carcinoma, occult, positron emission tomography, computed tomography, image fusion, 459
- Trachylobane, diterpene, HL-60, apoptosis, cytotoxicity, *Croton zambesicus*, 363
- TRACP 5b, radiotherapy, bone metastases, breast cancer, 4639
- Trait anxiety, testicular cancer, cancer-related fatigue, anemia, testosterone, 4647
- Transarterial chemo- embolization, hepatocellular carcinoma, acute liver damage, Lipiodol, ICG-R15, 2551
- Transcriptional activation, glioma, p53, phosphorylation, 213
- Transfection, ultrasound, cavitation, drug delivery, gene therapy, biotherapy, 149
- Transgenic mice, NPM-ALK, lymphoma, ALCL, 3191
- Transplantation, ovary, sex cord stromal tumors, cryopreserved ovarian tissue, 4107
- Transurethral resection, bladder cancer, radiochemotherapy, 1623
- TRAP assay, antitelomerase drug PIPER, cytotoxic effect, 3341
- Trastuzumab, 2C4, adjuvant therapy, HER2/neu, Herceptin™, metastatic breast cancer, pertuzumab, review, 1483
- Trastuzumab, HER2, LAK, ADCC, 827
- Trastuzumab, high-dose chemotherapy, breast cancer, ERBB2, 663
- Trastuzumab, metastatic breast cancer, immunotherapy, Herceptin, circulating HER-2/neu, review, 4599
- Trifunctional antibody, high-dose chemotherapy, metastatic breast cancer, stem-cell transplantation, T-cell reinfusion, 3047
- Trifunctional bispecific antibody, multicellular tumor spheroids, immune therapy, 4239
- Triglycerides, retinoids, retinoid glucuronides, breast cancer, cancer chemotherapy, mammary tumors, retinol, bone mineral content, 2391
- Triple chemotherapy, NSCLC, carboplatin, paclitaxel, vinorelbine, 1333
- Triptorelin, Gn-RH agonist, prostate cancer, leuprorelin, drug resistance, 577
- Trophoblast tumour cells, phytoestrogens, lignans, flaxseed, matairesinol, Biochanin A, 1817
- TS polymorphism, MTHFR polymorphism, prognosis, non-small cell lung cancer, 4455
- TS-1, advanced gastric cancer, cisplatin, docetaxel, phase II study, second-line chemotherapy, 2973
- TSP-1, myeloid leukemia, peptides, differentiation, apoptosis, 757
- TT-232, somatostatin analog, leukemia model, 325
- Tubular adenocarcinoma, EMR, group III, tubular adenoma, 3513
- Tubular adenoma, EMR, group III, tubular adenocarcinoma, 3513
- α -Tubulin, β -tubulin, rectal cancer, tumorigenesis, 3237
- β -Tubulin isotypes, microtubules, resistance, combretastatin A-4, 3865
- β -Tubulin, α -tubulin, rectal cancer, tumorigenesis, 3237
- Tumor antigen, DNA methylation, reverse transcriptase polymerase chain reaction, stomach neoplasms, immunohistochemistry, survival analysis, 2105
- Tumor antigen, HER-2, influenza virus, memory CTL, IL-15, 715
- Tumor antigen, immunotherapy, cytotoxic T lymphocytes, natural killer cells, antibody-based therapy, carcinoembryonic antigen, review, 3725
- Tumor antigen, Thomsen-Friedenreich, abort placenta, 1675
- Tumor budding, rectal carcinoma, invasion, 1269
- Tumor cells, bisphosphonate, anti-proliferative activity, structure-activity, 1139
- Tumor cells, high hydrostatic pressure, orthopedic surgery, apoptosis, chondrosarcoma, chondrocytes, 1977
- Tumor colony forming assay, regional chemotherapy, liver metastases, colorectal cancer, 795
- Tumor endothelial cells, angiogenic phenotype, antiangiogenesis, angiogenesis models, review, 3799
- Tumor immunity, dendritic cell, human, CTL, antigen presentation, 2177

- Tumor immunity, dendritic cells, OK-432, Toll-like receptor, TLR-4, 4231
- Tumor immunity, human, dendritic cells, 3445
- Tumor immunity, lung cancer, Th1, Tc1, Th2, Tc2, 2027
- Tumor marker, bladder cancer, TPA, HER-2/neu, uPAR, TP53, 635
- Tumor marker, cadherin-6, circulating cancer cells, renal cell carcinoma, 377
- Tumor marker, CEA, CA 19-9, rectal carcinoma, overall survival, prognostic factor, 1787
- Tumor marker, S-100, MIA, malignant melanoma, prognostic factors, 1779
- Tumor marker, small cell lung cancer, ProGRP, NSE, lung cancer, CEA, CA 125, CYFRA 21-1, SCC, 1773
- Tumor markers, breast cancer, hormones, 451
- Tumor markers, fuzzy logic, gastro-intestinal cancer, 1507
- Tumor markers, pancreatic adenocarcinoma, differentiation, CA 19-9, 3625
- Tumor markers, SCC, CEA, cervical cancer, prognosis, 1765
- Tumor markers, tumor specific antigens, immunogens, cancer-bearing host, review, 2345
- Tumor mouse model, SNC 80, non-peptide opioids, δ -opioid agonist, murine tumor cells, L5178Y-R lymphoma, 4563
- Tumor proliferation, GLUT1, glucose consumption, protein synthesis, 3431
- Tumor rejection antigen, SART-1, cell cycle, apoptosis, 1983
- Tumor resection, VX2, squamous cell carcinoma, metastases model, 4209
- Tumor specific antigens, immunogens, tumor markers, cancer-bearing host, review, 2345
- Tumor specificity, apoptosis, doxorubicin, DNA fragmentation, mdr1, 877
- Tumor specificity, berberine, DNA fragmentation, caspase, Bad, Bcl-2, 4053
- Tumor suppressor gene, RARRES3, TIG3, RIG1, breast cancer, estrogen receptor, progesterone receptor, 2453
- Tumor targeting, human monoclonal antibody, MK-1, Ep-CAM, 3733
- Tumor targeting, lipoplatin, cisplatin, gastric cancer, colon cancer, hepatocellular cancer, 3031
- Tumor vaccine, *Psidium guajava*, T regulatory cell, Th1/Th2 balance, herbal medicine, 3763
- Tumor, angiogenesis, digoxin, mice, neuroblastoma, 207
- Tumor-associated macrophages (TAM), gastric cancer, Fas ligand (FasL), cytotoxic T lymphocyte (CTL), immunomodulation, prognosis, 463
- Tumor-infiltrating B lymphocyte, monoclonal antibody, lung cancer, hybridoma, 3791
- Tumor-infiltrating lymphocytes, CD4, CD8, CD20, prostate carcinoma, PSA, 4435
- Tumor-promoting factors, fat, colon, carcinogenesis, caroverine, ubiquinone, 2793
- Tumor-specificity, 3, 5-dibenzoyl-1, 4-dihydropyridines, DNA fragmentation, caspase, Bcl-2, Bax, Bad, radical, 2033
- Tumorigenesis, α -tubulin, β -tubulin, rectal cancer, 3237
- Tumors, heparin, Fraxiparine, metastasis, mouse, 2869
- TUNEL assay, alvaradoin E, alvaradoin F, annexin V-FITC, anthracenone C-glycosides, apoptosis, DAPI, DiOC₆, hollow fiber test, mitochondrial membrane potential analysis, propidium iodide, 779
- Tyrosine kinase, c-kit, TGF- β 1, pancreatic cancer, immunohistochemistry, 3523
- Ubiquinone, tumour-promoting factors, fat, colon, carcinogenesis, caroverine, 2793
- UCN-01, cyclin cdk's, PKC, phosphoinositol 3-kinase, apoptosis, deoxyadenosine resistance, p53, flavopiridol, LY294002, roscovitine, wortmannin, leukemia cells, 101
- UFT, Skp2, radiation, prognosis, immunohistochemistry, 2471
- Ulcerative colitis, colon, crypts, colorectal cancer, 4551
- Ulcerative colitis, inflammatory polyps, pseudopolyps, hepatitis, budesonide, 2961
- Ultrasound contrast media, breast carcinoma, Doppler ultrasound, neoadjuvant chemotherapy, 595
- Ultrasound contrast media, Doppler ultrasound, salivary gland tumor, 2477
- Ultrasound, breast cancer, diagnostic accuracy, mammotome, vacuum biopsy, FNAC, 2465
- Ultrasound, cavitation, drug delivery, transfection, gene therapy, biotherapy, 149
- Ultraviolet rays, immunocompromised host, CD4+ , 1963
- Underarm cosmetics, breast cancer incidence, epidemiology, upper outer quadrant, cancer prevention, 2543
- β -Unsaturated ketones, codeinone, anticancer drugs, apoptosis, caspase-3, DNA fragmentation, 4037
- UPAR, bladder cancer, TPA, HER-2/neu, tumour marker, TP53, 635
- Upper lobe, brain metastasis, small cell lung cancer, right lung, left lung, lower lobe, gender, smoking, epidemiology, 1101
- Upper outer quadrant, breast cancer incidence, epidemiology, underarm cosmetics, cancer prevention, 2543
- Urease inhibition, *Capsicum annum* L. var. *angulosum* Mill. extracts, cytotoxicity, MDR reversal, anti-HIV activity, anti-*Helicobacter pylori* activity, 1991
- Urinary bladder, carcinoma *in situ*, ImmunoCyt/uCyt+™, BCG therapy, 3641
- Urinary bladder, small cell carcinoma, p53, prognosis, survival, 2001
- Urinary trypsin inhibitor (UTI), surgical stress, cancer metastasis, murine colon carcinoma cell, 815

- Urine, LOH, microsatellites, 4049
- Urine, prostate cancer, VEGF, 3645
- Uterine cervix melanoma, vulvar melanoma, melanoma of the vagina, ovarian melanoma, 1567
- Uterine cervix, SCC antigen, cancer, radiotherapy, 1663
- Vaccine, dendritic cells, activated lymphocytes, autologous tumor cells, 3771
- Vaccine, FasL, TGF- β , dendritic cells, 299
- Vaccine, MUC1, peptide, pancreas cancer, 3575
- Vaccines, murine polyomavirus, VLPs, gene therapy, immune therapy, review, 2601
- Vacuum biopsy, breast cancer, diagnostic accuracy, mammotome, FNAC, ultrasound, 2465
- Vaginal metastasis, lung cancer, 1645
- Vaginal ultrasound, CA125, ovarian cancer, CT scan, 1551
- Vascular disrupting agent, MN-029, radiation, cisplatin, 3899
- Vascular endothelial growth factor (VEGF), tenascin (Tn-C)-C, microvessel density (MVD), angiogenesis, non-small cell lung cancer (NSCLC), 489
- Vascular endothelial growth factor, SU6668, gastric cancer, peritoneal dissemination, 17
- Vascular endothelial growth factor, VEGF, anti-metastasis, 3973
- Vascular invasion, malignant fibrous histiocytoma, distant metastasis, 1337
- Vasculature, interleukin-12, hypoxia, perfusion, proliferation, ICAM-1, 1015
- VCAM-1, adhesive molecules, ICAM-1, colorectal cancer, diagnosis, 1597
- VDR, breast cancer, vitamin D, xenograft, 24(OH) $_2$ D $_2$, 235
- VDR, calcitriol, vitamin D analogue, combined treatment, *in vitro* assay, cancer, 2235
- VDR, vitamin D, calcitriol, vitamin D analog, seocalcitol, medium-chain triglyceride, canine transitional cell carcinoma, growth inhibition, cell cycle, 2689
- VEGF, alternative splicing, angiogenesis, cartilaginous tumors, 955
- VEGF, bevacizumab, colorectal cancer, 3619
- VEGF, green tea, epigallocatechin-3-gallate, EGCG analog, chemoprevention, 397
- VEGF, hollow fibre assay, anti-vascular effects, angiogenesis, H460 non-small cell lung carcinoma cell line, 1889
- VEGF, immunosuppression, macrophage, angiogenesis, AIN, 693
- VEGF, IP-10, pancreatic carcinoma, irinotecan, oxaliplatin, 5-fluorouracil, leucovorin, gemcitabine, 3287
- VEGF, lung cancer, angiogenesis, iNOS, oncoprotein, risk model, 497
- VEGF, lung cancer, NF κ B, apoptosis, p53, 69
- VEGF, ovarian endometriosis, angiogenesis, MVD, survivin, 4313
- VEGF, platelets, breast cancer, thrombospondin, tissue factor, 3963
- VEGF, prostate cancer, urine, 3645
- VEGF, roxithromycin (RXM), angiogenesis, HepG2, 133
- VEGF, soft tissue sarcoma, Flk-1, MVD, angiogenesis, 3591
- VEGF, thymidine kinase, TPS, endostatin, thyroid gland, cytosol, 1517
- VEGF-A, breast cancer, CLA, linoleic acid, 4061
- VEGF-C, HIF-1 α , VEGF-D, breast ductal carcinoma, 3003
- VEGF-C, metastasis, lymphangiogenesis, inflammation, TAMs, invasion, review, 4503
- VEGF-D, cell proliferation, breast cancer, cyclin, angiogenesis, 701
- VEGF-D, HIF-1 α , VEGF-C, breast ductal carcinoma, 3003
- VGA1155, vascular endothelial growth factor, anti-metastasis, 3973
- Vin, vulvar cancer, *Lichen sclerosus*, squamous cell hyperplasia, p53, immunohistology, carcinogenesis, prognosis, 1739
- Vincristine, anaplastic oligodendroglioma, procarbazine, ranimustine, 3715
- Vinflunine, head and neck squamous cell carcinoma, clonogenic assay, chemosensitivity *in vitro*, 4363
- Vinorelbine, 5-fluorouracil, epirubicin, breast cancer, 4493
- Vinorelbine, advanced cervical cancer, cisplatin, 2489
- Vinorelbine, epirubicin, breast cancer, 1343
- Vinorelbine, gefitinib ('Iressa', ZD1839), non-small cell lung cancer (NSCLC), 547
- Vinorelbine, NSCLC, triple chemotherapy, carboplatin, paclitaxel, 1333
- Vinorelbine, sequential chemotherapy, docetaxel, epirubicin, advanced breast cancer, 1309
- Viscum album*, immunomodulation, surgical stress, mistletoe therapy, granulocyte function, oxidative burst, 4753
- Viscum album*, mistletoe, immune-suppression, biotherapy, Isorel, immunomodulation, NK cells, T-helper cells, 4583
- Viscum album*, pancreatic cancer, mistletoe extract, mistletoe lectin, gemcitabine, intratumoral injection, antitumour activity, human cancer xenograft, 1969
- Vision loss, prostate cancer, bone metastasis, 3521
- Vital tumor cells, radiotherapy, oral squamous cell carcinoma, hyperfractionated irradiation, 1707
- Vitamin C, zinc, Comet assay, DNA damage, 3197
- Vitamin D analog, vitamin D, calcitriol, seocalcitol, medium-chain triglyceride, canine transitional cell carcinoma, growth inhibition, cell cycle, VDR, 2689
- Vitamin D analogue, calcitriol, combined treatment, VDR, *in vitro* assay, cancer, 2235
- Vitamin D, breast cancer, VDR, xenograft, 24(OH) $_2$ D $_2$, 235

- Vitamin D, calcitriol, vitamin D analog, seocalcitol, medium-chain triglyceride, canine transitional cell carcinoma, growth inhibition, cell cycle, VDR, 2689
- Vitamin D, cancer, 24(OH)₂D₂, antiproliferation, bisphosphonate, 1909
- Vitamin D, cancer, BCI-210, 27-OH-BCI-210, antiproliferation, 4333
- Vitamin D, prostate cancer, LNCaP cells, ibuprofen, NSAID, 3425
- VLPs, murine polyomavirus, gene therapy, immune therapy, vaccines, review, 2601
- Volumetry, gastrointestinal tumor, computed tomography, endoscopic ultrasonography, diagnosis, 3-D structure, 2935
- Von Willebrand antigen, lung cancer, carcinoembryonic antigen, 403
- Vulvar cancer, exclusive radiotherapy, adjuvant radiotherapy, surgery, 3089
- Vulvar cancer, vin, *Lichen sclerosus*, squamous cell hyperplasia, p53, immunohistology, carcinogenesis, prognosis, 1739
- Vulvar carcinoma, TGF- α , c-erbB-2, neoangiogenesis, immunohistology, prognosis, 1731
- Vulvar melanoma, melanoma of the vagina, uterine cervix melanoma, ovarian melanoma, 1567
- VX2, squamous cell carcinoma, metastases model, tumor resection, 4209
- Warfarin, catheters, prophylaxis, thrombosis, chemotherapy, 3143
- Watchful waiting, prostate cancer, therapy, radical prostatectomy, brachytherapy, cryotherapy, high intensity focused ultrasound, chemotherapy, 551
- Weekly paclitaxel, efficacy, toxicity, non-small cell lung cancer, NSCLC, 4611
- Well-differentiated liposarcomas, c-kit, dedifferentiated liposarcomas, imatinib-mesylate, GISTs, polymorphism, 2215
- Western blot, paraneoplastic neurological syndromes, atypical antibodies, rat cerebellum, 3211
- Wide-band irradiation mode, millimeter waves, monochromatic irradiation mode, RPMI 7932, cell morphology, 1023
- Wide-band low-power millimeter waves irradiation, MCF-7 human breast carcinoma cell line, cell ultrastructure, 1009
- Wnt signalling pathway, PPAR β/δ , cyclin D1, multiple intestinal neoplasia, aberrant crypt foci, azoxymethane, ApcMin/+ mice, β -catenin, 3781
- Wnt5a, breast, cancer, suppressor, survival, 731
- Wogonin, N-acetyltransferase, human leukemia cells, *N-acetyl-2-aminofluorene*, 2-aminofluorene, 127
- Wortmannin, cyclin cdk's, PKC, phosphoinositol 3-kinase, apoptosis, deoxyadenosine resistance, p53, flavopiridol, LY294002, roscovitine, UCN-01, leukemia cells, 101
- WP1034, acute myeloid leukemia, apoptosis, signal transduction, Jak-Stat, 1841
- X-ray irradiation, Sialyl Lewis A, Sialyl Lewis X, colon cancer, cell adhesion molecules, 875
- Xanthorrhizol, *C. xanthorrhiza*, apoptosis, HeLa, 2221
- Xenograft, breast cancer, vitamin D, VDR, 24(OH)₂D₂, 235
- Xenograft, multidrug resistance, MDR modifiers, P-glycoprotein, bisbenzylisoquinoline alkaloids, 1953
- Xenograft, prostate cancer, DU 145, radiotherapy, testis, estramustine, 2873
- Xenon, photodynamic therapy, acridine orange, excitation, illuminance, osteosarcoma, 3979
- Xenopus* oocyte, MDA-MB-231, fibroblast growth factor receptor, Grb14, breast cancer, 3877
- XP cells, hyperthermia, cisplatin, 2649
- XRCC1, lung cancer, DNA repair, single nucleotide polymorphism, APEX1, ADPRT, LIG3, 537
- YB-1, PCNA, p53, lung cancer, 3437
- Yemen, oral cancer, cyclin D1, p53, qat, India, 4699
- ZD 1839, cisplatin, SCCHN, 3985
- ZD 1839, gefitinib ('Iressa', non-small cell lung cancer (NSCLC), vinorelbine, 547
- Zinc, vitamin C, Comet assay, DNA damage, 3197
- Zoledronic acid, bone remodelling markers, N-terminal telopeptide of collagen type I, alkaline phosphatase, bone metastases, bisphosphonates, 1457

Authors Index

(Figures refer to page numbers)

- Aaltomaa S, 4435, 4707
 Abdelhaleem M, 2645
 Abe H, 443
 Abe Y, 483
 Abgrall JF, 3179
 Abnet CC, 425, 543
 Abonyi ME, 1315
 Abou-Issa H, 2391
 Acalovschi I, 4583
 Ackermann S, 2519
 Acquati M, 1391
 Acquaviva AM, 2065
 Adam M, 2815
 Addeo A, 3287
 Adema GJ, 1015
 Adunka O, 1871
 Agarwal R, 2891
 Agnantis NJ, 347, 3591
 Agostara B, 1343
 Ahmad A, 331
 Ahmad I, 331
 Ahmadi A, 2515
 Ahn JY, 2249
 Ahonen I, 33
 Aiba M, 3513
 Aiello Talamanca A, 4519
 Aigner KR, 4407
 Aikou T, 133
 Akahane M, 701
 Akahane T, 701
 Akakura K, 4595
 Akçetin ZY, 1607, 1611, 1623, 1629, 1783
 Akeyama A, 3709
 Akeyama T, 3741
 Akiba T, 2729
 Akiyama H, 1369, 2973
 Akiyama S, 1247, 2965
 Akiyoshi T, 3697, 3703, 3771
 Alam S, 765
 Alamara C, 3489
 Albers P, 3413
 Alberti W, 1321, 1803
 Alderisio M, 2187
 Alegakis A, 2141
 Alesse E, 3149
 Alexander J, 3781, 3883
 Alfano C, 4573
 Algaba F, 3243
 Ali S, 331
 Alicarte J, 1773
 Alimonti A, 3531
 Alken P, 183, 551
 Alken R-G, 3407
 Allison RR, 1123, 3159
 Al-Maghrebi M, 2573
 Alonso FJ, 3315
 Alshafie GA, 2391
 Al-Sharabi AK, 4699
 Altwein JE, 3243
 Alvarez-Aguila NP, 3625
 Alvarez-Mon M, 999
 Alvegard TA, 419
 Amaike H, 3847
 Amanti C, 3237
 Amato I, 1109
 Ambrogi V, 403
 Ambruosi C, 2493
 Amellem Ø, 2259
 Anastasiadis AG, 4481
 Andersson B, 2609
 Andersson LC, 2669
 Andersson P, 903
 Ando S, 85
 Andratschke M, 2821, 3911, 4075, 4239
 Andreasson K, 2601
 Androulakis G, 3629
 Angelopoulou MK, 4743
 Angelucci C, 3937
 Anim JT, 2573
 Annereau J-P, 4113
 Annila A, 33
 Anselmino A, 3203
 Ansqer Y, 243, 4535
 Antonaci A, 2483
 Antonicelli F, 2617
 Antoniou D, 2991, 3671
 Anuszevska EL, 2193
 Aoe K, 415
 Aogi K, 1197
 Aoki D, 133
 Aoki M, 3791
 Aozuka Y, 815, 3973
 Aperis G, 651
 Apice G, 4519
 Apostolikas N, 1471
 Araki A, 1337
 Araki K, 3003
 Araki Y, 3847
 Arampatzis I, 3023
 Aranton B, 1385
 Arastu HH, 3159
 Aravantinos G, 3103, 3553
 Ardavanis AS, 523, 4493
 Arikawa S, 305, 4157
 Arikuni H, 1197
 Arima K, 1881
 Arisi E, 2771
 Arlindo FC, 3469
 Arow K, 917
 Artale S, 4463
 Arthur G, 95
 Asahina H, 435
 Asanuma K, 3967
 Ascierio PA, 1441, 4577
 Asko-Seljavaara S, 2669
 Astner S, 4605
 Asumendi A, 1945
 Aszalos A, 4113
 Atakilit A, 751
 Atencia R, 1945
 Ater J, 4429
 Athanasiades A, 3671
 Athanassiadou S, 4543
 Atsuji K, 3847
 Atsumi T, 4029
 Audretsch W, 4615
 Auge JM, 1765, 1773, 1779
 Avila-Bront A, 273
 Avnet S, 1109
 Avril M-F, 1205
 Ayabe T, 3601
 Aydeniz B, 1895
 Azarbayjani F, 207
 Azuma H, 171
 Azzalin A, 4369
 Baatout S, 1039
 Baba E, 3445
 Baba H, 2713, 3117
 Baba T, 1193
 Babinsky A, 1687
 Bacchilega R, 4577
 Bachtiry B, 4673
 Backe J, 1747
 Backman U, 207
 Bader Y, 3407
 Bae SI, 4013
 Bafaloukos D, 3103
 Baghi M, 1871, 3665, 3985
 Bahlo M, 1687
 Bai C-H, 4719
 Bai M, 347
 Bai N-S, 313
 Baier PK, 2135, 3581
 Bajenova O, 23
 Bak M, 4319
 Bakkellund W, 3809
 Balbi C, 3999
 Baldini N, 1109
 Baldridge LA, 2001
 Baldus SE, 1349
 Balegno S, 3211
 Balle A, 1679
 Ballesta AM, 1773, 1779
 Band V, 3833
 Banerjee C, 2905
 Banerjee K, 2841
 Bani MR, 2519
 Banis C, 2141
 Banno K, 3547
 Bao Y, 3375
 Barbera M, 1179
 Barboro P, 3999
 Barbounis V, 651
 Bari M, 3871
 Barke A, 1787
 Barna G, 3321, 4179
 Barsoum AL, 2345
 Barth P, 4129
 Barthomeuf C, 3943
 Bartsch F, 4753
 Basili S, 403
 Basso SMM, 4559
 Battermann JJ, 4655
 Bauchart D, 3943
 Baumann H, 1871, 3985
 Baumeister P, 3197
 Baumgartner U, 2135, 3581
 Bavazzano M, 4451
 Beattie EC, 1919
 Beauduin M, 1211
 Beck Z, 2153
 Becker S, 2171
 Becker-Pergola G, 2171
 Beckmann MW, 2519, 4107
 Befrits R, 4393
 Behnam-Motlagh P, 2609
 Behrend M, 4389
 Behringer D, 4423
 Bekaert S, 1039, 3011
 Beke D, 3607
 Bellarosa D, 2119

- Belli F, 1309
 Bellon G, 2617
 Bellone G, 3287
 Bellos JK, 2449
 Bellucci A, 2681
 Belluti F, 1179
 Belogianni I, 2091
 Bemis L, 2215
 Bendardaf R, 3083
 Beneduci A, 1009, 1023
 Benes P, 4299
 Benöhr P, 1895
 Bensari A, 397
 Benson RM, 3833
 Berdeaux O, 3943
 Berg K, 291
 Bergemann C, 1581, 1639, 1675, 1713, 1817
 Berghmans T, 2385
 Bergli EN, 3095
 Bergman M, 2515
 Bergoc R, 4305
 Bernard-Gallon DJ, 2009
 Berndt SI, 537
 Bernicot I, 3179
 Berrocal A, 4611
 Berruti A, 4475
 Bertelli G, 2555
 Bertetto O, 3287
 Berthou C, 3179
 Berti F, 2837
 Bessho A, 2429
 Beuth J, 601
 Beyer C, 1147
 Bezieau S, 225
 Biagini G, 4313
 Bibby MC, 1889
 Bichler K-H, 1783
 Bieberschulte W, 2793
 Bieche I, 4679
 Bielawska-Pohl A, 2857
 Biesterfeld S, 3243
 Biete A, 1765
 Bignon J, 2129
 Bignon Y-J, 2009
 Billi AM, 2039
 Binaschi M, 2119
 Bischof A, 1581, 1639
 Bischof M, 4753
 Bisi A, 1179
 Bistoni G, 4573
 Bitossi R, 4475
 Bitterlich N, 1507
 Bittman R, 95
 Bittoun P, 2129
 Björnestal L, 4375
 Bladström A, 419
 Blanck G, 3889
 Blasco A, 4611
 Blin N, 2809
 Block S, 363
 Blomqvist C, 2669
 Blonski K, 3303
 Bloomer WD, 1865, 2161
 Blottière HM, 225
 Bobrowska-Hägerstrand M, 3173
 Boccardo F, 3999, 4277
 Bocher O, 1803
 Bodily JM, 765
 Bodrogi I, 4319
 Boehmer A, 4481
 Boeters I, 3303
 Boettcher H-D, 4639
 Boffetta P, 425
 Bofill M, 693
 Bofos I, 3489
 Böhler F, 3613
 Böhling T, 853, 2669
 Boisson-Vidal C, 2129
 Bojar H, 4615
 Bollschweiler E, 1349
 Boncompagni E, 4123
 Bonifacino A, 2465
 Bonnet C, 225
 Bono AV, 3243, 3937
 Bononi M, 505, 2417
 Bonsted A, 291
 Boomsma F, 3651
 Boratynski J, 2229
 Borchers H, 3243
 Borgese L, 1079
 Borke J, 63
 Borsato S, 4559
 Borsellino N, 4445
 Bortkiewicz P, 2789, 4293
 Bosch E, 1765, 1779
 Bossard C, 4679
 Bossone G, 3619
 Botti C, 1343
 Botti G, 2065, 4519
 Bouancheau D, 225
 Bouda J, 617
 Boudova L, 617
 Bouet-Toussaint F, 2177
 Boulikas T, 3031
 Bouras C, 2961
 Bourhis J, 4357
 Bouros D, 1427
 Bowden E, 23
 Boyano M-D, 1945
 Bozzo L, 2381
 Brackrock S, 1321
 Braganca J, 3469
 Bramerio E, 4463
 Branca M, 3469
 Brandi M, 1309
 Brandi ML, 1109
 Braud AC, 663
 Braun S, 2809
 Brauns SC, 4197
 Bravo JJ, 1115
 Bravo M, 1115
 Bravo-Cuellar A, 4091
 Brem H, 3825
 Bremnes RM, 4611
 Brennan P, 425
 Brenner K, 3607
 Bria E, 1343
 Briese J, 1603, 1667
 Briese V, 1567, 1581, 1603, 1633, 1639, 1645, 1667, 1675, 1713, 1719, 1761, 1811, 1817, 1823
 Brinck U, 2789, 4293
 Bringuier A-F, 243
 Brivio F, 3597
 Bromberg-White J, 765
 Brooks SA, 1829
 Broquet A, 225
 Browaey-Poly E, 3877
 Brown J, 981
 Brozova M, 1051
 Brozzetti S, 2417
 Brucale A, 4577
 Bruckner HW, 3637
 Bruel A, 757
 Bruland ØS, 9
 Bruns F, 1523, 1539, 1543, 1663, 1711
 Bruzewicz S, 2879
 Brychtova S, 4299
 Bu X, 2049
 Bubko I, 2193
 Buccheri G, 4685
 Buccinnà B, 3203
 Budischewski K, 4261
 Budzynska R, 2229
 Buecher B, 225
 Bühler P, 4733
 Buhmeida A, 3083
 Bui F, 4559
 Bullerdiel J, 3995
 Bundred NJ, 3963
 Büntzel J, 1539, 1711
 Burgemeister S, 4341
 Burillon J-P, 2489
 Burkholder I, 3303
 Burnol A-F, 3877
 Burton IE, 3963
 Burza A, 505
 Büssing A, 1449, 4753
 Bussink J, 1015
 Buttenschoen K, 795
 Buyru N, 2767
 Byrne GJ, 3963
 Caballero C, 4611
 Caballero-Hernández D, 4563
 Cafaggi S, 4123
 Cailliau K, 3877
 Caleno MP, 3531
 Calori L, 4577
 Calverley MJ, 2689
 Camp JR, 4165
 Campodonico F, 2381
 Campos D, 3215
 Campos L, 4135
 Camps C, 4611
 Candeloro G, 409
 Canepa G, 2381
 Cangemi V, 505
 Canon JL, 1211
 Cantarelli M, 2423
 Cantelli-Forti G, 2837
 Capen CC, 2689
 Capomolla E, 1309
 Caporaso N, 537
 Capponi G, 2381
 Caputo A, 1179
 Caputo M, 1079
 Carbonaro D, 331
 Carbone A, 3287
 Carbone M, 429
 Carboni R, 4513
 Cardarelli CO, 3925, 4113
 Carico E, 3237
 Caristi N, 4513
 Cariveau MJ, 1123, 3159
 Carlini P, 3531
 Carlsson L, 4399
 Carmignani G, 2493
 Carminati P, 2681
 Carnemolla B, 3999
 Carney W, 1433
 Carnino F, 1343
 Carrara M, 1179
 Carrera MP, 193
 Carrizales G, 3215

- Caruso MG, 3393
Case LD, 1101
Casini B, 1079
Cassandro R, 669
Castagna L, 3143
Castel T, 1779
Castelli M, 1079, 3341
Casu M, 3597
Catros-Quemener V, 2177
Cavallaro A, 505, 515
Cavallini A, 4287
Ceccarini M, 2423
Ceccaroni M, 2423
Cecchin D, 4559
Cemazar M, 839
Cenci M, 2187
Cenni E, 1109
Cerea G, 4463
Ceribelli A, 4713
Cerna M, 3387
Cerny R, 3387
Ceroni M, 3211
Cervantes-Munguía R, 4091
Cesta A, 409, 3149
Cha KY, 2249
Chaadaeva A, 3893
Chadha AS, 3517
Chai H, 779
Chalabi N, 2009
Chaloupkova A, 1051
Chandra A, 3355
Chandra P, 3355
Chang C-H, 2719
Chang CT-R, 683
Chang H-L, 4061, 4081
Chang S-C, 2453
Chanock S, 537
Chantal Hillarby M, 1851
Chao P-L, 2719
Chao W-R, 397
Charaffe-Jauffret E, 663
Chardigny J-M, 3943
Chassevent A, 2009
Chau NP, 3279
Chaubal S, 2821
Chaudhuri S, 2905
Chayama K, 709
Chen G, 3399
Chen G-W, 971, 4149
Chen H, 3877
Chen J-C, 4203
Chen K-T, 1421
Chen S-T, 2719
Chen W-J, 455
Chen Y, 4203
Chen Y-K, 1421, 4719
Chen Y-L, 1421
Cheng C-L, 2439
Cheng K-C, 971
Cheng L, 2001
Cheng Y-F, 455
Cheng Y-P, 2551
Chetrite GS, 2827
Chiappino I, 3287
Chiara S, 1391
Chiarelli LR, 4369
Chiavarina B, 4123
Chiba N, 2965
Chidichimo G, 1009, 1023
Chino O, 4417
Chiu K-Y, 2439
Chiu T-H, 127
Chiummariello S, 4573
Cho S, 709
Cho S-W, 2831
Chondros C, 3495
Chong J-M, 3183
Chong SY, 2249
Chou AS-B, 683
Chou J-M, 2453
Chow W-K, 2551
Chowdhury SA, 2055, 4037, 4053
Christofferson R, 207
Christophi C, 1413
Chuang C-K, 683
Chuang Y-C, 127
Chung DH, 4631
Chung J-G, 127, 971, 2069, 4149
Chung J-H, 4631
Chung LW, 881
Ciardi A, 505
Ciavattini A, 4313
Cilli M, 4123
Clagett-Dame M, 2391
Clare SE, 1895
Classen E, 2215
Clausen M, 1827
Cocca C, 4305
Cocco L, 2039
Coggin Jr JH, 2345
Cognetti F, 3531, 4769
Colantonio I, 2555
Coleman M, 369
Collan Y, 2535, 3083
Colucci G, 1309, 4445
Comella G, 1441
Comincini S, 4369
Comploj E, 3641
Consorti F, 2483
Cooper PA, 1889
Corato M, 3211
Cordell GA, 779
Cordon-Cardo C, 2789, 4293
Cornillon J, 4135
Cortes-Prieto J, 2827
Corvin S, 4481
Cory AH, 101
Cory JG, 101
Costa S, 3469
Costa-Bauza A, 2593
Crafa F, 515
Cremonesi M, 1343
Cricco G, 4305
Crickx B, 1205
Crocchi M, 4305
Csapo Z, 2885
Csoma E, 2153
Csuka O, 325, 4319
Cui J, 2943
Cui R, 489
Cundari S, 2681
Curiel DT, 1983
Curley Jr RW, 2391
Curotto A, 2493
Czejka M, 2985
D'Alessandro R, 403
D'Angelo R, 595
D'Arrigo C, 3999
D'Ottavio AM, 1343
Dahlstrand HM, 4375
Dalay N, 2767
Dalchow C, 4129
Dalianis T, 2601, 4375
Daly BM, 2801, 3159
Danae M, 4615
Danbara N, 2269
Dang D, 751
Dannos I, 3489
Daponte A, 1441
Darbre PD, 2543
Daver A, 2009
Davis JB, 43
Davis ME, 871
Daval PA, 43
Dawsey SM, 425, 543
De Aloysio D, 2423
De Angelis M, 2417
De Arruda Cardoso Smith M, 4069
De Braekeleer M, 1931, 3179
De Cesare A, 505
De Chiara A, 595, 4519
De Cobelli O, 577, 579
De Francesco GP, 3237
De Francesco V, 2567
De Iaco P, 2423
De Jong S, 255
De La Pintiere CT, 2177
De La Torre A, 3943
De Lutio Di Castelguidone E, 2477
De Marinis F, 4713
De Matteis A, 1343
De Meyer T, 3011
De Mulder PHM, 1015
De Pauw-Gillet M-C, 363
De Petris L, 4713
De Rose R, 1023
De Sabata MS, 1219
De Santis S, 4713
De Vries EFJ, 255
De Vries EGE, 3651
De Wilde PCM, 1015
Dealtry G, 4197
Debiton E, 3943
Dederichs F, 3413
Del Nonno F, 1079
Del Vecchio I, 4369
Delides A, 2141
Della Rocca C, 2483
Delle Piane M, 4451
Demachki S, 4069
Demant AW, 725
Demeter A, 2885
Demiris M, 651
Demmig-Adams B, 3871
Demonakou M, 2961
Dempke W, 1147
Den Otter W, 3893
Denis MG, 225
Deppert W, 213
Derchain S, 3469
Derka S, 2561
Deroide F, 693
Derradji H, 1039
Deschatrette J, 3279
Deutsch E, 4357
Devries A, 1523
Dhainaut C, 4535
Dhar DK, 463
Di Bisceglie M, 4445
Di Bonito M, 2065
Di Cocco B, 3619
Di Costanzo G, 2555
Di Lauro L, 1309

- Di Maio M, 3501
 Di Molfetta M, 4713
 Di Salvia R, 4713
 Diamantopoulou K, 4543
 Dicuonzo G, 669
 Didziapetris R, 4173
 Diehl P, 1977
 Dietl J, 1531, 1649, 1747
 Diez JC, 999
 Digjuni B, 2771
 Dimakou E, 3489
 Dimitriadou EM, 4743
 Dimitroulis J, 2991, 3671
 Dimmler A, 4107
 Dimopoulos J, 4673
 Dimopoulos MA, 3103, 3553
 Dimopoulou MN, 4743
 Dimou E, 2445
 Ding H-J, 1421
 Dinjens WNM, 913
 Dionellis G, 3489
 Dipaola RS, 313
 Dittrich R, 4107
 Dix D, 1385
 Dmitriev I, 1983
 Do S-H, 1029
 Dobre A, 4583
 Dobrenkov K, 85
 Doehn C, 4341
 Dogliotti L, 4475
 Doi M, 79
 Dome B, 4759
 Domingo JM, 1773
 Domínguez-Rodríguez JR, 4091
 Domke R, 1645
 Donahue M, 537
 Dong Y, 2639
 Dores GB, 3469
 Dosaka-Akita H, 435
 Douet-Guilbert N, 1931, 3179
 Dowdy SC, 2921
 Dreyer L, 2589
 Drobinskaya I, 3251
 Dubinett SM, 107
 Duca L, 2617
 Dudás J, 805
 Dueñas B, 193
 Dunkel L, 2873
 Dünne AA, 2675, 4129, 4209
 Durand D, 3943
 Dus D, 383, 2857
 Dutour A, 3799
 Dutta S, 2929
 Duvillard P, 1205
 Dyer A-M, 4471
 Dzimiras S, 2043
 Eberlein K, 4639
 Ebinuma H, 477
 Eble JN, 2001
 Ecke TH, 635
 Economopoulos T, 1457, 3103, 3553
 Eda R, 415
 Edler L, 3303
 Edwards JM, 3159
 Efferson CL, 715
 Effmert U, 1817
 Efremidis A, 651
 Efstathiou E, 3553
 Egawa K, 3709, 3741
 Egert A, 3191
 Eggermont AMM, 743
 Eggstein S, 2135, 3581
 Eguchi K, 483, 1197
 Ehrke MJ, 3905
 Ehrlichová M, 4215
 Eiter H, 3613
 El Sharouni SY, 4655
 El-Dein Saad A, 4245
 Elgrova L, 3387
 Ellis D, 751
 Elmberger G, 1397, 4375
 Elmishad AG, 429
 Elsässer D, 1629
 Elsässer-Beile U, 4733
 Emanuelli G, 3287
 Emionite L, 4277
 Encke A, 3023
 Ende S, 1607, 1611
 Endo H, 4231
 Endo Kazuya, 2713, 3117
 Endo Keigo, 4439
 Endoh Y, 443
 Enesel MB, 4583
 Eng H-L, 455, 527
 Engehausen DG, 1607, 1611, 1623, 1629, 1783
 Engström W, 1075
 Erhardt W, 2815
 Erhart K, 3613
 Eriguchi M, 3709, 3741
 Eriksen J, 2661
 Erjala K, 4363
 Erkkilä K, 2873
 Erzen M, 3469
 Escalon E, 3293
 Escobar HM, 3995
 Esenaliev RO, 149
 Eskelinen M, 531, 2527, 4623
 Espinosa M, 623
 Esposito V, 669
 Esteban F, 1115
 Estrov Z, 1841
 Etemadi A, 425
 Evans MJ, 1123, 2801, 3159
 Ewens A, 3905
 Ewers SB, 4663
 Fabi A, 3531, 4769
 Fabia G, 4559
 Fabris G, 4313
 Faderl S, 1841
 Faenza I, 2039
 Fahimi S, 543
 Falanga M, 2065, 3501
 Falkson CI, 2489
 Falkson G, 2489
 Fan W, 1953
 Fanucchi A, 2509
 Faried A, 2749, 3231, 3461, 4005, 4439
 Farkas R, 4763
 Farmakis D, 1457, 3553
 Farnsworth NR, 779
 Farrey K, 63
 Farris A, 1343
 Fasching PA, 2519
 Fatouros M, 3023
 Fazioli F, 4519
 Fea E, 2555
 Fechner G, 3413
 Feeley BT, 107
 Fehm T, 1551, 2171
 Feil G, 1783
 Feldmann G, 243, 4535
 Feller AC, 263
 Feng Z, 3309
 Fenoglio C, 4123
 Ferenczi E, 471, 4759
 Fermandjian S, 2129
 Fernández-Molina B, 3315
 Ferrajoli A, 1841
 Ferraresi V, 4769
 Ferrari E, 3501
 Ferrari M, 577
 Ferreira Leal M, 4069
 Ferreira M-JU, 3259, 4173
 Ferretti G, 3531
 Ferretti L, 4369
 Ferri M, 4577
 Ferrigno D, 4685
 Ferroni P, 403
 Feyerabend S, 4481
 Fiano V, 3203
 Fiebig HH, 1969
 Filella X, 1765, 1773, 1779
 Filice S, 595
 Filipits M, 4249
 Filippelli L, 1023
 Filosa A, 4313
 Fimognari C, 2837
 Fínek J, 1517, 1597, 1655, 1795, 1831, 3387
 Fiolka G, 1491
 Fiori E, 505
 Fischer G, 2789, 4293
 Fischer K, 1591, 1659
 Fiume R, 2039
 Fiuraskova M, 4299
 Fleer J, 4647
 Fleischmann J, 1611
 Focan C, 1211
 Focan-Henrard D, 1211
 Foggi P, 1309
 Fokt I, 2193
 Fonseca H, 3293
 Forest V, 4135
 Formato R, 3501
 Formelli F, 4179
 Fornara P, 1591, 1659
 Fornari D, 4049
 Fountzilias G, 319, 3103, 3553
 Fowler M, 2969
 Franciotta D, 3211
 Franco OE, 1881
 Frank C, 2929
 Frascogna V, 4357
 French D, 2187
 Freudenstein J, 139
 Friedl J, 4225
 Friedländer E, 1187
 Friedman H, 1263
 Friedrich RE, 1693, 1699, 1703, 1707
 Friese K, 1575, 1581, 1615, 1633, 1639, 1679, 1719, 1725, 1731, 1739, 1761, 1811
 Fritz P, 1969
 Fritzer-Szekeres M, 3407
 Fronk E-M, 4753
 Frontini L, 3597
 Fruehauf A, 1147
 Fröhlich D, 1539, 1711

- Fujii D, 1197
 Fujii S, 1237
 Fujii T, 463
 Fujimoto E, 3183
 Fujimoto K, 3709, 3741
 Fujimoto T, 4747
 Fujino H, 923
 Fujino T, 483
 Fujisawa M, 2757
 Fujisawa S, 161, 965, 2241, 3263, 3367, 3989, 4029
 Fujisawa S-I, 4053
 Fujishiro Y, 477
 Fujitake S-I, 1247
 Fujiwara H, 3847
 Fujiwara K, 547
 Fujiwara M, 2627
 Fujiyama J, 895
 Fukai Y, 2749, 3231, 3461, 4005, 4439
 Fukayama M, 3183
 Fuke H, 1243
 Fukuchi M, 2749, 3231, 3461, 4005, 4439
 Fukuchi Y, 489
 Fukuda K, 895, 3791
 Fukui H, 3335
 Fukui M, 2461, 3575
 Fukumori K, 459
 Fukumura K, 1283
 Fukuoka M, 2997
 Fukushima T, 3715
 Funahashi H, 875
 Fünsterer C, 1699
 Furukawa F, 3763
 Furukawa T, 17
- Gaal D, 325
 Gabbert H, 3251
 Gadducci A, 2509
 Gademann G, 3659
 Gaglia A, 1457
 Gailhofer S, 4407
 Gakiopoulou H, 3109
 Galati G, 1079, 3341
 Galetta D, 4445
 Gallipoli A, 595, 2477
 Gallo O, 2771
 Gallo R, 3149
 Galmiche J-P, 225
 Galmozzi F, 4277
 Gambacorta M, 4463
 Gambletsas E, 651
 Gamradt SC, 107
 Ganti AK, 3517
- Garbay C, 3877
 Garbero C, 2493
 Garcia A, 249
 García-Sastre A, 715
 García MJ, 193
 Garde J, 4611
 Gardner TA, 881
 Garfield S, 4113
 Gargini A, 2509
 Garkavij M, 4663
 Garrone O, 2555
 Garufi C, 1343
 Gasco M, 2555
 Gasmí J, 2489
 Gasperi V, 3871
 Gassel AM, 1649
 Gauger K, 1483
 Gavrilov V, 3425
 Gebauer G, 1477, 1551
 Gebbia N, 1309
 Gebbia V, 4445
 Geboes K, 4393
 Géczy L, 4319, 4759
 Geidel H, 1067
 Geissler M, 1787
 Gemba K, 547
 Genazzani AR, 2509
 Genetet N, 2177
 Genin C, 377
 Gentil-Perret A, 377
 Georgakopoulos E, 319
 Georgakopoulou S, 319
 Georgatou N, 2991
 Georgoulas V, 3559
 Geppert R, 1491
 Gerber B, 1615, 1719, 1761
 Gercel-Taylor C, 2113
 Gerdesmeyer L, 1977
 Gergely-Farnos E, 471
 Gerkens P, 363
 Gervais A, 2177
 Gezane-Csorba M, 3321
 Ghimenti C, 3203
 Ghio R, 4451
 Ghirardi O, 2681
 Ghoneum M, 859, 981, 4187
 Ghosh A, 2905
 Giacomelli L, 3237
 Giamboudakis P, 2991
 Giancesini G, 3937
 Giannarelli D, 1309
 Giannerini S, 2465
 Giannetta L, 4463
 Giannikaki E, 1927
 Giannini R, 4287
- Giannopoulos A, 3109
 Giarnieri E, 3237
 Gidaro G, 3237
 Gidaro S, 3237
 Giese A, 213
 Giese M, 1693, 1703
 Gietema JA, 3651
 Gille L, 2793
 Gil-Montoya JA, 1115
 Ginopoulos P, 3559
 Ginsburg R, 1263
 Giometto B, 3211
 Giotta F, 1309, 4445
 Giovagnoli A, 2465
 Giovagnoli MR, 2465, 3237
 Giovanella L, 1547
 Giuberti C, 3597
 Giunta S, 1343
 Giunti A, 1109
 Glasmacher A, 4591
 Glatzel M, 1539, 1711
 Glinskii AB, 1477
 Glinsky GV, 1477
 Gmeindl M, 4753
 Gminski R, 3355
 Gnant M, 4225
 Gobbi S, 1179
 Goda K, 1187, 2757
 Godlewska J, 2857
 Goedhals L, 2489
 Gogas H, 3103
 Goletz S, 1811
 Gollapudi S, 859, 981, 4187
 Gollwitzer H, 1977
 Golubkov V, 249
 Gómez-Contreras PC, 4091
 Gomez-Flores R, 4563
 Gonçalves A, 663
 Gontijo R, 3469
 Gonzalez Cao M, 1779
 González-Moles MA, 1115
 Goodwin R, 3825
 Gopalrao RK, 1131
 Gori R, 4577
 Gorzegno G, 4475
 Gosmar M, 2493
 Goso C, 2119
 Goteri G, 4313
 Goto S, 1297, 3709, 3741
 Goto T, 955
 Gotoh A, 2757
 Gotoh M, 4231
 Götte K, 2761
- Gottesman MM, 4113
 Goulet III R, 2367
 Goussia AC, 3591
 Goverud IL, 3781
 Gozdzik A, 2193
 Graas MP, 1211
 Grabert RC, 43
 Gradinger R, 1977
 Graefe H, 4075
 Graf N, 2583
 Graf W, 917
 Graff P, 2259
 Gramigni C, 3287
 Granchi D, 1109
 Granetto C, 2555
 Grankvist K, 2609
 Granowitz EV, 3833
 Grases F, 2593
 Gravina A, 1441
 Greggi S, 3501
 Gregorakis A, 3123
 Greiner T, 1969
 Greish K, 4245
 Grénman R, 4363
 Gretz N, 183
 Grimelius L, 3099
 Grip S, 1075
 Gröbe A, 4129
 Groeger AM, 669
 Gross E, 1803
 Grosu AL, 4605
 Grosu V, 4583
 Gruber BM, 2193
 Gruenberger T, 4249
 Gruffat D, 3943
 Grünewald V, 3431
 Grusch M, 3407
 Gryniewicz G, 2357
 Gstöttner W, 1871, 3665, 3985
 Gu C, 3437
 Gu Y, 1
 Guadagni F, 403
 Gudbjarnason S, 1877
 Guenin E, 1139
 Guepratte S, 1433
 Guercio S, 4475
 Guinebretiere JM, 1433
 Gunkel L, 1755
 Gutierrez B, 1803
 Gutiérrez A, 4305
 Guyotat D, 4135
 Guzińska-Ustymowicz K, 1269
 Gyémánt N, 3259, 4173

- Haak M, 183
 Haas GP, 1263
 Haase L, 4341
 Haase M, 1067
 Habiro A, 3347
 Hacene K, 1433
 Hachimine K, 3725, 3733
 Hadjimichael C, 1059
 Haga S, 1251
 Hagedorn H, 2821
 Hägerstrand H, 3173
 Hagiwara A, 895
 Haglund C, 853, 2669
 Hahne J, 3191
 Hakenberg OW, 1067
 Halapas A, 2449
 Hamada K, 1291
 Hamaguchi K, 3513
 Hamanaka Y, 3575
 Hambek M, 1871, 3665, 3985
 Hamilton J, 981
 Hammes LS, 3469
 Han J, 4631
 Han JH, 2249
 Hanagiri T, 1193, 3533
 Hanai K, 483
 Hanberg A, 903
 Hansen AB, 4049
 Hantschmann P, 1731, 1739
 Hara I, 3645
 Hara M, 3601
 Harada A, 69
 Harada K, 2471
 Harada T, 69, 3843
 Harbeck N, 1483
 Harday J, 3167
 Harisi R, 805, 4759
 Harita S, 2429
 Harlozinska A, 3327
 Haroun-Bouhedja F, 2129
 Harréus U, 3197
 Harrington KJ, 4527
 Harris D, 1841
 Hartmann J, 3407
 Haruta J, 1297
 Hasan J, 1889
 Hasanin E, 4245
 Hasegawa T, 875
 Hasegawa Y, 4569
 Hashiguchi S, 3979
 Hashimoto Ken, 161, 283, 305, 887, 2033, 2055, 2085, 4157
 Hashimoto Kiyoshi, 4569
 Hashimoto Koji, 1361, 3523
 Hasizume T, 483
 Hassan C, 2567
 Hatano N, 2639
 Hatjieleftheriou G, 1471
 Hatori S, 2973
 Hattori T, 435
 Hatzmann W, 4753
 Hauch H, 3585
 Hauer K, 2985
 Hauptmann S, 3431
 Havir M, 617
 Hawa, G, 3607
 Hayakawa K, 4403
 Hayashi M, 2399, 2435
 Hayashizaki Y, 895
 Hayes KA, 2689
 Hazama S, 3575
 He L, 3309
 He X, 537
 He Y, 3309
 Hecker E, 3355
 Heidari S, 2601
 Heike Y, 1197, 1983
 Heikkilä S, 3083
 Heinemann V, 3047
 Heinicke T, 4591
 Helidonis E, 2141
 Hellberg D, 611, 3041
 Heller F, 1551
 Heller N, 3407
 Helmichova E, 1655
 Hemmi H, 2785
 Henke J, 2815
 Henkel V, 1895
 Henne-Bruns D, 795
 Hennenlotter J, 1901
 Henrichs C, 1483
 Henriksen G, 9
 Henriksson R, 2609
 Heouaine A, 2555
 Herbacek I, 4673
 Herberger B, 4249
 Herbst H, 1671
 Herkommer K, 1303
 Hernádi Z, 1187
 Hernández L, 451
 Hernández-Flores G, 4091
 Herráez A, 999
 Herry A, 1931
 Herzog D, 2761
 Hes O, 617
 Hesselmann S, 1523
 Heymann M-F, 225
 Hibi K, 1247, 2627
 Hibshoosh H, 273
 Hicks ME, 4563
 Higami T, 1361, 3523
 Highland MA, 2391
 Hihara J, 821
 Hino M, 3747
 Hinoda Y, 3575
 Hirakawa K, 3271
 Hiraki A, 415
 Hirao N, 3547
 Hirata A, 3263, 3367
 Hirata K, 3541, 3755
 Hirayama N, 3973
 Hironaka K, 827, 2407
 Hirose K, 847
 Hirose Y, 3733
 His P, 2489
 Hiyama E, 2951
 Hlobilkova A, 4299
 Ho C-T, 313
 Ho H-C, 2439
 Ho M, 2645
 Ho Y-J, 2551
 Hoekstra HJ, 4647
 Hoekstra-Weebers JEHM, 4647
 Hoelscher AH, 1349
 Hofbauer LC, 3607
 Hoffman RM, 59
 Hoffmann I, 4107
 Hofmann C, 795
 Hög A, 3099
 Höger H, 4225
 Høget A, 291
 Holdenrieder S, 1597, 1655, 1795, 1831
 Hollingshead MG, 1865
 Hollmann C, 1803
 Holopainen JM, 33
 Holubec Jr L, 1517, 1597, 1655, 1795, 1831, 1835, 3387
 Holubec Sen L, 1597, 1655, 1831, 3387
 Hong J-W, 2705
 Hong SP, 2249
 Honig A, 1531, 1747
 Hoover F, 291
 Hopt UT, 2135, 3581
 Hori H, 3689, 3747
 Horiguchi J, 1291, 2957
 Horiguchi-Yamada J, 2631
 Horiuchi Y, 1297
 Hörmann K, 2761
 Horn T, 4049
 Hornebeck W, 2617
 Hornig A, 1539
 Horny H-P, 3303
 Horsman MR, 3399
 Horst E, 1523
 Horstmann M, 1901
 Horti J, 4759
 Horvath Z, 3407
 Hoshiai H, 2785
 Hoshijima H, 4037
 Hoshino M, 4231
 Hoshino Y, 4231
 Hoskin DW, 735
 Hosoi H, 1225
 Hosokawa M, 1197, 1983
 Hosokawa S, 3791
 Hospers GAP, 255, 629
 Hostanska K, 139
 Hostmark J, 2097
 Hotta K, 547, 2429
 Hotta T, 931
 Hottentrott C, 3023
 Houghton JA, 3321
 Hoving S, 743
 Hrehorovich VR, 3637
 Hrelia P, 2837
 Hsia T-C, 2069
 Hsieh B-T, 2719
 Hsieh D-S, 4719
 Hsieh J-F, 4719
 Hsu S, 63
 Hsu S-J, 2453
 Huang J, 3725
 Huang Y-T, 2017
 Huang Y-W, 871, 4061
 Huber R, 1969
 Hung G-U, 4737
 Hung M-W, 2719
 Hung S-W, 2551
 Huovinen R, 2535
 Husøy T, 3781
 Huuhtanen R, 2669
 Huynh HT, 117
 Hwang J-I, 2551
 Hwang SG, 2249
 Hyun JW, 391
 Iacoangeli A, 3341
 Iacopino F, 3937
 Iadicicco G, 563
 Iaffaioli VR, 2065, 3501
 Ibrahim SO, 4699
 Ichikawa T, 4595
 Ichikawa Y, 1237, 1327
 Ichiki Y, 1193

- Ichikura T, 3225
 Iczkowski KA, 2075
 Ida M, 1197
 Ierardi E, 2567
 Ieromonachou P, 1927
 Iesato H, 1291
 Iida T, 85
 Iijima K, 2957
 Iino Y, 2957
 Ike H, 1237, 1327
 Ikeda T, 79
 Ikematsu Y, 3575
 Ikenaka Y, 3335
 Illera JC, 4269
 Illmer C, 3407
 Imada T, 2973
 Imai K, 3575
 Imamoto T, 4595
 Imamura Y, 2627
 Imazawa M, 1247
 Imre G, 3321
 Imura M, 435
 Ina K, 1297
 Inada S, 3847
 Inagawa H, 463, 3679, 3747
 Inokuchi S, 4417
 Inose T, 4005
 Inoshima N, 69
 Inoue K, 4053
 Inoue M, 463, 3679
 Inoue T, 1243
 Inoue Y, 3541, 3755
 Inpanbutr N, 2689
 Ioannides CG, 715
 Ioannidis G, 523, 4493
 Iodice F, 3501
 Ionna F, 2477
 Iorfida M, 4513
 Iovanna JL, 833, 3419
 Ishibashi K, 1251, 4747
 Ishibashi T, 1273, 1283
 Ishida I, 3733
 Ishida K, 931, 3453
 Ishida T, 435
 Ishiguro K, 2027, 3003
 Ishiguro N, 4413
 Ishihara M, 3951, 4053
 Ishii A, 4693
 Ishii S, 79
 Ishii T, 1337
 Ishikawa T, 1237, 1327
 Ishioka C, 2965
 Ishiwata T, 489
 Ishiyama H, 4403
 Ismail N, 2221
 Isobe H, 435
 Isobe Y, 2935
 Isotalo T, 4435, 4707
 Itakura M, 1361, 3523
 Itashiki Y, 2471
 Ito H, 3003, 3481
 Ito K, 1243, 1247, 2627
 Ito M, 709
 Ito N, 2027, 3481
 Ito T, 895, 3763
 Ito Y, 171, 179, 509, 833, 3419
 Itoh H, 3541, 3755
 Itoh K, 1983
 Itoh M, 3183
 Iwaasa M, 3715
 Iwadate M, 443
 Iwahashi M, 931, 3453
 Iwanami K, 1291
 Iwasaki R, 1257
 Iwase H, 1297
 Iwase S, 2631
 Iwata S, 1337
 Iwazaki S, 1291
 Iyer R, 3055
 Izawa T, 3347
 Izbicka E, 3215
 Izumori K, 2639
 Izzo L, 505, 1079, 3341
 Jacob A, 3191
 Jacquemier J, 663
 Jäger M, 947
 Jäger R, 3191
 Jäger W, 1551
 Jagiello M, 2229
 Jahnke A, 1567, 1645
 Jakopovic M, 4663
 Jakse G, 3243
 Jakubiak A, 2857
 Jakubikova J, 3375
 Jalava P, 2535
 Jangi M, 1945
 Jankowska B, 4451
 Janni W, 1761
 Jansen B, 2697
 Janssen CHJM, 1465
 Jaromin A, 2857
 Jaroszewicz I, 2235
 Jarry A, 225
 Javle M, 3055
 Jawahar A, 675
 Jayson GC, 1889
 Jech M, 4225
 Jehl F, 2327
 Jellouschek H, 3243
 Jeney A, 805, 2885
 Jeon YK, 4631
 Jeong D-H, 1029
 Jeong K-S, 1029, 2831
 Jeong W-I, 1029
 Jepsen JV, 4049
 Jerevall P-L, 2515
 Jerusalem G, 1211
 Jeschke U, 1575, 1581, 1615, 1633, 1639, 1675, 1679, 1719, 1725, 1731, 1739, 1761, 1811, 1817
 Jespersen S, 3399
 Ji X, 2161
 Jia WW-G, 2049
 Jiang J, 4081
 Jiang S-Y, 2453
 Jiang WG, 731
 Jirillo A, 563
 Jocham D, 4341
 Joe AK, 273
 Johnke RM, 1123, 3159
 Johnsson A, 2661
 Jolois O, 363
 Joneberg J, 2601
 Jones L, 2969
 Jones RF, 1263
 Jones TD, 2001
 Jorch N, 2583
 Jordan A, 2145
 Jozereau D, 1491
 Juarez A, 4611
 Jubb E, 1889
 Juhl H, 23
 Jumbelic M, 1263
 Jung EJ, 2105
 Jurek D, 2793
 Kaczmarek L, 2857
 Kadoma Y, 965, 2241, 3367, 3989
 Kadota R, 1983
 Kadowaki K, 3755
 Kaewsakhorn T, 2689
 Kafousi M, 1927, 2743
 Kahlert S, 3047
 Kai H, 709
 Kairemo K, 33, 2873
 Kakizaki T, 483
 Kakudo K, 179, 833
 Kakuta H, 4157
 Kal HB, 4655
 Kalaidopoulou O, 3495
 Kalmus GW, 1123
 Kalofonos C, 3553
 Kalofonos H, 3067
 Kalofonos HP, 3103
 Kalogeraki A, 1927
 Kalpadakis C, 4743
 Kamangar F, 425, 543
 Kamath N, 331
 Kamidono S, 2757
 Kamina S, 347
 Kämmerer U, 1531, 1747
 Kanakis I, 1457
 Kanavakis E, 2979
 Kanavaros P, 347
 Kanazawa M, 443
 Kandilis K, 3559
 Kaneko T, 3709, 3741
 Kangasniemi A, 33
 Kankkunen J-P, 4707
 Kanska U, 2229
 Kanzaki N, 4231
 Kao C, 881
 Kao C-H, 1421, 4719
 Kao S-T, 4149
 Kapatsoris D, 2961
 Kapp M, 1531, 1649
 Kappas AM, 3023
 Kapranos N, 939
 Kaprara A, 2091
 Karamanos NK, 1457, 2851
 Karameris A, 3629
 Karamouzis M, 4493
 Karanikiotis C, 319
 Karapanagiotou E, 4527
 Karatza C, 3067
 Karavias D, 3067
 Karavitaki N, 3135
 Kardamakis D, 1059, 3067
 Kariatsumari K, 459
 Karim A, 675, 2969
 Karina M, 319, 3553
 Karita M, 2399
 Kärjä V, 4435, 4707
 Karlén P, 4393
 Karlsson U, 2929, 3159
 Karonen S-L, 33
 Karreman C, 4615
 Karsten U, 1581, 1675
 Kase S, 3843
 Kashimura S, 4231
 Kasuga T, 2705
 Katano Mitsuo, 3445, 3697, 3703, 3771
 Katano Motonobu, 2705
 Katayama H, 415

- Katayama T, 283
 Katis K, 2991
 Kato A, 3709, 3741
 Kato H, 1251, 2749, 3231, 3461, 4005, 4439
 Kato Satoshi, 2965
 Kato Syunsuke, 2965
 Kato Y, 477
 Katsouda E, 3495
 Katsube T, 847, 3513, 4747
 Katsuki T, 3541, 3755
 Katsuoka Y, 171
 Katz DM, 3833
 Katzmann JA, 2921
 Kaufmann M, 121, 4261
 Kaukinen S, 33
 Kausch I, 263
 Kawabuchi Y, 2407
 Kawaguchi M, 3547
 Kawaguchi O, 3481
 Kawaguchi S-I, 2471
 Kawai H, 4693
 Kawakami K, 4455
 Kawamoto T, 1193
 Kawano F, 4245
 Kawano K, 715
 Kawano T, 2631
 Kawaoka T, 3575
 Kawase M, 887,1991, 2033, 4037
 Kawashima T, 875
 Kawashima Y, 1291, 2471
 Kawasuji M, 4245
 Kawata N, 2579
 Kawata T, 3481
 Kawate S, 1291
 Kearney CM, 3865
 Keeney GL, 2921
 Keilholz U, 1333
 Keohavong P, 537
 Kéri GY, 325
 Kerr JS, 197
 Keszler G, 2885
 Khamis H, 917
 Khan S, 331
 Khatib Z, 3293
 Kholová I, 1517
 Kida M, 2935
 Kidogawa H, 3957
 Kijima H, 4417
 Kijima M, 1327
 Kiknavelidze K, 551
 Kikuchi E, 435
 Kikuchi H, 305, 887, 2033, 2055, 2085
 Kikuchi J, 435
 Kikuchi K, 477
 Kikuchi S, 2935
 Kikuchi S-I, 2777
 Kim EL, 213
 Kim Ho-Jun, 2831
 Kim Hyo Jin, 2249
 Kim J, 4013
 Kim JH, 391
 Kim JK, 2249
 Kim K-H, 1
 Kim MA, 2105
 Kim NK, 2249
 Kim S, 2249
 Kim S-H, 2831
 Kim S-R, 2831
 Kim T-H, 1029, 2831
 Kim WH, 2105, 4013
 Kimura Hideki, 85
 Kimura Hitoshi, 3231, 3461, 4005, 4439
 Kimura S, 923
 Kin S, 895
 Kinezaki M, 4499
 Kinghorn AD, 779
 Kinnunen PKJ, 33
 Kinoshita I, 435
 Kinoshita N, 283
 Kinugasa T, 3725, 3733
 Kirk KL, 3689
 Kirwan CC, 3963
 Kisanga ER, 4487
 Kishino D, 547
 Kishino K, 2055, 2085
 Kisseberth WC, 2689
 Kitadai Y, 709
 Kitade M, 3335
 Kitajima M, 17, 79, 3791
 Kitajima Y, 4021
 Kitanaka S, 3763
 Kitano M, 4403
 Kitayama J, 2737
 Kitsiou S, 2979
 Kitsoulis P, 347
 Kittas C, 2141
 Kiura K, 547, 2429
 Klapdor R, 1687
 Kleiman D, 4305
 Klopp R, 601
 Klouvas G, 3103
 Klutmann S, 1827
 Kluwe L, 213, 1699
 Knecht R, 121, 1871, 3665, 3985, 4261
 Knocke T-H, 4673
 Knoll T, 183, 551
 Knop J, 1703
 Knutsen HK, 3781
 Knutson JC, 235, 1909, 4333
 Ko D, 1
 Ko S-F, 455, 527
 Kobayashi D, 3967
 Kobayashi Kaoru, 179, 509, 3419
 Kobayashi Kayoko, 2729
 Kobayashi Kiyonori, 2935
 Kobayashi M, 1291
 Köbel M, 3431
 Koc M, 4215
 Koch E, 1901
 Koch MO, 2001
 Kodama M, 709
 Kodera Y, 1247, 2627
 Kodre V, 839
 Koga K, 3697, 3703, 3771
 Koga Y, 4021
 Kogure M, 4231
 Kohchi C, 3679, 3747
 Kohgo Y, 3347
 Kohlberger P, 617
 Kohn EC, 725
 Kohno K, 3437
 Kohnoe S, 2713, 3117
 Koi M, 2785
 Koibuchi Y, 2957
 Koike M, 1361, 2627, 3523
 Koivunen E, 33
 Koizumi K, 815, 3347
 Koizumi M, 3507
 Koizumi T, 283
 Koizumi W, 1257
 Kojima M, 3697
 Kokoris SI, 4743
 Kolar Z, 4299
 Kolb HJ, 3047
 Kolbow K, 3911
 Kolialexi A, 2979
 Koljonen V, 853
 Komiya A, 4595
 Komiyama T, 3507
 Kon H, 4693
 Kondo K, 923
 Konecny G, 3047
 Konishi J, 435
 Konishi T, 2737
 Konno S, 847, 3513
 Konno T, 4693
 Kontopidou FN, 4743
 Kontou S, 1471
 Koós K, 4173
 Kopf B, 4577
 Kopper L, 2869, 3321, 4179
 Korabiowska M, 2789, 4293
 Korkolis DP, 1409
 Kormunda S, 1597, 3387
 Kornafel J, 2879
 Kornberg LJ, 4349
 Kornmann M, 795
 Koshida K, 2729
 Koshiyama M, 4499
 Kosmas C, 3559
 Kosmidis C, 3559
 Kosmidis P, 3103
 Kostakis A, 2449
 Kotzerke J, 1067
 Koukourakis MI, 1427
 Kouloxouzidis G, 1409
 Koumakis G, 651
 Kounelis S, 939
 Kountourakis P, 1457
 Kouri-Bairaktari E, 939
 Kouskouni E, 3495
 Koutandos J, 3671
 Koutsilieris M, 2449, 3123, 3135
 Kovacs CJ, 1123, 2801, 3159
 Kovács G, 471, 4759
 Kovalszky I, 805
 Kovár J, 4215
 Koyama M, 1243
 Kozlak J, 383
 Kozubek A, 2857
 Kraemer M, 1139, 2655
 Kragl U, 1817
 Krämer S, 1551
 Krasnykh V, 1983
 Krasznai ZT, 1187
 Krause FS, 1607, 1611, 1623, 1629
 Krause W, 2145
 Krauspe R, 947
 Krauter G, 3355
 Kriegel S, 1679
 Kriese K, 3431
 Kristen P, 1649
 Kristiansen K, 3781
 Kristina K, 4075
 Kronen-Herzig A, 1477
 Kruck S, 1901
 Krüger S, 263
 Krüll A, 1321
 Kubo Akira, 2973
 Kubo Atsushi, 3481
 Kubo F, 133
 Kubo M, 3697, 3703

- Kubo S, 3689
 Kubo Tadahiko, 2951
 Kubo Takahiro, 955
 Kubo Toshikazu, 2461, 3979
 Kubota K, 2935
 Kubota Takeshi, 3847
 Kubota Tetsuro, 17, 3791
 Kuczyk M, 1901, 4481
 Kudlacek S, 3607
 Kudlackova I, 1051
 Kudo H, 157
 Kuehs U, 1901
 Küfer R, 1901
 Kuga H, 3445
 Kugler C, 3303
 Kuhn C, 1679
 Kulkarni TR, 2075
 Kulmala J, 4363
 Kulsum U, 4053
 Kuma K, 179, 509, 833, 3419
 Kumada S, 1297
 Kumai K, 17, 3791
 Kumamoto Y, 477
 Kumar S, 1851, 3963
 Kunert-Keil C, 1615, 1761
 Kunieda E, 3481
 Kunisaki C, 1369, 2973
 Kuopio T, 2535
 Kupka MS, 1679
 Kupka S, 2809
 Kurahashi T, 3645
 Kurek R, 1895
 Kuribayashi S, 3481
 Kurihara M, 1257
 Kurihara N, 477
 Kurihara T, 305, 4157
 Kurimoto M, 875
 Kuriyama S, 3335
 Kuriyama T, 299
 Kuroda T, 709
 Kuroki H, 3445
 Kuroki Masahide, 3725, 3733
 Kuroki Motomu, 3725, 3733
 Kuroki S, 3703
 Kurth AA, 4639
 Kurylak A, 2253
 Kusewitt DF, 1963
 Kusugami K, 1297
 Kusuzaki K, 1225
 Kutner A, 2235
 Kuwabara Y, 3547
 Kuwano H, 2749, 3231, 3461, 4005, 4439
 Kyratzis G, 3103
 Kyroudi A, 2141
 Kyrtsolis M-C, 4743
 Kyurkchiev S, 4727
 La Cesa A, 669
 Laack E, 3303
 Laengle F, 4249
 Lagadas A, 3559
 Lagerlund M, 1397
 Lagerros C, 1397
 Laguinge L, 23
 Lah TT, 587
 Lai HC, 4325
 Lai MY, 959
 Laine J, 2535
 Lakatos PL, 1315
 Lama G, 3937
 Lambert C, 377
 Lamerz R, 1655, 1831
 Lamlum H, 3083
 Lan Q, 537
 Lange I, 263
 Langer M, 3303
 Längler A, 2583
 Lantvit D, 779
 Lapp C, 63
 Lapp D, 63
 Lardeux B, 243
 Larina IV, 149
 Larosa G, 3619
 Larsen RH, 9
 Larsson A, 4399
 Larsson B, 917
 Larsson C, 683
 Lassus P, 2669
 Lategan A, 2489
 Laudisi A, 403
 Lausen B, 1629
 Laytragoon-Lewin N, 1397
 Lazaris A, 4543
 Le Bris M-J, 1931, 3179
 Le Corre L, 2009
 Le Doussal VE, 4679
 Le E, 3889
 Lecouvey M, 1139, 2655
 Ledderose G, 3047
 Ledoux D, 1139
 Lee BL, 2105
 Lee GK, 4631
 Lee G-P, 1029
 Lee H, 2439
 Lee HS, 2105, 4013
 Lee HZ, 959
 Lee J-H, 2069
 Lee L-T, 2017
 Lee M-S, 2453
 Lee M-T, 2017
 Lee P-PH, 2017
 Lee RJ, 343
 Lee T-K, 3159
 Lee T-W, 2719
 Lee YM, 2105, 4013
 Legrand A, 243
 Legrand C, 757
 Lehtonen J, 531, 2527, 4623
 Lehy T, 4535
 Leiber C, 4733
 Leistenschneider P, 2809
 Lejarcegui JA, 1765
 Lelong-Rebel IH, 3925
 Lembessis P, 2449, 3135
 Lenk SV, 635
 Lenti L, 2483
 Leris ACA, 731
 Lerma-Díaz JM, 4091
 Lescuyer A, 3877
 Lesniak MS, 3825
 Lesnick TG, 2921
 Letarte M, 1851
 Leung HWC, 959
 Levêque D, 2327
 Lewin F, 1397
 Lewis J, 63
 Li C, 1851, 3963
 Li G, 377
 Li H, 273
 Li J, 2943
 Li L, 1693, 1703
 Li LF, 53
 Li S, 59
 Li T-C, 2551
 Li T-M, 971
 Liang P, 2705
 Liang X-J, 4113
 Liao AC, 1421, 4719
 Liao C-S, 4719
 Liao S-K, 683
 Liapis CD, 2449
 Lidereau R, 4679
 Lieberman JR, 107
 Liebeskind A-K, 2583
 Lieder AM, 4141
 Lien EA, 4487
 Liepe K, 1067
 Lin Cheng-Chieh, 2551
 Lin Chin-Chung, 4149
 Lin C-L, 2049
 Lin H, 2001
 Lin J-G, 971, 2069
 Lin J-P, 2069
 Lin S-Y, 127
 Lin W-Y, 4737
 Lin Young C, 871, 4061, 4081
 Lin YQ, 107
 Lin Y-S, 2017
 Lin Yu-Chin, 2049
 Lindfors U, 657
 Lindhofer H, 3047, 4239
 Lindner P, 789
 Lindquist D, 4375
 Lindström AK, 611
 Lipponen P, 4435, 4707
 Lipska L, 1831
 Lirussi F, 4385
 Liska V, 1597
 Lissoni P, 3597
 Litlekalsoey J, 2097
 Litman T, 2661
 Liu G, 2705
 Liu H, 273
 Liu JM, 2129
 Liu NQ, 107
 Liu P, 4429
 Liu S, 4061
 Liu W-K, 3951
 Lizarraga F, 623
 Lo Casto M, 4277
 Lo Giudice P, 2681
 Lo Muzio L, 4313
 Lobelle JP, 1211
 Løberg EM, 3781
 Lobo C, 3315
 Lococo E, 2483
 Lodde M, 3641
 Loehberg CR, 2519
 Loening SA, 635
 Loertzer H, 1591, 1659
 Löfberg R, 4393
 Loggie BW, 369
 Loncarek J, 255
 Longatto-Filho A, 3469
 Lope Pihie AH, 2205, 2221
 Lopes C, 4269
 Lopez M, 1309
 Lopez-Beltran A, 2001
 Lopez-Guerrero JA, 497
 Lora J, 3315
 Loreau O, 3943
 Lorenz M, 3023
 Lörincz A, 3469
 Lörincz T, 3075
 Losito S, 3501
 Loubani O, 735
 Lovato A, 4577

- Lu H-F, 127, 2069
 Lu J, 2049
 Lucarini G, 4313
 Lucht M, 4733
 Ludvíková M, 1517, 1835
 Luebke T, 1349
 Lüftner D, 1491, 4599
 Lum HE, 43
 Lum LG, 43
 Lumachi F, 4385, 4559
 Lundgren J, 1397
 Luniewski W, 2857
 Lüthen F, 1675
 Lux MP, 2519
 Lynn Smith B, 2489
- Maccarrone M, 3871
 Mack B, 2821
 Mack MG, 3665
 MacLennan GT, 2001
 Madej J, 2043
 Madelenat P, 4535
 Madlener S, 3407
 Madureira AM, 3259, 4173
 Maeda H, 1131, 4245
 Maeda MYS, 3469
 Maeda T, 415
 Maehara Y, 2713, 3117
 Maekawa S-I, 3725
 Maffezzini M, 2381
 Mafodda A, 4513
 Magagnoli M, 3143
 Maggi CA, 2119
 Maggiorella L, 4357
 Magi S, 4577
 Magiakos G, 1471
 Magyar P, 471
 Mahteme H, 917
 Mai M, 1377
 Maier C, 1303
 Maier K, 3641
 Maisano R, 4513
 Makari-Judson GP, 3833
 Makatsoris T, 3067
 Maki J, 2033
 Makino K, 3747
 Makita F, 1291
 Makovitzky J, 1559, 1567, 1633, 1645, 1675, 1713, 1719, 1725, 1755, 1823
 Makuuchi H, 4417
 Malafarina V, 669
 Malamos N, 939, 3559
 Malcontenti-Wilson C, 1413
 Maldonado V, 623
- Malekzadeh R, 425
 Maltaris T, 4107
 Malvey J, 1779
 Manabe T, 875
 Mancuso A, 4713
 Manda R, 2749, 3231, 3461, 4005, 4439
 Mandelbrot L, 243, 4535
 Mandic R, 2675
 Mándoky L, 3061, 4319
 Manfredi V, 2493
 Manganella G, 2477
 Manganini V, 3597
 Mansukhani M, 273
 Manzione L, 4445
 Manzoli L, 2039
 Maraninchi D, 663
 Marchetti F, 4573
 Mardente S, 2483
 Mare M, 4513
 Marian B, 2793
 Mariani A, 2921
 Marinu-Aktipu K, 3211
 Mariotti S, 403
 Mark Evers B, 149
 Markland FS, 249
 Marolla P, 3619
 Márquez J, 3315
 Martelli A, 2493
 Martelli AM, 2039
 Martelli O, 4713
 Martin B, 2005, 2385
 Martín G, 4305
 Martin Jimenez J-L, 2145
 Martínez-Arribas F, 451
 Martínez-Martos JM, 193
 Martini F, 403
 Maruyama E, 171
 Maruyama I, 133
 Maruyama R, 1361, 3523
 Marzola MC, 4559
 Masamura S, 79
 Mascaux C, 2385
 Masci G, 3143
 Masedu F, 3089
 Mastro A, 2477
 Masuda N, 2749, 3231, 3461, 4005, 4439
 Masui H, 1237, 1327
 Matei DV, 577, 579
 Matés JM, 3315
 Matkowski R, 2879
 Matos J, 3469
 Matouskova E, 1051
 Matsubara T, 1225
- Matsuda G, 1369, 2973
 Matsui Y, 955
 Matsumine A, 1225
 Matsumoto H, 887
 Matsumoto Kentaro, 3541, 3755
 Matsumoto Kotaro, 3445, 3697, 3703, 3771
 Matsumoto Kunio, 3847
 Matsumoto M, 3957
 Matsumoto T, 207
 Matsumura Y, 3271
 Matsunami T, 2729
 Matsuo K, 1327
 Matsuo T, 2951
 Matsuo Y, 875
 Matsushita K, 133
 Matsuura K, 643, 827, 2407
 Matsuyama M, 4417
 Matsuyama S, 4231
 Matsuzaki Y, 3601
 Matsuzuka F, 179, 509, 3419
 Matthias C, 3197
 Matthiessen PF, 1449
 Mattioli F, 2493
 Maubec E, 1205
 Maude Leblanc J, 53
 Maurizi Enrici R, 3089
 Mautner VF, 1699
 Mavrommatis J, 3109
 Mavrou A, 2979
 Mayas MD, 193
 Mayer A, 3911, 4075
 Mazess RB, 235
 Mazumdar M, 2905
 Mazzocchi M, 4573
 Mazzoni G, 2417
 McCarthy K, 675, 2969
 McCollum CN, 3963
 McDowell G, 3963
 McKoy J, 273
 McLaughlin-Drubin M, 765, 1091
 Mcleod DG, 1
 Mearini E, 4399
 Medicina D, 4277
 Medina OP, 33
 Medina V, 4305
 Medina-Castro JM, 3625
 Meert A-P, 2005
 Mehdi SA, 3517
 Mehrotra R, 4699
 Meijer C, 255
 Meissner H, 213
 Melendez-Zajgla J, 623
- Mellado B, 1765
 Mellgren G, 4487
 Melnick SJ, 3293
 Melucci M, 1441
 Memeo L, 273
 Mencoboni M, 4451
 Mengele K, 1977
 Mengs U, 4733
 Menzel C, 4639
 Menzel H, 3047
 Merlano M, 2555
 Merseburger AS, 1901, 4481
 Mesnil M, 255
 Messerini L, 1353
 Mester J, 1829
 Meyer A, 4389
 Meyers C, 765, 1091
 Mi Q, 779
 Mian C, 3641
 Mian M, 3641
 Miccini M, 2417
 Michalak K, 383
 Michalopoulou P, 3671
 Michel MS, 183, 551
 Micke O, 1523, 1539, 1543, 1555, 1663, 1671, 1711
 Micksche M, 4673
 Midiri G, 3237
 Mielke S, 4423
 Miettinen M, 2669
 Migianu E, 2655
 Migliorino MR, 4713
 Mihalik R, 3321, 4179
 Mihich E, 3905
 Mikami Y, 2965
 Mikhailidis DP, 4281
 Milano A, 4519
 Milingos N, 3629
 Miller D, 1263
 Miller M, 43
 Milne P, 4197
 Miloso M, 2681
 Minagawa N, 3541
 Minami G, 3979
 Minami T, 69
 Mincheff M, 4727
 Minelli A, 4399
 Mineo D, 403
 Mineo TC, 403
 Mingazzini PL, 515, 2465
 Mingeot-Leclercq M-P, 363
 Mirri A, 4769
 Misasi R, 2483
 Missol-Kolka E, 1087
 Mitrus I, 1087

- Mittelmeier W, 1977
 Miura K, 489
 Miura M, 1327
 Miya A, 179, 509, 833, 3419
 Miyabe Y, 3507
 Miyake H, 3645
 Miyamoto K-I, 2729
 Miyamoto Y, 3709, 3741
 Miyauchi A, 179, 509, 833, 3419
 Miyazaki K, 4021
 Miyazaki S, 1225, 2965
 Miyazaki T, 2749, 3231, 3461, 4005, 4439
 Miyoshi T, 923
 Mizobata S, 931
 Mizobuchi S, 1131
 Mizuhara Y, 2729
 Mizukami M, 1193
 Mizukami Y, 3347
 Mochizuki H, 3225
 Modlich O, 4615
 Moenig SP, 1349
 Moeslein G, 3251
 Mogi S, 751
 Mohamad N, 4305
 Mohamed S, 197
 Moiseeva E, 3893
 Mokbel K, 731
 Mokka R, 4435, 4707
 Molina R, 1765, 1773, 1779
 Molls D, 3431
 Molls M, 2815, 4605
 Molnár J, 1991, 3061, 3259, 4173
 Moltz CC, 2929
 Momm F, 1787
 Monden Y, 923
 Monfardini S, 563
 Monia BP, 2697
 Montalto E, 4513
 Montesarchio V, 669
 Montik N, 4313
 Moon KC, 4631
 Morales M-C, 1945
 Morel F, 1931, 3179
 Morengi E, 3143
 Moreno-Baylach MJ, 497
 Mori S, 4519
 Morice P, 3179
 Morini S, 2567
 Morisaki T, 3445, 3771
 Morishita Y, 1291, 2957
 Morita M, 1193, 3437, 3533
 Moritani S, 2729
 Moriyama N, 483
 Morr AK, 1649
 Morshed SR, 161, 2033, 2085
 Mosca A, 4475
 Mose S, 4639
 Motohashi G, 2705
 Motohashi N, 305, 383, 1991, 4157
 Motoo Y, 833, 3419
 Moul JW, 1
 Mousa SA, 197
 Mross K, 4423
 Mrówczyńska L, 3173
 Mücke R, 1711
 Mueller A, 4107
 Mueller SB, 1671
 Mueller SC, 3565, 4341
 Mueller T, 1147
 Mueller W, 3251
 Mukherjee J, 2905
 Mulder NH, 255, 629
 Müller C, 1491
 Muller S, 2655
 Müller S, 3413
 Müller SC, 725
 Müller T, 1649
 Mullerat J, 693
 Mumford JL, 537
 Mumtaz FH, 4281
 Munakata M, 435
 Munck-Wikland E, 4375
 Muni R, 3619
 Murakami A, 3689
 Murakami T, 415
 Murakami Y, 3263, 3367, 4029
 Muralidharan V, 1413
 Muramaki M, 3645
 Murata H, 1225, 2461, 3979
 Murata K, 1243
 Murolo C, 1391
 Murotani Y, 2033
 Muscat JE, 4471
 Mushenkova N, 3893
 Mylona E, 3109, 4543
 Mylonas I, 1581, 1615, 1633, 1679, 1719, 1725, 1755, 1761
 Mystakidou K, 3495
 Naal F-D, 1977
 Nabeshima K, 3715
 Nadali G, 4743
 Nagai H, 3183
 Nagaoka R, 2957
 Nagar NS, 2841
 Nagasaka H, 4037
 Nagasawa H, 157, 3689
 Nagashima N, 3541, 3755
 Nagasue N, 463
 Nagata N, 3541, 3755
 Nagata Y, 1193
 Nagawa H, 2737
 Nagayasu T, 3957
 Nagele U, 4481
 Nagengast FM, 1465
 Nagy A, 1187
 Nagy E, 2153
 Nagy K, 3321
 Naim R, 2761
 Naka T, 931, 3453
 Nakada I, 2705
 Nakadate M, 435
 Nakai H, 2785
 Nakaike S, 3973
 Nakajima M, 2749, 3231, 3461, 4005, 4439,
 Nakamori M, 931, 3453
 Nakamura H, 2027
 Nakamura K, 3507
 Nakamura Masafumi, 3697, 3703, 3771
 Nakamura Masaki, 931, 3453
 Nakamura Masato, 483
 Nakamura Mitsunari, 3771
 Nakamura S, 2461
 Nakamura T, 3847
 Nakamura Yasushi, 833
 Nakamura Yoshihiro, 459
 Nakanishi Y, 69
 Nakano M, 483
 Nakano T, 1243
 Nakano Y, 3347
 Nakao A, 1247, 2627
 Nakase Y, 895
 Nakashima Hideaki, 2713, 3117
 Nakashima Hideki, 305, 1991
 Nakashima Hiroshi, 3697, 3703, 3771
 Nakata K, 3747
 Nakata S, 1193, 3533
 Nakatani Y, 931, 3453
 Nakayama M, 4403
 Nakayama T, 157
 Nakayama Y, 3541, 3755
 Nakazato H, 1377
 Nakopoulou L, 3109, 4543
 Nakshatri H, 2367
 Nava Z, 4215
 Nallapan M, 2221
 Nallapareddy S, 3055
 Namiki M, 2729
 Namisaki T, 3335
 Namork E, 3883
 Nanashima A, 3957
 Nanda A, 675, 2969
 Nano R, 3211
 Napolitano M, 4463
 Nardi M, 4513
 Nardoni C, 3531
 Naritaka Y, 847, 3513, 4747
 Nasioulas G, 2091
 Natale E, 515
 Naud P, 3469
 Naudé R, 4197
 Navajas F, 669
 Necozone S, 3089, 3149
 Nejako A, 1385
 Neri A, 2771
 Nesi G, 1353
 Nesland JM, 2943
 Netikova I, 1051
 Neubauer H, 1895
 Neukam FW, 2561
 Neumann R, 1433
 Nevozhay D, 2229, 2235
 Newbold RF, 731
 Nguyen LM, 2929
 Nguyen NP, 2929
 Nguyen PD, 2929
 Nguyen T, 63
 Ni J, 69
 Nickel J, 1603
 Nicoletti M, 121, 4261
 Nicolini G, 2681
 Nieder C, 2815, 4605
 Niederle B, 4225
 Niemer W, 601
 Niespolo R, 3597
 Nieto-Rementería N, 1945
 Nieves NJ, 2391
 Niibe Y, 4403
 Nikbakht H, 3303
 Nikfarjam M, 1413
 Niki N, 483
 Niki T, 3183
 Nikitovic D, 2851
 Nikolaidou M-E, 1471
 Nikolaou I, 4543
 Nikolaou M, 1457
 Nilsson O, 4399

- Ninane V, 2005, 2385
 Nio Y, 1361, 3523
 Nishida H, 2399
 Nishida Y, 4413
 Nishikawa H, 305, 887, 2033, 2055, 2085
 Nishikawa S, 435
 Nishimura M, 435
 Nishino H, 4043
 Nishishiro M, 305, 4157
 Nishizawa T, 3747
 Nisslein T, 139
 Nisticò C, 1343
 Nizze H, 1645
 Nobile MT, 1391
 Nogami N, 2429
 Noguchi K, 931, 3453
 Noguchi R, 3335
 Noguchi S, 833
 Nohl H, 2793
 Nolte I, 3995
 Noma K, 643
 Nomura Masaaki, 2729,
 Nomura Masato, 1369,
 2973
 Nonaka M, 3715
 Nordlander B, 1397
 Norum J, 3095
 Notarnicola M, 3393
 Novak JF, 1157
 Novarino A, 3287
 Nozawa S, 3547
 Núñez M, 4305
 Numico G, 2555
 Nuñez-Villar M-J, 451
 Nüsse M, 2837

 O'Brien KF, 3159
 Obert K, 4639
 Oberyszyn TM, 1963
 Ocelli M, 2555
 Ochel H-J, 3659
 Ochi M, 2951
 Oda M, 4455
 Ogata E, 3817
 Ogata T, 443
 Ogata Y, 547
 Ogawa J, 4693
 Ogawa Kazuhiko, 3507
 Ogawa Kenji, 847, 3513,
 4747
 Ogino A, 2429
 Ögmundsdóttir HM, 1877
 Oguma T, 1273, 1283
 Ogura S, 435

 Oh D, 2249
 Ohashi R, 489
 Ohashi T, 3481
 Ohgami K, 3843
 Ohgi S, 2027, 3003
 Ohira M, 3271
 Ohkawa S-I, 2435
 Ohkubo J, 459
 Ohkubo Y, 483
 Ohlsson A, 4375
 Ohmoto Y, 709
 Ohno Satoshi, 463, 3679
 Ohno Shigeaki, 3843
 Ohno Y, 463, 3679
 Ohshita A, 827, 2407
 Ohta K, 2407
 Ohta N, 4455
 Ohtani S, 4231
 Ohto H, 443, 4231
 Øijordsbakken G, 4699
 Ojima H, 2749, 3461, 4439
 Ojima T, 931, 3453
 Oka M, 3575
 Okada K, 3003
 Okada K-I, 4417
 Okada N, 3263
 Okada Y, 875
 Okajima E, 701
 Okamoto M, 4403
 Okamoto Y, 4417
 Okamura A, 1225
 Okamura N, 3689
 Okawaki M, 827, 2407
 Okazaki Y, 895
 Okimoto N, 2429
 Okita R, 643, 827, 2407
 Okumura T, 3347
 Olah J, 2885
 Olalu AA, 2573
 Olasz J, 4319
 Olivecrona H, 657
 Ollonen P, 531, 2527, 4623
 Olmos G, 999
 Olson KB, 3521
 Ølstørn HB, 3781
 Omar MS, 2229
 Omara-Opyene AL, 2075
 Omori H, 3523
 Onishi H, 3445, 3507, 3771
 Onishi T, 1881
 Onishi Y, 815
 Onitsuka T, 3601
 Ono H, 1369, 2973
 Ono I, 4693
 Ono K, 3533

 Onuki N, 4037
 Onuma E, 3817
 Opolon P, 4357
 Opolski A, 2043, 2229, 2235,
 2357, 2857
 Orbach-Arbouys S, 4091
 Ordi J, 1765
 Oriuchi N, 4439
 Orlando R, 4385
 Orosz M, 4759
 Orphanos G, 4493
 Ortiz-González J, 3625
 Ortíz-Lazareno PC, 4091
 Osaki A, 821
 Osaki M, 3003
 Osaki T, 1193
 Osborne BA, 3833
 Oshibe I, 4231
 Öst E, 4393
 Ostellino O, 4475
 Ostermann E, 2985
 Ostermann T, 1449
 Ostoros G, 471, 4759
 Osumi S, 1197
 Oszczapowicz I, 2043
 Oszczapowicz J, 2043
 Ota Y, 4455
 Otani Y, 17, 3791
 Otsuka K, 2965
 Otsuka Y, 1369, 2973
 Otsuki S, 2085
 Otsuki Y, 171
 Ottaiano A, 1441, 2065,
 4519
 Otto F, 1787
 Ou Y-C, 881, 2439
 Oudar O, 1139, 2655
 Oyama K, 4455
 Oyama Tetsunari, 2957
 Oyama Tohru, 133
 Oyama Tsunehiro, 1193,
 3437, 3533

 Pacetti U, 3619
 Padilla J, 497
 Pagoni N, 3067
 Pahisa J, 1765
 Paiss T, 1303
 Pakos EE, 3591
 Paku S, 805, 2869
 Pal A, 331
 Palermo S, 3641
 Palese P, 715
 Palla E, 2509
 Pallud C, 1433

 Palmedo H, 4591
 Palmieri G, 1441
 Palmieri I, 515
 Pan XQ, 343, 3167
 Panayiotides I, 2141
 Pang Q, 3399
 Pang S-T, 683
 Pangalis GA, 4743
 Panke JE, 1555
 Pansara M, 2075
 Paoletti G, 1309
 Papachristou DJ, 3591
 Papadogiannakis N, 657
 Papadogiannis A, 4743
 Papadopoulos T, 2519
 Papadopoulou MV, 1865,
 2161
 Papaevangelou M, 1409
 Papaioannou S, 1059
 Papaldo P, 3531
 Papanastasiou P, 3123
 Papathanassiou Z, 3067
 Papiris S, 3489
 Papoudou-Bai A, 347
 Papp Z, 2885
 Paprocka M, 383
 Paredes RMM, 1219
 Paris MK, 563
 Park S-J, 2831
 Park YD, 391
 Parker K, 3855
 Parpa E, 3495
 Pasetto LM, 563
 Pasqualini JR, 2827
 Passebosc-Faure K, 377
 Patel AR, 3521
 Patlakas G, 1427
 Patnaik A, 3215
 Patrone E, 3999
 Patwardhan R, 2969
 Pauli C, 2821, 3911, 4075
 Paulsen JE, 3781, 3883
 Pavlaki A, 2141
 Pavlidis N, 3103, 3553
 Pazaitou-Panayiotou K,
 2091
 Pecen L, 1517
 Pecherstorfer M, 3607
 Pectasides D, 1457, 3103,
 3553
 Peczyńska-Czoch W, 2857
 Pedersen M, 3399
 Pedicini V, 3143
 Pedrazzoli P, 4463
 Peeters WJM, 1015

- Pehamberger H, 2697
 Pelczynska M, 2235
 Peña L, 4269
 Pentikäinen V, 2873
 Perabo FGE, 725, 3565, 4341
 Percivale P, 1391
 Perdereau D, 3877
 Perez Alenza MD, 4269
 Perez D, 313
 Pérez-Yarza G, 1945
 Perik PJ, 3651
 Permi P, 33
 Perrett CW, 693
 Perrone Donnorso R, 1079
 Perrone F, 1343
 Perrotta E, 1009
 Perut F, 1109
 Pesta M, 1597, 3387
 Peták I, 3321, 4179
 Peters A, 3303
 Peters O, 2583
 Peters S, 121
 Peters WHM, 1465
 Petraki C, 3123
 Petrocelli V, 2465
 Petrosino T, 595
 Petsas T, 3067
 Pettersen EO, 2259
 Pettersen I, 3809
 Peulen O, 363
 Pezzullo L, 2477
 Pezzuto JM, 779
 Pfragner R, 4225
 Phifer SS, 779
 Philippe J-C, 2827
 Piazzi L, 1179
 Piccinini M, 3203
 Pichlmeier U, 4639
 Pichon MF, 1433
 Piechulla B, 1817
 Pienta KJ, 3521
 Pieramici T, 4313
 Pietsch T, 2583
 Pignata S, 2065, 3501
 Pignataro L, 2771
 Pignotti E, 2423
 Pikner R, 1517, 1597, 1655
 Pilarinou E, 1889
 Pilichos C, 2961
 Pilkington GJ, 3855
 Pillich RT, 3341
 Pimentel Assumpção P, 4069
 Pinney KG, 3865
 Pisani T, 2187, 2465
 Pisano C, 2065, 2681, 3501
 Piscanti S, 4463
 Pizza C, 1309
 Pizzolo G, 4743
 Plataniotis G, 1471
 Plucienniczak A, 1087
 Podratz KC, 2921
 Poehls UG, 2519
 Poellinger L, 903
 Poetter R, 4673
 Pogány G, 805
 Poggio M, 4475
 Polistena A, 2417
 Pollán M, 451
 Pollmann D, 4599
 Polozowski A, 2879
 Polyzos A, 3559
 Porpiglia F, 4475
 Portarena I, 403
 Porwit-McDonald A, 683
 Possinger K, 1491, 4599
 Poulsen AL, 4049
 Poulter LW, 693
 Pourshams A, 425
 Preza A, 2961
 Priebe W, 1841, 2193
 Prieto A, 999
 Prieto RM, 2593
 Prior TGT, 4141
 Prisack H-B, 4615
 Pronai L, 4763
 Prott F-J, 1663
 Pruneri G, 2771
 Psychogiou H, 1409
 Pugliese R, 4463
 Pugnali A, 4313
 Puhalla H, 4249
 Puig S, 1779
 Pycha A, 3641
 Pyrhönen S, 3083
 Qin H, 63
 Queiroga FL, 4269
 Queiroz Calcagno D, 4069
 Quetin-Leclercq J, 363
 Raaphorst GP, 53, 2649
 Rác G, 2869
 Raffetto N, 3089
 Rafi MM, 313
 Raitanen M, 4363
 Raju B, 4699
 Rakhshani N, 425
 Ramachandran C, 3293
 Ramachandran R, 3293
 Ramaswamy A, 4209
 Ramírez-Expósito MJ, 193
 Ramm U, 4639
 Ramondetti C, 3203
 Ramos DM, 751
 Rampa A, 1179
 Ramqvist T, 2601
 Randi A, 4305
 Rannikko S, 2873
 Rao P, 1131
 Rapisarda V, 4577
 Raptis SA, 1457
 Rasio D, 3531
 Raub M, 1543
 Raubenheimer EJ, 2589
 Raveendran Nair PK, 3293
 Razis E, 3103
 Rea S, 409, 3149
 Rebella L, 4451
 Recchia F, 409, 3149
 Reck M, 1501
 Reerink O, 629
 Rehda E, 1603
 Reichling J, 139
 Reimann-Berg N, 3995
 Reinert C, 2583
 Reiser A, 1895
 Reitberger E, 3911
 Renne G, 579
 Rennie A, 1147
 Reuning U, 1977
 Revelos K, 3123
 Reyes-Lim E, 779
 Rezai A, 4615
 Rhim JS, 1
 Rhomberg W, 3613
 Rice KC, 4563
 Richter D-U, 1581, 1633, 1639, 1675, 1713, 1755, 1817
 Riedel F, 2761
 Rieger J, 3665
 Rieger L, 1531, 1649
 Riegman PHJ, 913
 Riehle, DL, 2921
 Riemann K, 2809
 Ries J, 2561
 Riethdorf L, 1321
 Rigamonti LM, 2681
 Rigas B, 4471
 Rigatos GA, 523, 4493
 Rigatos SK, 3671
 Rigaud M, 3799
 Rinaldo M, 595
 Rinaudo MT, 3203
 Rinner B, 4225
 Rising A, 1075
 Ristamäki R, 3083
 Ristimäki A, 2669
 Risuleo G, 1079, 3341
 Rith T, 1607
 Rivera E, 4305
 Rizell M, 789
 Roberts TR, 731
 Robinet A, 2617
 Robinson WA, 2215
 Rocco B, 577, 579
 Röcken C, 3659
 Rödel C, 1623
 Rodriguez G, 1219
 Rodriguez S, 3293
 Rodríguez Burbano R, 4069
 Rodríguez-Padilla C, 4563
 Roelofs HMJ, 1465
 Rohrer JW, 2345
 Rohr-Udilova N, 2793
 Rokutanda N, 2957
 Rokyta Z, 617
 Roller M, 121, 4261
 Romeo S, 2483
 Romero J, 273
 Romiti A, 2567
 Ronchetti D, 2771
 Ronquist G, 4399
 Rooney S, 2199, 4255
 Roostaeian J, 107
 Rosati G, 4445
 Rose S, 2929
 Roselli M, 403
 Rosen RT, 313
 Rosenbaum RE, 4471
 Röser K, 1321
 Rossi E, 563, 1343
 Rosso R, 1391
 Rostock M, 1969
 Roteli-Martins C, 3469
 Roth MJ, 425
 Rothman N, 537
 Roukos DH, 3023
 Rovirosa A, 1765
 Rubagotti A, 3999
 Rubio CA, 903, 1353, 2503, 3099, 4393, 4551
 Rubio L, 497
 Ruby E, 4759
 Ruiz-Ávila I, 1115
 Runge R, 1067
 Rupert K, 3387
 Ruschenburg I, 2789

- Russi E, 2555
Rusu C, 4583
Rutgeerts P, 4393
Ruth W, 1817
Rutqvist LE, 1397
Ryan MF, 2199, 4255
Ryska A, 1517, 1835
Ryu S-Y, 2831
- Saadatian-Elahi M, 425
Sabillon JU, 1219
Sabourin JC, 4679
Sadar MD, 4595
Sadaria M, 2367
Safont MJ, 4611
Saggio G, 409, 3149
Sahagún-Flores JE, 4091
Sahmoun AE, 1101, 3517
Saidi F, 543
Saigenji K, 1257
Saijo A, 2435
Saikawa Y, 17, 3791
Saiki I, 815, 3973
Saiko P, 3407
Saito H, 3817
Saito M, 3183
Saito T, 4231
Saitou Y, 1243
Sajedi M, 3585
Sakagami H, 161, 283, 305, 887, 1991, 2033, 2055, 2085, 2241, 3263, 3951, 4037, 4053, 4157
Sakakura C, 895
Sakamoto S, 157, 4595
Sakamoto T, 171, 1251
Sakata R, 459
Sakayori M, 2965
Sakiyama S, 923
Sako T, 3755
Sakuma K, 3183
Sakurai H, 815, 2957
Sakuramoto S, 2935
Sakuta T, 133
Salat C, 3047
Salesi N, 3619, 4769
Sallah S, 2929
Saller R, 139
Salmon JP, 1211
Salomon L, 4535
Salvet J, 1655
Samadder P, 95
Samarzija M, 4663
Samata K, 3973
Sambataro G, 2771
- Sanada I, 4245
Sanidas E, 2743
Santala M, 4101
Santarelli M, 3089
Santini D, 669
Santoro A, 3143
Santoro TJ, 1101
Santos C, 1219
Sapundzhiev N, 4209
Sarcina I, 2567
Sarian L, 3469
Saridaki Z, 2743
Sarika L, 2091
Sarkar AK, 331
Sarkar P, 2905
Sasaguri S, 1131
Sasaki H, 3689
Sasaki S, 2737
Sasaki T, 3507
Sassa S, 157
Sato K, 3817, 4021
Sato M, 875, 2471
Satoh A, 1257
Satoh K, 283, 887, 2033, 4157
Satoh R, 2055, 2085
Satomi Takeno S, 4069
Satomi Y, 4043
Sauer H, 3047
Sauer R, 1623
Sauerbruch T, 4591
Sawada N, 923
Sawai H, 875
Sawhney HS, 3637
Sayyah J, 23
Sbarcea A, 4583
Scala S, 1441
Scardino E, 577, 579
Scarpa RM, 4475
Scarpati D, 4451
Scarsella G, 3341
Schaaf A, 183
Schaefer U, 1543, 1671
Schäfer U, 1523, 1539, 1555, 1663
Schaller N, 1747
Schallier D, 1211
Schauwecker J, 1977
Scheer R, 1969
Schelz Z, 1991
Schenk Y, 1693
Schenkel J, 3191
Schiavetto I, 4463
Schiffer D, 3203
Schildhauer S, 1491, 4599
- Schilling D, 4481
Schindlbeck C, 1615
Schlatterer B, 3355
Schlatterer J, 3355
Schlatterer K, 3355
Schlechte HH, 635
Schmelzle R, 1693, 1703
Schmid H, 2809
Schmid H-J, 2583
Schmidt DH, 725, 3413, 3565, 4341
Schmidt W, 601
Schmitt M, 1977
Schmitt WD, 3431
Schmittel A, 1333
Schmoll H-J, 1147
Schmucker M, 2519
Schneider Joachim, 1507
Schneider Jose, 451
Schneider PM, 1349
Scholz R, 2145
Schönekaes KG, 1711
Schoppmann SF, 4503
Schorle H, 3191
Schroeder W, 1349
Schrott KM, 1607, 1611, 1623, 1629, 1783
Schueler J, 1969, 2985
Schüller P, 1523, 1555
Schulte-Herman R, 2793
Schultheis A, 947
Schulz H, 2789
Schulze G, 635, 1507
Schulze K, 1333
Schulze M, 1333
Schulz-Wendtland R, 2519
Schumacher U, 1829, 3303
Schürmann A, 3431
Schuster G, 63
Schwartz GG, 1101
Schwartz M, 4049
Schwarz R, 1321
Scobee JJ, 2113
Scorilas A, 3123
Scott-Algara D, 4091
Sculier J-P, 2005, 2385
Sebestyén A, 3321, 4179
Sebo TJ, 2921
Sedlak J, 3375
Sedlakova E, 4299
Segawa Y, 2429
Segura JA, 3315
Sehouli J, 4599
Seim J, 2259
Sekikawa A, 2435
- Sekikawa K, 443
Sekine S, 435
Seliger C, 1575
Selmeçli L, 4763
Selzer E, 2697
Sen E, 765, 1091
Seo J-Y, 1919
Seo N, 3763
Seo T, 991
Sepéhr A, 543
Seracchioli R, 2423
Sersa G, 839
Sesterhenn AM, 2675, 4129
Seto M, 1225
Setta M, 2879
Sevenich M, 2789
Shabani N, 1581, 1615, 1633, 1679, 1725, 1761
Shabbir M, 4281
Shah A, 701, 2033
Shah GV, 2075
Shanshen Z, 2943
Shany S, 3425
Sharma S, 107
Sheen-Chen S-M, 455, 527
Sheikh S, 331
Shen M, 537
Shen P, 369
Shen Y-Y, 1421, 4719
Shi W, 3899
Shibaguchi H, 3725, 3733
Shibahara T, 1881
Shibao K, 3541, 3755
Shibata H, 2965
Shibata S, 4043, 4413
Shibayama T, 2579
Shibuya K, 4029
Shichijo S, 1983
Shields-Botella J, 2827
Shigematsu N, 3481
Shigeoka Y, 4569
Shih CC, 3167
Shimada H, 1237, 1327, 1369, 2973
Shimada J, 887
Shimada K, 1257
Shimada M, 1297
Shimakawa T, 847, 3513
Shimanuki Y, 489
Shimao K, 847
Shimbo M, 4595
Shimizu E, 4569
Shimizu K, 489, 821
Shimizu T, 2997, 3601

- Shimomura K, 895
 Shimose S, 2951
 Shimozato O, 299
 Shinagawa N, 435
 Shinkai T, 2429
 Shinmoto H, 3481
 Shioyama Y, 3507
 Shiozawa S, 1251
 Shirai T, 2399
 Shirakawa T, 2757
 Shiraki K, 1243
 Shirao K, 2997
 Shirataki Y, 1991, 2055
 Shiratori K, 3843
 Shiwa M, 1197
 Shnyder SD, 1889
 Shoji M, 3263, 3367
 Shoji Y, 305
 Shord SS, 4165
 Shu S, 4061
 Shyu R-Y, 2453
 Siakantaris MP, 4743
 Sica G, 3937
 Siddiqui EJ, 4281
 Siegl V, 4225
 Siehl JM, 1333
 Siemann DW, 3899
 Siena S, 4463
 Sigurdsson LS, 1877
 Silvan G, 4269
 Simeone E, 1441, 4577
 Simon P, 1901
 Singh B, 63
 Singh NP, 4325
 Singh RP, 2891
 Sirera R, 4611
 Sitia M, 725
 Siwko M, 2857
 Sjöqvist U, 4393
 Skarlos DV, 3103
 Skiadas I, 319
 Skofitsch G, 4225
 Skvara H, 2697
 Skyrilas A, 347
 Sleijfer DT, 3651, 4647
 Sluiter WJ, 255
 Smedsrød B, 3809
 Smith D, 675
 Smith HJ, 2929
 Smith LM, 369
 Sneck M, 33
 So T, 1193
 Södergren T, 1397
 Söderlund S, 4393
 Söderström T, 3173
 Sohara Y, 1991
 Sohda M, 2749, 3231, 3461, 4005, 4439
 Sohi JS, 3517
 Soini Y, 4101
 Solbach C, 121, 4261
 Soleiman A, 4249
 Solomayer E-F, 2171
 Soma G-I, 463, 3679, 3747
 Somerville L, 101
 Son H-Y, 2831
 Song JS, 391
 Sorvari P, 2873
 Sotlar K, 1895, 2809
 Soto-Vera D, 4753
 Sparreboom A, 4423
 Speer R, 1581, 1895
 Speiser P, 617
 Spila A, 403
 Srivastava S, 1
 Staar S, 1713
 Stachs A, 1559, 1823
 Stachura J, 4293
 Ståhlberg K, 2873
 Stahn Rainer, 1811
 Stahn Renate, 1811
 Stål O, 2515
 Stanganelli I, 4577
 Stanton KJ, 2367
 Stathopoulos EN, 1927, 2743
 Stathopoulos GP, 2445, 2991, 3031, 3671
 Stathopoulos J, 2445, 3671
 Staub M, 2885
 Stefanou D, 3591
 Steffen Krause F, 1783
 Steidler A, 183
 Stein GM, 4753
 Steinacker A, 2789
 Steiner M, 3425
 Stemmler HJ, 3047
 Stendahl U, 611, 3041
 Stenzl A, 1901, 4481
 Stephan H, 3613
 Sterzer S, 1739
 Steven K, 4049
 Stieber P, 1597, 1655, 1795, 1831
 Stift A, 4225
 Stødkilde Jørgensen H, 3399
 Stokke T, 2259
 Stonerock LA, 2391
 Strada G, 3597
 Straeter J, 795
 Straface SV, 1023
 Strand C, 2661
 Stratakos G, 3489
 Strausz J, 471
 Stravodimos C, 3109
 Stravodimos K, 4543
 Strebhard K, 1871, 3985
 Strickland PT, 425
 Strojnik TJ, 587
 Stropahl G, 1559
 Stroppa I, 3237
 Strothoff D, 1803
 Strugnell SA, 235, 1909, 4333
 Styczynski J, 2253
 Su C-C, 971
 Su C-K, 2439
 Su C-T, 1421, 4719
 Su Y-H, 4203
 Suder E, 2879
 Sudo M, 3183
 Suehiro Y, 3575
 Sugaya M, 1193, 3533
 Sugihara M, 1297
 Sugimoto K, 1243
 Sugimoto T, 1225
 Sugimoto Y, 4061, 4081
 Sugimura Y, 1881
 Sugio K, 1193, 3437, 3533
 Sugita T, 2951
 Sui L, 2639
 Sui M, 1953
 Sumitomo M, 923, 4499
 Sun T-H, 2645
 Sun X, 59
 Sunaga K, 887
 Sundin A, 917
 Sunheimer R, 1263
 Sunose Y, 1291
 Suo Z, 2943
 Supriatno , 2471
 Surowiak P, 2879
 Susumu N, 3547
 Sutnar A, 1597
 Sutterlin A, 1531
 Sutterlin MW, 1531, 1649
 Suyama T, 4595
 Suzuki F, 887, 2085
 Suzuki H, 4595
 Suzuki M, 85
 Suzuki N, 463, 3679
 Suzuki R, 1131
 Suzuki S, 157, 443
 Suzuki Y, 2027
 Sveinbjörnsson B, 3809
 Svensson E, 207
 Svirshchevskaya E, 3893
 Svoboda T, 617
 Svobodova S, 1597, 1655, 1831
 Swiatoniowski G, 2879
 Switalska M, 2235
 Syrigos KN, 3489, 4527
 Syrjänen K, 3083, 3469
 Syrjänen S, 3469
 Szabo BG, 629
 Szabo DG, 1667
 Szabó G, 1187
 Szakács G, 4113
 Szala S, 1087
 Szarka K, 2153
 Szekeres T, 3407
 Szende B, 2869
 Szendrői M, 805, 3075
 Sziller I, 2885
 Szondy K, 471, 4759
 Taari K, 2873
 Tabata M, 547, 2429
 Tabiti K, 1895
 Tabuchi H, 3271
 Tabuchi T, 2705
 Tachibana M, 463
 Tada A, 2579
 Tada Y, 299
 Tagawa M, 299
 Tajino T, 2777
 Tajiri H, 1197
 Takada K, 3183
 Takada W, 2435
 Takagi K, 459
 Takagi T, 895
 Takahashi F, 489
 Takahashi H, 875
 Takahashi K, 489, 2579
 Takahashi Y, 923, 1377
 Takamura Y, 509, 833, 3419
 Takashima K, 3847
 Takashima R, 435
 Takashima S, 1197, 1983
 Takata D, 2957
 Takae Y, 1197
 Takayama F, 2085
 Takayama K, 69
 Takayama S, 79
 Takeda A, 2777, 3481
 Takehara A, 4455
 Takemura H, 991
 Takenoshita S, 443
 Takeshita H, 2461, 3979
 Takeuchi A, 2399


- Takeuchi M, 2579
 Takeuchi R, 4037
 Takeuchi Y, 1337
 Takeyama H, 415, 875
 Takeyoshi I, 1291
 Takigawa M, 3763
 Takigawa N, 1197, 2429, 2579
 Takiguchi Y, 299
 Takita J, 4439
 Takita K-I, 443
 Takiuchi H, 1257
 Takue Y, 1983
 Talja M, 4435, 4707
 Talvensaari-Mattila A, 4101
 Tambaro R, 3501
 Tamez-Guerra P, 4563
 Tamez-Guerra R, 4563
 Tampellini M, 4475
 Tan GT, 779
 Tan Y, 59
 Tanabe S, 1257
 Tanahashi Y, 1291
 Tanaka D, 459
 Tanaka K, 1237, 1327
 Tanaka Makiko, 4417
 Tanaka Makoto, 3973
 Tanaka Masao, 3445, 3697, 3703,
 Tanaka Masaru, 4173
 Tanaka Motohiro, 2729
 Tanaka S, 709
 Tanaka T, 1991
 Tani M, 931
 Tani S, 1991
 Taniguchi Y, 2027
 Tanimoto M, 547, 2429
 Tanno S, 3347
 Tanvetyanon T, 429
 Tarpin C, 663
 Tasaki A, 3697, 3703, 3771
 Tatangelo F, 2065
 Tatezaki S-I, 1337
 Tatsumi K, 299
 Tatti S, 3469
 Taveggia P, 1391
 Tayal S, 2215
 Taylor B, 4113
 Taylor DD, 2113
 Teel RW, 117
 Tegerstedt K, 2601
 Tejada M, 325
 Tejedor MC, 999
 Tempfer C, 617
 Temple I, 3963
 Ten Hagen TLM, 743
 Tennvall J, 4663
 Terada H, 3747
 Terakubo S, 305
 Teranuma H, 283
 Terao S, 2757
 Terasaka H, 161, 2241
 Terashima M, 4231
 Terpe H, 1559
 Terzoli E, 1343
 Teshima T, 3507
 Testori A, 4577
 Tezak S, 4663
 Tezol A, 2767
 Thalassinou N, 3135
 Thallinger C, 2697
 Thalmann G, 183
 Than GN, 1667
 Thanner F, 1649
 Thiam TT, 2205
 Thiel E, 1333
 Thomaidis A, 757
 Thomas J-L, 2827
 Thomas P, 23
 Thompson CS, 4281
 Thorgeirsson UP, 701
 Threatte G, 1263
 Thurnher M, 2345
 Tichy M, 4299
 Tilanus HW, 913
 Tímár F, 805
 Tímár J, 805, 3075
 Tiszlavicz L, 3061
 Tocchi A, 2417
 Todorov J, 1623
 Todorova K, 4727
 Toga T, 3523
 Toge T, 643, 821, 827, 2407
 Togo S, 1237, 1327
 Tokuda M, 2639
 Tokura Y, 3763
 Tokuyama J, 17, 477
 Tomao F, 2567
 Tomao S, 2567
 Tomasello L, 1391
 Tombolini V, 3089
 Tomita K, 2399, 4569
 Tomita M, 3601
 Tomoda C, 179, 509, 3419
 Tomonaga M, 3709, 3741
 Tonel E, 3287
 Tonini G, 669
 Tonomura N, 3833
 Tonosaki K, 4029
 Topolcan O, 1517, 1597, 1655, 1795, 1831, 1835, 3387
 Torne A, 1765
 Tóth J, 3075
 Tostain J, 377
 Toufexi H, 3559
 Touhami-Carrier M, 757
 Toutirais O, 2177
 Tozon N, 839
 Tranquilli AL, 4313
 Tredici S, 4451
 Tregnaghi A, 4559
 Treska V, 3387
 Tretiakova M, 2001
 Tribble E, 235
 Tribukait B, 4393
 Tripepi S, 1009
 Trnka F, 1157
 Trojan L, 183, 551
 Troxel A, 273
 Truksa J, 4215
 Tryfonopoulos D, 4493
 Tsaftaris P, 4743
 Tsai C-C, 4737
 Tsai L-C, 2719
 Tsai S-C, 4737
 Tsai T-H, 2719
 Tsai Y-H, 2049
 Tsamandas AC, 3067
 Tsangaris GTH, 2979
 Tsantekidou-Pozova S, 1427
 Tsatsakis AM, 2851
 Tschampa HJ, 4591
 Tsekeris PG, 3591
 Tseng S-H, 4203
 Tserkezoglou A, 1471
 Tsiatas ML, 3495
 Tsiiftsis D, 1927
 Tsubura A, 2269
 Tsuchiya A, 1251
 Tsuchiya H, 2399, 2777
 Tsuchiya Y, 815
 Tsuda N, 715
 Tsuda T, 887
 Tsugu H, 3715
 Tsuji N, 3967
 Tsuji Y, 2461
 Tsujimoto H, 895
 Tsujita E, 2713, 3117
 Tsujita-Kyutoku M, 2269
 Tsukada Katsuhiko, 2749, 3231, 3461, 4005, 4439
 Tsukada Kazuhiro, 815
 Tsukamoto R, 2269
 Tsukazaki K, 3547
 Tsukushi S, 4413
 Tsunenari T, 3817
 Tsurudome Y, 3541, 3755
 Tsuyuguchi M, 923
 Tsuyuki A, 477
 Tsuzuki T, 1297
 Tucci G, 3237
 Tuinman MA, 4647
 Tukiainen E, 853, 2669
 Tulassay Z, 4763
 Turpeenniemi-Hujanen T, 4101
 Tüzel E, 1623
 Tyler B, 3825
 Tzanakakis GN, 2851
 Tzanela M, 3135
 Tzenou T, 4743
 Ubukata H, 2705
 Uchibayashi T, 2729
 Uchida A, 1225, 2429
 Uchida T, 4499
 Uchino J, 69
 Ueda T, 4595
 Ueda Haruhiko, 2785
 Ueda Hideki, 3979
 Ueda K, 931, 3453
 Ueda S, 463
 Ueda T, 991
 Ueda Y, 3973
 Uefuji K, 3225
 Uehara N, 2269
 Uemura M, 3335
 Ueno H, 821
 Ueno S, 133
 Ueno T, 3575
 Ueoka H, 547, 2429, 2579
 Ugocsai K, 3061
 Umehara A, 4747
 Umemori Y, 415
 Umemura S, 2429
 Untch M, 3047
 Unten S, 4157
 Uozaki H, 3183
 Upadhyay U, 3825
 Updike MS, 871
 Uramoto H, 1193, 3437, 3533
 Urasaki Y, 991
 Urben CM, 235
 Uruno T, 509, 833, 3419
 Ushiku T, 3183
 Uto Y, 3689

- Vaalburg W, 255
Vaccaro A, 1343
Václavíková R, 4215
Vadrot N, 243
Vaghi M, 3597
Vainas I, 2091
Vairaktaris E, 2561
Valenti P, 1179
Valentini G, 4369
Valenza R, 1343
Valenzuela MT, 193
Valeriani M, 3089
Valerio MR, 1309
Vallon-Christensson J, 2661
Vallone P, 595, 2477
Valrance M, 235
Valtanen H, 33
Van De Venter M, 4197
Van Dekken H, 913
Van Der Graaf WTA, 3651
Van Der Kogel AJ, 1015
Van Der Logt EMJ, 1465
Van Der Voort R, 1015
Van Dillen IJ, 255
Van Heerden WFP, 2589
van Herpen CML, 1015
Van Hooijdonk Z, 1465
Van Oostveldt P, 1039, 3011
Van Q, 1841
Van Schijndel A, 1015
Van Tiel ST, 743
Van Veldhuisen DJ, 3651
Van Waes C, 751
Vanbuskirk A, 1963
Vandenberg TA, 2497
Vannemreddy P, 2969
Vanzulli A, 4463
Varela R, 577, 579
Vasiliou S, 2561
Vassilakopoulos TP, 4743
Vassilomanolakis M, 651
Vassilopoulos PP, 1409
Vasstrand EN, 4699
Vassy J, 2129
Vatne V, 2097
Vaupel P, 3413
Vecchione A, 2187, 2465, 2567, 3531, 3619
Velasco V, 1205
Veltri E, 3619
Venturoli S, 2423
Venuta S, 1023
Vera-Sempere FJ, 497
Verdebout J-M, 2005
Vereb G, 1187
Veress G, 2153
Vergnon J-M, 4135
Veronese S, 4463
Verschueren RCJ, 629
Vertechy M, 2681
Verweij F, 577, 579
Vesci L, 2681
Vesely P, 1051
Veslemes M, 2991, 3671
Vesovic Z, 1303
Viale M, 4123
Vibits H, 4049
Vici P, 1309
Vidiri A, 4769
Viens P, 663
Vigano P, 3597
Vigneswaran N, 2841
Vilain JP, 3877
Vincenzi B, 669
Viñolas N, 1773
Viret F, 663
Virzi V, 669
Visca P, 1079
Visokai V, 1597, 1655, 1831
Vissac-Sabatier C, 2009
Vissers KJ, 913
Vlahos A, 3495
Vlassopoulou V, 3135
Vlastos Franzén A, 2601
Vogel M, 1725
Vogel U, 1895
Vogel W, 1303
Vogl T, 3665
Voigt W, 1147
Volakakis N, 3031
Volpino P, 505
Von Plehn G, 1787
Von Ruecker A, 3565
Von Sivers K, 3099
Vos P, 2929
Vougiouka M, 3031
Vrekoussis T, 1927, 2743
Vylliotis A, 2561
Wacheck V, 2697
Wada A, 299
Wagner S, 2583
Wakabayashi H, 305, 4157
Wakasugi H, 1983
Wakatabe R, 1197
Waldmann J, 1559
Waldschläger J, 1817
Waleh NS, 397
Walker F, 4535
Walker JR, 2391
Wall ME, 779
Wallach J, 2617
Wallwiener D, 1895, 2171
Walz A, 4239
Walzel H, 1575
Wang C-H, 4203
Wang H-J, 1919
Wang L-S, 871, 4061
Wang N, 3763
Wang X, 1811
Wang XI, 2001
Wang Y-F, 331
Wang Y-R, 4333
Wang Zhaoyi, 369
Wang Zhuo, 2367
Wani MC, 779
Wardelmann E, 725, 4591
Warmuth-Metz M, 2583
Warnecke G, 213
Warrington K, 1851
Washiya K, 4693
Wasowska M, 2043
Wataha J, 63
Watanabe A, 2713, 3117
Watanabe G, 4455
Watanabe Kiyo, 1251, 4747
Watanabe Kumiko, 443
Watanabe Masahiko, 2935
Watanabe Masanari, 4569
Watanabe N, 3967
Watanabe S-I, 459
Watanabe T, 2737
Watanabe Yasuo, 2639
Watanabe Yoh, 2785
Watanabe Yoshinori, 2705
Wdzieczak-Bakala J, 2129
Weber RJ, 4563
Weber W, 1219
Wehbe H, 3865
Weischede S, 4179
Weiss T, 4583
Weissenberger C, 1787
Welch R, 537
Wellmann A, 3191
Welsh J, 235
Wen B, 4357
Weng W-H, 683
Wenner J, 419
Wentzel-Larsen T, 2097
Wernecke K-D, 1491
Werner E, 601
Werner JA, 2675, 4129, 4141, 4209
Werner M, 601
Wernert N, 3191
Wesolowska O, 383
Westhoff B, 947
Westphal M, 213
Wetterauer U, 4733
Wexler EJ, 197
White E, 313
Wick M, 871
Wickramasinghe NS, 2841
Wiest I, 1575
Wietrzyk J, 2043, 2235, 2357, 2857
Wiggers T, 629
Wigington DP, 1909, 4333
Wilding GE, 3055
Wilhelm-Ogunbiyi K, 3303
Willems A, 1483
Willert PL, 3565
Willich N, 1523, 1555, 1663, 1671
Willis B, 675
Willroth PO, 1667
Wilmanowski R, 1811
Wiltfang J, 2561
Wincovitch S, 4113
Wingren S, 2515
Winkler S, 3995
Winslet MC, 693
Wirger A, 725, 3565, 4341
Wisniewski S, 2327
Witthohn K, 3303
Wobbles T, 1465
Wolf P, 4733
Wolff JEA, 2583, 3585, 4429
Wolff Vorbeck G, 2135, 3581
Wolfrom C, 3279
Wollenberg B, 2821, 3911, 4075, 4239
Woloszczuk W, 3607
Wood KJ, 4141
Wördehoff H, 3659
Wrba F, 4249
Wrede B, 4429
Wróbel A, 3173
Wu CH, 959
Wu J-M, 4203
Wu L-T, 2069
Wysocki M, 2253

- Xing Y, 1131
Xu F, 2943
Xynotroulas J, 2445
- Yagawa H, 847
Yagihashi A, 3967
Yaginuma H, 4231
Yamada Hiromi, 3733
Yamada Hisashi, 2631
Yamada R, 1251, 2973
Yamada T, 1291
Yamada Yasuhide, 2997
Yamada Yoshihisa, 4413
Yamada-Okabe H, 3817
Yamagishi H, 895, 3847
Yamagishi S, 1237, 1327
Yamagishi T, 3973
Yamaguchi F, 2639
Yamaguchi K, 847
Yamaguchi S, 1237
Yamaguchi T, 1297
Yamaguchi Y, 643, 827, 2407
Yamamoto K, 3575
Yamamoto Masaaki, 3715
Yamamoto Minoru, 875
Yamamoto Morio, 1131
Yamamoto Naotaka, 85
Yamamoto Norihiko, 1243
Yamamoto Norio, 2399
Yamamoto S, 4417
Yamamura T, 283
Yamanaka K, 3645
Yamanaka N, 3697, 3703
Yamanaka Y, 1243
Yamasaki A, 4569
Yamasaki J, 895
Yamashita Y, 821
Yamaue H, 931, 3453
Yamaura G, 2965
Yamawaki I, 2435
Yamaya C, 4693
- Yamazaki K, 435
Yamazaki M, 3335
Yanase K, 3335
Yang C-R, 2439
Yang C-T, 2049
Yang DP, 2649
Yang G, 3055
Yang HK, 2105
Yang L-X, 1919
Yang XJ, 2001
Yang Y, 1919
Yang Z, 59
Yano H, 3957
Yano S, 1361, 3523
Yano T, 2935
Yano Y, 1273, 1283
Yanokura M, 3547
Yao K, 4403
Yao X, 3763
Yapijakis C, 2561
Yashima Y, 3437
Yashiro M, 3271
Yasui H, 2997
Yasui N, 955
Yasui T, 2085
Yasumoto K, 1193, 3437, 3533
Yasunaga Y, 2951
Yasutake T, 3957
Ye W, 4061
Yeager M, 537
Yeh C-C, 971
Yin J-J, 4113
Yokoe I, 4053
Yokogawa K, 2729
Yokomizo H, 4747
Yokomori T, 1291
Yokouchi H, 435
Yokoyama K, 4157
Yonemoto T, 1337
Yoo S-H, 4631
Yoon W-K, 2831
- Yoshida A, 3747
Yoshida Hideo, 2471
Yoshida Hiroshi, 179, 509, 833, 3419
Yoshida I, 2579
Yoshida Kazuhiko, 3843
Yoshida Kazuhiro, 821
Yoshida Kiyohito, 4747
Yoshida Masashi, 17, 3791
Yoshida Miho, 1291
Yoshida T, 2957
Yoshihara K, 443
Yoshii J, 3335
Yoshiji H, 3335
Yoshimatsu K, 847, 1251, 4747
Yoshimatsu T, 1193, 3437, 3533
Yoshimura M, 3847
Yoshioka I, 815
Yoshioka T, 2965
Yoshizato K, 213
Young LAF, 4165
Younus J, 2497
Yu C-S, 127
Yu F-S, 127
Yu J-C, 2453
Yuan C-C, 2719
Yukata K, 955
Yukio N, 4595
Yung Follo M, 2039
Yuri T, 2269
- Zabel M, 2235
Zacharias W, 2841
Zafirellis K, 3629
Zafiropoulos A, 2851
Zagrodzki B, 2857
Zaiss I, 2761
Zalesak B, 4299
Zampi G, 1353
- Zampiron A, 1179
Zanna C, 2681
Zapf S, 213
Zarkovic N, 4583
Zaveri NT, 397
Zeidler R, 4239
Zeis M, 2345
Zelano G, 3937
Zervas A, 3109, 4543
Zetterquist H, 657
Zhang A, 331
Zhang G, 3309
Zhang Hongquan, 3889
Zhang Hui, 3309
Zhang X, 369
Zhou HE, 881
Zheng T, 537
Zhong W, 2943
Zhou C, 69
Zhu H, 3309
Zhu J, 1919
Zhu LX, 107
Zhu X, 1953
Zidanik B, 587
Zideck T, 4673
Zieger S, 3197
Zieglschmid V, 1803
Zilling T, 419
Zinser GM, 235
Ziras N, 3559
Zirganos N, 1409
Zojer N, 3607
Zoras O, 1927, 2743
Zou W, 369
Zoubak S, 4727
Zovoilis T, 2091
Zucali PA, 3143
Zucchetta P, 4559
Zugor V, 1629
Zullo A, 2567
Zuntini M, 1109
Zwahlen M, 1219

Errata Volume 21, 2001

Volume 21 (2001), page 405: Figure 2E should be replaced by:



Errata, Volume 24, 2004

Volume 24 (2004), page 307: The authors' names should read:

EDWARD KYU-HO HAN, CHRIS BUTLER, HAICHAO ZHANG, JEAN M. SEVERIN,
WENYING QIN, TOM F. HOLZMAN, EARL J. GUBBINS, ROBERT L. SIMMER,
SAUL ROSENBERG, VINCENT L. GIRANDA, SHI-CHUNG NG and Y. LUO

Volume 24 (2004), page 3881: The third author's name should read:

KLAUS STREBHARDT

Volume 24, page 3907:

The authors' names should read:

EDWARD KYU-HO HAN, CHRIS BUTLER, HAICHAO ZHANG, JEAN M. SEVERIN,
WENYING QIN, TOM F. HOLZMAN, EARL J. GUBBINS, ROBERT L. SIMMER,
SAUL ROSENBERG, VINCENT L. GIRANDA, SHI-CHUNG NG and Y. LUO

Errata, Volume 25, 2005

Volume 25, pages 101-106:

In all of the experiments in which flavopiridol was used, the concentrations were in nanomolar and not micromolar. The concentrations of all of the other drugs were correct as published. This holds for the data in Tables I, II, III, IV, V and VII and Figure 1.

Volume 25, page 1157:

Abstract, line 17: Picomolar should be changed to nanomolar.

Volume 25, page 1803:

The fourth author's name should read:

WINFIRED ALBERTI

Volume 25, page 1871:

The third author's name should read:

HELENA BAUMANN

Editorial Staff

Managing Editor and Executive Publisher: J.G. DELINASSIOS, Athens, Greece

Assistant Managing Editor: S. AZOUDIS

Production Editor: E. ILIADIS, Athens, Greece

Editorial Office

International Institute of Anticancer Research,

1st km Kapandritiou-Kalamou Rd.,

Kapandriti, P.O.Box 22, Attiki 19014, Greece.

Telephone and Fax: 0030-22950-53389.

Please visit the IAR website: www.iar-anticancer.org

e-mails:

Editor: editor@iar-anticancer.org

Journals: journals@iar-anticancer.org

IAR website: iar@iar-anticancer.org

Publication Data: ANTICANCER RESEARCH (AR) is published bimonthly. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

Copyright: Once a manuscript has been published in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author to the Journal.

Annual Subscription Rates 1981, 1982, 1983, 1984, 1985, 1986, 1987, 1988, 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006: Institutional subscription for Europe: Euro 1580 per volume. Institutional subscription for all other continents: Euro 1685 per volume. Personal subscription for Europe: Euro 760 per volume. Personal subscription for all other continents: Euro 820 per volume. Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-25, 1981-2005) are available at 50% discount on the above rates.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the publisher. Cheques should be made payable to J.G. Delinassios, Executive Publisher of Anticancer Research, Athens, Greece and should be sent to the Editorial Office.

Correspondence: (subscription orders, reprint orders, change of address, disposition of submitted manuscripts, and general editorial matters) should be directed to Dr. J. G. Delinassios, Executive Publisher and Managing Editor, Editorial Office.

Advertising: Correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including *Current Contents (Life*

Sciences), *Science Citation Index*, *Index Medicus*, *Biological Abstracts*, *Chemical Abstracts*, *Excerpta Medica*, *University of Sheffield Biomedical Information Service*, *Current Clinical Cancer*, *AIDS Abstracts*, *Progress in Palliative Care*, *Cambridge Scientific Abstracts*, *Cancergram (International Cancer Research Data Bank)*, *MEDLINE*, *Reference Update - RIS Inc.*, *PASCAL-CNRS*, *Inpharma-Reactions (Datastar, BRS)*, *CABS*, *Immunology Abstracts*, *Telegen Abstracts*, *Genetics Abstracts*, *Nutrition Research Newsletter*, *Dairy Science Abstracts*, *Current Titles in Dentistry*, *Inpharma Weekly*, *BioBase*, *MedBase*, *CAB Abstracts/Global Health Databases and Investigational Drugs Database*.

Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by ANTICANCER RESEARCH, provided that the base fee of \$2.00 per copy, plus 0.40 per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0250-7005/2005 \$2.00 +0.40.

The Editors and Publishers of the journal ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing herein.

Editorial Office

International Institute of Anticancer Research,

1st km Kapandritiou-Kalamou Rd.,

Kapandriti, P.O.Box 22, Attiki 19014, Greece.

Telephone and Fax: 0030-22950-53389.

PHOTOCOMPOSITION BY IAR

PRINTED BY A. ELEFTHEROS - ATHENS - GREECE

PRINTED ON ACID - FREE PAPER

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy advises that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 1200 words) and announcements of newly received books and journals related to cancer; and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts regarding grammar and style.

Format. Two types of papers may be submitted: (i) full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background - Materials and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods, or Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements, and (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, rather than photographic copies. A charge will be made for a colour plate.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in «Chemical Abstracts». Standard abbreviations are preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of «Index Medicus» and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216,1981. 2 McGuire WL and Chamness GC: Studies on the oestrogen receptor in breast cancer. *In: Receptors for Reproductive Hormones* (O' Malley BW and Chamnes GC, eds). New York, Plenum Publ Corp. 1973, pp 113-136.

Submission of Manuscripts. An original and two copies of the manuscript (including all photographs and graphs) should be sent to: Dr. J. G. Delinassios, Managing Editor, Anticancer Research, Editorial Office, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O.Box 22, Attiki 19014, Greece. A floppy disc should also be submitted indicating the computer-processing program using the text form ASCII FILE. Authors are invited to submit along with their manuscripts a short list of possible reviewers and any previous publications which could facilitate reviewing. Manuscripts should be accompanied by six adhesive labels with the name and address of the Author to whom correspondence should be sent. Only the original copy of the submitted manuscript will be returned to Authors upon rejection. The number of recently accepted manuscripts will be entered in the Anticancer Research page "Author's Service" as soon as a decision has been reached.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free of charge. Additional copies may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.